

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
21 March 2002 (21.03.2002)

PCT

(10) International Publication Number  
WO 02/22802 A1

(51) International Patent Classification<sup>7</sup>: C12N 15/00,  
15/12, C07K 14/435

Drive, Lafayette Hill, PA 19444 (US). STRUM, Jay, C.  
[US/US]; Five Moore Drive, Research Triangle Park, NC  
27709 (US). XIE, Qing [CN/US]; 310 Sawmill Lane,  
Horsham, PA 19044 (US).

(21) International Application Number: PCT/US01/28462

(74) Agents: FEDON, Jason, C. et al.; SmithKline Beecham  
Corporation, Corporate Intellectual Property, UW2220,  
709 Swedeland Road, P.O. Box 1539, King of Prussia, PA  
19406-0939 (US).

(22) International Filing Date:  
13 September 2001 (13.09.2001)

(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, CA, CH, CN, CO, CR, CU, CZ,  
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,  
HU, ID, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,  
LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO,  
NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR,  
TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(25) Filing Language: English

(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BJ, CJ, CF,  
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,  
TG).

(26) Publication Language: English

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- with sequence listing part of description published separately in electronic form and available upon request from the International Bureau

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(71) Applicants (for all designated States except US):  
SMITHKLINE BEECHAM CORPORATION [US/US]; One Franklin Plaza, Philadelphia, PA 19103 (US). SMITHKLINE BEECHAM P.L.C. [GB/GB]; New Horizons Court, Great West Road, Brentford, Middlesex TW8 9EP (GB). GLAXO GROUP LIMITED [GB/GB]; Glaxo House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): AGARWAL, Pankaj [IN/US]; 251 West DeKalb Pike, King of Prussia, PA 19406 (US). GOGSWELL, John, P. [US/US]; Five Moore Drive, Research Triangle Park, NC 27709 (US). LAI, Ying-Ta [CN/US]; 516 Spruce Avenue, Upper Darby, PA 19082 (US). MARTENSEN, Shelby, A. [US/US]; Five Moore Drive, Research Triangle Park, NC 27709 (US). SMITH, Randall, F. [US/US]; 4138 Presidential



WO 02/22802 A1

(54) Title: NOVEL COMPOUNDS

(57) Abstract: Polypeptides and polynucleotides of the genes set forth in Table I and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing polypeptides and polynucleotides of the genes set forth in Table I in diagnostic assays.

## Novel Compounds

### Field of Invention

This invention relates to newly identified polypeptides and polynucleotides encoding such polypeptides, to their use in diagnosis and in identifying compounds that may be agonists, antagonists that are potentially useful in therapy, and to production of such polypeptides and polynucleotides. The polynucleotides and polypeptides of the present invention also relate to proteins with signal sequences which allow them to be secreted extracellularly or membrane-associated (hereinafter often referred collectively as secreted proteins or secreted polypeptides).

### Background of the Invention

The drug discovery process is currently undergoing a fundamental revolution as it embraces "functional genomics", that is, high throughput genome- or gene-based biology. This approach as a means to identify genes and gene products as therapeutic targets is rapidly superseding earlier approaches based on "positional cloning". A phenotype, that is a biological function or genetic disease, would be identified and this would then be tracked back to the responsible gene, based on its genetic map position.

Functional genomics relies heavily on high-throughput DNA sequencing technologies and the various tools of bioinformatics to identify gene sequences of potential interest from the many molecular biology databases now available. There is a continuing need to identify and characterise further genes and their related polypeptides/proteins, as targets for drug discovery.

Proteins and polypeptides that are naturally secreted into blood, lymph and other body fluids, or secreted into the cellular membrane are of primary interest for pharmaceutical research and development. The reason for this interest is the relative ease to target protein therapeutics into their place of action (body fluids or the cellular membrane). The natural pathway for protein secretion into extracellular space is the endoplasmic reticulum in eukaryotes and the inner membrane in prokaryotes (Palade, 1975, *Science*, 189, 347; Milstein, Brownlee, Harrison, and Mathews, 1972, *Nature New Biol.*, 239, 117; Blobel, and Dobberstein, 1975, *J. Cell. Biol.*, 67, 835). On the other hand, there is no known natural pathway for exporting a protein from the exterior of the cells into the cytosol (with the exception of pinocytosis, a mechanism of snake venom toxin intrusion into cells). Therefore targeting protein therapeutics into cells poses extreme difficulties.

The secreted and membrane-associated proteins include but are not limited

to all peptide hormones and their receptors (including but not limited to insulin, growth hormones, chemokines, cytokines, neuropeptides, integrins, kallikreins, lamins, melanins, natriuretic hormones, neropsin, neurotropins, pituitary hormones, pleiotropins, prostaglandins, secretogranins, selectins, thromboglobulins, 5 thymosins), the breast and colon cancer gene products, leptin, the obesity gene protein and its receptors, serum albumin, superoxide dismutase, spliceosome proteins, 7TM (transmembrane) proteins also called as G-protein coupled receptors, immunoglobulins, several families of serine proteinases (including but not limited to proteins of the blood coagulation cascade, digestive enzymes), deoxyribonuclease 10 I, etc.

Therapeutics based on secreted or membrane-associated proteins approved by FDA or foreign agencies include but are not limited to insulin, glucagon, growth hormone, chorionic gonadotropin, follicle stimulating hormone, luteinizing hormone, calcitonin, adrenocorticotrophic hormone (ACTH), vasopressin, 15 interleukines, interferones, immunoglobulins, lactoferrin (diverse products marketed by several companies), tissue-type plasminogen activator (Alteplase by Genentech), hyaularindase (Wydase by Wyeth-Ayerst), dornase alpha (Pulmozyme by Genentech), Chymodictactin (chymopapain by Knoll), alglucerase (Ceredase by Genzyme), streptokinase (Kabikinase by Pharmacia) (Streptase by Astra), etc. This 20 indicates that secreted and membrane-associated proteins have an established, proven history as therapeutic targets. Clearly, there is a need for identification and characterization of further secreted and membrane-associated proteins which can play a role in preventing, ameliorating or correcting dysfunction or disease, including but not limited to diabetes, breast-, prostate-, colon cancer and other 25 malignant tumors, hyper- and hypotension, obesity, bulimia, anorexia, growth abnormalities, asthma, manic depression, dementia, delirium, mental retardation, Huntington's disease, Tourette's syndrome, schizophrenia, growth, mental or sexual development disorders, and dysfunctions of the blood cascade system including those leading to stroke. The proteins of the present invention which include the signal 30 sequences are also useful to further elucidate the mechanism of protein transport which at present is not entirely understood, and thus can be used as research tools.

### Summary of the Invention

The present invention relates to particular polypeptides and polynucleotides of the 35 genes set forth in Table I, including recombinant materials and methods for their production. Such polypeptides and polynucleotides are of interest in relation to methods of treatment of

certain diseases, including, but not limited to, the diseases set forth in Tables III and V, hereinafter referred to as "diseases of the invention". In a further aspect, the invention relates to methods for identifying agonists and antagonists (e.g., inhibitors) using the materials provided by the invention, and treating conditions associated with imbalance of

5 polypeptides and/or polynucleotides of the genes set forth in Table I with the identified compounds. In still a further aspect, the invention relates to diagnostic assays for detecting diseases associated with inappropriate activity or levels the genes set forth in Table I. Another aspect of the invention concerns a polynucleotide comprising any of the nucleotide sequences set forth in the Sequence Listing and a polypeptide comprising a polypeptide

10 encoded by the nucleotide sequence. In another aspect, the invention relates to a polypeptide comprising any of the polypeptide sequences set forth in the Sequence Listing and recombinant materials and methods for their production. Another aspect of the invention relates to methods for using such polypeptides and polynucleotides. Such uses include the treatment of diseases, abnormalities and disorders (hereinafter simply referred to as diseases)

15 caused by abnormal expression, production, function and or metabolism of the genes of this invention, and such diseases are readily apparent by those skilled in the art from the homology to other proteins disclosed for each attached sequence. In still another aspect, the invention relates to methods to identify agonists and antagonists using the materials provided by the invention, and treating conditions associated with the imbalance with the identified

20 compounds. Yet another aspect of the invention relates to diagnostic assays for detecting diseases associated with inappropriate activity or levels of the secreted proteins of the present invention.

#### Description of the Invention

25 In a first aspect, the present invention relates to polypeptides the genes set forth in Table I. Such polypeptides include:

(a) an isolated polypeptide encoded by a polynucleotide comprising a sequence set forth in the Sequence Listing, herein when referring to polynucleotides or polypeptides of the Sequence Listing, a reference is also made to the Sequence Listing referred to in the

30 Sequence Listing;

(b) an isolated polypeptide comprising a polypeptide sequence having at least 95%, 96%, 97%, 98%, or 99% identity to a polypeptide sequence set forth in the Sequence Listing;

(c) an isolated polypeptide comprising a polypeptide sequence set forth in the Sequence Listing;

(d) an isolated polypeptide having at least 95%, 96%, 97%, 98%, or 99% identity to a polypeptide sequence set forth in the Sequence Listing;

(e) a polypeptide sequence set forth in the Sequence Listing; and

(f) an isolated polypeptide having or comprising a polypeptide sequence that has an Identity Index of 0.95, 0.96, 0.97, 0.98, or 0.99 compared to a polypeptide sequence set forth in the Sequence Listing;

5 (g) fragments and variants of such polypeptides in (a) to (f).

Polypeptides of the present invention are believed to be members of the gene families set forth in Table II. They are therefore of therapeutic and diagnostic interest for the reasons

10 set forth in Tables III and V. The biological properties of the polypeptides and polynucleotides of the genes set forth in Table I are hereinafter referred to as "the biological activity" of polypeptides and polynucleotides of the genes set forth in Table I. Preferably, a polypeptide of the present invention exhibits at least one biological activity of the genes set forth in Table I.

15 Polypeptides of the present invention also include variants of the aforementioned polypeptides, including all allelic forms and splice variants. Such polypeptides vary from the reference polypeptide by insertions, deletions, and substitutions that may be conservative or non-conservative, or any combination thereof. Particularly preferred variants are those in which several, for instance from 50 to 30, from 30 to 20, from 20 to 10,

20 from 10 to 5, from 5 to 3, from 3 to 2, from 2 to 1 or 1 amino acids are inserted, substituted, or deleted, in any combination.

Preferred fragments of polypeptides of the present invention include an isolated polypeptide comprising an amino acid sequence having at least 30, 50 or 100 contiguous amino acids from an amino acid sequence set forth in the Sequence Listing, or an isolated

25 polypeptide comprising an amino acid sequence having at least 30, 50 or 100 contiguous amino acids truncated or deleted from an amino acid sequence set forth in the Sequence Listing. Preferred fragments are biologically active fragments that mediate the biological activity of polypeptides and polynucleotides of the genes set forth in Table I, including those with a similar activity or an improved activity, or with a decreased undesirable

30 activity. Also preferred are those fragments that are antigenic or immunogenic in an animal, especially in a human.

Fragments of a polypeptide of the invention may be employed for producing the corresponding full-length polypeptide by peptide synthesis; therefore, these variants may be employed as intermediates for producing the full-length polypeptides of the invention. A

35 polypeptide of the present invention may be in the form of the "mature" protein or may be a

part of a larger protein such as a precursor or a fusion protein. It is often advantageous to include an additional amino acid sequence that contains secretory or leader sequences, pro-sequences, sequences that aid in purification, for instance multiple histidine residues, or an additional sequence for stability during recombinant production.

5 Polypeptides of the present invention can be prepared in any suitable manner, for instance by isolation from naturally occurring sources, from genetically engineered host cells comprising expression systems (*vide infra*) or by chemical synthesis, using for instance automated peptide synthesizers, or a combination of such methods. Means for preparing such polypeptides are well understood in the art.

10 In a further aspect, the present invention relates to polynucleotides of the genes set forth in Table I. Such polynucleotides include:

- (a) an isolated polynucleotide comprising a polynucleotide sequence having at least 95%, 96%, 97%, 98%, or 99% identity to a polynucleotide sequence set forth in the Sequence Listing;
- 15 (b) an isolated polynucleotide comprising a polynucleotide set forth in the Sequence Listing;
- (c) an isolated polynucleotide having at least 95%, 96%, 97%, 98%, or 99% identity to a polynucleotide set forth in the Sequence Listing;
- (d) an isolated polynucleotide set forth in the Sequence Listing;
- 20 (e) an isolated polynucleotide comprising a polynucleotide sequence encoding a polypeptide sequence having at least 95%, 96%, 97%, 98%, or 99% identity to a polypeptide sequence set forth in the Sequence Listing;
- (f) an isolated polynucleotide comprising a polynucleotide sequence encoding a polypeptide set forth in the Sequence Listing;
- 25 (g) an isolated polynucleotide having a polynucleotide sequence encoding a polypeptide sequence having at least 95%, 96%, 97%, 98%, or 99% identity to a polypeptide sequence set forth in the Sequence Listing;
- (h) an isolated polynucleotide encoding a polypeptide set forth in the Sequence Listing;
- (i) an isolated polynucleotide having or comprising a polynucleotide sequence that has an Identity Index of 0.95, 0.96, 0.97, 0.98, or 0.99 compared to a polynucleotide sequence set forth in the Sequence Listing;
- 30 (j) an isolated polynucleotide having or comprising a polynucleotide sequence encoding a polypeptide sequence that has an Identity Index of 0.95, 0.96, 0.97, 0.98, or 0.99 compared to a polypeptide sequence set forth in the Sequence Listing; and

polynucleotides that are fragments and variants of the above mentioned polynucleotides or that are complementary to above mentioned polynucleotides, over the entire length thereof.

Preferred fragments of polynucleotides of the present invention include an isolated polynucleotide comprising an nucleotide sequence having at least 15, 30, 50 or 100

5 contiguous nucleotides from a sequence set forth in the Sequence Listing, or an isolated polynucleotide comprising a sequence having at least 30, 50 or 100 contiguous nucleotides truncated or deleted from a sequence set forth in the Sequence Listing.

Preferred variants of polynucleotides of the present invention include splice variants, allelic variants, and polymorphisms, including polynucleotides having one or more 10 single nucleotide polymorphisms (SNPs).

Polynucleotides of the present invention also include polynucleotides encoding polypeptide variants that comprise an amino acid sequence set forth in the Sequence Listing and in which several, for instance from 50 to 30, from 30 to 20, from 20 to 10, from 10 to 5, from 5 to 3, from 3 to 2, from 2 to 1 or 1 amino acid residues are substituted, deleted or 15 added, in any combination.

In a further aspect, the present invention provides polynucleotides that are RNA transcripts of the DNA sequences of the present invention. Accordingly, there is provided an RNA polynucleotide that:

(a) comprises an RNA transcript of the DNA sequence encoding a polypeptide set 20 forth in the Sequence Listing;

(b) is a RNA transcript of a DNA sequence encoding a polypeptide set forth in the Sequence Listing;

(c) comprises an RNA transcript of a DNA sequence set forth in the Sequence Listing; or

25 (d) is a RNA transcript of a DNA sequence set forth in the Sequence Listing; and RNA polynucleotides that are complementary thereto.

The polynucleotide sequences set forth in the Sequence Listing show homology with the polynucleotide sequences set forth in Table II. A polynucleotide sequence set forth in the Sequence Listing is a cDNA sequence that encodes a polypeptide set forth in the 30 Sequence Listing. A polynucleotide sequence encoding a polypeptide set forth in the Sequence Listing may be identical to a polypeptide encoding a sequence set forth in the Sequence Listing or it may be a sequence other than a sequence set forth in the Sequence Listing, which, as a result of the redundancy (degeneracy) of the genetic code, also encodes a polypeptide set forth in the Sequence Listing. A polypeptide of a sequence set forth in the 35 Sequence Listing is related to other proteins of the gene families set forth in Table II, having

homology and/or structural similarity with the polypeptides set forth in Table II. Preferred polypeptides and polynucleotides of the present invention are expected to have, *inter alia*, similar biological functions/properties to their homologous polypeptides and polynucleotides. Furthermore, preferred polypeptides and polynucleotides of the present

5 invention have at least one activity of the genes set forth in Table I.

Polynucleotides of the present invention may be obtained using standard cloning and screening techniques from a cDNA library derived from mRNA from the tissues set forth in Table IV (see for instance, Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989)).

10 Polynucleotides of the invention can also be obtained from natural sources such as genomic DNA libraries or can be synthesized using well known and commercially available techniques.

When polynucleotides of the present invention are used for the recombinant production of polypeptides of the present invention, the polynucleotide may include the

15 coding sequence for the mature polypeptide, by itself, or the coding sequence for the mature polypeptide in reading frame with other coding sequences, such as those encoding a leader or secretory sequence, a pre-, or pro- or prepro- protein sequence, or other fusion peptide portions. For example, a marker sequence that facilitates purification of the fused polypeptide can be encoded. In certain preferred embodiments of this aspect of the

20 invention, the marker sequence is a hexa-histidine peptide, as provided in the pQE vector (Qiagen, Inc.) and described in Gentz *et al.*, Proc Natl Acad Sci USA (1989) 86:821-824, or is an HA tag. A polynucleotide may also contain non-coding 5' and 3' sequences, such as transcribed, non-translated sequences, splicing and polyadenylation signals, ribosome binding sites and sequences that stabilize mRNA.

25 Polynucleotides that are identical, or have sufficient identity to a polynucleotide sequence set forth in the Sequence Listing, may be used as hybridization probes for cDNA and genomic DNA or as primers for a nucleic acid amplification reaction (for instance, PCR). Such probes and primers may be used to isolate full-length cDNAs and genomic clones encoding polypeptides of the present invention and to isolate cDNA and genomic

30 clones of other genes (including genes encoding paralogs from human sources and orthologs and paralogs from other species) that have a high sequence similarity to sequences set forth in the Sequence Listing, typically at least 95% identity. Preferred probes and primers will generally comprise at least 15 nucleotides, preferably, at least 30 nucleotides and may have at least 50, if not at least 100 nucleotides. Particularly preferred probes will have between

30 and 50 nucleotides. Particularly preferred primers will have between 20 and 25 nucleotides.

A polynucleotide encoding a polypeptide of the present invention, including homologs from other species, may be obtained by a process comprising the steps of

5 screening a library under stringent hybridization conditions with a labeled probe having a sequence set forth in the Sequence Listing or a fragment thereof, preferably of at least 15 nucleotides; and isolating full-length cDNA and genomic clones containing the polynucleotide sequence set forth in the Sequence Listing. Such hybridization techniques are well known to the skilled artisan. Preferred stringent hybridization conditions include

10 overnight incubation at 42°C in a solution comprising: 50% formamide, 5xSSC (150mM NaCl, 15mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5x Denhardt's solution, 10 % dextran sulfate, and 20 microgram/ml denatured, sheared salmon sperm DNA; followed by washing the filters in 0.1x SSC at about 65°C. Thus the present invention also includes isolated polynucleotides, preferably with a nucleotide sequence of at least 100,

15 obtained by screening a library under stringent hybridization conditions with a labeled probe having the sequence set forth in the Sequence Listing or a fragment thereof, preferably of at least 15 nucleotides.

The skilled artisan will appreciate that, in many cases, an isolated cDNA sequence will be incomplete, in that the region coding for the polypeptide does not extend all the way

20 through to the 5' terminus. This is a consequence of reverse transcriptase, an enzyme with inherently low "processivity" (a measure of the ability of the enzyme to remain attached to the template during the polymerisation reaction), failing to complete a DNA copy of the mRNA template during first strand cDNA synthesis.

There are several methods available and well known to those skilled in the art to

25 obtain full-length cDNAs, or extend short cDNAs, for example those based on the method of Rapid Amplification of cDNA ends (RACE) (see, for example, Frohman et al., Proc Nat Acad Sci USA 85, 8998-9002, 1988). Recent modifications of the technique, exemplified by the Marathon (trade mark) technology (Clontech Laboratories Inc.) for example, have significantly simplified the search for longer cDNAs. In the Marathon (trade mark)

30 technology, cDNAs have been prepared from mRNA extracted from a chosen tissue and an 'adaptor' sequence ligated onto each end. Nucleic acid amplification (PCR) is then carried out to amplify the "missing" 5' end of the cDNA using a combination of gene specific and adaptor specific oligonucleotide primers. The PCR reaction is then repeated using 'nested' primers, that is, primers designed to anneal within the amplified product (typically an

35 adapter specific primer that anneals further 3' in the adaptor sequence and a gene specific

primer that anneals further 5' in the known gene sequence). The products of this reaction can then be analyzed by DNA sequencing and a full-length cDNA constructed either by joining the product directly to the existing cDNA to give a complete sequence, or carrying out a separate full-length PCR using the new sequence information for the design of the 5' 5 primer.

Recombinant polypeptides of the present invention may be prepared by processes well known in the art from genetically engineered host cells comprising expression systems. Accordingly, in a further aspect, the present invention relates to expression systems comprising a polynucleotide or polynucleotides of the present invention, to host cells which 10 are genetically engineered with such expression systems and to the production of polypeptides of the invention by recombinant techniques. Cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA constructs of the present invention.

For recombinant production, host cells can be genetically engineered to incorporate 15 expression systems or portions thereof for polynucleotides of the present invention.

Polynucleotides may be introduced into host cells by methods described in many standard laboratory manuals, such as Davis *et al.*, *Basic Methods in Molecular Biology* (1986) and Sambrook *et al.* (*ibid*). Preferred methods of introducing polynucleotides into host cells include, for instance, calcium phosphate transfection, DEAE-dextran mediated transfection, 20 transfection, micro-injection, cationic lipid-mediated transfection, electroporation, transduction, scrape loading, ballistic introduction or infection.

Representative examples of appropriate hosts include bacterial cells, such as *Streptococci*, *Staphylococci*, *E. coli*, *Streptomyces* and *Bacillus subtilis* cells; fungal cells, such as yeast cells and *Aspergillus* cells; insect cells such as *Drosophila S2* and *Spodoptera 25 Sf9* cells; animal cells such as CHO, COS, HeLa, C127, 3T3, BHK, HEK 293 and Bowes melanoma cells; and plant cells.

A great variety of expression systems can be used, for instance, chromosomal, episomal and virus-derived systems, *e.g.*, vectors derived from bacterial plasmids, from bacteriophage, from transposons, from yeast episomes, from insertion elements, from yeast 30 chromosomal elements, from viruses such as baculoviruses, papova viruses, such as SV40, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses and retroviruses, and vectors derived from combinations thereof, such as those derived from plasmid and bacteriophage genetic elements, such as cosmids and phagemids. The expression systems may contain control regions that regulate as well as engender expression. Generally, any 35 system or vector that is able to maintain, propagate or express a polynucleotide to produce a

polypeptide in a host may be used. The appropriate polynucleotide sequence may be inserted into an expression system by any of a variety of well-known and routine techniques, such as, for example, those set forth in Sambrook *et al.*, (*ibid*). Appropriate secretion signals may be incorporated into the desired polypeptide to allow secretion of the 5 translated protein into the lumen of the endoplasmic reticulum, the periplasmic space or the extracellular environment. These signals may be endogenous to the polypeptide or they may be heterologous signals.

If a polypeptide of the present invention is to be expressed for use in screening assays, it is generally preferred that the polypeptide be produced at the surface of the cell. 10 In this event, the cells may be harvested prior to use in the screening assay. If the polypeptide is secreted into the medium, the medium can be recovered in order to recover and purify the polypeptide. If produced intracellularly, the cells must first be lysed before the polypeptide is recovered.

Polypeptides of the present invention can be recovered and purified from 15 recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography is employed for purification. Well known techniques 20 for refolding proteins may be employed to regenerate active conformation when the polypeptide is denatured during intracellular synthesis, isolation and/or purification.

Polynucleotides of the present invention may be used as diagnostic reagents, through detecting mutations in the associated gene. Detection of a mutated form of a gene is characterized by the polynucleotides set forth in the Sequence Listing in the cDNA or 25 genomic sequence and which is associated with a dysfunction. Will provide a diagnostic tool that can add to, or define, a diagnosis of a disease, or susceptibility to a disease, which results from under-expression, over-expression or altered spatial or temporal expression of the gene. Individuals carrying mutations in the gene may be detected at the DNA level by a variety of techniques well known in the art.

30 Nucleic acids for diagnosis may be obtained from a subject's cells, such as from blood, urine, saliva, tissue biopsy or autopsy material. The genomic DNA may be used directly for detection or it may be amplified enzymatically by using PCR, preferably RT-PCR, or other amplification techniques prior to analysis. RNA or cDNA may also be used in similar fashion. Deletions and insertions can be detected by a change in size of the 35 amplified product in comparison to the normal genotype. Point mutations can be identified

by hybridizing amplified DNA to labeled nucleotide sequences of the genes set forth in Table I. Perfectly matched sequences can be distinguished from mismatched duplexes by RNase digestion or by differences in melting temperatures. DNA sequence difference may also be detected by alterations in the electrophoretic mobility of DNA fragments in gels, 5 with or without denaturing agents, or by direct DNA sequencing (see, for instance, Myers *et al.*, *Science* (1985) 230:1242). Sequence changes at specific locations may also be revealed by nuclease protection assays, such as RNase and S1 protection or the chemical cleavage method (see Cotton *et al.*, *Proc Natl Acad Sci USA* (1985) 85: 4397-4401).

An array of oligonucleotides probes comprising polynucleotide sequences or 10 fragments thereof of the genes set forth in Table I can be constructed to conduct efficient screening of *e.g.*, genetic mutations. Such arrays are preferably high density arrays or grids. Array technology methods are well known and have general applicability and can be used to address a variety of questions in molecular genetics including gene expression, genetic linkage, and genetic variability, see, for example, M. Chee *et al.*, *Science*, 274, 610-613 15 (1996) and other references cited therein.

Detection of abnormally decreased or increased levels of polypeptide or mRNA expression may also be used for diagnosing or determining susceptibility of a subject to a disease of the invention. Decreased or increased expression can be measured at the RNA level using any of the methods well known in the art for the quantitation of polynucleotides, such as, for 20 example, nucleic acid amplification, for instance PCR, RT-PCR, RNase protection, Northern blotting and other hybridization methods. Assay techniques that can be used to determine levels of a protein, such as a polypeptide of the present invention, in a sample derived from a host are well-known to those of skill in the art. Such assay methods include radio-immunoassays, competitive-binding assays, Western Blot analysis and ELISA assays.

25 Thus in another aspect, the present invention relates to a diagnostic kit comprising:  
(a) a polynucleotide of the present invention, preferably the nucleotide sequence set forth in the Sequence Listing, or a fragment or an RNA transcript thereof;  
(b) a nucleotide sequence complementary to that of (a);  
(c) a polypeptide of the present invention, preferably the polypeptide set forth in the 30 Sequence Listing or a fragment thereof; or  
(d) an antibody to a polypeptide of the present invention, preferably to the polypeptide set forth in the Sequence Listing.

It will be appreciated that in any such kit, (a), (b), (c) or (d) may comprise a substantial component. Such a kit will be of use in diagnosing a disease or susceptibility to 35 a disease, particularly diseases of the invention, amongst others.

The polynucleotide sequences of the present invention are valuable for chromosome localisation studies. The sequences set forth in the Sequence Listing are specifically targeted to, and can hybridize with, a particular location on an individual human chromosome. The mapping of relevant sequences to chromosomes according to the present invention is an important first step in correlating those sequences with gene associated disease. Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. Such data are found in, for example, V. McKusick, Mendelian Inheritance in Man (available online through Johns Hopkins University Welch Medical Library). The relationship between genes and diseases that have been mapped to the same chromosomal region are then identified through linkage analysis (co-inheritance of physically adjacent genes). Precise human chromosomal localisations for a genomic sequence (gene fragment etc.) can be determined using Radiation Hybrid (RH) Mapping (Walter, M. Spillett, D., Thomas, P., Weissenbach, J., and Goodfellow, P., (1994) A method for constructing radiation hybrid maps of whole genomes, *Nature Genetics* 7, 22-28). A number of RH panels are available from Research Genetics (Huntsville, AL, USA) e.g. the GeneBridge4 RH panel (Hum Mol Genet 1996 Mar;5(3):339-46 A radiation hybrid map of the human genome. Gyapay G, Schmitt K, Fizames C, Jones H, Vega-Czarny N, Spillett D, Muselet D, Prud'Homme JF, Dib C, Auffray C, Morissette J, Weissenbach J, Goodfellow PN). To determine the chromosomal location of a gene using this panel, 93 PCRs are performed using primers designed from the gene of interest on RH DNAs. Each of these DNAs contains random human genomic fragments maintained in a hamster background (human / hamster hybrid cell lines). These PCRs result in 93 scores indicating the presence or absence of the PCR product of the gene of interest. These scores are compared with scores created using PCR products from genomic sequences of known location. This comparison is conducted at <http://www.genome.wi.mit.edu/>.

The polynucleotide sequences of the present invention are also valuable tools for tissue expression studies. Such studies allow the determination of expression patterns of polynucleotides of the present invention which may give an indication as to the expression patterns of the encoded polypeptides in tissues, by detecting the mRNAs that encode them. The techniques used are well known in the art and include *in situ* hybridization techniques to clones arrayed on a grid, such as cDNA microarray hybridization (Schena *et al*, *Science*, 270, 467-470, 1995 and Shalon *et al*, *Genome Res*, 6, 639-645, 1996) and nucleotide amplification techniques such as PCR. A preferred method uses the TAQMAN (Trade mark) technology available from Perkin Elmer. Results from these studies can provide an

indication of the normal function of the polypeptide in the organism. In addition, comparative studies of the normal expression pattern of mRNAs with that of mRNAs encoded by an alternative form of the same gene (for example, one having an alteration in polypeptide coding potential or a regulatory mutation) can provide valuable insights into the 5 role of the polypeptides of the present invention, or that of inappropriate expression thereof in disease. Such inappropriate expression may be of a temporal, spatial or simply quantitative nature.

A further aspect of the present invention relates to antibodies. The polypeptides of the invention or their fragments, or cells expressing them, can be used as immunogens to 10 produce antibodies that are immunospecific for polypeptides of the present invention. The term "immunospecific" means that the antibodies have substantially greater affinity for the polypeptides of the invention than their affinity for other related polypeptides in the prior art.

Antibodies generated against polypeptides of the present invention may be obtained 15 by administering the polypeptides or epitope-bearing fragments, or cells to an animal, preferably a non-human animal, using routine protocols. For preparation of monoclonal antibodies, any technique which provides antibodies produced by continuous cell line cultures can be used. Examples include the hybridoma technique (Kohler, G. and Milstein, C., *Nature* (1975) 256:495-497), the trioma technique, the human B-cell hybridoma 20 technique (Kozbor *et al.*, *Immunology Today* (1983) 4:72) and the EBV-hybridoma technique (Cole *et al.*, *Monoclonal Antibodies and Cancer Therapy*, 77-96, Alan R. Liss, Inc., 1985).

Techniques for the production of single chain antibodies, such as those described in 25 U.S. Patent No. 4,946,778, can also be adapted to produce single chain antibodies to polypeptides of this invention. Also, transgenic mice, or other organisms, including other mammals, may be used to express humanized antibodies.

The above-described antibodies may be employed to isolate or to identify clones 30 expressing the polypeptide or to purify the polypeptides by affinity chromatography. Antibodies against polypeptides of the present invention may also be employed to treat diseases of the invention, amongst others.

Polypeptides and polynucleotides of the present invention may also be used as 35 vaccines. Accordingly, in a further aspect, the present invention relates to a method for inducing an immunological response in a mammal that comprises inoculating the mammal with a polypeptide of the present invention, adequate to produce antibody and/or T cell immune response, including, for example, cytokine-producing T cells or cytotoxic T cells.

to protect said animal from disease, whether that disease is already established within the individual or not. An immunological response in a mammal may also be induced by a method comprises delivering a polypeptide of the present invention *via* a vector directing expression of the polynucleotide and coding for the polypeptide *in vivo* in order to induce 5 such an immunological response to produce antibody to protect said animal from diseases of the invention. One way of administering the vector is by accelerating it into the desired cells as a coating on particles or otherwise. Such nucleic acid vector may comprise DNA, RNA, a modified nucleic acid, or a DNA/RNA hybrid. For use a vaccine, a polypeptide or a nucleic acid vector will be normally provided as a vaccine formulation (composition). The 10 formulation may further comprise a suitable carrier. Since a polypeptide may be broken down in the stomach, it is preferably administered parenterally (for instance, subcutaneous, intra-muscular, intravenous, or intra-dermal injection). Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions that may contain anti-oxidants, buffers, bacteriostats and solutes that render the formulation isotonic with the 15 blood of the recipient; and aqueous and non-aqueous sterile suspensions that may include suspending agents or thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampoules and vials and may be stored in a freeze-dried condition requiring only the addition of the sterile liquid carrier immediately prior to use. The vaccine formulation may also include adjuvant systems for enhancing the 20 immunogenicity of the formulation, such as oil-in water systems and other systems known in the art. The dosage will depend on the specific activity of the vaccine and can be readily determined by routine experimentation.

Polypeptides of the present invention have one or more biological functions that are of relevance in one or more disease states, in particular the diseases of the invention 25 hereinbefore mentioned. It is therefore useful to identify compounds that stimulate or inhibit the function or level of the polypeptide. Accordingly, in a further aspect, the present invention provides for a method of screening compounds to identify those that stimulate or inhibit the function or level of the polypeptide. Such methods identify agonists or antagonists that may be employed for therapeutic and prophylactic purposes for such 30 diseases of the invention as hereinbefore mentioned. Compounds may be identified from a variety of sources, for example, cells, cell-free preparations, chemical libraries, collections of chemical compounds, and natural product mixtures. Such agonists or antagonists so-identified may be natural or modified substrates, ligands, receptors, enzymes, etc., as the case may be, of the polypeptide; a structural or functional mimetic thereof (see Coligan *et* 35 *al.*, Current Protocols in Immunology 1(2):Chapter 5 (1991)) or a small molecule. Such

small molecules preferably have a molecular weight below 2,000 daltons, more preferably between 300 and 1,000 daltons, and most preferably between 400 and 700 daltons. It is preferred that these small molecules are organic molecules.

The screening method may simply measure the binding of a candidate compound to 5 the polypeptide, or to cells or membranes bearing the polypeptide, or a fusion protein thereof, by means of a label directly or indirectly associated with the candidate compound. Alternatively, the screening method may involve measuring or detecting (qualitatively or 10 quantitatively) the competitive binding of a candidate compound to the polypeptide against a labeled competitor (e.g. agonist or antagonist). Further, these screening methods may test 15 whether the candidate compound results in a signal generated by activation or inhibition of the polypeptide, using detection systems appropriate to the cells bearing the polypeptide. Inhibitors of activation are generally assayed in the presence of a known agonist and the effect on activation by the agonist by the presence of the candidate compound is observed. Further, the screening methods may simply comprise the steps of mixing a candidate 15 compound with a solution containing a polypeptide of the present invention, to form a mixture, measuring an activity of the genes set forth in Table I in the mixture, and comparing activity of the mixture of the genes set forth in Table I to a control mixture which contains no candidate compound.

Polypeptides of the present invention may be employed in conventional low 20 capacity screening methods and also in high-throughput screening (HTS) formats. Such HTS formats include not only the well-established use of 96- and, more recently, 384-well micotiter plates but also emerging methods such as the nanowell method described by Schullek *et al.*, *Anal Biochem.*, 246, 20-29, (1997).

Fusion proteins, such as those made from Fc portion and polypeptide of the genes set forth 25 in Table I, as hereinbefore described, can also be used for high-throughput screening assays to identify antagonists for the polypeptide of the present invention (see D. Bennett *et al.*, *J Mol Recognition*, 8:52-58 (1995); and K. Johanson *et al.*, *J Biol Chem*, 270(16):9459-9471 (1995)).

The polynucleotides, polypeptides and antibodies to the polypeptide of the present 30 invention may also be used to configure screening methods for detecting the effect of added compounds on the production of mRNA and polypeptide in cells. For example, an ELISA assay may be constructed for measuring secreted or cell associated levels of polypeptide using monoclonal and polyclonal antibodies by standard methods known in the art. This can be used to discover agents that may inhibit or enhance the production of polypeptide 35 (also called antagonist or agonist, respectively) from suitably manipulated cells or tissues.

A polypeptide of the present invention may be used to identify membrane bound or soluble receptors, if any, through standard receptor binding techniques known in the art. These include, but are not limited to, ligand binding and crosslinking assays in which the polypeptide is labeled with a radioactive isotope (for instance,  $^{125}\text{I}$ ), chemically modified (for instance, biotinylated), or fused to a peptide sequence suitable for detection or purification, and incubated with a source of the putative receptor (cells, cell membranes, cell supernatants, tissue extracts, bodily fluids). Other methods include biophysical techniques such as surface plasmon resonance and spectroscopy. These screening methods may also be used to identify agonists and antagonists of the polypeptide that compete with the binding of the polypeptide to its receptors, if any. Standard methods for conducting such assays are well understood in the art.

Examples of antagonists of polypeptides of the present invention include antibodies or, in some cases, oligonucleotides or proteins that are closely related to the ligands, substrates, receptors, enzymes, etc., as the case may be, of the polypeptide, e.g., a fragment of the ligands, substrates, receptors, enzymes, etc.; or a small molecule that bind to the polypeptide of the present invention but do not elicit a response, so that the activity of the polypeptide is prevented.

Screening methods may also involve the use of transgenic technology and the genes set forth in Table I. The art of constructing transgenic animals is well established. For example, the genes set forth in Table I may be introduced through microinjection into the male pronucleus of fertilized oocytes, retroviral transfer into pre- or post-implantation embryos, or injection of genetically modified, such as by electroporation, embryonic stem cells into host blastocysts. Particularly useful transgenic animals are so-called "knock-in" animals in which an animal gene is replaced by the human equivalent within the genome of that animal. Knock-in transgenic animals are useful in the drug discovery process, for target validation, where the compound is specific for the human target. Other useful transgenic animals are so-called "knock-out" animals in which the expression of the animal ortholog of a polypeptide of the present invention and encoded by an endogenous DNA sequence in a cell is partially or completely annulled. The gene knock-out may be targeted to specific cells or tissues, may occur only in certain cells or tissues as a consequence of the limitations of the technology, or may occur in all, or substantially all, cells in the animal. Transgenic animal technology also offers a whole animal expression-cloning system in which introduced genes are expressed to give large amounts of polypeptides of the present invention

Screening kits for use in the above described methods form a further aspect of the present invention. Such screening kits comprise:

- (a) a polypeptide of the present invention;
- (b) a recombinant cell expressing a polypeptide of the present invention;
- 5 (c) a cell membrane expressing a polypeptide of the present invention; or
- (d) an antibody to a polypeptide of the present invention;

which polypeptide is preferably that set forth in the Sequence Listing.

It will be appreciated that in any such kit, (a), (b), (c) or (d) may comprise a substantial component.

10

### Glossary

The following definitions are provided to facilitate understanding of certain terms used frequently hereinbefore.

15 "Antibodies" as used herein includes polyclonal and monoclonal antibodies, chimeric, single chain, and humanized antibodies, as well as Fab fragments, including the products of an

Fab or other immunoglobulin expression library.

20 "Isolated" means altered "by the hand of man" from its natural state, *i.e.*, if it occurs in nature, it has been changed or removed from its original environment, or both. For example, a polynucleotide or a polypeptide naturally present in a living organism is not "isolated," but the same polynucleotide or polypeptide separated from the coexisting materials of its natural state is "isolated", as the term is employed herein. Moreover, a polynucleotide or polypeptide that is introduced into an organism by transformation, genetic manipulation or by any other recombinant method is "isolated" even if it is still present in 25 said organism, which organism may be living or non-living.

30 "Secreted protein activity or secreted polypeptide activity" or "biological activity of the secreted protein or secreted polypeptide" refers to the metabolic or physiologic function of said secreted protein including similar activities or improved activities or these activities with decreased undesirable side-effects. Also included are antigenic and immunogenic activities of said secreted protein.

"Secreted protein gene" refers to a polynucleotide comprising any of the attached nucleotide sequences or allelic variants thereof and/or their complements.

"Polynucleotide" generally refers to any polyribonucleotide (RNA) or polydeoxyribonucleotide (DNA), which may be unmodified or modified RNA or DNA.

35 "Polynucleotides" include, without limitation, single- and double-stranded DNA, DNA that

is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, "polynucleotide" refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA. The term "polynucleotide" also includes DNAs or RNAs containing one or more modified bases and DNAs or RNAs with backbones modified for stability or for other reasons. "Modified" bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications may be made to DNA and RNA; thus, "polynucleotide" embraces chemically, enzymatically or metabolically modified forms of polynucleotides as typically found in nature, as well as the chemical forms of DNA and RNA characteristic of viruses and cells. "Polynucleotide" also embraces relatively short polynucleotides, often referred to as oligonucleotides.

"Polypeptide" refers to any polypeptide comprising two or more amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres.

"Polypeptide" refers to both short chains, commonly referred to as peptides, oligopeptides or oligomers, and to longer chains, generally referred to as proteins. Polypeptides may contain amino acids other than the 20 gene-encoded amino acids. "Polypeptides" include amino acid sequences modified either by natural processes, such as post-translational processing, or by chemical modification techniques that are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature. Modifications may occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present to the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be branched as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched and branched cyclic polypeptides may result from post-translation natural processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, biotinylation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cystine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation,

myristylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination (see, for instance, Proteins - Structure and Molecular Properties, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York, 5 1993; Wold, F., Post-translational Protein Modifications: Perspectives and Prospects, 1-12, in Post-translational Covalent Modification of Proteins, B. C. Johnson, Ed., Academic Press, New York, 1983; Seifter *et al.*, "Analysis for protein modifications and nonprotein cofactors", *Meth Enzymol*, 182, 626-646, 1990, and Rattan *et al.*, "Protein Synthesis: Post-translational Modifications and Aging", *Ann NY Acad Sci*, 663, 48-62, 1992).

10 "Fragment" of a polypeptide sequence refers to a polypeptide sequence that is shorter than the reference sequence but that retains essentially the same biological function or activity as the reference polypeptide. "Fragment" of a polynucleotide sequence refers to a polynucleotide sequence that is shorter than the reference sequence set forth in the Sequence Listing.

15 "Variant" refers to a polynucleotide or polypeptide that differs from a reference polynucleotide or polypeptide, but retains the essential properties thereof. A typical variant of a polynucleotide differs in nucleotide sequence from the reference polynucleotide. Changes in the nucleotide sequence of the variant may or may not alter the amino acid sequence of a polypeptide encoded by the reference polynucleotide. Nucleotide changes 20 may result in amino acid substitutions, additions, deletions, fusions and truncations in the polypeptide encoded by the reference sequence, as discussed below. A typical variant of a polypeptide differs in amino acid sequence from the reference polypeptide. Generally, alterations are limited so that the sequences of the reference polypeptide and the variant are closely similar overall and, in many regions, identical. A variant and reference polypeptide 25 may differ in amino acid sequence by one or more substitutions, insertions, deletions in any combination. A substituted or inserted amino acid residue may or may not be one encoded by the genetic code. Typical conservative substitutions include Gly, Ala; Val, Ile, Leu; Asp, Glu; Asn, Gln; Ser, Thr; Lys, Arg; and Phe and Tyr. A variant of a polynucleotide or polypeptide may be naturally occurring such as an allele, or it may be a variant that is not 30 known to occur naturally. Non-naturally occurring variants of polynucleotides and polypeptides may be made by mutagenesis techniques or by direct synthesis. Also included as variants are polypeptides having one or more post-translational modifications, for instance glycosylation, phosphorylation, methylation, ADP ribosylation and the like. Embodiments include methylation of the N-terminal amino acid, phosphorylations of 35 serines and threonines and modification of C-terminal glycines.

"Allele" refers to one of two or more alternative forms of a gene occurring at a given locus in the genome.

"Polymorphism" refers to a variation in nucleotide sequence (and encoded polypeptide sequence, if relevant) at a given position in the genome within a population.

5 "Single Nucleotide Polymorphism" (SNP) refers to the occurrence of nucleotide variability at a single nucleotide position in the genome, within a population. An SNP may occur within a gene or within intergenic regions of the genome. SNPs can be assayed using Allele Specific Amplification (ASA). For the process at least 3 primers are required. A common primer is used in reverse complement to the polymorphism being assayed. This  
10 common primer can be between 50 and 1500 bps from the polymorphic base. The other two (or more) primers are identical to each other except that the final 3' base wobbles to match one of the two (or more) alleles that make up the polymorphism. Two (or more) PCR reactions are then conducted on sample DNA, each using the common primer and one of the Allele Specific Primers.

15 "Splice Variant" as used herein refers to cDNA molecules produced from RNA molecules initially transcribed from the same genomic DNA sequence but which have undergone alternative RNA splicing. Alternative RNA splicing occurs when a primary RNA transcript undergoes splicing, generally for the removal of introns, which results in the production of more than one mRNA molecule each of that may encode different amino acid  
20 sequences. The term splice variant also refers to the proteins encoded by the above cDNA molecules.

25 "Identity" reflects a relationship between two or more polypeptide sequences or two or more polynucleotide sequences, determined by comparing the sequences. In general, identity refers to an exact nucleotide to nucleotide or amino acid to amino acid correspondence of the two polynucleotide or two polypeptide sequences, respectively, over the length of the sequences being compared.

30 "% Identity" - For sequences where there is not an exact correspondence, a "% identity" may be determined. In general, the two sequences to be compared are aligned to give a maximum correlation between the sequences. This may include inserting "gaps" in either one or both sequences, to enhance the degree of alignment. A % identity may be determined over the whole length of each of the sequences being compared (so-called global alignment), that is particularly suitable for sequences of the same or very similar length, or over shorter, defined lengths (so-called local alignment), that is more suitable for sequences of unequal length.

"Similarity" is a further, more sophisticated measure of the relationship between two polypeptide sequences. In general, "similarity" means a comparison between the amino acids of two polypeptide chains, on a residue by residue basis, taking into account not only exact correspondences between a between pairs of residues, one from each of the sequences 5 being compared (as for identity) but also, where there is not an exact correspondence, whether, on an evolutionary basis, one residue is a likely substitute for the other. This likelihood has an associated "score" from which the "% similarity" of the two sequences can then be determined.

Methods for comparing the identity and similarity of two or more sequences are 10 well known in the art. Thus for instance, programs available in the Wisconsin Sequence Analysis Package, version 9.1 (Devereux J et al, Nucleic Acids Res, 12, 387-395, 1984, available from Genetics Computer Group, Madison, Wisconsin, USA), for example the programs BESTFIT and GAP, may be used to determine the % identity between two polynucleotides and the % identity and the % similarity between two polypeptide sequences. 15 BESTFIT uses the "local homology" algorithm of Smith and Waterman (J Mol Biol, 147, 195-197, 1981, Advances in Applied Mathematics, 2, 482-489, 1981) and finds the best single region of similarity between two sequences. BESTFIT is more suited to comparing two polynucleotide or two polypeptide sequences that are dissimilar in length, the program assuming that the shorter sequence represents a portion of the longer. In comparison, GAP 20 aligns two sequences, finding a "maximum similarity", according to the algorithm of Needleman and Wunsch (J Mol Biol, 48, 443-453, 1970). GAP is more suited to comparing sequences that are approximately the same length and an alignment is expected over the entire length. Preferably, the parameters "Gap Weight" and "Length Weight" used in each program are 50 and 3, for polynucleotide sequences and 12 and 4 for polypeptide sequences, 25 respectively. Preferably, % identities and similarities are determined when the two sequences being compared are optimally aligned.

Other programs for determining identity and/or similarity between sequences are 30 also known in the art, for instance the BLAST family of programs (Altschul S F et al, J Mol Biol, 215, 403-410, 1990, Altschul S F et al, Nucleic Acids Res., 25:389-3402, 1997, available from the National Center for Biotechnology Information (NCBI), Bethesda, Maryland, USA and accessible through the home page of the NCBI at www.ncbi.nlm.nih.gov) and FASTA (Pearson W R, Methods in Enzymology, 183, 63-99, 1990; Pearson W R and Lipman D J, Proc Nat Acad Sci USA, 85, 2444-2448, 1988, available as part of the Wisconsin Sequence Analysis Package).

Preferably, the BLOSUM62 amino acid substitution matrix (Henikoff S and Henikoff J G, Proc. Nat. Acad Sci. USA, 89, 10915-10919, 1992) is used in polypeptide sequence comparisons including where nucleotide sequences are first translated into amino acid sequences before comparison.

5 Preferably, the program BESTFIT is used to determine the % identity of a query polynucleotide or a polypeptide sequence with respect to a reference polynucleotide or a polypeptide sequence, the query and the reference sequence being optimally aligned and the parameters of the program set at the default value, as hereinbefore described.

"Identity Index" is a measure of sequence relatedness which may be used to  
10 compare a candidate sequence (polynucleotide or polypeptide) and a reference sequence. Thus, for instance, a candidate polynucleotide sequence having, for example, an Identity Index of 0.95 compared to a reference polynucleotide sequence is identical to the reference sequence except that the candidate polynucleotide sequence may include on average up to five differences per each 100 nucleotides of the reference sequence. Such differences are  
15 selected from the group consisting of at least one nucleotide deletion, substitution, including transition and transversion, or insertion. These differences may occur at the 5' or 3' terminal positions of the reference polynucleotide sequence or anywhere between these terminal positions, interspersed either individually among the nucleotides in the reference sequence or in one or more contiguous groups within the reference sequence. In other words, to  
20 obtain a polynucleotide sequence having an Identity Index of 0.95 compared to a reference polynucleotide sequence, an average of up to 5 in every 100 of the nucleotides of the in the reference sequence may be deleted, substituted or inserted, or any combination thereof, as hereinbefore described. The same applies *mutatis mutandis* for other values of the Identity Index, for instance 0.96, 0.97, 0.98 and 0.99.

25 Similarly, for a polypeptide, a candidate polypeptide sequence having, for example, an Identity Index of 0.95 compared to a reference polypeptide sequence is identical to the reference sequence except that the polypeptide sequence may include an average of up to five differences per each 100 amino acids of the reference sequence. Such differences are selected from the group consisting of at least one amino acid deletion, substitution,  
30 including conservative and non-conservative substitution, or insertion. These differences may occur at the amino- or carboxy-terminal positions of the reference polypeptide sequence or anywhere between these terminal positions, interspersed either individually among the amino acids in the reference sequence or in one or more contiguous groups within the reference sequence. In other words, to obtain a polypeptide sequence having an  
35 Identity Index of 0.95 compared to a reference polypeptide sequence, an average of up to 5

in every 100 of the amino acids in the reference sequence may be deleted, substituted or inserted, or any combination thereof, as hereinbefore described. The same applies *mutatis mutandis* for other values of the Identity Index, for instance 0.96, 0.97, 0.98 and 0.99.

5 The relationship between the number of nucleotide or amino acid differences and the Identity Index may be expressed in the following equation:

$$n_a \leq x_a - (x_a \cdot I),$$

in which:

$n_a$  is the number of nucleotide or amino acid differences,

$x_a$  is the total number of nucleotides or amino acids in a sequence set forth in the

10 Sequence Listing,

$I$  is the Identity Index,

• is the symbol for the multiplication operator, and

in which any non-integer product of  $x_a$  and  $I$  is rounded down to the nearest integer prior to subtracting it from  $x_a$ .

15 "Homolog" is a generic term used in the art to indicate a polynucleotide or polypeptide sequence possessing a high degree of sequence relatedness to a reference sequence. Such relatedness may be quantified by determining the degree of identity and/or similarity between the two sequences as hereinbefore defined. Falling within this generic term are the terms "ortholog", and "paralog". "Ortholog" refers to a polynucleotide or 20 polypeptide that is the functional equivalent of the polynucleotide or polypeptide in another species. "Paralog" refers to a polynucleotide or polypeptide that within the same species which is functionally similar.

25 "Fusion protein" refers to a protein encoded by two, often unrelated, fused genes or fragments thereof. In one example, EP-A-0 464 533-A discloses fusion proteins comprising various portions of constant region of immunoglobulin molecules together with another human protein or part thereof. In many cases, employing an immunoglobulin Fc region as a part of a fusion protein is advantageous for use in therapy and diagnosis resulting in, for example, improved pharmacokinetic properties [see, e.g., EP-A 0232 262]. On the other hand, for some uses it would be desirable to be able to delete the Fc part after the fusion 30 protein has been expressed, detected and purified.

All publications and references, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference in their entirety as if each individual publication or reference were specifically and individually indicated to be incorporated by reference herein as being fully set forth. Any patent application to which

this application claims priority is also incorporated by reference herein in its entirety in the manner described above for publications and references.

Table L

Gene Name	GSK Gene ID	Nucleic Acid SEQ ID NO's	Corresponding Protein SEQ ID NO's
sbg960509cbrecpt	960509	SEQ ID NO:1	SEQ ID NO:45
sbg614126complfH	614126	SEQ ID NO:2 SEQ ID NO:3	SEQ ID NO:46 SEQ ID NO:47
sbg120703RNase	120703	SEQ ID NO:4	SEQ ID NO:48
sbg98530TS	98530	SEQ ID NO:5 SEQ ID NO:6	SEQ ID NO:49 SEQ ID NO:50
sbg563917RDP	63917	SEQ ID NO:7 SEQ ID NO:8	SEQ ID NO:51 SEQ ID NO:52
sbg618069LRR	618069	SEQ ID NO:9 SEQ ID NO:10	SEQ ID NO:53 SEQ ID NO:54
sbg934114Relaxin	934114	SEQ ID NO:11	SEQ ID NO:55
sbg99174LOX-like	99174	SEQ ID NO:12	SEQ ID NO:56
sbg995002PIGR	995002	SEQ ID NO:13	SEQ ID NO:57
sbg1033026C1q	1033026	SEQ ID NO:14 SEQ ID NO:15	SEQ ID NO:58 SEQ ID NO:59
sbg1003675RNase	1003675	SEQ ID NO:16	SEQ ID NO:60
sbg1015258PLM	1015258	SEQ ID NO:17	SEQ ID NO:61
sbg1003328IG	1003328	SEQ ID NO:18 SEQ ID NO:19	SEQ ID NO:62 SEQ ID NO:63
sbg1020829SGLT	1020829	SEQ ID NO:20	SEQ ID NO:64
sbg1005450UDPGT	1005450	SEQ ID NO:21 SEQ ID NO:22	SEQ ID NO:65 SEQ ID NO:66
sbg1002620T1a	1002620	SEQ ID NO:23 SEQ ID NO:24	SEQ ID NO:67 SEQ ID NO:68
sbg1002620T1b	1002620	SEQ ID NO:25	SEQ ID NO:69
sbg102200MCTa	102200	SEQ ID NO:26 SEQ ID NO:27	SEQ ID NO:70 SEQ ID NO:71
sbg102200MCTb	102200	SEQ ID NO:28	SEQ ID NO:72
sbg1020380LYG	1020380	SEQ ID NO:29 SEQ ID NO:30	SEQ ID NO:73 SEQ ID NO:74
sbg1007026SGLT	1007026	SEQ ID NO:31	SEQ ID NO:75
sbg1012732GLUT	1012732	SEQ ID NO:32 SEQ ID NO:33	SEQ ID NO:76 SEQ ID NO:77
sbg1012732GLUTb	1012732	SEQ ID NO:34	SEQ ID NO:78
sbg1018172CSP	1018172	SEQ ID NO:35 SEQ ID NO:36	SEQ ID NO:79 SEQ ID NO:80
sbg1004570ERGIC	1004570	SEQ ID NO:37 SEQ ID NO:38	SEQ ID NO:81 SEQ ID NO:82
sbg1016995IGBrecpt	1016995	SEQ ID NO:39 SEQ ID NO:40	SEQ ID NO:83 SEQ ID NO:84
sbg1151bSREC	1151	SEQ ID NO:41 SEQ ID NO:42	SEQ ID NO:85 SEQ ID NO:86
sbg1399854ANK	1399854	SEQ ID NO:43 SEQ ID NO:44	SEQ ID NO:87 SEQ ID NO:88

Table II

Gene Name	Gene Family	Closest Polynucleotide by homology	Closest Polypeptide by homology	Cell Localization (by homology)
sbg960509 cbrecept	Carbohydrate-binding receptor	GB:AC007395 Direct submitted (25-APR-1999) Genome Sequencing Center, Washington University School of Medicine, 4444 Forest Park Parkway, St. Louis, MO 63108, USA	Mouse Kupffer cell c-type lectin receptor, gi: 7949066 Submitted (25-OCT-1996) to the DDBJ/EMBL/GenBank databases.	Membrane-bound
sbg614126 complfH	Complement factor H	SC:AL353809 Submitted (20-JAN-2001) by Sanger Centre, Hinxton, Cambridgeshire, CB10 1SA, UK.	Human H-factor like 1, gi:11321587 Estaller,C., Koistinen,V., Schwaebel,W., Dierich,M.P., and Weiss,E.H. J. Immunol. 146, 3190-3196 (1991)	Secreted
sbg120703 RNase	RNase	GB:AL157687 Direct Submitted (24-MAY-2000) to the EMBL/GenBank/DDBJ databases by Genoscope.	Human keratinocyte-derived RNase-like protein, geneseqp: Y44192 Submitted by INNOGENETICS NV Application number and publication date: EP-943679-A1, 22-SEP-99	Secreted
sbg98530T S	Thrombospordin type I	GB:AC027307 Submitted (30-MAR-2000) Production Sequencing Facility, DOE Joint Genome Institute, 2800 Mitchell Drive, Walnut Creek, CA 94598, USA	Mouse RIKEN cDNA 2010109H09 gene, gi:13385092 The RIKEN Genome Exploration Research Group Phase II Team and FANTOM Consortium. Nature 409, 685-690 (2001)	Secreted
sbg563917 RDP	Renal dipeptidase	GB:AC009077 Directly submitted (03-AUG-1999) by Production Sequencing Facility, DOE Joint Genome Institute, 2800 Mitchell Drive, Walnut Creek, CA 94598, USA	Human putative metallopeptidase (family M19) gi:11641273 Chen,J.M., Fortunato,M. and Barrett, A.J. Submitted (02-NOV-2000) Chen J.M., MRC Molecular Enzymology Laboratory, The Babraham Institute, Babraham, Cambridge, CB2 4AT, UK	Secreted

Table II (cont.).

Gene Name	Gene Family	Closest Polynucleotide by homology	Closest Polypeptide by homology	Cell Localization (by homology)
sbg618069	Leucine-rich repeat	GB:AL589765 Submitted (16-MAR-2001) by Sanger Centre, Hinxton, Cambridgeshire, CB10 1SA, UK.	Macaca fascicularis brain protein, gi: 9651088 Submitted (28-JUL-2000) to the DDBJ/EMBL/GenBank databases. Katsuyuki Hashimoto, National Institute of Infectious Diseases, Division of Genetic Resources; 23-1, Toyama 1-chome, Shinjuku-ku, Tokyo 162-8640, Japan	Membrane-bound
sbg934114	Insulin	JGI:CIT978SKB_5506 Found at Joint Genome Institute DoE/LLNL/LBNL/LANL.	Mouse insulin-like peptide (relaxin/insulin-like protein), gi:7387805 Conklin D, Lofton-Day CE, Haldeman BA, Ching A, Whitmore TE, Lok S, Jaspers S. 1999. Genomics 60:50-56.	Secreted
sbg99174L	C-type lectin	GB:AL137062 Direct submitted (09-AUG-2000) Sanger Centre, Hinxton, Cambridgeshire, CB10 1SA, UK.	Mouse putative protein, gi: 12855891 The RIKEN Genome Exploration Research Group Phase II Team and FANTOM Consortium. Nature 409, 685-690 (2001)	Membrane-bound
sbg995002	Polymeric immunoglobulin receptor (PIGR)	GB:AC027192 Direct submitted (28-MAR-2000) Whitehead Institute/MIT Center for Genome Research, 320 Charles Street, Cambridge, MA 02141, USA.	Human TANGO 354 protein, geneseqp: B66271 Submitted by (MILL-) MILLENNIUM PHARM INC Application number and publication date: WO200100673-A1, 04-JAN-01	Membrane-bound
sbg103302	C1q	GB:AL359736 Direct submitted (22-AUG-2000) Sanger Centre, Hinxton, Cambridgeshire, CB10 1SA, UK.	Human adipocyte-specific secretory protein, gi: 4757760 Maeda,K., Okubo,K., Shimomura,I., Funahashi,T., Matsuzawa,Y. and Matsubara,K. Biochem. Biophys. Res. Commun. 221 (2), 286-289 (1996)	Secreted

Table II (cont.).

Gene Name	Gene Family	Closest Polynucleotide by homology	Closest Polypeptide by homology	Cell Localization (by homology)
sbg100367 5RNase	RNase	EMBL:CNS01RIH Found at European Molecular Biology Laboratory.	Chinchilla brevicaudata pancreatic ribonuclease, gi:133205 Van Den Berg A, Van Den Hende-Timmer L, Beintema JJ. 1976. Biochim Biophys Acta 453:400-9.	Secreted
sbg101525 8PLM	Phospholemmann (PLM)	GB:AL022345 Direct submitted (10-DEC-1999) by Sanger Centre, Hinxton, Cambridgeshire, CB10 1SA, UK.	Human phospholemmann-like protein, geneseqp:W51104 Submitted by (HUMA-) HUMAN GENOME SCI INC Application number and publication date: WO9839448-A2, 11-SEP-98	Membrane-bound
sbg100332 8IG	Immunoglobulin	EMBL:HSBA536C5 Found at European Molecular Biology Laboratory.	Human immune system molecule, geneseqp:B15536 Submitted by (INCY-) INCYTE PHARM INC Application number and publication date: WO200060080-A2, 12-OCT-00	Membrane-bound
sbg102082 9SGLT	Na+/glucose cotransporter	GB:AJ009617 Directly submitted (17-JUL-1998) by MPIMG, Abt Lehrach, Max Planck Institut fuer Molekulare Genetik, Ihnestrasse 73, Berlin, 14195, Germany.	Oryctolagus cuniculus Na/glucose cotransporters, gi:520469 Pajor,A.M. 1994 Biochim. Biophys. Acta 1194 (2), 349-51.	Membrane-bound
sbg100545 0UDPGT	UDP-glucuronosyltransferase(UDPGT)	GB:AC016612 Submitted (04-DEC-1999) Production Sequencing Facility, DOE Joint Genome Institute, 2800 Mitchell Drive, Walnut Creek, CA 94598, USA	Human PRO1780 protein , geneseqp: B24025 Submitted by GENENTECH INC Application number and publication date: WO200053750-A1, 14-SEP-00	Membrane-bound
sbg100262 0T1a	Cysteine-rich secretory protein (CRISP) trypsin inhibitor	GB:AC025280 Submitted (08-MAR-2000) by Production Sequencing Facility, DOE Joint Genome Institute, 2800 Mitchell Drive, Walnut Creek, CA 94598, USA	Human hypothetical protein DKFZp434B044, gi: 13899332 Wiemann,S., Weil,B. et al. Genome Res. 11 (3), 422-435 (2001)	Secreted

Table II (cont.).

Gene Name	Gene Family	Closest Polynucleotide by homology	Closest Polypeptide by homology	Cell Localization (by homology)
sbg100262-0T1b	Cysteine-rich secretory protein (CRISP) trypsin inhibitor	GB:AC025280 Submitted (08-MAR-2000) by Production Sequencing Facility, DOE Joint Genome Institute, 2800 Mitchell Drive, Walnut Creek, CA 94598, USA	Rat late gestation lung protein 1 , gi:4324682 Kaplan,F., Ledoux,P., Kassamali,F.Q., Gagnon,S., Post,M., Koehler,D., Deimling,J. and Sweezey,N.B. Am. J. Physiol. 276 (6), L1027-L1036 (1999)	Secreted
sbg102200-MCTa	Monocarb oxylate cotransporter (MCT1)	GB: AC015918 Directly submitted (17-NOV-1999) by Whitehead Institute/MIT Center for Genome Research, 320 Charles Street, Cambridge, MA 02141, USA.	Mouse unnamed protein product, gi:7670446 Submitted (12-APR-2000) to the DDBJ/EMBL/GenBank databases by Katsuyuki Hashimoto, National Institute of Infectious Diseases, Division of Genetic Resources; 23-1, Toyama 1-chome, Shinjuku-ku, Tokyo 162-8640, Japan	Membrane-bound
sbg102200-MCTb	Monocarb oxylate cotransporter (MCT1)	GB: AC015918 Directly submitted (17-NOV-1999) by Whitehead Institute/MIT Center for Genome Research, 320 Charles Street, Cambridge, MA 02141, USA.	Human solute carrier 16 (monocarboxylic acid transporters), member 8, gi:13655082 Submitted (17-APR-2001) by National Center for Biotechnology Information, NIH, Bethesda, MD 20894, USA	Membrane-bound
sbg102038-OLYG	Goose-type lysozyme G	GB:AC023965 Directly submitted (20-FEB-2000) by Whitehead Institute/MIT Center for Genome Research, 320 Charles Street, Cambridge, MA 02141, USA	Lysozyme G (1,4-beta-N-acetylmuramidas E) (Goose-type lysozyme). gi:126634 Schoentgen, F., Jolles,J. and Jolles, P. Eur. J. Biochem. 123 (3), 489-497 (1982)	Secreted
sbg100702-6SGLT	Sodium-glucose cotransporter	GB:AC046167 Direct submitted (13-APR-2000) Whitehead Institute/MIT Center for Genome Research, 320 Charles Street, Cambridge, MA 02141.	Human transport protein TPPT-13, geneseqp: B60093 Submitted by INCYTE GENOMICS INC Application number and publication date: WO200078953-A2, 28-DEC-00	Membrane-bound

Table II (cont.).

Gene Name	Gene Family	Closest Polynucleotide by homology	Closest Polypeptide by homology	Cell Localization (by homology)
sbg101273 2GLUT	Glucose transporter	GB:AP000350 Direct submitted (10-JUN-1999) to the DDBJ/EMBL/GenBank databases. Nobuyoshi Shimizu, Keio university, school of medicine, Molecular Biology; 35 Shinanomachi, Shinjuku-ku, Tokyo 160-0016, Japan.	Human glucose transporter GLUT10, gi:13540598 Submitted (10-FEB-2000) Joost H.G., Institute of Pharmacology and Toxicology, Medical Faculty, Technical University of Aachen, Wendlingweg 2, Aachen, D-52057, GERMANY	Membrane-bound
sbg101273 2GLUTb	Glucose transporter	GB:AP000350 Direct submitted (10-JUN-1999) to the DDBJ/EMBL/GenBank databases. Nobuyoshi Shimizu, Keio university, school of medicine, Molecular Biology; 35 Shinanomachi, Shinjuku-ku, Tokyo 160-0016, Japan.	Human glucose transporter GLUT10, gi:13540598 Submitted (10-FEB-2000) Joost H.G., Institute of Pharmacology and Toxicology, Medical Faculty, Technical University of Aachen, Wendlingweg 2, Aachen, D-52057, GERMANY	Membrane-bound
sbg101817 2CSP	Chondroitin sulfate proteoglycan	EMBL:AL354819, and SC:AL590007. Submitted (30-APR-2001 and 04-MAY-2001) by Sanger Centre, Hinxton, Cambridgeshire, CB10 1SA, UK. EMBL:AC017111, Submitted (09-DEC-1999) Genome Sequencing Center, Washington University School of Medicine, 4444 Forest Park Parkway, St. Louis, MO 63108, USA	Lytechinus variegatus embryonic blastocoelar extracellular matrix protein , gi:9837426 Submitted (14-JUL-2000) Biological Sciences, Carnegie Mellon University, 4400 Fifth Ave, Pittsburgh, PA 15213, USA	Secreted
sbg100457 0ERGIC	ER-Golgi intermediate compartment protein	GB:AC020705 Submitted (08-JAN-2000) Genome Sequencing Center, Washington University School of Medicine, 4444 Forest Park Parkway, St. Louis, MO 63108, USA	Human ERGL protein, gi:11141891 Submitted (06-SEP-2000) Laboratory of Molecular Biology, NCI, NIH, 37 Convent Dr., Bldg. 37, Rm. 4B20, Bethesda, MD 20892, USA	Membrane-bound

Table II (cont.)

Gene Name	Gene Family	Closest Polynucleotide by homology	Closest Polypeptide by homology	Cell Localization (by homology)
sbg101699 SIGBrect	Immunoglobulin receptor	GB:AL353721 Submitted (07-JUL-2001) Sanger Centre, Hinxton, Cambridgeshire, CB10 1SA, UK.	Human immunoglobulin superfamily receptor translocation associated 1, gi:14550416 Hatzivassiliou,G., Miller,I.J., Takizawa,J., et al. <i>Immunity</i> 14 (3), 277-289 (2001)	Membrane-bound
sbg1151bS REC	EGF-like LDL receptor protein	GB:AC005500 Chen,F., D,L., Do,T., Dumanski,J.P. and Roe,B.A. Direct submission (31-MAY-01) Department Of Chemistry and Biochemistry, The University Of Oklahoma, 620 Parrington Oval, Room 208, Norman, OK 73019, USA	Human nurse cell receptor B6TNC#10b, geneseqp: B60395 Submitted by (SHIO ) SHIONOGI & CO LTD Application number and publication date: JP2000308492-A, 07-NOV-00	Membrane-bound
sbg139985 4ANK	The ankyrin repeat family	GB: AC020658 Direct submitted (08-JAN-2000) Multimegabase Sequencing Center, University of Washington, PO BOX 357730, Seattle, WA 98195, USA	Human KIAA1223 protein, gi:6330617 Nagase T, Ishikawa K, Kikuno R, Hirosawa M, Nomura N, and Ohara O; 1999 <i>DNA Res</i> 6:337-45.	Cytosolic

Table III

Gene Name	Uses	Associated Diseases
sbg960509 cbrecpt	<p>An embodiment of the invention is the use of sbg960509cbrecpt in the treatment or diagnosis of cancer. A close homologue of sbg960509cbrecpt is Langerin. Langerin was a type II Ca2+-dependent lectin, an endocytic receptor and expressed by Langerhans cells (LC). Transfection of Langerin cDNA into fibroblasts created a compact network of membrane structures with typical features of Birbeck granules(BG). It was proposed that induction of BG was a consequence of the antigen-capture function of Langerin, allowing routing into these organelles and providing access to a nonclassical antigen-processing pathway (Valladeau J, Ravel O, Dezutter-Dambuyant C, Moore K, Kleijmeer M, Liu Y, Duvert-Frances V, Vincent C, Schmitt D, Davoust J, Caux C, Lebecque S, Saeland S. 2000. <i>Immunity</i> Jan;12(1):71-81). A striking incongruity was found between variably spliced transcripts for the second asialoglycoprotein receptor polypeptide, H2, in normal and transformed human liver cells (Paietta E, Stockert RJ, Racevskis J. 1992. <i>Hepatology</i> Mar;15(3):395-402). Human macrophage cell surface C-type lectin was demonstrated to recognize Tn Ag, a well-known human carcinoma-associated epitope (Suzuki N, Yamamoto K, Toyoshima S, Osawa T, Irimura T. 1996. <i>J Immunol</i> Jan 1;156(1):128-35).</p>	Autoimmune disorder and cancer
sbg614126 complfH	<p>An embodiment of the invention is the use of sbg614126complfH in the diagnosis or treatment of cancer, Alzheimer disease, and/or tumor cell evasion. A close homologue of sbg614126complfH is Human complement factor H. Human complement factor H was detected by the AM34 antibody in the cerebrospinal fluid from an Alzheimer's disease patient. It was recently found that AM34 was capable of staining senile plaques positively and factor H was associated with senile plaques in the human brain (Honda S, Itoh F, Yoshimoto M, Ohno S, Hinoda Y, Imai K. 2000. <i>J Gerontol A Biol Sci Med Sci</i> May;55(5):M265-9). It was also suggested that exceptional resistance of human H2 glioblastoma cells to complement-mediated killing was due to the production and binding of factor H and factor H-like protein 1 (Junnikkala S, Jokiranta TS, Friese MA, Jarva H, Zipfel PF, Meri S. 2000. <i>J Immunol</i> Jun 1;164(11):6075-81). Moreover, factor H was shown to bind to bone sialoprotein and osteopontin and enable tumor cell evasion of complement-mediated attack (Fedarko NS, Fohr B, Robey PG, Young MF, Fisher LW. 2000. <i>J Biol Chem</i> Jun 2;275(22):16666-72). Finally, complement factor H gene mutation was associated with autosomal recessive atypical hemolytic uremic syndrome (Ying L, Katz Y, Schlesinger M, Carmi R, Shalev H, Haider N, Beck G, Sheffield VC, Landau D. 1999. <i>Am J Hum Genet</i> Dec;65(6):1538-46).</p>	Alzheimer's disease, cancer, tumor metastasis and autosomal recessive atypical hemolytic uremic syndrome

Table III (cont.).

Gene Name	Uses	Associated Diseases
sbg120703 RNase	An embodiment of the invention is the use of sbg120703RNase as a tool for anticancer therapy, and treating apoptosis-related disorders. It has been shown that a genetic-engineered pancreatic RNase has cytotoxic action on mouse and human tumor cells, but lacks any appreciable toxicity on human and mouse normal cells. This variant of human pancreatic RNase selectively sensitizes cells derived from a human thyroid tumor to apoptotic death. Because of its selectivity for tumor cells, and because of its human origin, this protein is thought to represent a promising tool for anticancer therapy (Piccoli R, Di Gaetano S, De Lorenzo C, Grauso M, Monaco C, Spalletti-Cernia D, Laccetti P, Cinatl J, Matousek J, D'Alessio G. 1999. Proc Natl Acad Sci U S A 96:7768-73). In addition, RNase itself can be used to treat an RNA viral infection, and its antagonist may be useful in treating apoptosis-related disorders.	Cancer and infection
sbg98530TS	An embodiment of the invention is the use of sbg98530TS in the wound healing processes, development of the nervous system, and affecting cell migration, survival, or angiogenesis. Close homologues of sbg98530TS are thrombospondins. The thrombospondins are a family of proteins found widely in the embryonic extracellular matrix, and the expression patterns and in vitro properties of many thrombospondins suggest potential roles in the guidance of cell and growth cone migration, especially during the development of the nervous system (Adams JC, 2000. Tucker RP Dev Dyn 218:280-99). Cell interactions with extracellular matrices are important to pathological changes that occur during cell transformation and tumorigenesis. The thrombospondin-1 has been suggested to modulate tumor phenotype by affecting cell migration, survival, or angiogenesis (Liaw L, Crawford HC. 1999. Braz J Med Biol Res 32:805-12). In addition, thrombospondin-1 is also a transient component of extracellular matrix in developing and repairing tissues (Adams JC. 1997. Int J Biochem Cell Biol 29:861-5).	Cancer, wound healing disorders
sbg563917RDP	An embodiment of the invention is the use of sbg563917RDP in treatment or diagnosis of chronic renal failure and aged eye lenses and cataracts. Close homologues of sbg563917RDP are renal and lens dipeptidases. It has been reported that the renal dipeptidase activity was significantly lower in the chronic renal failure group (Fukumura Y, Kera Y, Oshitani S, Ushijima Y, Kobayashi I, Liu Z, Watanabe T, Yamada R, Kikuchi H, Kawazu S and Yabuuchi M. 1999 Ann Clin Biochem Mar;36 ( Pt 2):221-5). In contrast, increased lens dipeptidase activity was detected in aging and cataracts (Sulochana KN, Ramakrishnan S and Punitham R. 1999 Br J Ophthalmol Jul;83(7):885).	Renal diseases, aging, cataract, cancer, and Alzheimer disease

Table III (cont.).

Gene Name	Uses	Associated Diseases
sbg618069 LRR	An embodiment of the invention is the use of sbg618069LRR in treatment or diagnosis of neural development and the adult nervous system disorders. Close homologues of sbg618069LRR are Leucine-rich repeat proteins. Leucine-rich repeat protein, the spineless-aristapedia, has been shown to interact with tango bHLH-PAS proteins for controlling antennal and tarsal development in <i>Drosophila</i> (Emmons RB, Duncan D, Estes PA, Kiefel P, Mosher JT, Sonnenfeld M, Ward MP, Duncan I and Crews ST. 1999. Development Sep;126(17):3937-45). In mouse, neuronal Leucine-Rich Repeat NLRR-1 and NLRR-2 mRNAs were expressed primarily in the central nervous system and may play significant but distinct roles in neural development and in the adult nervous system (Taguchi A, Wanaka A, Mori T, Matsumoto K, Imai Y, Tagaki T and Tohyama M. 1996. Brain Res Mol Brain Res Jan;35(1-2):31-40). Furthermore, a new member of the leucine-rich repeat superfamily GAC1 was amplified and overexpressed in malignant gliomas (Almeida A, Zhu XX, Vogt N, Tyagi R, Muleris M, Dutrillaux AM, Dutrillaux B, Ross D, Malfoy B and Hanash S. 1998. Oncogene Jun 11;16(23):2997-3002).	Tango-associated diseases, disorders associated with the preservation and maintenance of gastrointestinal mucosa and the repair of acute and chronic mucosal lesions, Parkinson's disease, Alzheimer's disease, ALS, neuropathies, cancer, wound healing and tissue repair
sbg934114 Relaxin	An embodiment of the invention is the use of sbg934114Relaxin in treatment or diagnosis of collagen remodeling, breast cancer, and uterine contractile disorders. A close homologue of sbg934114Relaxin is Relaxin. Relaxin has various biologic activities, including the induction of collagen remodeling and consequent softening of the tissues of the birth canal during delivery, the inhibition of uterine contractile activity, and the stimulation of growth and differentiation of the mammary gland (Bani D. 1997. Gen Pharmacol 28:13-22). Relaxin belongs to the insulin superfamily, and is produced primarily by the corpus luteum in both pregnant and nonpregnant females. In males, relaxin is synthesized in the prostate and released in the seminal fluid (Goldsmith LT, Weiss G, Steinert BG. 1995. Endocrinol Metab Clin North Am 24:171-86). It has been further demonstrated that relaxin regulates growth and differentiation of breast cancer cells in culture, promotes dilation of blood vessels in several organs, including the uterus, the mammary gland, the lung and the heart, has a chronotropic action on the heart, inhibits the release of histamine by mast cells, depresses aggregation of platelets and their release by megakaryocytes, and influences the secretion of hormones by the pituitary gland (Bani D. 1997. Gen Pharmacol 28:13-22). In addition, some reports have shown that relaxin is effective in decreasing skin involvement in systemic sclerosis (Furst DE. 1998. Curr Opin Rheumatol 10:123-8).	Cancer, rheumatic diseases, heart diseases, systemic sclerosis (scleroderma), and preterm birth

Table III (cont.).

Gene Name	Uses	Associated Diseases
sbg99174L OX-like	An embodiment of the invention is the use of sbg99174LOX-like in treatment or diagnosis of endothelial function or atherosclerosis. A close homologue of sbg99174LOX-like is oxidized low-density lipoprotein receptor 1. sbg99174LOX-like as well as oxidized low-density lipoprotein receptor 1, contain a C-type lectin domain (CTL) (Colonna M, Samaridis J, Angman L. 2000. <i>Eur J Immunol</i> 30:697-704). Evidence suggests that oxidized low-density lipoprotein (OxLDL) plays a critical role in the changes in endothelial function. Lectin-like OxLDL receptor-1 (LOX-1) is the major endothelial OxLDL receptor. Functional changes of endothelial cells are implicated in the earliest stage of the pathogenesis of atherosclerosis (Aoyama T, Sawamura T, Furutani Y, Matsuoka R, Yoshida MC, Fujiwara H, Masaki T. <i>Biochem J</i> . 1999;339 (Pt 1):177-84).	Cardiovascular disorders (e.g. atherosclerosis, hypertension, stroke),
sbg995002 PIGR	An embodiment of the invention is the use of sbg995002PIGR to actively transport IgA and IgM to the apical surface of epithelia. A close homologue of sbg995002PIGR is polymeric-immunoglobulin receptor. The polymeric-immunoglobulin receptor binds polymeric IgA and IgM at the basolateral surface of epithelial cells. PIGR knockout mice completely lack active external IgA and IgM translocation, but remain normal and fertile (Johansen FE, Pekna M, Norderhaug IN, Haneberg B, Hietala MA, Krajci P, Betsholtz C, Brandtzæg P. 1999. <i>J Exp Med</i> 190:915-22). In addition, it has been reported that PIGR can be upregulated by tumor necrosis factor (TNF)-alpha (Takenouchi-Ohkubo N, Takahashi T, Tsuchiya M, Mestecky J, Moldoveanu Z, Moro I; 2000. <i>Immunogenetics</i> 51:289-95).	Infection and inflammation such as inflammatory bowel disease, gluten-sensitive enteropathy, and urinary tract infection)
sbg103302 6C1q	An embodiment of the invention is the use of sbg1033026C1q to regulate central nervous system functions. A close homologue of sbg1033026C1q is C1q-related factor. C1q is a subunit of the C1 enzyme complex that activates the serum complement system. It has been shown that human C1q-related factor (CRF) transcript is expressed at highest levels in the brain, particularly in the brainstem. Similarly, in mouse brain CRF transcripts are most abundant in areas of the nervous system involved in motor function (Berube NG, Swanson XH, Bertram MJ, Kittle JD, Didenko V, Baskin DS, Smith JR, and Pereira-Smith OM., 1999, <i>Brain Res. Mol. Brain Res.</i> 63:233-240). Moreover, ACRP30 is structurally similar to complement factor C1q, and it forms large homooligomers that undergo a series of post-translational modifications. ACRP30 proteins may be a factor that participates in the complex balanced system of energy homeostasis involving food intake, carbohydrate catabolism, and lipid catabolism (Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF; 1995; <i>J Biol Chem</i> 270:26746-9).	Central nervous system disorder
sbg100367 5RNase	An embodiment of the invention is the use of sbg1003675RNase as a promising tool for anticancer therapy, and apoptosis-related disorders. A close homologue of sbg1003675RNase is RNase. It has been shown that a genetic-engineered pancreatic RNase has cytotoxic action on mouse and human tumor cells, but lacks any appreciable	Viral infection, and tumor

	<p>toxicity on human and mouse normal cells. This variant of human pancreatic RNase selectively sensitized cells derived from a human thyroid tumor to apoptotic death. Because of its selectivity for tumor cells, and because of its human origin, this protein was thought to represent a promising tool for anticancer therapy (Piccoli R, Di Gaetano S, De Lorenzo C, Grauso M, Monaco C, Spalletti-Cernia D, Laccetti P, Cinatl J, Matousek J, D'Alessio G. 1999. Proc Natl Acad Sci U S A 96:7768-73). Moreover, RNase itself can be used to treat an RNA viral infection, and its antagonist of this RNase may be useful in treating apoptosis-related disorders.</p>	
sbg101525 8PLM	<p>An embodiment of the invention is the use of sbg101525PLM to regulate skeletal and cardiac muscle disorders. A close homologue of sbg101525PLM is phospholemmann. The phospholemmann (PLM) is enriched in skeletal muscle and the heart, and is a major substrate phosphorylated in response to insulin and adrenergic stimulation. All phospholemmann proteins are small and have a single transmembrane domain (Chen LS, Lo CF, Numann R, Cuddy M. 1997. Genomics 41:435-4). Phospholemmann can be phosphorylated by protein kinases A and C to induce a hyperpolarization-activated chloride current, and therefore may play a role in muscle contraction. Recently phospholemmann was shown to be a substrate for myotonic dystrophy protein kinase, and therefore is associated with the disease, an autosomal dominant-inherited disorder with prominent effects on skeletal and cardiac muscle (Mounsey JP, John JE 3rd, Helmke SM, Bush EW, Gilbert J, Roses AD, Perryman MB, Jones LR, Moorman JR. 2000. J Biol Chem ;275:23362-7).</p>	Myotonic muscular dystrophy
sbg100332 8IG	<p>An embodiment of the invention is the use of sbg1003328IG to generate immunosuppressants to suppress immune responses. A close homologue of sbg1003328IG is V7, a human leukocyte surface protein (Stockinger H, Gadd SJ, Eher R, Majdic O, Schreiber W, Kasirerk W, Strass B, Schnabl E, Knapp W. 1990. J Immunol 145:3889-97). sbg1003328IG is an immunoglobulin (Ig)-like membrane protein containing three potential Ig domains, and it has an overall strong sequence similarity to V7.</p>	Cancer, infection, autoimmune disorder, hematopoietic disorder, wound healing disorders, and inflammation
sbg102082 9SGLT	<p>An embodiment of the invention is the use of sbg1020829SGLT to regulate Na(+) -dependent glucose transport. A close homologue of sbg1020829SGLT is Na+/glucose cotransporters. The human intestinal Na+/glucose cotransporter (SGLT1) was cloned and sequenced. Close homology was observed between the human and rabbit intestinal Na+/glucose cotransporters, and a significant homology was found between these and the <i>Escherichia coli</i> Na+/proline cotransporter (putP) indicating that the mammalian Na+/glucose and prokaryote Na+/proline cotransporters sharing a common ancestral gene (Hediger MA, Turk E, Wright EM. 1989 Proc Natl Acad Sci U S A Aug;86(15):5748-52). In addition, study of intestinal biopsies of glucose/galactose malabsorption (GCM) patients has revealed a specific defect in Na(+) -dependent absorption of glucose in the brush border. A single missense mutation was found in SGLT1 amplified from the genomic DNA derived from members of a family affected with GGM. This mutated SGLT1 cosegregated with the GGM</p>	Cancer, infection, autoimmune disorder, hematopoietic disorder, wound healing disorders, inflammation and glucose/galactose malabsorption

	phenotype and resulted in a complete loss of Na(+) -dependent glucose transport in <i>Xenopus</i> oocytes injected with this complementary RNA (Turk E, Zabel B, Mundlos S, Dyer J, Wright EM. 1991 <i>Nature</i> Mar 28;350(6316):354-6).	
sbg100545 0UDPGT	An embodiment of the invention is the use of sbg100545UDPGT to regulate estrogen and androgen catabolism in peripheral steroid target tissues. A close homologue of sbg100545UDPGT is UDP-glucuronosyltransferase (UDPGT) gene. Mutations had been found in the promoter and coding regions of UDP-glucuronosyltransferase (UDPGT) gene in seven patients with Crigler-Najjar syndrome type II caused by reduction in hepatic bilirubin UDPGT activity (Yamamoto K, Soeda Y, Kamisako T, Hosaka H, Fukano M, Sato H, Fujiyama Y, Adachi Y, Satoh Y, Bamba T. 1998. <i>J Hum Genet</i> 43(2):111-4). A case of Gilbert syndrome caused by a homozygous missense mutation of the bilirubin UDPGT gene was also reported (Maruo Y, Sato H, Yamano T, Doida Y, Shimada M. 1998. <i>J Pediatr</i> Jun;132(6):1045-7). In addition, monkey UDPGT UGT1A9 had been cloned and the mRNA was expressed in extrahepatic estrogen-responsive tissues indicating its potential role in estrogen metabolism (Albert C, Vallee M, Beaudry G, Belanger A, Hum DW. 1999. <i>Endocrinology</i> Jul;140(7):3292-302). Human UDPGT UGT2B23 transcript was also expressed in extrahepatic tissues including prostate, mammary gland, epididymis, testis, and ovary. The activity of UGT2B23 was tested with 62 potential endogenous substrates and was demonstrated to be active on 6 steroids and the bile acid, hyodeoxycholic acid suggesting that UGT2B23 might play an important role in estrogen and androgen catabolism in peripheral steroid target tissues (Barbier O, Levesque E, Belanger A, Hum DW. 1999. <i>Endocrinology</i> Dec;140(12):5538-48).	Cancer, infection, autoimmune disorder, hematopoietic disorder, wound healing disorders, inflammation Gilbert syndrome, Crigler-Najjar syndrome (CN) type II, and steroid hormone catabolism malfunction
sbg100262 0T1a	An embodiment of the invention is the use of sbg1002620T1a to regulate human tumor cells. A close homologue of sbg1002620T1a is human hypothetical protein DKFZp434B044. This gene is also similar to trypsin inhibitor which contains Sc7 family of extracellular domains at its N-terminal region (Genome Res. 11 (3), 422-435 (2001)). Trypsin inhibitor P25TI sequence had similarity to CRISP family proteins including insect venom allergens, mammalian testis-specific proteins and plant pathogenesis-related proteins. mRNA encoding P25TI and another two glioma pathogenesis-related protein GliPR and RTVP-1, which were also shown to be structurally similar to CRISP family proteins was frequently expressed in human tumor tissues but not detected in normal human tissue cell lines (Yamakawa T, Miyata S, Ogawa N, Koshikawa N, Yasumitsu H, Kanamori T, Miyazaki K. 1998. <i>Biochim Biophys Acta</i> Jan 21; 1395(2):202-8., Murphy EV, Zhang Y, Zhu W, Biggs J. 1995. <i>Gene</i> Jun 14;159(1):131-5., Rich T, Chen P, Furman F, Huynh N, Israel MA.1996. <i>Gene</i> Nov 21;180(1-2):125-30).	Cancer, infection, autoimmune disorder, hematopoietic disorder, wound healing disorders, inflammation, blood coagulation disorders, cellular adhesion disorders, pancreatitis, shock, multi-organ failure, and gastrointestinal ulceration
sbg100262 0T1b	An embodiment of the invention is the use of sbg1002620T1b as a marker for some nervous system tumors, and to regulate expression of human neuroblastoma and glioblastoma. A close homologue of sbg1002620T1b is late-gestation lung 1 (LGL1) protein. Late-gestation lung 1 (LGL1) protein showed 81% homology to P25TI, the trypsin	Cancer, infection, autoimmune disorder, hematopoietic disorder, wound healing disorders,

	<p>inhibitor purified from the culture medium of human glioblastoma cells (Kaplan F, Ledoux P, Kassamali FQ, Gagnon S, Post M, Koehler D, Deimling J, Sweezey NB. 1999. Am J Physiol Jun;276(6 Pt 1):L1027-36; Koshikawa N, Nakamura T, Tsuchiya N, Isaji M, Yasumitsu H, Umeda M, Miyazaki K. 1996. J Biochem (Tokyo) Feb;119(2):334-9). The cDNA encoding P25TI was isolated and the sequence had similarity to CRISP family proteins including insect venom allergens, mammalian testis-specific proteins and plant pathogenesis-related proteins. P25TI mRNA was frequently expressed in human neuroblastoma and glioblastoma but not detected in normal human tissues cell lines (Yamakawa T, Miyata S, Ogawa N, Koshikawa N, Yasumitsu H, Kanamori T, Miyazaki K. 1998. Biochim Biophys Acta Jan 21; 1395(2):202-8). Another two glioma pathogenesis-related protein GliPR and RTVP-1 were also shown to be structurally similar to CRISP family proteins. The GLIPR gene was highly expressed in the human brain tumor, glioblastoma multiforme/astrocytoma, but neither in normal fetal or adult brain tissue, nor in other nervous system tumors (Murphy EV, Zhang Y, Zhu W, Biggs J. 1995. Gene Jun 14;159(1):131-5). Multiple RTVP-1 mRNA species were highly expressed in a panel of cell lines from nervous system tumors arising from glia, in contrast, the expression of these RNAs was low or absent in nonglial-derived nervous system tumor cell lines (Rich T, Chen P, Furman F, Huynh N, Israel MA. 1996. Gene Nov 21;180(1-2):125-30).</p>	<p>inflammation, blood coagulation disorders, cellular adhesion disorders, pancreatitis, shock, multi-organ failure, and gastrointestinal ulceration</p>
sbg102200 MCTa	<p>An embodiment of the invention is the use of sbg102200MCTa in regulating cancer cells, including the hematopoietic lineages, Burkitt's lymphoma, and solid tumor cells. A close homologue of sbg102200MCTa is MCT1 from Chinese hamster and mouse. Mouse H+-monocarboxylate cotransporter (MCT1) was cloned and sequenced from Ehrlich Lettre tumour cells, the sequence of MCT1 is 93% and 87% homologous to MCT1 from Chinese hamster and human, respectively. N-glycanase-F treatment and an in vitro translation experiments demonstrated that glycosylation was not required for MCT1 function (Carpenter L, Poole RC, Halestrap AP. 1996. Biochim Biophys Acta Mar 13;1279(2):157-63). Chick monocarboxylate transporter MCT3 cloned from retinal pigment epithelium (RPE) cDNA library was found only expressed in RPE cells. A rat thyroid epithelial cell line FRTL transfected with pCl-neo/MCT3 showed enhanced pyruvate uptake suggesting that MCT3 may regulate lactate levels in the interphotoreceptor space (Yoon H, Fanelli A, Grollman EF, Philip NJ. 1997. Biochem Biophys Res Commun May 8;234(1):90-4). In human, MCT2 had been implicated as a primary pyruvate transporter in man. The mRNAs of MCT1 and MCT2 were found co-expressed in various human cancer cell lines, including the hematopoietic lineages HL60, K562, MOLT-4, Burkitt's lymphoma Raji, and solid tumor cells such as SW480, A549, and G361. These findings suggested that human MCT1 and MCT2 may have distinct biological roles (Lin RY, Vera JC, Chaganti RS, Golde DW. 1998. J Biol Chem Oct 30;273(44):28959-65).</p>	<p>Cancer, infection, autoimmune disorder, hematopoietic disorder, wound healing disorders, and inflammation</p>
sbg102200 MCTb	<p>An embodiment of the invention is the use of sbg102200MCTb in regulating cancer cells, including the hematopoietic lineages, Burkitt's lymphoma, and solid tumor</p>	<p>Cancer, infection, autoimmune disorder,</p>

	<p>cells. A close homologue of sbg102200MCTb is MCT1 from Chinese hamster and mouse. Mouse H+-monocarboxylate cotransporter (MCT1) was cloned and sequenced from Ehrlich Lettre tumour cells, the sequence of MCT1 is 93% and 87% homologous to MCT1 from Chinese hamster and human, respectively. N-glycanase-F treatment and an in vitro translation experiments demonstrated that glycosylation was not required for MCT1 function (Carpenter L, Poole RC, Halestrap AP. 1996. <i>Biochim Biophys Acta</i> Mar 13;1279(2):157-63). Chick monocarboxylate transporter MCT3 cloned from retinal pigment epithelium (RPE) cDNA library was found only expressed in RPE cells. A rat thyroid epithelial cell line FRTL transfected with pCl-neo/MCT3 showed enhanced pyruvate uptake suggesting that MCT3 may regulate lactate levels in the interphotoreceptor space (Yoon H, Fanelli A, Grollman EF, Philp NJ. 1997. <i>Biochem Biophys Res Commun</i> May 8;234(1):90-4). In human, MCT2 had been implicated as a primary pyruvate transporter in man. The mRNAs of MCT1 and MCT2 were found co-expressed in various human cancer cell lines, including the hematopoietic lineages HL60, K562, MOLT-4, Burkitt's lymphoma Raji, and solid tumor cells such as SW480, A549, and G361. These findings suggested that human MCT1 and MCT2 may have distinct biological roles (Lin RY, Vera JC, Chaganti RS, Golde DW. 1998. <i>J Biol Chem</i> Oct 30;273(44):28959-65).</p>	hematopoietic disorder, wound healing disorders, and inflammation
sbg102038 OLYG	<p>An embodiment of the invention is the use of sbg102038OLYG in the immune system and enhance the activity of immunoagents and may serve as biomarkers of periodontal disease activity. Close homologues of sbg102038OLYG are lysozymes. Lysozymes are bacteriolytic defensive agents and have been adapted to serve a digestive function (Qasba PK, Kumar S, 1997, <i>Crit Rev Biochem Mol Biol</i> 32:255-306). Those in tissue and body fluids are involved in the immune system and enhance the activity of immunoagents. Lysozymes may serve as biomarkers of periodontal disease activity from inflammatory cell origin (Eley BM, and Cox SW, 1998, <i>Br Dent J</i> 184:323-8).</p>	Cancer, infection, autoimmune disorder, hematopoietic disorder, wound healing disorders, and inflammation
sbg100702 6SGLT	<p>An embodiment of the invention is the use of sbg1007026SGLT, a human sodium-glucose cotransporter, in regulation of Glucose/galactose malabsorption (GGM), familial renal glycosuria, and diabetic renal disorders. Close homologues of sbg1007026SGLT are other sodium-glucose cotransporters from humans and rabbits. Human sodium-glucose cotransporters are responsible for the active accumulation of glucose in cells (Hediger MA, Turk E, Wright EM. 1989. <i>Proc Natl Acad Sci U S A</i> 86:5748-52). The renal sodium-glucose cotransporter may be related to the pathophysiology of renal diseases such as familial renal glycosuria and diabetic renal disorders (Kanai Y, Lee WS, You G, Brown D, Hediger MA. 1994. <i>J Clin Invest</i> 93:397-404). In addition, study of glucose/galactose malabsorption (GGM) patients has revealed a specific defect in sodium-dependent absorption of glucose in the brush border, and the consequent severe diarrhea and dehydration caused by glucose/galactose malabsorption are usually lethal unless these sugars are eliminated from the diet (Turk E, Zabel B, Mundlos S, Dyer J, Wright EM. 1991 <i>Nature</i> 350:354-6).</p>	Glucose/galactose malabsorption (GGM), familial renal glycosuria, and diabetic renal disorders

sbg101273 2GLUT	<p>An embodiment of the invention is the use of sbg101273GLUT, in the maintenance of cellular homeostasis and metabolism. Close homologues of sbg101273GLUT are transmembrane glucose transporters (gluts). Glucose uptake is achieved by transmembrane glucose transporters (gluts), and the transport of glucose across plasma membranes is important for the maintenance of cellular homeostasis and metabolism. Glucose is taken up by cells and then phosphorylated to glucose-6-phosphate, and glucose utilization by cancer cells is greatly enhanced when compared with that by normal tissue. Tumor tissue is frequently associated with the abnormal and/or over-expression of glucose transporters, especially glut1 (Smith TA. 1999. Br J Biomed Sci 56:285-92). Increased utilization of glucose in glomerular cells cause the increased expression and activity of aldose reductase, protein kinase C and TGF-beta, which have been implicated in excessive extracellular matrix accumulation in diabetic nephropathy (Z Katedry i Zakladu Patofizjologii, Akaemii Medycznej w Poznaniu. 1999. Przegl Lek 56:793-9). Changes in endothelial glucose transport and GLUT1 abundance in the barriers of the brain and retina may severely affect glucose delivery to these tissues and major implications in the development of two major diabetic complications, insulin-induced hypoglycemia and diabetic retinopathy (Kumagai AK. 1999. Diabetes Metab Res Rev 15:261-73).</p>	Tumor, diabetic nephropathy, and insulin-induced hypoglycemia
sbg101273 2GLUTb	<p>An embodiment of the invention is the use of sbg101273GLUTb, in the maintenance of cellular homeostasis and metabolism. Close homologues of sbg101273GLUTb are transmembrane glucose transporters (gluts). Glucose uptake is achieved by transmembrane glucose transporters (gluts), and the transport of glucose across plasma membranes is important for the maintenance of cellular homeostasis and metabolism. Glucose is taken up by cells and then phosphorylated to glucose-6-phosphate, and glucose utilization by cancer cells is greatly enhanced when compared with that by normal tissue. Tumor tissue is frequently associated with the abnormal and/or over-expression of glucose transporters, especially glut1 (Smith TA. 1999. Br J Biomed Sci 56:285-92). Increased utilization of glucose in glomerular cells cause the increased expression and activity of aldose reductase, protein kinase C and TGF-beta, which have been implicated in excessive extracellular matrix accumulation in diabetic nephropathy (Z Katedry i Zakladu Patofizjologii, Akaemii Medycznej w Poznaniu. 1999. Przegl Lek 56:793-9). Changes in endothelial glucose transport and GLUT1 abundance in the barriers of the brain and retina may severely affect glucose delivery to these tissues and major implications in the development of two major diabetic complications, insulin-induced hypoglycemia and diabetic retinopathy (Kumagai AK. 1999. Diabetes Metab Res Rev 15:261-73).</p>	Tumor, diabetic nephropathy, and insulin-induced hypoglycemia
sbg101817 2CSP	<p>An embodiment of the invention is the use of sbg1018172CSP in regulation of melanoma, autoimmune disorders, hematopoietic disorder, wound healing, and inflammation. A close homologue of sbg1018172CSP is melanoma-associated chondroitin sulfate proteoglycan</p>	Melanoma, infection, autoimmune disorder, hematopoietic

	(MCSP) core protein NG2. The MCSP core protein NG2 can act as a coreceptor for spreading and focal contact formation in association with alpha 4 beta 1 integrin in melanoma cells (Iida J, Meijne AM, Spiro RC, Roos E, Furcht LT, McCarthy JB. 1995. <i>Cancer Res</i> Mar 15;55(10):2177-85). Cloning of MCSP recognized by mAb 9.2.27 showed that the core protein contained an open reading frame of 2322 AAs, encompassing a large extracellular domain, a hydrophobic transmembrane region, and a relatively short cytoplasmic tail. MCSP RNA was detected in human melanoma cell lines and in biopsies prepared from melanoma skin metastases but not in other human cancer cells or a variety of human fetal and adult tissues (Pluschke G, Vanek M, Evans A, Dittmar T, Schmid P, Itin P, Filardo EJ, Reisfeld RA. 1996. <i>Proc Natl Acad Sci U S A</i> Sep 3;93(18):9710-5).	disorder, wound healing, and inflammation
sbg1004570ERGIC	An embodiment of the invention is the use of sbg1004570ERGIC as a probe for studying protein trafficking in the secretory pathway which is crucial for the elucidation and treatment of many inherited and acquired diseases, such as cystic fibrosis, Alzheimer's disease and viral infections in regulation of melanoma, autoimmune disorders, hematopoietic disorder, wound healing, and inflammation. A close homologue of sbg1004570ERGIC is ERGIC-53, an ER-Golgi intermediate compartment (ERGIC) protein. A ERGIC protein was elevated more than two fold in HT-29 colon adenocarcinoma cells resistant to the the antitumor drug KRN5500. Together with other information, the cellular secretory pathway was suggested a primary determinant of sensitivity to KRN550 (Kamishohara M, Kenney S, Domergue R, Vistica DT, Sausville EA. 2000. <i>Exp Cell Res</i> May 1;256(2):468-79). Mutations in ERGIC-53 was shown to cause combined deficiency of coagulation factors V and VIII and it was suggested that ERGIC-53 might function as a molecular chaperone for the transport from ER to Golgi of a specific subset of secreted proteins, including coagulation factors V and VII (Nichols WC, Seligsohn U, Zivelin A, Terry VH, Hertel CE, Wheatley MA, Moussalli MJ, Hauri HP, Ciavarella N, Kaufman RJ, Ginsburg D. 1998. <i>Cell</i> Apr 3;93(1):61-70). In addition, ERGIC-53 was reviewed as an attractive probe for studying numerous aspects of protein trafficking in the secretory pathway which is crucial for the elucidation and treatment of many inherited and acquired diseases, such as cystic fibrosis, Alzheimer's disease and viral infections (Hauri HP, Kappeler F, Andersson H, Appenzeller C. 2000. <i>J Cell Sci</i> Feb;113 ( Pt 4):587-96).	Cancer, infection, autoimmune disorder, hematopoietic disorder, wound healing disorders, inflammation, and Alzheimer's disease
sbg1016995IGBrecpt	An embodiment of the invention is the use of sbg1016995IGBrecpt in the clearance of circulating autoantibodies and immune complexes. A close homologue of sbg1016995IGBrecpt is guinea pig Fc receptor for immunoglobulin (Tominaga M, Sakata A, Ohmura T, Yamashita T, Koyama J, Onoue K. 1990. <i>Biochem Biophys Res Commun</i> Apr 30;168(2):683-9). IgG Fc-receptor polymorphisms have been reported recently in patients with guillain-Barre syndrome indicating the role of IgG Fc-receptor in the clearance of circulating autoantibodies and immune complexes (Vedeler CA, Raknes G, Myhr KM, Nyland H. 2000. <i>Neurology</i> Sep 12;55(5):705-7).	Auto-immune diseases, allergy, and guillain-Barre syndrom

sbg1151bS REC	<p>An embodiment of the invention is the use of sbg1151bSREC, a scavenger receptor, in the regulation of pathogenesis in atherosclerosis and the formation of foam cells in atherosclerotic lesions. A close homologue of sbg1151bSREC is scavenger receptor class A type I and type II. Most of the scavenger receptors interacted with several structurally different ligands such as oxidized low density lipoprotein (Ox-LDL) and acetyl LDL. Several studies showed Ox-LDL was involved in the pathogenesis of atherosclerosis (Steinbrecher UP. 1999 <i>Biochim Biophys Acta</i> Jan 4;1436(3):279-98). In macrophages scattered in aortic walls without atherosclerotic lesions, scavenger receptor class A type I and type II (SRA) was detected weakly but consistently. In contrast, in atherosclerotic lesions, macrophages around the core region showed a strong immunoreactivity to SRA indicating the involvement of SRA in the formation of foam cells in atherosclerotic lesions (Nakata A, Nakagawa Y, Nishida M, Nozaki S, Miyagawa J, Nakagawa T, Tamura R, Matsumoto K, Kameda-Takemura K, Yamashita S and Matsuzawa Y. <i>Arterioscler Thromb Vasc Biol</i> 1999 May;19(5):1333-9).</p>	Atherosclerosis disease
sbg139985 4ANK	<p>An embodiment of the invention is the use of sbg1399854ANK in protein-protein interactions and it may act by inhibiting protein of cyclin dependent kinase. The present invention contains both death domain and ankyrin repeat region. The death domain is involved in cell death signaling (Cleveland J. and Ihle J.N. 1995. <i>Cell</i> 81:479-482). Ankyrin repeats (ANK) are tandem repeat modules of about 33 amino acids. Many ankyrin repeat regions are known to be involved in protein-protein interaction (Svetlana Gorina and Nikola P. Pavletich; 1996 <i>Science</i> 274:1001-1005).</p>	Cancer, infection, autoimmune disorder, hematopoietic disorder, wound healing disorders, and inflammation

**Table IV. Quantitative, Tissue-specific mRNA expression detected using SybrMan**

Quantitative, tissue-specific, mRNA expression patterns of the genes were measured using SYBR-Green Quantitative PCR (Applied Biosystems, Foster City, CA; see Schmittgen T.D. et al., Analytical Biochemistry 285:194-204, 2000) and human cDNAs prepared from various human tissues. Gene-specific PCR primers were designed using the first nucleic acid sequence listed in the Sequence List for each gene. The threshold cycle ( $C_t$ ) is defined as the fractional cycle number at which the reporter fluorescence generated by cleavage of the probe reaches a threshold defined as 10 times the background. In cases sequence detection system software predicted more than one PCR product, Taqman was used for the specific PCR amplification as indicated under the specific genes.

In each gene's first subset table, two replicate measurements of gene of identification (GOI) mRNA were measured from various human tissues (column 3 and 4). The average GOI mRNA copies of the two replicates were made from each tissue RNA (column 5). The average amount of 18S rRNA from each tissue RNA was measured (column 6) and used for normalization. To make each tissue with the same amount of 50 ng of 18S rRNA, the normalization factor (column 7) was calculated by dividing 50 ng with the amount of 18S rRNA measured from each tissue (column 6). The mRNA copies per 50 ng of total RNA were obtained by multiplying each GOI normalization factor and the average mRNA copies (column 8).

Fold changes shown in each gene's second subset table were only calculated for disease tissues which have a normal counterpart. There are blanks in the fold change column for all samples that do not have counterparts. In addition, the fold change calculations are the fold change in the disease sample as compared to the normal sample. Accordingly, there will not be a fold change calculation next to any of the normal samples. For patient matched cancer pairs (colon, lung, and breast), each tumor is compared to its specific normal counterpart. When patient-matched normal/disease pairs do not exist, each disease sample was compared back to the average of all the normal samples of that same tissue type. For example, normal brain from the same patient that provided Alzheimer's brain is not applicable. Three normal brain samples and 4 Alzheimer's brain samples are used in the fold change. Three normal samples were averaged, and each of the Alzheimer's samples was compared back to that average.

**Abbreviations**

ALZ Alzheimer's Disease  
 CT CLONTECH (1020 East Meadow Circle Palo Alto, CA 94303-4230, USA)  
 KC Sample prepared by GSK investigator  
 COPD chronic obstructive pulmonary disease  
 endo endothelial  
 VEGF vascular endothelial growth factor  
 bFGF basic fibroblast growth factor  
 BM bone marrow  
 osteo osteoblast  
 OA osteoarthritis  
 RA rheumatoid arthritis  
 PBL peripheral blood lymphocytes  
 PBMNC peripheral blood mononuclear cells  
 HIV human immunodeficiency virus  
 HSV Herpes simplex virus  
 HPV human papilloma virus

**Gene Name sbg960509cbrecpt**

5 Lowest overall expression in normal and disease samples. Highest normal expression in the whole brain, fetal liver, and uterus. Highest disease expression in 2 of the lung tumor samples, one of the breast tumor samples, and one of the normal breast samples. Downregulation in 1 of 4 colon tumors implies an involvement in cancer of the colon. Downregulation in 2 of 4 AD brain samples as well as high expression in whole brain suggests an involvement in Alzheimer's disease. Downregulation in 3 of 3 COPD lung samples and downregulation in 4 of 4 asthmatic lung samples implicates this gene in COPD and asthma. Upregulation in 2 of 3 heart samples proposes roles in non-obstructive and obstructive DCM. Patterns difficult to interpret due to Cts > 35. Moderate to low expression in 10 immune cells. Moderate expression in OA and RA synovium.

Sample sbg960509cbrecpt	Ct (sample 1 and 2)	Mean GOI copies (sample 1)	Mean GOI copies (sample 2)	Averag e GOI Copies	18S rRNA (ng)	50 ng/18S rRNA (ng)	copies of mRNA detecte d/50 ng total RNA
Subcutaneous Adipocytes Zenbio	40, 40	0	0	0.00	3.06	16.34	0.00
Subcutaneous Adipose Zenbio	40, 40	0	0	0.00	0.96	52.36	0.00
Adrenal Gland Clontech	40, 40	0	0	0.00	0.61	81.97	0.00
Whole Brain Clontech	33.26, 32.07	24.63	48.4	36.52	7.24	6.91	252.18
Fetal Brain Clontech	40, 40	0	0	0.00	0.48	103.95	0.00
Cerébellum Clontech	40, 40	0	0	0.00	2.17	23.04	0.00
Cervix	40, 40	0	0	0.00	2.42	20.66	0.00
Colon	40, 40	0	0	0.00	2.71	18.45	0.00
Endometrium	40, 40	0.81	0	0.41	0.73	68.21	27.63
Esophagus	40, 40	0	0	0.00	1.37	36.50	0.00
Heart Clontech	40, 40	0	0	0.00	1.32	37.88	0.00
Hypothalamus	40, 40	0	0	0.00	0.32	155.28	0.00
Ileum	40, 40	0	0	0.00	2.58	19.38	0.00
Jejunum	35.56, 34.42	6.66	12.71	9.69	6.60	7.58	73.37
Kidney	40, 40	0	0	0.00	2.12	23.58	0.00
Liver	40, 40	0	0	0.00	1.50	33.33	0.00
Fetal Liver Clontech	33.46, 34.83	14.95	27.51	21.23	10.40	4.81	102.07
Lung	40, 40	0	0	0.00	2.57	19.46	0.00
Mammary Gland Clontech	40, 40	21.94	10.06	16.00	13.00	3.85	61.54
Myometrium	40, 40	0	0	0.00	2.34	21.37	0.00
Omentum	40, 40	0	0	0.00	3.94	12.69	0.00
Ovary	40, 40	0	0	0.00	4.34	11.52	0.00
Pancreas	40, 40	0	0	0.00	0.81	61.80	0.00
Head of Pancreas	40, 40	0	0	0.00	1.57	31.85	0.00
Parotid Gland	40, 40	0	0	0.00	5.48	9.12	0.00
Placenta Clontech	40, 40	0.39	0	0.20	5.26	9.51	1.85
Prostate	40, 40	0	0	0.00	3.00	16.67	0.00
Rectum	40, 40	0	0	0.00	1.23	40.65	0.00
Salivary Gland	34.79, 40	10.31	0	5.16	7.31	6.84	35.26

Clontech							
Skeletal Muscle Clontech	40, 40	0	0	0.00	1.26	39.68	0.00
Skin	40, 40	0	0	0.00	1.21	41.32	0.00
Small Intestine Clontech	40, 40	0	0	0.00	0.98	51.07	0.00
Spleen	40, 40	0	0	0.00	4.92	10.16	0.00
Stomach	35.8, 38.29	5.82	1.41	3.62	2.73	18.32	66.21
Testis Clontech	40, 40	0	0	0.00	0.57	87.87	0.00
Thymus Clontech	35.13, 35.08	8.48	8.75	8.62	9.89	5.06	43.55
Thyroid	40, 40	0	0	0.00	2.77	18.05	0.00
Trachea Clontech	35.26, ND	7.9	ND	7.90	9.71	5.15	40.68
Urinary Bladder	40, ND	0	ND	0.00	5.47	9.14	0.00
Uterus	35.09, 33.87	8.67	17.4	13.04	5.34	9.36	122.05
genomic	26.62	1067.33					
b-actin	27.44	670.43					
1.00E+05	19.22	100000					
1.00E+05	19.38	100000					
1.00E+04	22.78	10000					
1.00E+04	20.52	10000					
1.00E+03	26.45	1000					
1.00E+03	27.03	1000					
1.00E+02	30.99	100					
1.00E+02	31.26	100					
1.00E+01	40	0					
1.00E+01	40	0					
1.00E-00	40	0					
1.00E-00	40	0					
NTC	40	0					
NTC	40	0					

Sample sbg960509cbrecpt	Reg number (GSK identifier )	Ct	Mean GOI copies	copies of mRNA detecte d/50 ng total RNA	Sample	Fold Change in Disease Populat ion
colon normal GW98-167	21941	29.42		332.32	colon normal	
colon tumor GW98-166	21940	30.95	66.31	132.62	colon tumor	-2.51
colon normal GW98-178	22080	31.32	53.01	106.02	colon normal	
colon tumor GW98-177	22060	30.57	83.1	166.20	colon tumor	1.57
colon normal GW98-561	23514	31.44	49.16	98.32	colon normal	
colon tumor GW98-560	23513	31.81	39.47	78.94	colon tumor	-1.25
colon normal GW98-894	24691	29.44	164.69	329.38	colon normal	
colon tumor GW98-893	24690	34.42	8.18	16.36	colon tumor	-20.13
lung normal GW98-3	20742	28.04	383.11	766.22	lung normal	

lung tumor GW98-2	20741	34.22	9.19	18.38	lung tumor	-41.69
lung normal GW97-179	20677	30.93	66.74	133.48	lung normal	
lung tumor GW97-178	20676	27.11	667.61	1335.22	lung tumor	10.00
lung normal GW98-165	21922	28.31	323.99	647.98	lung normal	
lung tumor GW98-164	21921	30.92	67.22	134.44	lung tumor	-4.82
lung normal GW98-282	22584	31.76	40.67	81.34	lung normal	
lung tumor GW98-281	22583	29.61	148.67	297.34	lung tumor	3.66
breast normal GW00-392	28750	27.64	487.44	487.44	breast normal	
breast tumor GW00-391	28746	27.47	539.99	1079.98	breast tumor	2.22
breast normal GW00-413	28798	33.36	15.44	15.44	breast normal	
breast tumor GW00-412	28797	30.88	68.84	137.68	breast tumor	8.92
breast normal GW00-235:238	27592-95	34.74	6.73	6.73	breast normal	
breast tumor GW00-231:234	27588-91	33.73	12.41	12.41	breast tumor	1.84
breast normal GW98-621	23656	27.7	469.27	938.54	breast normal	
breast tumor GW98-620	23655	33.1	18.13	36.26	breast tumor	-25.88
brain normal BB99-542	25507	31.46	48.61	97.22	brain normal	
brain normal BB99-406	25509	34.17	9.52	19.04	brain normal	
brain normal BB99-904	25546	35.69	3.79	7.58	brain normal	
brain stage 5 ALZ BB99-874	25502	40	0	0.00	brain stage 5 ALZ	-41.28
brain stage 5 ALZ BB99-887	25503	34.96	5.91	11.82	brain stage 5 ALZ	-3.49
brain stage 5 ALZ BB99-862	25504	33.13	17.82	35.64	brain stage 5 ALZ	-1.16
brain stage 5 ALZ BB99-927	25542	40	0	0.00	brain stage 5 ALZ	-41.28
CT lung KC	normal	29.53	155.88	311.76	CT lung	
lung 26 KC	normal				lung 26	
lung 27 KC	normal	39.2	0.46	0.46	lung 27	
lung 24 KC	COPD	40	0	0.00	lung 24	-104.07
lung 28 KC	COPD	40	0	0.00	lung 28	-104.07
lung 23 KC	COPD	34.81	6.44	6.44	lung 23	-16.16
lung 25 KC	normal	40	0	0.00	lung 25	
asthmatic lung ODO3112	29321	38.99	0.52	0.52	asthmatic lung	-200.14
asthmatic lung ODO3433	29323	33.69	12.65	25.30	asthmatic lung	-4.11
asthmatic lung ODO3397	29322	33.53	13.98	27.96	asthmatic lung	-3.72
asthmatic lung ODO4928	29325	34.27	8.96	17.92	asthmatic lung	-5.81
endo cells KC	control	40	0	0.00	endo cells	
endo VEGF KC		40	0	0.00	endo VEGF	0.00
endo bFGF KC		40	0	0.00	endo bFGF	0.00
heart Clontech	normal	35.53	4.19	8.38	heart	
heart ( T-1 ) ischemic	29417	34	10.5	21.00	heart T-1	2.51
heart (T-14) non-obstructive DCM	29422	31.16	58.24	116.48	heart T-14	13.90
heart (T-3399) DCM	29426	28.35	317.67	635.34	heart T-3399	75.82

adenoid GW99-269	26162	31.52	46.93	93.86	adenoid	
tonsil GW98-280	22582	30.82	71.35	142.70	tonsil	
T cells PC00314	28453	34.36	8.47	16.94	T cells	
PBMNC		40	0	0.00	PBMNC	
monocyte		40	0	0.00	monocyte	
B cells PC00665	28455	40	0	0.00	B cells	
dendritic cells 28441		31.52	47.02	94.04	dendritic cells	
neutrophils	28440	36.13	2.91	2.91	neutrophils	
eosinophils	28446	40	0	0.00	eosinophils	
BM unstim		40	0	0.00	BM unstim	
BM stim		40	0	0.00	BM stim	0.00
osteо dif		40	0	0.00	osteо dif	0.00
osteо undif		40	0	0.00	osteо undif	
chondrocytes		40	0	0.00	chondrocytes	
OA Synovium IP12/01	29462	32.08	33.47	33.47	OA Synovium	
OA Synovium NP10/01	29461	31.43	49.5	99.00	OA Synovium	
OA Synovium NP57/00	28464	30.42	91.04	182.08	OA Synovium	
RA Synovium NP03/01	28466	32.11	32.84	65.68	RA Synovium	
RA Synovium NP71/00	28467	31.07	61.51	123.02	RA Synovium	
RA Synovium NP45/00	28475	36.21	2.78	5.56	RA Synovium	
OA bone (biobank)	29217	31.49	47.85	47.85	OA bone (biobank)	
OA bone Sample 1	J. Emory	30.11	109.44	218.88	OA bone	
OA bone Sample 2	J. Emory	32.6	24.52	49.04	OA bone	
Cartilage (pool)	Normal	32.09	33.26	66.52	Cartilage (pool)	
Cartilage (pool)	OA	33.1	18.07	36.14	Cartilage (pool)	-1.84
PBL uninfected	28441	27.68	474.91	949.82	PBL uninfected	
PBL HIV IIIB	28442	31.76	40.5	81.00	PBL HIV IIIB	-11.73
MRC5 uninfected (100%)	29158	40	0	0.00	MRC5 uninfected (100%)	
MRC5 HSV strain F	29178	34.15	9.61	19.22	MRC5 HSV strain F	19.22
W12 cells	29179	40	0	0.00	W12 cells	
Keratinocytes	29180	38.16	0.85	1.70	Keratinocytes	
B-actin control		27.02	707.5			
genomic		26.1	1232.73			
1.00E+05		18.64	100000			
1.00E+05		18.95	100000			
1.00E+04		22.4	10000			
1.00E+04		22.17	10000			
1.00E+03		26.34	1000			
1.00E+03		25.94	1000			
1.00E+02		31.03	100			
1.00E+02		32.83	100			
1.00E+01		33.21	10			
1.00E+01		32.93	10			
1.00E-00		40	0			
1.00E-00		40	0			
NTC		40	0			

## Gene Name sbg960509cbrecept

Disease tissues	Fold Change in Disease Population Relative to Normal
colon tumor	-2.51
colon tumor	1.57
colon tumor	-1.25
colon tumor	-20.13
lung tumor	-41.69
lung tumor	10.00
lung tumor	-4.82
lung tumor	3.66
breast tumor	2.22
breast tumor	8.92
breast tumor	1.84
breast tumor	-25.88
brain stage 5 ALZ	-41.28
brain stage 5 ALZ	-3.49
brain stage 5 ALZ	-1.16
brain stage 5 ALZ	-41.28
lung 24	-104.07
lung 28	-104.07
lung 23	-16.16
asthmatic lung	-200.14
asthmatic lung	-4.11
asthmatic lung	-3.72
asthmatic lung	-5.81
endo VEGF	0.00
endo bFGF	0.00
heart T-1	2.51
heart T-14	13.90
heart T-3399	75.82
BM stim	0.00
osteo undif	0.00
Cartilage (pool)	-1.84
PBL HIV IIIB	-11.73
MRC5 HSV strain F	19.22

## 5 Gene Name sbg614126complfH

Moderate to low overall expression in normal and disease samples. Highest normal expression in liver and fetal liver. Lower (but still significant expression) is seen in the whole brain, ovary, and uterus. Highest disease expression in 2 of the breast tumor samples, one of the normal brain samples, one of the normal lungs, one of the OA synovium samples, and the HSV-infected MRC5 cells. Upregulation in 1 of 4 colon tumors suggests a role in cancer of the colon. Downregulation in 2 of 4 lung tumors and upregulation in 1 of 4 breast tumors suggest roles in cancers of the lung and breast. Downregulation in 3 of 3 COPD lung samples as well as downregulation in 4 of 4 asthmatic lungs implies an involvement in chronic obstructive pulmonary disease and asthma. Upregulation in 1 of 3 heart samples suggests a role in DCM. Upregulation in HSV implicates involvement in herpes simplex virus as a potential host factor. Moderate to low expression in immune cells, RA and OA synovium bone, and chondrocytes.

Sample sbg614126complfH	Ct (sample 1)	Mean GOI	Mean GOI	Average GOI	18S rRNA	50 ng/18S	copies of
----------------------------	------------------	-------------	-------------	----------------	-------------	--------------	--------------

	and 2)	copies (sample 1)	copies (sample 2)	Copies	(ng)	rRNA (ng)	mRNA detecte d/50 ng total RNA
Subcutaneous Adipocytes Zenbio	40, 40	0	0	0.00	3.06	16.34	0.00
Subcutaneous Adipose Zenbio	40, 40	0	0	0.00	0.96	52.36	0.00
Adrenal Gland Clontech	40, 40	0	0	0.00	0.61	81.97	0.00
Whole Brain Clontech	32.34, 31.88	46.5	61.71	54.11	7.24	6.91	373.65
Fetal Brain Clontech	40, 40	0	0	0.00	0.48	103.95	0.00
Cerebellum Clontech	40, 40	0	0	0.00	2.17	23.04	0.00
Cervix	40, 35.04	0	8.88	4.44	2.42	20.66	91.74
Colon	40, 40	0	0	0.00	2.71	18.45	0.00
Endometrium	40, 40	0	0	0.00	0.73	68.21	0.00
Esophagus	40, 40	0	0	0.00	1.37	36.50	0.00
Heart Clontech	40, 40	0	0	0.00	1.32	37.88	0.00
Hypothalamus	40, 39.79	0	0.48	0.24	0.32	155.28	37.27
Ileum	40, 36.32	0	4.04	2.02	2.58	19.38	39.15
Jejunum	33.25, 34.19	26.6	14.98	20.79	6.60	7.58	157.50
Kidney	40, 40	0	0	0.00	2.12	23.58	0.00
Liver	28.77, 28.81	417.4	407.38	412.39	1.50	33.33	13746. 33
Fetal Liver Clontech	29.63, 29.5	246.38	266.67	256.53	10.40	4.81	1233.2 9
Lung	40, 40	0	0	0.00	2.57	19.46	0.00
Mammary Gland Clontech	34.19, 40	14.9	0	7.45	13.00	3.85	28.65
Myometrium	35.76, 40	5.7	0	2.85	2.34	21.37	60.90
Omentum	36.04, 33.62	4.81	21.16	12.99	3.94	12.69	164.78
Ovary	34.29, 32.95	14.02	31.93	22.98	4.34	11.52	264.69
Pancreas	40, 40	0	0	0.00	0.81	61.80	0.00
Head of Pancreas	38.98, 35.35	0.79	7.32	4.06	1.57	31.85	129.14
Parotid Gland	34.58, 33.83	11.74	18.68	15.21	5.48	9.12	138.78
Placenta Clontech	35.73, 35.66	5.82	6.06	5.94	5.26	9.51	56.46
Prostate	40, 40	0	0	0.00	3.00	16.67	0.00
Rectum	40, 40	0.38	0	0.19	1.23	40.65	7.72
Salivary Gland Clontech	40, 40	0.3	0	0.15	7.31	6.84	1.03
Skeletal Muscle Clontech	40, 40	0	0.28	0.14	1.26	39.68	5.56
Skin	40, 40	0	0.33	0.17	1.21	41.32	6.82
Small Intestine Clontech	40, 40	0	0	0.00	0.98	51.07	0.00
Spleen	40, 40	0	0	0.00	4.92	10.16	0.00
Stomach	40, 36	0	4.92	2.46	2.73	18.32	45.05
Testis Clontech	40, 40	0	0	0.00	0.57	87.87	0.00

Thymus Clontech	40, 37.06	0	2.56	1.28	9.89	5.06	6.47
Thyroid	40, 40	0	0.31	0.16	2.77	18.05	2.80
Trachea Clontech	40, 40	0.28	0	0.14	9.71	5.15	0.72
Urinary Bladder	40, 34.13	0	15.53	7.77	5.47	9.14	70.98
Uterus	33.21, 32.79	27.27	35.32	31.30	5.34	9.36	293.02
genomic	26.93	1288.98					
b-actin	27.55	878.74					
1.00E+05	20.07	100000					
1.00E+05	20.14	100000					
1.00E+04	23.43	10000					
1.00E+04	23.34	10000					
1.00E+03	26.84	1000					
1.00E+03	27.02	1000					
1.00E+02	31.72	100					
1.00E+02	31.32	100					
1.00E+01	33.78	10					
1.00E+01	35.79	10					
1.00E-00	40	0					
1.00E-00	40	0					
NTC	40	0					
NTC	40	0					

Sample sbg614126complfH	Reg number (GSK identifier )	Ct	Mean GOI copies	copies of mRNA detecte d/50 ng total RNA	Sample	Fold Change in Disease Populatio n
colon normal GW98-167	21941	34.6	13.63	27.26	colon normal	
colon tumor GW98-166	21940	35.71	7.35	14.70	colon tumor	-1.85
colon normal GW98-178	22080	40	0	0.00	colon normal	
colon tumor GW98-177	22060	39.81	0.75	1.50	colon tumor	1.50
colon normal GW98-561	23514	38.61	1.45	2.90	colon normal	
colon tumor GW98-560	23513	34.84	11.95	23.90	colon tumor	8.24
colon normal GW98-894	24691	39.05	1.14	2.28	colon normal	
colon tumor GW98-893	24690	40	0	0.00	colon tumor	-2.28
lung normal GW98-3	20742	35.78	7.04	14.08	lung normal	
lung tumor GW98-2	20741	40	0	0.00	lung tumor	-14.08
lung normal GW97-179	20677	33.99	19.21	38.42	lung normal	
lung tumor GW97-178	20676	40	0.49	0.98	lung tumor	-39.20
lung normal GW98-165	21922	39.63	0.82	1.64	lung normal	
lung tumor GW98-164	21921	38.89	1.24	2.48	lung tumor	1.51
lung normal GW98-282	22584	40	0	0.00	lung normal	
lung tumor GW98-281	22583	40	0	0.00	lung tumor	0.00

breast normal GW00-392	28750	32.71	39.28	39.28	breast normal	
breast tumor GW00-391	28746	31.65	70.89	141.78	breast tumor	3.61
breast normal GW00-413	28798	35.83	6.88	6.88	breast normal	
breast tumor GW00-412	28797	33.17	30.3	60.60	breast tumor	8.81
breast normal GW00-235:238	27592-95	36.73	4.16	4.16	breast normal	
breast tumor GW00-231:234	27588-91	35.98	6.33	6.33	breast tumor	1.52
breast normal GW98-621	23656	37.38	2.89	5.78	breast normal	
breast tumor GW98-620	23655	34.95	11.23	22.46	breast tumor	3.89
brain normal BB99-542	25507	32.26	50.34	100.68	brain normal	
brain normal BB99-406	25509	40	0.57	1.14	brain normal	
brain normal BB99-904	25546	34.68	13.04	26.08	brain normal	
brain stage 5 ALZ BB99-874	25502	40	0	0.00	brain stage 5 ALZ	-42.63
brain stage 5 ALZ BB99-887	25503	35.87	6.73	13.46	brain stage 5 ALZ	-3.17
brain stage 5 ALZ BB99-862	25504	39.2	1.05	2.10	brain stage 5 ALZ	-20.30
brain stage 5 ALZ BB99-927	25542	40	0	0.00	brain stage 5 ALZ	-42.63
CT lung KC	normal	39.4	0.93	1.86	CT lung	
lung 26 KC	normal				lung 26	
lung 27 KC	normal	40	0	0.00	lung 27	
lung 24 KC	COPD	40	0	0.00	lung 24	-0.62
lung 28 KC	COPD	40	0	0.00	lung 28	-0.62
lung 23 KC	COPD	40	0	0.00	lung 23	-0.62
lung 25 KC	normal	40	0	0.00	lung 25	
asthmatic lung ODO3112	29321	36.52	4.68	4.68	asthmatic lung	7.55
asthmatic lung ODO3433	29323	40	0	0.00	asthmatic lung	-0.62
asthmatic lung ODO3397	29322	40	0	0.00	asthmatic lung	-0.62
asthmatic lung ODO4928	29325	38.18	1.85	3.70	asthmatic lung	5.97
endo cells KC	control	40	0	0.00	endo cells	
endo VEGF KC		40	0	0.00	endo VEGF	0.00
endo bFGF KC		40	0	0.00	endo bFGF	0.00
heart Clontech	normal	40	0	0.00	heart	
heart ( T-1 ) ischemic	29417	40	0	0.00	heart T-1	0.00
heart (T-14) non-obstructive DCM	29422	40	0	0.00	heart T-14	0.00
heart (T-3399) DCM	29426	36.03	6.13	12.26	heart T-3399	12.26
adenoid GW99-269	26162	34.08	18.19	36.38	adenoid	
tonsil GW98-280	22582	37.46	2.77	5.54	tonsil	
T cells PC00314	28453	40	0	0.00	T cells	
PBMNC		40	0	0.00	PBMNC	
monocyte		40	0	0.00	monocyte	

B cells PC00665	28455	34.56	13.99	27.98	B cells	
dendritic cells 28441		40	0	0.00	dendritic cells	
neutrophils	28440	33.76	21.85	21.85	neutrophils	
eosinophils	28446	40	0	0.00	eosinophils	
BM unstim		40	0	0.00	BM unstim	
BM stim		40	0	0.00	BM stim	0.00
osteо dif		40	0	0.00	osteо dif	0.00
osteо undif		40	0	0.00	osteо undif	
chondrocytes		34.25	16.55	41.38	chondrocytes	
OA Synovium IP12/01	29462	40	0	0.00	OA Synovium	
OA Synovium NP10/01	29461	40	0	0.00	OA Synovium	
OA Synovium NP57/00	28464	33.1	31.54	63.08	OA Synovium	
RA Synovium NP03/01	28466	40	0	0.00	RA Synovium	
RA Synovium NP71/00	28467	40	0	0.00	RA Synovium	
RA Synovium NP45/00	28475	40	0	0.00	RA Synovium	
OA bone (biobank)	29217	40	0	0.00	OA bone (biobank)	
OA bone Sample 1	J. Emory	40	0	0.00	OA bone	
OA bone Sample 2	J. Emory	40	0	0.00	OA bone	
Cartilage (pool)	Normal	40	0	0.00	Cartilage (pool)	
Cartilage (pool)	OA	40	0	0.00	Cartilage (pool)	0.00
PBL uninfected	28441	36.12	5.84	11.68	PBL uninfected	
PBL HIV IIIB	28442	36.1	5.9	11.80	PBL HIV IIIB	1.01
MRC5 uninfected (100%)	29158	40	0	0.00	MRC5 uninfected (100%)	
MRC5 HSV strain F	29178	31.83	64.08	128.16	MRC5 HSV strain F	128.16
W12 cells	29179	40	0	0.00	W12 cells	
Keratinocytes	29180	40	0	0.00	Keratinocytes	
B-actin control		27.26	820.77			
genomic		26.18	1496.25			
1.00E+05		19.13	100000			
1.00E+05		19.38	100000			
1.00E+04		22.56	10000			
1.00E+04		22.67	10000			
1.00E+03		26.01	1000			
1.00E+03		26.44	1000			
1.00E+02		30.93	100			
1.00E+02		30.1	100			
1.00E+01		38.59	10			
1.00E+01		33.26	10			
1.00E-00		40	0			
1.00E-00		40	0			
NTC		40	0			

## Gene Name sbg614126complfH

Disease tissues	Fold Change in Disease Population Relative to Normal
colon tumor	-1.85
colon tumor	1.50
colon tumor	8.24
colon tumor	-2.28
lung tumor	-14.08
lung tumor	-39.20
lung tumor	1.51
lung tumor	0.00
breast tumor	3.61
breast tumor	8.81
breast tumor	1.52
breast tumor	3.89
brain stage 5 ALZ	-42.63
brain stage 5 ALZ	-3.17
brain stage 5 ALZ	-20.30
brain stage 5 ALZ	-42.63
lung 24	-0.62
lung 28	-0.62
lung 23	-0.62
asthmatic lung	7.55
asthmatic lung	-0.62
asthmatic lung	-0.62
asthmatic lung	5.97
endo VEGF	0.00
endo bFGF	0.00
heart T-1	0.00
heart T-14	0.00
heart T-3399	12.26
BM stim	0.00
osteo undif	0.00
Cartilage (pool)	0.00
PBL HIV IIIB	1.01
MRC5 HSV strain F	128.16

## Gene Name sbg120703RNase

5 Moderate to low overall expression in normal and disease samples. Highest normal expression in whole brain and salivary gland. Moderate expression in the fetal liver and the thymus. Highest disease expression in 2 of the normal lung samples, one of the lung tumor samples, the normal cartilage pool, and the HSV-infected MRC5 cells. Upregulation in 1 of 4 colon tumors suggests a role in cancer of the colon. Downregulation in 2 of 4 lung tumor samples suggests possible implication in lung cancer. Upregulation in 2 of 4 breast tumors implies an involvement in cancers of the breast. Downregulation in 3 of 3 COPD lung samples implies an involvement in COPD.

10 Upregulation in 3 of 3 heart samples implicates this gene in diseases of the heart such as DCM and ischemia. High expression in the OA and RA synovium and the OA bone samples suggests a possible involvement in osteoarthritis and rheumatoid arthritis. Upregulation in HSV implicates this gene in herpes simplex virus as a potential host factor. Moderate to low expression in immune cells.

15

Sample sbg120703RNase	Ct (sample 1 and 2)	Mean GOI copies (sample 1)	Mean GOI copies (sample 2)	Averag e GOI Copies	18S rRNA (ng)	50 ng/18S rRNA (ng)	copies of mRNA detecte d/50 ng total RNA
Subcutaneous Adipocytes Zenbio	40, 36.24	0	2.54	1.27	3.06	16.34	20.75
Subcutaneous Adipose Zenbio	36.58, 40	2.07	0	1.04	0.96	52.36	54.19
Adrenal Gland Clontech	40, 40	0.22	0	0.11	0.61	81.97	9.02
Whole Brain Clontech	28.62, 28.6	245.21	247.41	246.31	7.24	6.91	1701.04
Fetal Brain Clontech	40, 40	0.3	0	0.15	0.48	103.95	15.59
Cerebellum Clontech	40, 40	0.29	0	0.15	2.17	23.04	3.34
Cervix	35.3, 40	4.45	0	2.23	2.42	20.66	45.97
Colon	40, 40	0.26	0	0.13	2.71	18.45	2.40
Endometrium	40, 38.38	0	0.7	0.35	0.73	68.21	23.87
Esophagus	36.11, 37.01	2.74	1.6	2.17	1.37	36.50	79.20
Heart Clontech	40, 40	0	0	0.00	1.32	37.88	0.00
Hypothalamus	40, 40	0	0	0.00	0.32	155.28	0.00
Ileum	39.31, 36.07	0.4	2.8	1.60	2.58	19.38	31.01
Jejunum	34.13, 39.51	8.98	0.36	4.67	6.60	7.58	35.38
Kidney	40, 40	0.48	0	0.24	2.12	23.58	5.66
Liver	34.4, 36.04	7.64	2.86	5.25	1.50	33.33	175.00
Fetal Liver Clontech	31.46, 31.39	44.65	46.4	45.53	10.40	4.81	218.87
Lung	34.21, 35.61	8.59	3.71	6.15	2.57	19.46	119.65
Mammary Gland Clontech	34.9, 35.65	5.67	3.6	4.64	13.00	3.85	17.83
Myometrium	40, 38.99	0	0.49	0.25	2.34	21.37	5.24
Omentum	38.39, 34.35	0.7	7.89	4.30	3.94	12.69	54.51
Ovary	35, 33.21	5.34	15.64	10.49	4.34	11.52	120.85
Pancreas	40	0	0	0.00	0.81	61.80	0.00
Head of Pancreas	40	0	0	0.00	1.57	31.85	0.00
Parotid Gland	32.22, 33.49	28.28	13.18	20.73	5.48	9.12	189.14
Placenta Clontech	37, 39.59	1.6	0.34	0.97	5.26	9.51	9.22
Prostate	35.03, 35.75	5.23	3.4	4.32	3.00	16.67	71.92
Rectum	38.25, 40	0.76	0.21	0.49	1.23	40.65	19.72
Salivary Gland Clontech	30.01, 29.73	106.25	125.78	116.02	7.31	6.84	793.54
Skeletal Muscle Clontech	40, 39.16	0.41	0.44	0.43	1.26	39.68	16.87
Skin	37.21, 35.01	1.42	5.31	3.37	1.21	41.32	139.05
Small Intestine Clontech	40, 40	0	0.19	0.10	0.98	51.07	4.85
Spleen	35.4, 35.9	4.2	3.11	3.66	4.92	10.16	37.14
Stomach	36.12, 40	2.73	0.21	1.47	2.73	18.32	26.92
Testis Clontech	40, 40	0	0	0.00	0.57	87.87	0.00

Thymus Clontech	31.88, 31.42	34.61	45.62	40.12	9.89	5.06	202.81
Thyroid	40, 35.22	0	4.67	2.34	2.77	18.05	42.15
Trachea Clontech	35.38, 37.52	4.26	1.17	2.72	9.71	5.15	13.98
Urinary Bladder	38.77, 40	0.56	0.31	0.44	5.47	9.14	3.98
Uterus	33.66, 37.55	11.93	1.16	6.55	5.34	9.36	61.28
genomic	25.78	1342.66					
b-actin	27.27	551.42					
1.00E+05	19.03	100000					
1.00E+05	19.08	100000					
1.00E+04	22.28	10000					
1.00E+04	22.27	10000					
1.00E+03	25.85	1000					
1.00E+03	25.6	1000					
1.00E+02	30.44	100					
1.00E+02	29.33	100					
1.00E+01	34.4	10					
1.00E+01	34.48	10					
1.00E-00							
1.00E-00							
NTC	40	-1					
NTC	40	0					

Sample sbg120703RNase	Reg number (GSK identifier)	Ct	Mean GOI copies	copies of mRNA detected/ 50 ng total RNA	Sample	Fold Change in Disease Population
colon normal GW98-167	21941	29.03	142.85	285.70	colon normal	
colon tumor GW98-166	21940	28.31	226.87	453.74	colon tumor	1.59
colon normal GW98-178	22080	33.08	10.78	21.56	colon normal	
colon tumor GW98-177	22060	29.33	118.09	236.18	colon tumor	10.95
colon normal GW98-561	23514	30.02	76.09	152.18	colon normal	
colon tumor GW98-560	23513	30.42	58.89	117.78	colon tumor	-1.29
colon normal GW98-894	24691	29.07	139.29	278.58	colon normal	
colon tumor GW98-893	24690	30.3	63.5	127.00	colon tumor	-2.19
lung normal GW98-3	20742	26.86	574.4	1148.80	lung normal	
lung tumor GW98-2	20741	30.07	73.89	147.78	lung tumor	-7.77
lung normal GW97-179	20677	29.74	90.79	181.58	lung normal	
lung tumor GW97-178	20676	27.63	351.24	702.48	lung tumor	3.87
lung normal GW98-165	21922	26.63	663.94	1327.88	lung normal	
lung tumor GW98-164	21921	29.38	114.52	229.04	lung tumor	-5.80
lung normal GW98-282	22584	30	77.02	154.04	lung normal	
lung tumor GW98-281	22583	29.64	97.04	194.08	lung tumor	1.26
breast normal GW00-392	28750	29.08	138.57	138.57	breast normal	
breast tumor GW00-391	28746	28.77	169.53	339.06	breast tumor	2.45
breast normal GW00-413	28798	32.72	13.55	13.55	breast normal	
breast tumor GW00-412	28797	31.01	40.4	80.80	breast tumor	5.96

breast normal GW00-235:238	27592-95	34.39	4.68	4.68	breast normal	
breast tumor GW00-231:234	27588-91	31.4	31.48	31.48	breast tumor	6.73
breast normal GW98-621	23656	28.54	195.6	391.20	breast normal	
breast tumor GW98-620	23655	30.37	60.84	121.68	breast tumor	-3.21
brain normal BB99-542	25507	32.94	11.79	23.58	brain normal	
brain normal BB99-406	25509	32.22	18.66	37.32	brain normal	
brain normal BB99-904	25546	32.3	17.71	35.42	brain normal	
brain stage 5 ALZ BB99-874	25502	32.82	12.76	25.52	brain stage 5 ALZ	-1.26
brain stage 5 ALZ BB99-887	25503	30.31	63.18	126.36	brain stage 5 ALZ	3.94
brain stage 5 ALZ BB99-862	25504	31.42	31.08	62.16	brain stage 5 ALZ	1.94
brain stage 5 ALZ BB99-927	25542	33.35	9.08	18.16	brain stage 5 ALZ	-1.77
CT lung KC	normal	30.41	59.49	118.98	CT lung	
lung 26 KC	normal				lung 26	
lung 27 KC	normal	37.69	0.57	0.57	lung 27	
lung 24 KC	COPD	40	0	0.00	lung 24	-40.17
lung 28 KC	COPD	40	0	0.00	lung 28	-40.17
lung 23 KC	COPD	40	0	0.00	lung 23	-40.17
lung 25 KC	normal	36.86	0.97	0.97	lung 25	
asthmatic lung ODO3112	29321	33.08	10.79	10.79	asthmatic lung	-3.72
asthmatic lung ODO3433	29323	29.94	80.31	160.62	asthmatic lung	4.00
asthmatic lung ODO3397	29322	29.79	87.94	175.88	asthmatic lung	4.38
asthmatic lung ODC4928	29325	30.08	73.39	146.78	asthmatic lung	3.65
endo cells KC	control	40	0.13	0.13	endo cells	
endo VEGF KC		40	0	0.00	endo VEGF	-0.13
endo bFGF KC		40	0.12	0.12	endo bFGF	-1.08
heart Clontech	normal	34.66	3.95	7.90	heart	
heart ( T-1 ) ischemic	29417	30.43	58.48	116.96	heart T-1	14.81
heart (T-14) non-obstructive DCM	29422	30.3	63.76	127.52	heart T-14	16.14
heart (T-3399) DCM	29426	31.14	37.27	74.54	heart T-3399	9.44
adenoid GW99-269	26162	33.15	10.31	20.62	adenoid	
tonsil GW98-280	22582	30.26	65.22	130.44	tonsil	
T cells PC00314	28453	33.29	9.45	18.90	T cells	
PBMNC		40	0	0.00	PBMNC	
monocyte		40	0	0.00	monocyte	
B cells PC00665	28455	32.25	18.35	36.70	B cells	
dendritic cells 28441		30.52	55.34	110.68	dendritic cells	
neutrophils	28440	31.61	27.61	27.61	neutrophils	
eosinophils	28446	33.2	10.01	20.02	eosinophils	
BM unstim		40	0	0.00	BM unstim	
BM stim		40	0	0.00	BM stim	0.00
osteo dif		40	0	0.00	osteo dif	0.00
osteo undif		40	0	0.00	osteo undif	
chondrocytes		29.65	96.25	240.63	chondrocytes	

OA Synovium IP12/01	29462	28.59	190.09	190.09	OA Synovium	
OA Synovium NP10/01	29461	29.06	140.66	281.32	OA Synovium	
OA Synovium NP57/00	28464	28.38	216.61	433.22	OA Synovium	
RA Synovium NP03/01	28466	29.43	111	222.00	RA Synovium	
RA Synovium NP71/00	28467	28.35	220.48	440.96	RA Synovium	
RA Synovium NP45/00	28475	28.7	176.79	353.58	RA Synovium	
OA bone (biobank)	29217	30.6	52.6	52.60	OA bone (biobank)	
OA bone Sample 1	J. Emory	29.64	97.1	194.20	OA bone	
OA bone Sample 2	J. Emory	30.85	44.71	89.42	OA bone	
Cartilage (pool)	Normal	28.07	264.86	529.72	Cartilage (pool)	
Cartilage (pool)	OA	30.47	56.97	113.94	Cartilage (pool)	-4.65
PBL uninfected	28441	33.41	8.73	17.46	PBL uninfected	
PBL HIV IIIB	28442	32.1	20.17	40.34	PBL HIV IIIB	2.31
MRC5 uninfected (100%)	29158	31.09	38.5	77.00	MRC5 uninfected (100%)	
MRC5 HSV strain F	29178	28.24	237.46	474.92	MRC5 HSV strain F	6.17
W12 cells	29179	28.83	162.45	324.90	W12 cells	
Keratinocytes	29180	29.21	127.89	255.78	Keratinocytes	
B-actin control		26.99	528.52			
genomic		25.66	1229.15			
1.00E+05		18.76	100000			
1.00E+05		19.03	100000			
1.00E+04		22.01	10000			
1.00E+04		22.05	10000			
1.00E+03		26.01	1000			
1.00E+03		25.68	1000			
1.00E+02		30.57	100			
1.00E+02		30.32	100			
1.00E+01		32.24	10			
1.00E+01		40	0			
1.00E-00		40	0			
1.00E-00		40	0			
NTC		40	0			

Gene Name sbg120703RNase

Disease tissues	Fold Change in Disease Population Relative to Normal
colon tumor	1.59
colon tumor	10.95
colon tumor	-1.29
colon tumor	-2.19
lung tumor	-7.77

lung tumor	3.87
lung tumor	-5.80
lung tumor	1.26
breast tumor	2.45
breast tumor	5.96
breast tumor	6.73
breast tumor	-3.21
brain stage 5 ALZ	-1.26
brain stage 5 ALZ	3.94
brain stage 5 ALZ	1.94
brain stage 5 ALZ	-1.77
lung 24	-40.17
lung 28	-40.17
lung 23	-40.17
asthmatic lung	-3.72
asthmatic lung	4.00
asthmatic lung	4.38
asthmatic lung	3.65
endo VEGF	-0.13
endo bFGF	-1.08
heart T-1	14.81
heart T-14	16.14
heart T-3399	9.44
BM stim	0.00
osteo undif	0.00
Cartilage (pool)	-4.65
PBL HIV IIIB	2.31
MRC5 HSV strain F	6.17

**Gene Name sbg98530TS**

5 Moderate overall expression in normal and disease samples. Highest normal expression in whole brain, endometrium, and testis. Moderate expression in normal heart, skeletal muscle, and esophagus. Shows expression in most of the GI tract samples as well as the female reproductive tract samples. Highest disease expression in one of the colon tumor samples, all 3 of the heart samples, and the chondrocytes. Data predominantly shows a muscle-specific pattern of expression.

10 Upregulation in 1 of 4 colon tumors and upregulation in 2 of 4 breast tumors implies an involvement in cancers of the colon and breast. Downregulation in 3 of 3 COPD samples implies a role in chronic obstructive pulmonary disease. Downregulation in HSV implicates involvement in herpes simplex virus as a potential host factor. Moderate to low overall expression in immune cells. High expression in chondrocytes and OA and RA synovium suggests possible involvement in osteoarthritis and rheumatoid arthritis.

15

Sample sbg98530TS	Ct (sample 1 and 2)	Mean GOI copies (sample 1)	Mean GOI copies (sample 2)	Averag e GOI Copies	18S rRNA (ng)	50 ng/18S rRNA (ng)	copies of mRNA detecte d/50 ng total RNA
Subcutaneous Adipocytes Zenbio	40, 36.35	0	4.22	2.11	3.06	16.34	34.48
Subcutaneous Adipose Zenbio	35.78, 40	5.89	0	2.95	0.96	52.36	154.19
Adrenal Gland Clontech	40, 40	0	0	0.00	0.61	81.97	0.00

Whole Brain Clontech	26.63, 26.42	1253.02	1414.2	1333.61	7.24	6.91	9210.01
Fetal Brain Clontech	40, 37.33	0	2.38	1.19	0.48	103.95	123.70
Cerebellum Clontech	35.9, 40	5.5	0	2.75	2.17	23.04	63.36
Cervix	33.47, 34.27	22.86	14.26	18.56	2.42	20.66	383.47
Colon	34.49, 34.05	12.58	16.28	14.43	2.71	18.45	266.24
Endometrium	33.28, 32.94	25.41	31.15	28.28	0.73	68.21	1929.06
Esophagus	33.61, 32.9	21.02	31.85	26.44	1.37	36.50	964.78
Heart Clontech	33.32, 33.03	24.91	29.42	27.17	1.32	37.88	1028.98
Hypothalamus	40, 40	0	0	0.00	0.32	155.28	0.00
Ileum	35.89, 33.37	5.53	24.14	14.84	2.58	19.38	287.50
Jejunum	31.55, 31.42	70.2	75.71	72.96	6.60	7.58	552.69
Kidney	40, 35.5	0	6.96	3.48	2.12	23.58	82.08
Liver	34.29, 33.63	14.07	20.78	17.43	1.50	33.33	580.83
Fetal Liver Clontech	32.16, 32.92	49.02	31.52	40.27	10.40	4.81	193.61
Lung	40, 35.78	0		2.95	2.57	19.46	57.30
Mammary Gland Clontech	31.42, 32.08	75.62	51.54	63.58	13.00	3.85	244.54
Myometrium	32.93, 32.03	31.21	52.84	42.03	2.34	21.37	897.97
Omentum	35.21, 40	8.23	0	4.12	3.94	12.69	52.22
Ovary	35.36, 35.51	7.53	6.89	7.21	4.34	11.52	83.06
Pancreas	40, 40	0	0	0.00	0.81	61.80	0.00
Head of Pancreas	40, 37.54	0	2.11	1.06	1.57	31.85	33.60
Parotid Gland	31.67, 31.01	65.33	96.46	80.90	5.48	9.12	738.09
Placenta Clontech	33.13, 32.05	27.88	52.3	40.09	5.26	9.51	381.08
Prostate	35.03, 40	9.13	5.22	7.18	3.00	16.67	119.58
Rectum	40, 35.19	0	8.32	4.16	1.23	40.65	169.11
Salivary Gland Clontech	32.41, 34.06	42.32	16.15	29.24	7.31	6.84	199.97
Skeletal Muscle Clontech	33.93, 33.76	17.41	19.28	18.35	1.26	39.68	727.98
Skin	40, 40	0	0	0.00	1.21	41.32	0.00
Small Intestine Clontech	34.11	11.73	15.7	13.72	0.98	51.07	700.46
Spleen	36.08, 40	4.94	0.37	2.66	4.92	10.16	26.98
Stomach	40, 40	0	0	0.00	2.73	18.32	0.00
Testis Clontech	35.54, 33.26	6.79	25.83	16.31	0.57	87.87	1433.22
Thymus Clontech	33.66, 34.12	20.35	15.62	17.99	9.89	5.06	90.93
Thyroid	40, 35.46	0	7.12	3.56	2.77	18.05	64.26
Trachea Clontech	32.08, 31.84	51.54	59.21	55.38	9.71	5.15	285.14
Urinary Bladder	34.75, 36.99	10.8	2.91	6.86	5.47	9.14	62.66
Uterus	31.79, 32.2	60.97	47.95	54.46	5.34	9.36	509.93
genomic	26.8	1133.17					
b-actin	27.6	706.62					
1.00E+05	19.53	100000					
1.00E+05	19.54	100000					
1.00E+04	22.8	10000					
1.00E+04	23.02	10000					
1.00E+03	26.14	1000					
1.00E+03	26.59	1000					

1.00E+02	31.41	100					
1.00E+02	30.97	100					
1.00E+01	40	0					
1.00E+01	35.24	10					
1.00E-00	40	0					
1.00E-00	40	0					
NTC	40	0					
NTC	40	0					

Sample sbg98530TS	Reg number (GSK identifier )	Ct	Mean GOI copies	copies of mRNA detecte d/50 ng total RNA	Sample	Fold Change in Disease Populat ion
colon normal GW98-167	21941	26.26	1792.89	3585.78	colon normal	
colon tumor GW98-166	21940	26.2	1856.22	3712.44	colon tumor	1.04
colon normal GW98-178	22080	27.25	986.8	1973.60	colon normal	
colon tumor GW98-177	22060	26.7	1369.12	2738.24	colon tumor	1.39
colon normal GW98-561	23514	27.55	821.35	1642.70	colon normal	
colon tumor GW98-560	23513	24.64	4748.96	9497.92	colon tumor	5.78
colon normal GW98-894	24691	27.27	971.87	1943.74	colon normal	
colon tumor GW98-893	24690	25.35	3093.47	6186.94	colon tumor	3.18
lung normal GW98-3	20742	27.02	1133.68	2267.36	lung normal	
lung tumor GW98-2	20741	27.26	981.94	1963.88	lung tumor	-1.15
lung normal GW97-179	20677	29.14	315.07	630.14	lung normal	
lung tumor GW97-178	20676	28.15	571.76	1143.52	lung tumor	1.81
lung normal GW98-165	21922	27.86	682.2	1364.40	lung normal	
lung tumor GW98-164	21921	27.45	871.19	1742.38	lung tumor	1.28
lung normal GW98-282	22584	28.12	581.74	1163.48	lung normal	
lung tumor GW98-281	22583	29.32	283.71	567.42	lung tumor	-2.05
breast normal GW00-392	28750	27.85	687.38	687.38	breast normal	
breast tumor GW00-391	28746	26.61	1444.19	2888.38	breast tumor	4.20
breast normal GW00-413	28798	28.43	483.03	483.03	breast normal	
breast tumor GW00-412	28797	25.49	2836.66	5673.32	breast tumor	11.75
breast normal GW00- 235:238	27592-95	32.26	48.29	48.29	breast normal	
breast tumor GW00- 231:234	27588-91	29.07	328.46	328.46	breast tumor	6.80
breast normal GW98-621	23656	26.82	1279.07	2558.14	breast normal	
breast tumor GW98-620	23655	26.8	1289.27	2578.54	breast tumor	1.01
brain normal BB99-542	25507	29.03	337.63	675.26	brain normal	
brain normal BB99-406	25509	29.19	305.6	611.20	brain normal	
brain normal BB99-904	25546	30.44	144.55	289.10	brain normal	
brain stage 5 ALZ BB99- 874	25502	28.47	471.8	943.60	brain stage 5 ALZ	1.80
brain stage 5 ALZ BB99- 887	25503	27.3	955.52	1911.04	brain stage 5 ALZ	3.64

brain stage 5 ALZ BB99-862	25504	27.42	891.77	1783.54	brain stage 5 ALZ	3.40
brain stage 5 ALZ BB99-927	25542	29.31	285.16	570.32	brain stage 5 ALZ	1.09
CT lung KC	normal	27.96	643.88	1287.76	CT lung	
lung 26 KC	normal	35.82	5.66	5.66	lung 26	
lung 27 KC	normal	40	0	0.00	lung 27	
lung 24 KC	COPD	40	0	0.00	lung 24	-325.52
lung 28 KC	COPD	35.3	7.73	7.73	lung 28	-42.11
lung 23 KC	COPD	36.67	3.39	3.39	lung 23	-96.02
lung 25 KC	normal	35.11	8.67	8.67	lung 25	
asthmatic lung ODO3112	29321	31.01	102.08	102.08	asthmatic lung	-3.19
asthmatic lung ODO3433	29323	29.76	216.81	433.62	asthmatic lung	1.33
asthmatic lung ODO3397	29322	29.83	208.08	416.16	asthmatic lung	1.28
asthmatic lung ODO4928	29325	30.37	150.17	300.34	asthmatic lung	-1.08
endo cells KC	control	37.54	2	2.00	endo cells	
endo VEGF KC		35.77	5.83	5.83	endo VEGF	2.92
endo bFGF KC		40	0	0.00	endo bFGF	-2.00
heart Clontech	normal	26.09	1982.44	3964.88	heart	
heart ( T-1 ) ischemic	29417	24	6956.27	13912.54	heart T-1	3.51
heart (T-14) non-obstructive DCM	29422	24.55	5010.03	10020.06	heart T-14	2.53
heart (T-3399) DCM	29426	24.05	6766.57	13533.14	heart T-3399	3.41
adenoid GW99-269	26162	30.56	134.11	268.22	adenoid	
tonsil GW98-280	22582	27.94	651.01	1302.02	tonsil	
T cells PC00314	28453	29.8	212.45	424.90	T cells	
PBMNC		33.01	30.69	30.69	PBMNC	
monocyte		33.42	23.9	47.80	monocyte	
B cells PC00665	28455	33.52	22.59	45.18	B cells	
dendritic cells 28441		29.07	329.58	659.16	dendritic cells	
neutrophils	28440	30.39	149	149.00	neutrophils	
eosinophils	28446	35.41	7.25	14.50	eosinophils	
BM unstim		34.24	14.65	14.65	BM unstim	
BM stim		36.61	3.51	3.51	BM stim	-4.17
osteodif		30.55	135.33	135.33	osteodif	3.02
osteoundif		32.38	44.88	44.88	osteoundif	
chondrocytes		25.35	3089.54	7723.85	chondrocytes	
OA Synovium IP12/01	29462	28.75	398.53	398.53	OA Synovium	
OA Synovium NP10/01	29461	27.04	1119.77	2239.54	OA Synovium	
OA Synovium NP57/00	28464	28.85	375.92	751.84	OA Synovium	
RA Synovium NP03/01	28466	28.14	574.66	1149.32	RA Synovium	
RA Synovium NP71/00	28467	27.58	806.11	1612.22	RA Synovium	
RA Synovium NP45/00	28475	28.04	611.1	1222.20	RA Synovium	
OA bone (biobank)	29217	30.25	161.3	161.30	OA bone (biobank)	
OA bone Sample 1	J. Emory	31.24	89.29	178.58	OA bone	
OA bone Sample 2	J. Emory	30.98	104.34	208.68	OA bone	

Cartilage (pool)	Normal	29.86	204.47	408.94	Cartilage (pool)	
Cartilage (pool)	OA	29.37	275.09	550.18	Cartilage (pool)	1.35
PBL uninfected	28441	26.45	1598.39	3196.78	PBL uninfected	
PBL HIV IIIB	28442	27.57	814.58	1629.16	PBL HIV IIIB	-1.96
MRC5 uninfected (100%)	29158	25.13	3539.95	7079.90	MRC5 uninfected (100%)	
MRC5 HSV strain F	29178	30.49	139.89	279.78	MRC5 HSV strain F	-25.31
W12 cells	29179	26.72	1359.04	2718.08	W12 cells	
Keratinocytes	29180	26.41	1633.77	3267.54	Keratinocytes	
B-actin control		27.87	678.8			
genomic		26.9	1214.71			
1.00E+05		19.86	100000			
1.00E+05		19.82	100000			
1.00E+04		23.15	10000			
1.00E+04		23.21	10000			
1.00E+03		26.62	1000			
1.00E+03		26.79	1000			
1.00E+02		31.2	100			
1.00E+02		32.2	100			
1.00E+01		40	0			
1.00E+01		34.53	10			
1.00E-00		40	0			
1.00E-00		40	0			
NTC		40	0			

Gene Name sbg98530TS

Disease tissues	Fold Change in Disease Population Relative to Normal
colon tumor	1.04
colon tumor	1.39
colon tumor	5.78
colon tumor	3.18
lung tumor	-1.15
lung tumor	1.81
lung tumor	1.28
lung tumor	-2.05
breast tumor	4.20
breast tumor	11.75
breast tumor	6.80
breast tumor	1.01
brain stage 5 ALZ	1.80
brain stage 5 ALZ	3.64
brain stage 5 ALZ	3.40
brain stage 5 ALZ	1.09
lung 24	-325.52
lung 28	-42.11
lung 23	-96.02
asthmatic lung	-3.19
asthmatic lung	1.33

asthmatic lung	1.28
asthmatic lung	-1.08
endo VEGF	2.92
endo bFGF	-2.00
heart T-1	3.51
heart T-14	2.53
heart T-3399	3.41
BM stim	-4.17
osteoblast undif	3.02
Cartilage (pool)	1.35
PBL HIV IIIB	-1.96
MRC5 HSV strain F	-25.31

## Gene Name sbg563917RDP

5 Moderate to low overall expression in normal and disease samples. Highest normal expression in testis liver, trachea, and whole brain. Shows good expression in most of the GI tract samples.

10 Highest disease expression in T cells, B cells, neutrophils, and eosinophils. Upregulation in 1 of 4 breast tumors implies involvement in cancer of the breast. Downregulation in 3 of 3 COPD lungs suggests an involvement in chronic obstructive pulmonary disease. Downregulation in the ischemic heart sample implicates this gene in ischemic heart disease. Downregulation in the VEGF and bFGF-treated endothelial cells suggests a role in angiogenesis. Upregulation in HSV implicates involvement in herpes simplex virus as a potential host factor.

Sample sbg563917RDP	Ct (sample 1 and 2)	Mean GOI copies (sample 1)	Mean GOI copies (sample 2)	Avera ge GOI Copies	18S rRNA (ng)	50 ng/18S rRNA (ng)	copies of mRNA detec ted/50 ng total RNA
Subcutaneous Adipocytes Zenbio	35.34, 40	3.66	0	1.83	3.06	16.34	29.90
Subcutaneous Adipose Zenbio	40, 40	0		0.00	0.96	52.36	0.00
Adrenal Gland Clontech	40, 40	0	0	0.00	0.61	81.97	0.00
Whole Brain Clontech	30.09, 30.01	91.85	96.8	94.33	7.24	6.91	651.42
Fetal Brain Clontech	40, 40	0	0	0.00	0.48	103.95	0.00
Cerebellum Clontech	35.19, 40	4.03	0	2.02	2.17	23.04	46.43
Cervix	36.08, 40	2.33	0	1.17	2.42	20.66	24.07
Colon	36.07, 35.1	2.35	4.24	3.30	2.71	18.45	60.79
Endometrium	35.01, 40	4.49	0	2.25	0.73	68.21	153.14
Esophagus	34.94, 40	4.68	0	2.34	1.37	36.50	85.40
Heart Clontech	40, 40	0	0	0.00	1.32	37.88	0.00
Hypothalamus	40, 40	0	0	0.00	0.32	155.28	0.00
Ileum	35.24, 40	3.89	0	1.95	2.58	19.38	37.69
Jejunum	35.37, 33.35	3.6	12.44	8.02	6.60	7.58	60.76
Kidney	40, 34.97	0	4.6	2.30	2.12	23.58	54.25
Liver	33.51, 34.6	11.25	5.78	8.52	1.50	33.33	283.83
Fetal Liver Clontech	33.19, 35.54	13.75	3.25	8.50	10.40	4.81	40.87
Lung	34.32	6.84	2.28	4.56	2.57	19.46	88.72
Mammary Gland Clontech	40, 35.14	0	4.15	2.08	13.00	3.85	7.98

Myometrium	40, 40	0	0.09	0.05	2.34	21.37	0.96
Omentum	36.17, 33.01	2.2	15.32	8.76	3.94	12.69	111.17
Ovary	40, 40	0	0	0.00	4.34	11.52	0.00
Pancreas	40, 40	0	0	0.00	0.81	61.80	0.00
Head of Pancreas	40, 40	0	0	0.00	1.57	31.85	0.00
Parotid Gland	35.43, 39.81	3.46	0.24	1.85	5.48	9.12	16.88
Placenta Clontech	33.7, 35.45	10.02	3.42	6.72	5.26	9.51	63.88
Prostate	40, 40	0	0	0.00	3.00	16.67	0.00
Rectum	40, 40	0	0	0.00	1.23	40.65	0.00
Salivary Gland Clontech	34.89, 40	4.83	0	2.42	7.31	6.84	16.52
Skeletal Muscle Clontech	40, 40	0	0	0.00	1.26	39.68	0.00
Skin	40, 40	0	0	0.00	1.21	41.32	0.00
Small Intestine Clontech	40, 40	0	0	0.00	0.98	51.07	0.00
Spleen	35.01, 33.36	4.48	12.38	8.43	4.92	10.16	85.67
Stomach	33.38, 34.18	12.18	7.48	9.83	2.73	18.32	180.04
Testis Clontech	34.25, 32.86	7.17	16.84	12.01	0.57	87.87	1054.92
Thymus Clontech	32.14, 33.25	26.17	13.24	19.71	9.89	5.06	99.62
Thyroid	40, 40	0	0.09	0.05	2.77	18.05	0.81
Trachea Clontech	31.41, 31	41.04	52.65	46.85	9.71	5.15	241.22
Urinary Bladder	40, 35.05	0	4.38	2.19	5.47	9.14	20.02
Uterus	33.77, 33.41	9.62	12	10.81	5.34	9.36	101.22
genomic	26.54	813.56					
b-actin	27.39	481.34					
1.00E+05	18.71	100000					
1.00E+05	18.92	100000					
1.00E+04	22.44	10000					
1.00E+04	22.11	10000					
1.00E+03	26.05	1000					
1.00E+03	26.11	1000					
1.00E+02	30.4	100					
1.00E+02	30.17	100					
1.00E+01	33.87	10					
1.00E+01	33.26	10					
1.00E-00	40	0					
1.00E-00	40	0					
NTC	40	0					
NTC	40	0					

Sample sbg563917RDP	Reg number (GSK identifier )	Ct	Mean GOI copies	copies of mRNA detec- ted/50 ng total RNA	Sample	Fold Change in Disease Population
colon normal GW98-167	21941	30.39	148.35	296.70	colon normal	

colon tumor GW98-166	21940	30.93	110.14	220.28	colon tumor	-1.35
colon normal GW98-178	22080	32.93	36.71	73.42	colon normal	
colon tumor GW98-177	22060	34.8	13.09	26.18	colon tumor	-2.80
colon normal GW98-561	23514	31.41	84.68	169.36	colon normal	
colon tumor GW98-560	23513	32.09	58.33	116.66	colon tumor	-1.45
colon normal GW98-894	24691	30.02	182.15	364.30	colon normal	
colon tumor GW98-893	24690	31.12	99.26	198.52	colon tumor	-1.84
lung normal GW98-3	20742	28.4	443.99	887.98	lung normal	
lung tumor GW98-2	20741	33.59	25.44	50.88	lung tumor	-17.45
lung normal GW97-179	20677	28.63	391.85	783.70	lung normal	
lung tumor GW97-178	20676	29.16	292.08	584.16	lung tumor	-1.34
lung normal GW98-165	21922	29.13	296.8	593.60	lung normal	
lung tumor GW98-164	21921	30.22	163.43	326.86	lung tumor	-1.82
lung normal GW98-282	22584	31.71	71.72	143.44	lung normal	
lung tumor GW98-281	22583	31.74	70.77	141.54	lung tumor	-1.01
breast normal GW00-392	28750	31.49	81.02	81.02	breast normal	
breast tumor GW00-391	28746	33.58	25.62	51.24	breast tumor	-1.58
breast normal GW00-413	28798	35.07	11.31	11.31	breast normal	
breast tumor GW00-412	28797	31.99	61.52	123.04	breast tumor	10.88
breast normal GW00-235:238	27592-95	35.63	8.3	8.30	breast normal	
breast tumor GW00-231:234	27588-91	34.33	16.97	16.97	breast tumor	2.04
breast normal GW98-621	23656	32.07	58.95	117.90	breast normal	
breast tumor GW98-620	23655	32.71	41.33	82.66	breast tumor	-1.43
brain normal BB99-542	25507	30.16	168.86	337.72	brain normal	
brain normal BB99-406	25509	31.12	99.35	198.70	brain normal	
brain normal BB99-904	25546	31.14	98.44	196.88	brain normal	
brain stage 5 ALZ BB99-874	25502	33.16	32.39	64.78	brain stage 5 ALZ	-3.77
brain stage 5 ALZ BB99-887	25503	29.32	267.28	534.56	brain stage 5 ALZ	2.19
brain stage 5 ALZ BB99-862	25504	30.36	150.72	301.44	brain stage 5 ALZ	1.23
brain stage 5 ALZ BB99-927	25542	30.1	174.01	348.02	brain stage 5 ALZ	1.42
CT lung KC	normal	31.06	102.88	205.76	CT lung	
lung 26 KC	normal	32.15	56.21	56.21	lung 26	
lung 27 KC	normal	35.96	6.92	6.92	lung 27	
lung 24 KC	COPD	40	0	0.00	lung 24	-70.34
lung 28 KC	COPD	36.21	6.05	6.05	lung 28	-11.63
lung 23 KC	COPD	34.83	12.87	12.87	lung 23	-5.47
lung 25 KC	normal	34.89	12.45	12.45	lung 25	
asthmatic lung ODO3112	29321	32.57	44.76	44.76	asthmatic lung	-1.57
asthmatic lung ODO3433	29323	32.4	49.04	98.08	asthmatic lung	1.39
asthmatic lung ODO3397	29322	31.79	68.64	137.28	asthmatic lung	1.95
asthmatic lung ODO4928	29325	31.34	88.11	176.22	asthmatic lung	2.51
endo cells KC	control	35.77	7.68	7.68	endo cells	
endo VEGF KC		40	0	0.00	endo VEGF	-7.68

endo bFGF KC		40	0	0.00	endo bFGF	-7.68
heart Clontech	normal	31.09	100.75	201.50	heart	
heart ( T-1 ) ischemic	29417	34.75	13.46	26.92	heart T-1	-7.49
heart (T-14) non-obstructive DCM	29422	33.69	24.17	48.34	heart T-14	-4.17
heart (T-3399) DCM	29426	33.48	27.16	54.32	heart T-3399	-3.71
adenoid GW99-269	26162	30.49	140.7	281.40	adenoid	
tonsil GW98-280	22582	30.07	177.32	354.64	tonsil	
T cells PC00314	28453	27.79	622.1	1244.20	T cells	
PBMNC		36.19	6.11	6.11	PBMNC	
monocyte		33.24	30.91	61.82	monocyte	
B cells PC00665	28455	26.37	1355.2	2710.40	B cells	
dendritic cells 28441		28.69	378.62	757.24	dendritic cells	
neutrophils	28440	23.28	7420.47	7420.47	neutrophils	
eosinophils	28446	25.33	2408.94	4817.88	eosinophils	
BM unstim		32.24	53.57	53.57	BM unstim	
BM stim		31.92	64.05	64.05	BM stim	1.20
osteodif		40	0	0.00	osteodif	0.00
osteoundif		40	0	0.00	osteoundif	
chondrocytes		37.59	2.82	7.05	chondrocytes	
OA Synovium IP12/01	29462	31.77	69.48	69.48	OA Synovium	
OA Synovium NP10/01	29461	31.16	96.93	193.86	OA Synovium	
OA Synovium NP57/00	28464	30.84	115.69	231.38	OA Synovium	
RA Synovium NP03/01	28466	30.96	108.37	216.74	RA Synovium	
RA Synovium NP71/00	28467	29.2	285.91	571.82	RA Synovium	
RA Synovium NP45/00	28475	29.87	198.12	396.24	RA Synovium	
OA bone (biobank)	29217	29.67	220.64	220.64	OA bone (biobank)	
OA bone Sample 1	J. Emory	30.54	136.41	272.82	OA bone	
OA bone Sample 2	J. Emory	29.38	259.07	518.14	OA bone	
Cartilage (pool)	Normal	31.34	87.88	175.76	Cartilage (pool)	
Cartilage (pool)	OA	32.9	37.23	74.46	Cartilage (pool)	-2.36
PBL uninfected	28441	30.55	135.85	271.70	PBL uninfected	
PBL HIV IIIB	28442	31.02	104.8	209.60	PBL HIV IIIB	-1.30
MRC5 uninfected (100%)	29158	35.11	11.06	22.12	MRC5 uninfected (100%)	
MRC5 HSV strain F	29178	29.63	226.14	452.28	MRC5 HSV strain F	20.45
W12 cells	29179	37.87	2.42	4.84	W12 cells	
Keratinocytes	29180	36.14	6.26	12.52	Keratinocytes	
B-actin control		27.14	887.42			
genomic		26.16	1520.17			
1.00E+05		19.22	100000			
1.00E+05		19.2	100000			
1.00E+04		22.49	10000			
1.00E+04		22.62	10000			
1.00E+03		26.23	1000			
1.00E+03		26.05	1000			
1.00E+02		30.26	100			

1.00E+02		31.03	100				
1.00E+01		38.68	10				
1.00E+01		33.47	10				
1.00E-00		40	0				
1.00E-00		40	0				
NTC		40	0				

## Gene Name sbg563917RDP

Disease tissues	Fold Change in Disease Population Relative to Normal
colon tumor	-1.35
colon tumor	-2.80
colon tumor	-1.45
colon tumor	-1.84
lung tumor	-17.45
lung tumor	-1.34
lung tumor	-1.82
lung tumor	-1.01
breast tumor	-1.58
breast tumor	10.88
breast tumor	2.04
breast tumor	-1.43
brain stage 5 ALZ	-3.77
brain stage 5 ALZ	2.19
brain stage 5 ALZ	1.23
brain stage 5 ALZ	1.42
lung 24	-70.34
lung 28	-11.63
lung 23	-5.47
asthmatic lung	-1.57
asthmatic lung	1.39
asthmatic lung	1.95
asthmatic lung	2.51
endo VEGF	-7.68
endo bFGF	-7.68
heart T-1	-7.49
heart T-14	-4.17
heart T-3399	-3.71
BM stim	1.20
osteo undif	0.00
Cartilage (pool)	-2.36
PBL HIV IIIB	-1.30
MRC5 HSV strain F	20.45

## 5 Gene Name sbg618069LRR

Low overall expression in normal and disease samples. Highest normal expression in whole brain, fetal brain, cerebellum, and thymus. Highest disease expression in one of the colon tumor samples, one of the lung tumor samples, and the uninfected PBL cells. Downregulation in 2 of 4 colon tumors suggests a role in cancer of the colon. Upregulation in 1 of 4 lung tumors and upregulation in 2 of 4 breast tumors suggest roles in cancers of the lung and breast. Downregulation in 3 of 3 COPD lung samples implicates a role for this gene in COPD. Upregulation in the stimulated bone marrow. Downregulation in an HIV-infected cell line as well as moderate expression in immune

10

cells suggests an involvement in HIV. Upregulation in HSV implicates involvement in herpes simplex virus as a potential host factor.

Sample sbg618069LRR	Ct (sample 1 and 2)	Mean GOI copies (sample 1)	Mean GOI copies (sample 2)	Average GOI Copies	18S rRNA (ng)	50 ng/18S rRNA (ng)	copies of mRNA detecte d/50 ng total RNA
Subcutaneous Adipocytes Zenbio	35.24, 34.33	4.38	7.65	6.02	3.06	16.34	98.28
Subcutaneous Adipose Zenbio	40, 40	0	0.08	0.04	0.96	52.36	2.09
Adrenal Gland Clontech	39.9, 38.74	0.13	0.51	0.32	0.61	81.97	26.23
Whole Brain Clontech	27.02, 26.51	673.36	916.93	795.15	7.24	6.91	5491.33
Fetal Brain Clontech	40, 40	0.13	6.01	3.07	0.48	103.95	319.13
Cerebellum Clontech	32.15, 32.13	28.98	29.44	29.21	2.17	23.04	673.04
Cervix	40, 40	0	0	0.00	2.42	20.66	0.00
Colon	36.53, 39.88	1.98	0.25	1.12	2.71	18.45	20.57
Endometrium	37.98, 40	0.82	0.19	0.51	0.73	68.21	34.45
Esophagus	38.86, 40	0.48	0.15	0.32	1.37	36.50	11.50
Heart Clontech	34.17, 34.72	8.41	6.03	7.22	1.32	37.88	273.48
Hypothalamus	40, 40	0	0.07	0.04	0.32	155.28	5.43
Ileum	40, 40	0.17	0.11	0.14	2.58	19.38	2.71
Jejunum	33.07, 34.34	16.52	7.58	12.05	6.60	7.58	91.29
Kidney	36.05, 40	2.67	0.21	1.44	2.12	23.58	33.96
Liver	38.72, 40	0.52	0.61	0.57	1.50	33.33	18.83
Fetal Liver Clontech	33.28, 36.35	14.52	2.22	8.37	10.40	4.81	40.24
Lung	40, 40	0.13	0.08	0.11	2.57	19.46	2.04
Mammary Gland Clontech	40, 34.19	0	8.33	4.17	13.00	3.85	16.02
Myometrium	40, 40	0.28	0	0.14	2.34	21.37	2.99
Omentum	35.01, 35.36	5.04	4.07	4.56	3.94	12.69	57.80
Ovary	34.24, 40	8.07	0.26	4.17	4.34	11.52	47.98
Pancreas	40, 40	0.11	0.13	0.12	0.81	61.80	7.42
Head of Pancreas	40, 40	0	0	0.00	1.57	31.85	0.00
Parotid Gland	34.01, 34.28	9.31	7.9	8.61	5.48	9.12	78.51
Placenta Clontech	40, 40	0	0.07	0.04	5.26	9.51	0.33
Prostate	40, 39.13	0.15	0.4	0.28	3.00	16.67	4.58
Rectum	40, 39.55	0.21	0.31	0.26	1.23	40.65	10.57
Salivary Gland Clontech	32.35, 33.08	25.74	16.45	21.10	7.31	6.84	144.29
Skeletal Muscle Clontech	34.78, 40	5.81	0.27	3.04	1.26	39.68	120.63
Skin	40, 40	0	0	0.00	1.21	41.32	0.00
Small Intestine Clontech	40, 40	0.16	0	0.08	0.98	51.07	4.09
Spleen	35.59, 40	3.53	0.59	2.06	4.92	10.16	20.93
Stomach	36.73, 40	1.76	0.11	0.94	2.73	18.32	17.12
Testis Clontech	37.91, 40	0.86	0.1	0.48	0.57	87.87	42.18

Thymus Clontech	30.22, 29.94	94.88	112.23	103.56	9.89	5.06	523.53
Thyroid	35.15, 40	4.62	0	2.31	2.77	18.05	41.70
Trachea Clontech	33.49, 34.21	12.75	8.22	10.49	9.71	5.15	53.99
Urinary Bladder	40, 40	0.09	0.08	0.09	5.47	9.14	0.78
Uterus	35.26, 33.03	4.31	16.97	10.64	5.34	9.36	99.63
genomic	26.04	1229.54					
b-actin	27.25	584.19					
1.00E+05	19.09	100000					
1.00E+05	19.04	100000					
1.00E+04	22.35	10000					
1.00E+04	22.35	10000					
1.00E+03	26.07	1000					
1.00E+03	26.26	1000					
1.00E+02	30.64	100					
1.00E+02	30.38	100					
1.00E+01	34.04	10					
1.00E+01	33.52	10					
1.00E-00	40	0					
1.00E-00	40	0					
NTC	40	0					
NTC	40	0					

Sample sbg618069LRR	Reg number (GSK identifier )	Ct	Mean GOI copies	copies of mRNA detec- ted/50 ng total RNA	Sample	Fold Change in Disease Popula- tion
colon normal GW98-167	21941	29.52	176.51	353.02	colon normal	
colon tumor GW98-166	21940	33.45	18.5	37.00	colon tumor	-9.54
colon normal GW98-178	22080	31.82	47.14	94.28	colon normal	
colon tumor GW98-177	22060	29.68	160.67	321.34	colon tumor	3.41
colon normal GW98-561	23514	30.33	110.78	221.56	colon normal	
colon tumor GW98-560	23513	33.11	22.39	44.78	colon tumor	-4.95
colon normal GW98-894	24691	28.1	396.95	793.90	colon normal	
colon tumor GW98-893	24690	26.93	779.99	1559.98	colon tumor	1.96
lung normal GW98-3	20742	30.41	105.78	211.56	lung normal	
lung tumor GW98-2	20741	26.28	1128.28	2256.56	lung tumor	10.67
lung normal GW97-179	20677	29.28	201.91	403.82	lung normal	
lung tumor GW97-178	20676	28.35	345.36	690.72	lung tumor	1.71
lung normal GW98-165	21922	28.42	331.95	663.90	lung normal	
lung tumor GW98-164	21921	30.98	76.05	152.10	lung tumor	-4.36
lung normal GW98-282	22584	34.15	12.36	24.72	lung normal	
lung tumor GW98-281	22583	32.08	40.6	81.20	lung tumor	3.28
breast normal GW00-392	28750	29.67	161.68	161.68	breast normal	
breast tumor GW00-391	28746	28.98	239.65	479.30	breast tumor	2.96
breast normal GW00-413	28798	31.78	48.04	48.04	breast normal	

breast tumor GW00-412	28797	29.69	159.55	319.10	breast tumor	6.64
breast normal GW00-235:238	27592-95	34.18	12.14	12.14	breast normal	
breast tumor GW00-231:234	27588-91	29.2	211.28	211.28	breast tumor	17.40
breast normal GW98-621	23656	29.72	157.4	314.80	breast normal	
breast tumor GW98-620	23655	31.12	70.17	140.34	breast tumor	-2.24
brain normal BB99-542	25507	30.81	83.89	167.78	brain normal	
brain normal BB99-406	25509	31.02	74.28	148.56	brain normal	
brain normal BB99-904	25546	31.39	60.08	120.16	brain normal	
brain stage 5 ALZ BB99-874	25502	32.54	31.07	62.14	brain stage 5 ALZ	-2.34
brain stage 5 ALZ BB99-887	25503	30.65	92.1	184.20	brain stage 5 ALZ	1.27
brain stage 5 ALZ BB99-862	25504	31.68	50.92	101.84	brain stage 5 ALZ	-1.43
brain stage 5 ALZ BB99-927	25542	31.39	60.36	120.72	brain stage 5 ALZ	-1.21
CT lung KC	normal	30.47	101.87	203.74	CT lung	
lung 26 KC	normal				lung 26	
lung 27 KC	normal	39.27	0.65	0.65	lung 27	
lung 24 KC	COPD	40	0	0.00	lung 24	-68.13
lung 28 KC	COPD	37.38	1.93	1.93	lung 28	-35.30
lung 23 KC	COPD	34.28	11.47	11.47	lung 23	-5.94
lung 25 KC	normal	40	0	0.00	lung 25	
asthmatic lung ODO3112	29321	33.17	21.73	21.73	asthmatic lung	-3.14
asthmatic lung ODO3433	29323	32.35	34.64	69.28	asthmatic lung	1.02
asthmatic lung ODO3397	29322	30.83	83.1	166.20	asthmatic lung	2.44
asthmatic lung ODO4928	29325	30.94	77.99	155.98	asthmatic lung	2.29
endo cells KC	control	40	0	0.00	endo cells	
endo VEGF KC		40	0	0.00	endo VEGF	0.00
endo bFGF KC		40	0	0.00	endo bFGF	0.00
heart Clontech	normal	30.52	99.45	198.90	heart	
heart ( T-1 ) ischemic	29417	28.78	270.18	540.36	heart T-1	2.72
heart (T-14) non-obstructive DCM	29422	29.62	166.76	333.52	heart T-14	1.68
heart (T-3399) DCM	29426	30.05	129.76	259.52	heart T-3399	1.30
adenoid GW99-269	26162	29.05	230.93	461.86	adenoid	
tonsil GW98-280	22582	29.77	152.22	304.44	tonsil	
T cells PC00314	28453	31.6	53.48	106.96	T cells	
PBMNC		39.8	0.48	0.48	PBMNC	
monocyte		40	0	0.00	monocyte	
B cells PC00665	28455	31.56	54.77	109.54	B cells	
dendritic cells 28441		34.09	12.8	25.60	dendritic cells	
neutrophils	28440	34.03	13.21	13.21	neutrophils	
eosinophils	28446	40	0	0.00	eosinophils	
BM unstim		40	0	0.00	BM unstim	
BM stim		35.71	5.04	5.04	BM stim	5.04
osteo dif		40	0	0.00	osteo dif	0.00
osteo undif		40	0	0.00	osteo undif	

chondrocytes		33.5	17.89	44.73	chondrocytes	
OA Synovium IP12/01	29462	32.24	37.02	37.02	OA Synovium	
OA Synovium NP10/01	29461	27.95	434.95	869.90	OA Synovium	
OA Synovium NP57/00	28464	30.9	79.82	159.64	OA Synovium	
RA Synovium NP03/01	28466	31.79	47.9	95.80	RA Synovium	
RA Synovium NP71/00	28467	33.06	23.05	46.10	RA Synovium	
RA Synovium NP45/00	28475	32.76	27.41	54.82	RA Synovium	
OA bone (biobank)	29217	32.02	42.02	42.02	OA bone (biobank)	
OA bone Sample 1	J. Emory	31.32	62.63	125.26	OA bone	
OA bone Sample 2	J. Emory	33.13	22.24	44.48	OA bone	
Cartilage (pool)	Normal	30.76	86.51	173.02	Cartilage (pool)	
Cartilage (pool)	OA	33.13	22.15	44.30	Cartilage (pool)	-3.91
PBL uninfected	28441	26.78	847.01	1694.02	PBL uninfected	
PBL HIV IIIB	28442	28.21	374.26	748.52	PBL HIV IIIB	-2.26
MRC5 uninfected (100%)	29158	40	0	0.00	MRC5 uninfected (100%)	
MRC5 HSV strain F	29178	31.26	64.96	129.92	MRC5 HSV strain F	129.92
W12 cells	29179	40	0	0.00	W12 cells	
Keratinocytes	29180	39.77	0.49	0.98	Keratinocytes	
B-actin control		27.18	675.17			
genomic		25.96	1358.6			
1.00E+05		18.58	100000			
1.00E+05		18.53	100000			
1.00E+04		22.04	10000			
1.00E+04		22.1	10000			
1.00E+03		25.85	1000			
1.00E+03		26.11	1000			
1.00E+02		34.02	100			
1.00E+02		30.53	100			
1.00E+01		32.98	10			
1.00E+01		40	0			
1.00E-00		40	0			
1.00E-00		38.21	1			
NTC		40	0			

## Gene Name sbg618069LRR

Disease tissues	Fold Change in Disease Population Relative to Normal
colon tumor	-9.54
colon tumor	3.41
colon tumor	-4.95
colon tumor	1.96
lung tumor	10.67
lung tumor	1.71
lung tumor	-4.36
lung tumor	3.28

breast tumor	2.96
breast tumor	6.64
breast tumor	17.40
breast tumor	-2.24
brain stage 5 ALZ	-2.34
brain stage 5 ALZ	1.27
brain stage 5 ALZ	-1.43
brain stage 5 ALZ	-1.21
lung 24	-68.13
lung 28	-35.30
lung 23	-5.94
asthmatic lung	-3.14
asthmatic lung	1.02
asthmatic lung	2.44
asthmatic lung	2.29
endo VEGF	0.00
endo bFGF	0.00
heart T-1	2.72
heart T-14	1.68
heart T-3399	1.30
BM stim	5.04
osteo dif	0.00
Cartilage (pool)	-3.91
PBL HIV IIIB	-2.26
MRC5 HSV strain F	129.92

**Gene Name sbg934114Relaxin**

5 Low overall expression in normal and disease samples. Highest normal expression in testis, liver, and whole brain. Highest disease expression in 3 of the normal lung samples, one of the normal tumor samples, the HSV-infected MRC5 cells, the adenoid, and the T cells. Highest disease expression in 2 of the normal lung samples, one of the lung tumor samples, 1 of the normal breast samples, 1 of the breast tumor samples, and the uninfected PBL samples. Downregulation in 1 of 4 colon tumors and downregulation in 2 of 4 lung tumors imply roles in cancers of the colon and lung.

10 Downregulation in 3 of 3 COPD lung samples and upregulation in 3 of 4 asthmatic lung samples implicates this gene in COPD and asthma. Upregulation in 2 of 3 heart samples proposes roles in non-obstructive and obstructive DCM. Downregulation in the OA cartilage pool and low expression in RA and OA synovium, OA bone, and chondrocytes suggests an involvement in osteoarthritis and rheumatoid arthritis. Downregulation in an HIV-infected primary cell line suggests an involvement in HIV. Upregulation in HSV implicates involvement in herpes simplex virus as a potential host factor.

Sample sbg934114Relaxin	Ct (sample 1 and 2)	Mean GOI copies (sample 1)	Mean GOI copies (sample 2)	Average GOI Copies	18S rRNA (ng)	50 ng/18S rRNA (ng)	copies of mRNA detec- ted/50 ng total RNA
Subcutaneous Adipocytes Zenbio	37.4, 40	5.41	0	2.71	3.06	16.34	44.20

Subcutaneous Adipose Zenbio	40, 40	0.73	0	0.37	0.96	52.36	19.11
Adrenal Gland Clontech	40, 40	0.73	0.69	0.71	0.61	81.97	58.20
Whole Brain Clontech	33.52, 34.72	47.76	24.26	36.01	7.24	6.91	248.69
Fetal Brain Clontech	39.51, 40	1.65	0.86	1.26	0.48	103.95	130.46
Cerebellum Clontech	40, 39.84	0.99	1.37	1.18	2.17	23.04	27.19
Cervix	40, 40	1.05	0	0.53	2.42	20.66	10.85
Colon	40, 37.31	0	5.7	2.85	2.71	18.45	52.58
Endometrium	40, 40	0	0	0.00	0.73	68.21	0.00
Esophagus	40, 40	0	0	0.00	1.37	36.50	0.00
Heart Clontech	38.11, 40	3.63	1.31	2.47	1.32	37.88	93.56
Hypothalamus	40, 40	0	1.06	0.53	0.32	155.28	82.30
Ileum	40, 36.79	0	7.62	3.81	2.58	19.38	73.84
Jejunum	35.14, 35.9	19.25	12.54	15.90	6.60	7.58	120.42
Kidney	40, 40	0	0	0.00	2.12	23.58	0.00
Liver	37.25, 35.17	5.88	18.92	12.40	1.50	33.33	413.33
Fetal Liver Clontech	40, 37.38	0.73	5.47	3.10	10.40	4.81	14.90
Lung	37.07, 40	6.52	0	3.26	2.57	19.46	63.42
Mammary Gland Clontech	40, 40	0	0	0.00	13.00	3.85	0.00
Myometrium	37.95, 40	3.98	0	1.99	2.34	21.37	42.52
Omentum	36.24, 37.04	10.39	6.63	8.51	3.94	12.69	107.99
Ovary	35.29, 36.26	17.66	10.28	13.97	4.34	11.52	160.94
Pancreas	39.48, 40	1.69	0	0.85	0.81	61.80	52.22
Head of Pancreas	36.17, 39.82	10.79	1.39	6.09	1.57	31.85	193.95
Parotid Gland	40, 38.66	0	2.67	1.34	5.48	9.12	12.18
Placenta Clontech	40, 36.57	0	8.63	4.32	5.26	9.51	41.02
Prostate	36.91, 40	7.14	0	3.57	3.00	16.67	59.50
Rectum	40, 37.34	0	5.61	2.81	1.23	40.65	114.02
Salivary Gland Clontech	40, 40	0	0	0.00	7.31	6.84	0.00
Skeletal Muscle Clontech	40, 39.45	0	1.71	0.86	1.26	39.68	33.93
Skin	39.2, 40	1.98	0	0.99	1.21	41.32	40.91
Small Intestine Clontech	40, 40	0	0	0.00	0.98	51.07	0.00
Spleen	36, 40	11.84	0	5.92	4.92	10.16	60.16
Stomach	35.48, 39.19	15.9	1.98	8.94	2.73	18.32	163.74
Testis Clontech	40, 36.09	0	11.27	5.64	0.57	87.87	495.17
Thymus Clontech	34.34, 36.66	30.03	8.2	19.12	9.89	5.06	96.64
Thyroid	40, 40	0	0	0.00	2.77	18.05	0.00
Trachea Clontech	40, 37.8	0	4.33	2.17	9.71	5.15	11.15
Urinary Bladder	40, 40	0	0	0.00	5.47	9.14	0.00
Uterus	37.11, 35.16	6.36	18.96	12.66	5.34	9.36	118.54
genomic	27.61	1307.98					
b-actin	27.15	1697.68					
1.00E+05	19.88	100000					
1.00E+05	20.05	100000					
1.00E+04	24.01	10000					

1.00E+04	23.92	10000					
1.00E+03	27.98	1000					
1.00E+03	27.6	1000					
1.00E+02	32.89	100					
1.00E+02	32.2	100					
1.00E+01	36.1	10					
1.00E+01							
1.00E-00							
1.00E-00							
NTC	40	0					
NTC	40	0					

Sample sbg934114Relaxin	Reg number (GSK identifier )	Ct	Mean GOI copies	copies of mRNA detec- ted/50 ng total RNA	Sample	Fold Change in Disease Popula- tion
colon normal GW98-167	21941	36.1	22.33	44.66	colon normal	
colon tumor GW98-166	21940	36.47	18.37	36.74	colon tumor	-1.22
colon normal GW98-178	22080	35.7	27.58	55.16	colon normal	
colon tumor GW98-177	22060	38.05	7.98	15.96	colon tumor	-3.46
colon normal GW98-561	23514	33.57	84.85	169.70	colon normal	
colon tumor GW98-560	23513	37.66	9.8	19.60	colon tumor	-8.66
colon normal GW98-894	24691	36.39	19.09	38.18	colon normal	
colon tumor GW98-893	24690	36.43	18.74	37.48	colon tumor	-1.02
lung normal GW98-3	20742	32.48	150.6	301.20	lung normal	
lung tumor GW98-2	20741	36.65	16.64	33.28	lung tumor	-9.05
lung normal GW97-179	20677	33.22	102.07	204.14	lung normal	
lung tumor GW97-178	20676	32.31	164.63	329.26	lung tumor	1.61
lung normal GW98-165	21922	32.08	185.96	371.92	lung normal	
lung tumor GW98-164	21921	35.14	37.09	74.18	lung tumor	-5.01
lung normal GW98-282	22584	36.41	18.93	37.86	lung normal	
lung tumor GW98-281	22583	35.24	35.13	70.26	lung tumor	1.86
breast normal GW00-392	28750	34.04	66.25	66.25	breast normal	
breast tumor GW00-391	28746	37.9	8.61	17.22	breast tumor	-3.85
breast normal GW00-413	28798	36.36	19.44	19.44	breast normal	
breast tumor GW00-412	28797	36.79	15.49	30.98	breast tumor	1.59
breast normal GW00- 235:238	27592-95	36.91	14.52	14.52	breast normal	
breast tumor GW00- 231:234	27588-91	35.43	31.71	31.71	breast tumor	2.18
breast normal GW98-621	23656	36.26	20.51	41.02	breast normal	
breast tumor GW98-620	23655	35.76	26.68	53.36	breast tumor	1.30
brain normal BB99-542	25507	37.99	8.21	16.42	brain normal	
brain normal BB99-406	25509	40	1.41	2.82	brain normal	
brain normal BB99-904	25546	40	0	0.00	brain normal	
brain stage 5 ALZ BB99-	25502	38.65	5.82	11.64	brain stage 5 ALZ	1.81

874						
brain stage 5 ALZ BB99-887	25503	37	13.9	27.80	brain stage 5 ALZ	4.33
brain stage 5 ALZ BB99-862	25504	37.4	11.24	22.48	brain stage 5 ALZ	3.51
brain stage 5 ALZ BB99-927	25542	38	8.19	16.38	brain stage 5 ALZ	2.55
CT lung KC	normal	35.32	33.59	67.18	CT lung	
lung 26 KC	normal	37.02	13.72	13.72	lung 26	
lung 27 KC	normal	40	0	0.00	lung 27	
lung 24 KC	COPD	39.97	2.78	2.78	lung 24	-7.81
lung 28 KC	COPD	40	0	0.00	lung 28	-21.71
lung 23 KC	COPD	39.06	4.67	4.67	lung 23	-4.65
lung 25 KC	normal	38.61	5.92	5.92	lung 25	
asthmatic lung ODO3112	29321	36.02	23.31	23.31	asthmatic lung	1.07
asthmatic lung ODO3433	29323	34.12	63.36	126.72	asthmatic lung	5.84
asthmatic lung ODO3397	29322	33.99	68.06	136.12	asthmatic lung	6.27
asthmatic lung ODO4928	29325	33.77	76.08	152.16	asthmatic lung	7.01
endo cells KC	control	40	0	0.00	endo cells	
endo VEGF KC		40	0	0.00	endo VEGF	0.00
endo bFGF KC		38.16	7.54	7.54	endo bFGF	7.54
heart Clontech	normal	40	0	0.00	heart	
heart ( T-1 ) ischemic	29417	40	1.36	2.72	heart T-1	2.72
heart (T-14) non-obstructive DCM	29422	36.31	20.01	40.02	heart T-14	40.02
heart (T-3399) DCM	29426	37.17	12.7	25.40	heart T-3399	25.40
adenoid GW99-269	26162	33.33	96.07	192.14	adenoid	
tonsil GW98-280	22582	34.86	42.85	85.70	tonsil	
T cells PC00314	28453	33.48	88.65	177.30	T cells	
PBMNC		40	0	0.00	PBMNC	
monocyte		40	0	0.00	monocyte	
B cells PC00665	28455	32.44	153.68	307.36	B cells	
dendritic cells 28441		35.78	26.47	52.94	dendritic cells	
neutrophils	28440	36.18	21.43	21.43	neutrophils	
eosinophils	28446	39.2	4.34	8.68	eosinophils	
BM unstim		39.56	3.6	3.60	BM unstim	
BM stim		40	1.34	1.34	BM stim	-2.69
osteodif		40	0	0.00	osteodif	0.00
osteoundif		40	0	0.00	osteoundif	
chondrocytes		36.64	16.79	41.98	chondrocytes	
OA Synovium IP12/01	29462	34.75	45.45	45.45	OA Synovium	
OA Synovium NP10/01	29461	36.02	23.28	46.56	OA Synovium	
OA Synovium NP57/00	28464	34.24	59.37	118.74	OA Synovium	
RA Synovium NP03/01	28466	37.88	8.71	17.42	RA Synovium	
RA Synovium NP71/00	28467	36.02	23.22	46.44	RA Synovium	
RA Synovium NP45/00	28475	34.9	41.9	83.80	RA Synovium	
OA bone (biobank)	29217	33.59	83.75	83.75	OA bone (biobank)	
OA bone Sample 1	J. Emory	37.31	11.8	23.60	OA bone	

OA bone Sample 2	J. Emory	37.47	10.81	21.62	OA bone	
Cartilage (pool)	Normal	34.61	49.07	98.14	Cartilage (pool)	
Cartilage (pool)	OA	40	0	0.00	Cartilage (pool)	-98.14
PBL uninfected	28441	33.86	72.8	145.60	PBL uninfected	
PBL HIV IIIB	28442	37.08	13.28	26.56	PBL HIV IIIB	-5.48
MRC5 uninfected (100%)	29158	39.01	4.81	9.62	MRC5 uninfected (100%)	
MRC5 HSV strain F	29178	31.5	252.68	505.36	MRC5 HSV strain F	52.53
W12 cells	29179	39.84	3.1	6.20	W12 cells	
Keratinocytes	29180	39.07	4.64	9.28	Keratinocytes	
B-actin control		27.9	1683.49			
genomic		28.13	1492.71			
1.00E+05		20.5	100000			
1.00E+05		20.61	100000			
1.00E+04		24.56	10000			
1.00E+04		24.17	10000			
1.00E+03		28.14	1000			
1.00E+03		28.32	1000			
1.00E+02		34.26	100			
1.00E+02		32.76	100			
1.00E+01		38.07	10			
1.00E+01		37.53	10			
1.00E-00		40	0			
1.00E-00		40	1			
NTC		38.42	-1			

Gene Name sbg934114Relaxin

Disease tissues	Fold Change in Disease Population Relative to Normal
colon tumor	-1.22
colon tumor	-3.46
colon tumor	-8.66
colon tumor	-1.02
lung tumor	-9.05
lung tumor	1.61
lung tumor	-5.01
lung tumor	1.86
breast tumor	-3.85
breast tumor	1.59
breast tumor	2.18
breast tumor	1.30
brain stage 5 ALZ	1.81
brain stage 5 ALZ	4.33
brain stage 5 ALZ	3.51
brain stage 5 ALZ	2.55
lung 24	-7.81
lung 28	-21.71
lung 23	-4.65
asthmatic lung	1.07

asthmatic lung	5.84
asthmatic lung	6.27
asthmatic lung	7.01
endo VEGF	0.00
endo bFGF	7.54
heart T-1	2.72
heart T-14	40.02
heart T-3399	25.40
BM stim	-2.69
osteо dif	0.00
Cartilage (pool)	-98.14
PBL HIV IIIB	-5.48
MRC5 HSV strain F	52.53

**Gene Name sbg99174LOX-like**

5 Moderate overall expression in normal and disease samples. Highest normal expression in whole brain, liver, skin, spleen, testis. Shows relatively good expression in the female reproductive samples as well as the GI tract samples. Highest disease expression in one of the normal lung samples, one of the asthmatic lung samples, neutrophils, eosinophils, 2 of the RA synovium samples, and one of the OA bone samples. Downregulation in 1 of 4 lung tumor samples suggests possible implication in lung cancer. Upregulation in 2 of 4 breast tumors implies an involvement in cancers of the breast. Downregulation in 1 of 4 AD brains along with the high expression seen in the brain suggests an involvement in Alzheimer's disease. Downregulation in 2 of 3 COPD lung samples implies an involvement in chronic obstructive pulmonary disease. Upregulation in 1 of 4 asthmatic lung samples implies a role in asthma. Downregulation in OA cartilage and high expression in OA and RA synovium suggests possible involvement in osteoarthritis and rheumatoid arthritis. Corroborating high expression in the T cells provides additional evidence for a role in RA/OA. Moderate expression in other immune cells.

Sample sbg99174LOX-like	Ct (sample 1 and 2)	Mean GOI copies (sample 1)	Mean GOI copies (sample 2)	Average GOI Copies	18S rRNA (ng)	50 ng/18S rRNA (ng)	copies of mRNA detected/50 ng total RNA
Subcutaneous Adipocytes Zenbio	39.67, 34.48	0.53	11.91	6.22	3.06	16.34	101.63
Subcutaneous Adipose Zenbio	40, 39.75	0.39	0.51	0.45	0.96	52.36	23.56
Adrenal Gland Clontech	38.61, 37.69	1	1.75	1.38	0.61	81.97	112.70
Whole Brain Clontech	30.59, 31.07	122.95	92.57	107.76	7.24	6.91	744.20
Fetal Brain Clontech	40, 40	0	0.29	0.15	0.48	103.95	15.07
Cerebellum Clontech	40, 40	0.4	0.4	0.40	2.17	23.04	9.22
Cervix	35.77, 40	5.52	0.62	3.07	2.42	20.66	63.43
Colon	40, 39.41	0.34	0.62	0.48	2.71	18.45	8.86
Endometrium	40, 38.65	0	0.98	0.49	0.73	68.21	33.42
Esophagus	40, 40	0.35	0.41	0.38	1.37	36.50	13.87
Heart Clontech	39.33, 40	0.65	0	0.33	1.32	37.88	12.31
Hypothalamus	40, 39.54	0	0.58	0.29	0.32	155.28	45.03
Ileum	35.42, 35.76	6.79	5.55	6.17	2.58	19.38	119.57
Jejunum	34.13, 33.4	14.77	22.9	18.84	6.60	7.58	142.69

Kidney	40, 37.22	0.68	2.32	1.50	2.12	23.58	35.38
Liver	33.5, 33.86	21.47	17.3	19.39	1.50	33.33	646.17
Fetal Liver Clontech	32.78, 33.23	33.08	25.33	29.21	10.40	4.81	140.41
Lung	33.96, 34.44	16.33	12.25	14.29	2.57	19.46	278.02
Mammary Gland Clontech	35.05, 36.02	8.51	4.76	6.64	13.00	3.85	25.52
Myometrium	35.08, 35.49	8.34	6.52	7.43	2.34	21.37	158.76
Omentum	37.6, 35.05	1.83	8.49	5.16	3.94	12.69	65.48
Ovary	35.57, 32.76	6.21	33.46	19.84	4.34	11.52	228.51
Pancreas	40, 40	0	0.42	0.21	0.81	61.80	12.98
Head of Pancreas	40, 38.65	0.56	0.98	0.77	1.57	31.85	24.52
Parotid Gland	35.28, 40	7.4	0.64	4.02	5.48	9.12	36.68
Placenta Clontech	40, 39.17	0.32	0.72	0.52	5.26	9.51	4.94
Prostate	40, 35.34	0	7.15	3.58	3.00	16.67	59.58
Rectum	37.29, 39.02	2.22	0.78	1.50	1.23	40.65	60.98
Salivary Gland Clontech	40, 38.15	0.27	1.32	0.80	7.31	6.84	5.44
Skeletal Muscle Clontech	40, 38.56	0.56	1.03	0.80	1.26	39.68	31.55
Skin	35.1, 34.19	8.22	14.22	11.22	1.21	41.32	463.64
Small Intestine Clontech	40, 40	0	0.85	0.43	0.98	51.07	21.71
Spleen	32.2, 32.08	46.76	50.49	48.63	4.92	10.16	494.16
Stomach	34.28, 34.07	13.5	15.3	14.40	2.73	18.32	263.74
Testis Clontech	34.05, 32.7	15.46	34.82	25.14	0.57	87.87	2209.14
Thymus Clontech	33.85, 32.4	17.44	41.71	29.58	9.89	5.06	149.52
Thyroid	34.22, 34.29	13.93	13.37	13.65	2.77	18.05	246.39
Trachea Clontech	32.51, 32.4	38.89	41.53	40.21	9.71	5.15	207.05
Urinary Bladder	35.47, 40	6.6	0	3.30	5.47	9.14	30.16
Uterus	33.8, 33.6	18.01	20.22	19.12	5.34	9.36	178.98
genomic	26.31	1603.29					
b-actin	27.35	860.96					
1.00E+05	19.71	100000					
1.00E+05	19.88	100000					
1.00E+04	22.98	10000					
1.00E+04	23.01	10000					
1.00E+03	26.44	1000					
1.00E+03	26.54	1000					
1.00E+02	31.28	100					
1.00E+02	31.29	100					
1.00E+01	35.79	10					
1.00E+01	34.36	10					
1.00E-00	38.32	1					
1.00E-00	40	1					
NTC	40	0					
NTC	40	0					

Sample sbg99174LOX-like	Reg number	Ct	Mean GOI	copies of	Sample	Fold Change
----------------------------	---------------	----	-------------	--------------	--------	----------------

	(GSK identifier )		copies	mRNA detecte d/50 ng total RNA		in Disease Population
colon normal GW98-167	21941	29.81	184.31	368.62	colon normal	
colon tumor GW98-166	21940	29.25	254.48	508.96	colon tumor	1.38
colon normal GW98-178	22080	32.06	50.31	100.62	colon normal	
colon tumor GW98-177	22060	31.77	59.28	118.56	colon tumor	1.18
colon normal GW98-561	23514	33.21	25.83	51.66	colon normal	
colon tumor GW98-560	23513	31.74	60.51	121.02	colon tumor	2.34
colon normal GW98-894	24691	30.17	149.84	299.68	colon normal	
colon tumor GW98-893	24690	29.41	232.23	464.46	colon tumor	1.55
lung normal GW98-3	20742	25.76	1914.72	3829.44	lung normal	
lung tumor GW98-2	20741	30.12	154.63	309.26	lung tumor	-12.38
lung normal GW97-179	20677	29.59	209.5	419.00	lung normal	
lung tumor GW97-178	20676	27.2	835.04	1670.08	lung tumor	3.99
lung normal GW98-165	21922	28.22	462.22	924.44	lung normal	
lung tumor GW98-164	21921	29.27	251.87	503.74	lung tumor	-1.84
lung normal GW98-282	22584	30.18	149.17	298.34	lung normal	
lung tumor GW98-281	22583	28.47	399.41	798.82	lung tumor	2.68
breast normal GW00-392	28750	30.24	143.58	143.58	breast normal	
breast tumor GW00-391	28746	30.16	151.08	302.16	breast tumor	2.10
breast normal GW00-413	28798	31.51	68.87	68.87	breast normal	
breast tumor GW00-412	28797	28.91	310.66	621.32	breast tumor	9.02
breast normal GW00-235:238	27592-95	40	0	0.00	breast normal	
breast tumor GW00-231:234	27588-91	33.55	21.28	21.28	breast tumor	21.28
breast normal GW98-621	23656	31.57	66.56	133.12	breast normal	
breast tumor GW98-620	23655	31.15	84.8	169.60	breast tumor	1.27
brain normal BB99-542	25507	29.55	214.38	428.76	brain normal	
brain normal BB99-406	25509	29.15	270.89	541.78	brain normal	
brain normal BB99-904	25546	30.48	124.98	249.96	brain normal	
brain stage 5 ALZ BB99-874	25502	33.57	20.99	41.98	brain stage 5 ALZ	-9.69
brain stage 5 ALZ BB99-887	25503	29.89	176.42	352.84	brain stage 5 ALZ	-1.15
brain stage 5 ALZ BB99-862	25504	31.65	63.83	127.66	brain stage 5 ALZ	-3.19
brain stage 5 ALZ BB99-927	25542	31.04	90.73	181.46	brain stage 5 ALZ	-2.24
CT lung KC	normal	29.94	170.8	341.60	CT lung	
lung 26 KC	normal	30.63	115.04	115.04	lung 26	
lung 27 KC	normal	32.22	45.83	45.83	lung 27	
lung 24 KC	COPD	34.16	14.91	14.91	lung 24	-9.21
lung 28 KC	COPD	33.51	21.7	21.70	lung 28	-6.33
lung 23 KC	COPD	32.51	38.67	38.67	lung 23	-3.55
lung 25 KC	normal	32.18	46.79	46.79	lung 25	
asthmatic lung ODO3112	29321	31.84	56.95	56.95	asthmatic lung	-2.41

asthmatic lung ODO3433	29323	31.12	86.42	172.84	asthmatic lung	1.26
asthmatic lung ODO3397	29322	27.13	867.31	1734.62	asthmatic lung	12.63
asthmatic lung ODO4928	29325	30.25	142.92	285.84	asthmatic lung	2.08
endo cells KC	control	31.23	81.05	81.05	endo cells	
endo VEGF KC		31.87	56.15	56.15	endo VEGF	-1.44
endo bFGF KC		32.64	35.97	35.97	endo bFGF	-2.25
heart Clontech	normal	35.46	7.06	14.12	heart	
heart ( T-1 ) ischemic	29417	35.73	6.03	12.06	heart T-1	-1.17
heart (T-14) non-obstructive DCM	29422	34.34	13.49	26.98	heart T-14	1.91
heart (T-3399) DCM	29426	33.65	20.01	40.02	heart T-3399	2.83
adenoid GW99-269	26162	31.2	82.69	165.38	adenoid	
tonsil GW98-280	22582	30.8	103.96	207.92	tonsil	
T cells PC00314	28453	28.16	480.4	960.80	T cells	
PBMNC		30.25	143.11	143.11	PBMNC	
monocyte		30.05	160.68	321.36	monocyte	
B cells PC00665	28455	30.75	107.02	214.04	B cells	
dendritic cells 28441		30.32	137.17	274.34	dendritic cells	
neutrophils	28440	26.32	1390.87	1390.87	neutrophils	
eosinophils	28446	25.07	2854.44	5708.88	eosinophils	
BM unstim		30.72	109.05	109.05	BM unstim	
BM stim		28.61	369.2	369.20	BM stim	3.39
osteо dif		40	0	0.00	osteо dif	-0.28
osteо undif		40	0.28	0.28	osteо undif	
chondrocytes		34.3	13.76	34.40	chondrocytes	
OA Synovium IP12/01	29462	27.56	676.63	676.63	OA Synovium	
OA Synovium NP10/01	29461	31.41	73.19	146.38	OA Synovium	
OA Synovium NP57/00	28464	28.02	518.05	1036.10	OA Synovium	
RA Synovium NP03/01	28466	27.03	921.88	1843.76	RA Synovium	
RA Synovium NP71/00	28467	27.04	914.02	1828.04	RA Synovium	
RA Synovium NP45/00	28475	29.06	285.08	570.16	RA Synovium	
OA bone (biobank)	29217	26.78	1065.84	1065.84	OA bone (biobank)	
OA bone Sample 1	J. Emory	30.27	141.07	282.14	OA bone	
OA bone Sample 2	J. Emory	27.04	917.04	1834.08	OA bone	
Cartilage (pool)	Normal	28.23	461.21	922.42	Cartilage (pool)	
Cartilage (pool)	OA	33.16	26.65	53.30	Cartilage (pool)	-17.31
PBL uninfected	28441	28.72	346.97	693.94	PBL uninfected	
PBL HIV IIIB	28442	28.54	384.02	768.04	PBL HIV IIIB	1.11
MRC5 uninfected (100%)	29158	31.64	64.07	128.14	MRC5 uninfected (100%)	
MRC5 HSV strain F	29178	31.53	68.31	136.62	MRC5 HSV strain F	1.07
W12 cells	29179	34.44	12.72	25.44	W12 cells	
Keratinocytes	29180	36.02	5.1	10.20	Keratinocytes	
B-actin control		27.2	835.98			
genomic		26.76	1073.72			
1.00E+05		19.13	100000			
1.00E+05		19.61	100000			

1.00E+04		22.79	10000			
1.00E+04		22.5	10000			
1.00E+03		26.36	1000			
1.00E+03		26.23	1000			
1.00E+02		31.25	100			
1.00E+02		30.82	100			
1.00E+01		35.02	10			
1.00E+01		35.15	10			
1.00E-00		40	0			
1.00E-00		40	0			
NTC		40	0			

## Gene Name sbg99174LOX-like

Disease tissues	Fold Change in Disease Population Relative to Normal
colon tumor	1.38
colon tumor	1.18
colon tumor	2.34
colon tumor	1.55
lung tumor	-12.38
lung tumor	3.99
lung tumor	-1.84
lung tumor	2.68
breast tumor	2.10
breast tumor	9.02
breast tumor	21.28
breast tumor	1.27
brain stage 5 ALZ	-9.69
brain stage 5 ALZ	-1.15
brain stage 5 ALZ	-3.19
brain stage 5 ALZ	-2.24
lung 24	-9.21
lung 28	-6.33
lung 23	-3.55
asthmatic lung	-2.41
asthmatic lung	1.26
asthmatic lung	12.63
asthmatic lung	2.08
endo VEGF	-1.44
endo bFGF	-2.25
heart T-1	-1.17
heart T-14	1.91
heart T-3399	2.83
BM stim	3.39
osteo dif	-0.28
Cartilage (pool)	-17.31
PBL HIV IIIB	1.11
MRC5 HSV strain F	1.07

Extremely low overall expression in normal and disease samples. Highest normal expression in the colon and the parotid gland. Highest disease expression in the one of the lung tumors and one of the colon tumors. Upregulation in 1 of 4 colon tumors and 1 of 4 lung tumors imply roles in cancers of the colon and lung. Downregulation in 3 of 4 AD brain samples as well as high expression in whole brain suggests an involvement in Alzheimer's disease. Downregulation in 3 of 3 COPD lung samples implicates this gene in COPD. Downregulation in the ischemic and non-obstructive DCM heart samples suggests a role for this gene in cardiovascular disease. Upregulation in the stimulated bone marrow sample. Upregulation in HSV implicates involvement in herpes simplex virus as a potential host factor. High expression in neutrophils and eosinophils.

10

Sample sbg995002PIGR	Ct (sample 1 and 2)	Mean GOI copies (sample 1)	Mean GOI copies (sample 2)	Average GOI Copies	18S rRNA (ng)	50 ng/18S rRNA (ng)	copies of mRNA detec- ted/50 ng total RNA
Subcutaneous Adipocytes Zenbio	40, 40	0	0	0.00	3.06	16.34	0.00
Subcutaneous Adipose Zenbio	40, 40	0	0	0.00	0.96	52.36	0.00
Adrenal Gland Clontech	40, 40	0	0	0.00	0.61	81.97	0.00
Whole Brain Clontech	36.78, 40	11.16	0	5.58	7.24	6.91	38.54
Fetal Brain Clontech	40, 40	0	0	0.00	0.48	103.95	0.00
Cerebellum Clontech	40, 40	0	0	0.00	2.17	23.04	0.00
Cervix	40, 40	0	0	0.00	2.42	20.66	0.00
Colon	37.16, 37.12	8.81	9.05	8.93	2.71	18.45	164.76
Endometrium	40, 40	0	0	0.00	0.73	68.21	0.00
Esophagus	40, 40	0	0	0.00	1.37	36.50	0.00
Heart Clontech	40, 40	0	0	0.00	1.32	37.88	0.00
Hypothalamus	40, 40	0	0	0.00	0.32	155.28	0.00
Ileum	40, 40	0	0	0.00	2.58	19.38	0.00
Jejunum	40, 40	0	0	0.00	6.60	7.58	0.00
Kidney	40, 40	0	0	0.00	2.12	23.58	0.00
Liver	40, 39.16	0	2.58	1.29	1.50	33.33	43.00
Fetal Liver Clontech	40, 40	0	0	0.00	10.40	4.81	0.00
Lung	40, 40	0	0	0.00	2.57	19.46	0.00
Mammary Gland Clontech	40, 39.18	0	2.55	1.28	13.00	3.85	4.90
Myometrium	40, 40	0	0	0.00	2.34	21.37	0.00
Omentum	40, 38.04	0	5.15	2.58	3.94	12.69	32.68
Ovary	39.29, 40	2.37	0	1.19	4.34	11.52	13.65
Pancreas	40, 40	0	0	0.00	0.81	61.80	0.00
Head of Pancreas	40, 40	0	0	0.00	1.57	31.85	0.00
Parotid Gland	36.7, 37.94	11.72	5.46	8.59	5.48	9.12	78.38
Placenta Clontech	40, 40	0	0	0.00	5.26	9.51	0.00
Prostate	40, 40	0	0	0.00	3.00	16.67	0.00
Rectum	40, 40	0	0	0.00	1.23	40.65	0.00
Salivary Gland Clontech	37.23, 39.21	8.45	2.5	5.48	7.31	6.84	37.45
Skeletal Muscle Clontech	40, 40	0	0	0.00	1.26	39.68	0.00

Skin	40, 40	0	0	0.00	1.21	41.32	0.00
Small Intestine Clontech	40, 40	0	0	0.00	0.98	51.07	0.00
Spleen	40, 38.76	1.25	3.3	2.28	4.92	10.16	23.12
Stomach	40, 39.25	1.25	2.43	1.84	2.73	18.32	33.70
Testis Clontech	40, 40	0	0	0.00	0.57	87.87	0.00
Thymus Clontech	37.82, 40	5.88	0	2.94	9.89	5.06	14.86
Thyroid	40, 40	0	0	0.00	2.77	18.05	0.00
Trachea Clontech	40, 40	0	0	0.00	9.71	5.15	0.00
Urinary Bladder	40, 40	0	0	0.00	5.47	9.14	0.00
Uterus	38.34, 40	4.27	0	2.14	5.34	9.36	19.99
genomic	29.66	888.99					
b-actin	30.72	462.87					
1.00E+05	22.2	100000					
1.00E+05	22.14	100000					
1.00E+04	25.72	10000					
1.00E+04	25.66	10000					
1.00E+03	29.16	1000					
1.00E+03	29.07	1000					
1.00E+02	32.37	100					
1.00E+02	34.12	100					
1.00E+01	37.12	10					
1.00E+01	37.11	10					
1.00E-00	40	0					
1.00E-00	40	0					
NTC	40	0					
NTC	38.03	-1					

Sample sbg995002PIGR	Reg number (GSK identifier )	Ct	Mean GOI copies	copies of mRNA detecte d/50 ng total RNA	Sample	Fold Change in Disease Populati on
colon normal GW98-167	21941	33.43	149.84	299.68	colon normal	
colon tumor GW98-166	21940	32.49	274.64	549.28	colon tumor	1.83
colon normal GW98-178	22080	40	0	0.00	colon normal	
colon tumor GW98-177	22060	31.11	675.8	1351.60	colon tumor	1351.60
colon normal GW98-561	23514	37.74	9.09	18.18	colon normal	
colon tumor GW98-560	23513	35.81	31.94	63.88	colon tumor	3.51
colon normal GW98-894	24691	33.17	177.11	354.22	colon normal	
colon tumor GW98-893	24690	31.61	488.49	976.98	colon tumor	2.76
lung normal GW98-3	20742	35.48	39.55	79.10	lung normal	
lung tumor GW98-2	20741	28.32	4121.56	8243.12	lung tumor	104.21
lung normal GW97-179	20677	36.47	20.69	41.38	lung normal	
lung tumor GW97-178	20676	37.24	12.59	25.18	lung tumor	-1.64
lung normal GW98-165	21922	37.32	11.96	23.92	lung normal	
lung tumor GW98-164	21921	36.07	26.9	53.80	lung tumor	2.25

lung normal GW98-282	22584	38.49	5.58	11.16	lung normal	
lung tumor GW98-281	22583	37.89	8.24	16.48	lung tumor	1.48
breast normal GW00-392	28750	39.03	3.93	3.93	breast normal	
breast tumor GW00-391	28746	38.01	7.65	15.30	breast tumor	3.89
breast normal GW00-413	28798	40	0	0.00	breast normal	
breast tumor GW00-412	28797	38.67	4.98	9.96	breast tumor	9.96
breast normal GW00-235:238	27592-95	40	0	0.00	breast normal	
breast tumor GW00-231:234	27588-91	40	0	0.00	breast tumor	0.00
breast normal GW98-621	23656	36.12	26.13	52.26	breast normal	
breast tumor GW98-620	23655	40	0	0.00	breast tumor	-52.26
brain normal BB99-542	25507	37.14	13.43	26.86	brain normal	
brain normal BB99-406	25509	40	0	0.00	brain normal	
brain normal BB99-904	25546	40	0	0.00	brain normal	
brain stage 5 ALZ BB99-874	25502	40	0	0.00	brain stage 5 ALZ	-8.95
brain stage 5 ALZ BB99-887	25503	40	0.51	1.02	brain stage 5 ALZ	-8.78
brain stage 5 ALZ BB99-862	25504	40	0.88	1.76	brain stage 5 ALZ	-5.09
brain stage 5 ALZ BB99-927	25542	40	1.9	3.80	brain stage 5 ALZ	-2.36
CT lung KC	normal	36.59	19.23	38.46	CT lung	
lung 26 KC	normal	40	0	0.00	lung 26	
lung 27 KC	normal	40	0	0.00	lung 27	
lung 24 KC	COPD	40	0	0.00	lung 24	-9.62
lung 28 KC	COPD	40	0	0.00	lung 28	-9.62
lung 23 KC	COPD	40	0	0.00	lung 23	-9.62
lung 25 KC	normal	40	0	0.00	lung 25	
asthmatic lung ODO3112	29321	40	0	0.00	asthmatic lung	-9.62
asthmatic lung ODO3433	29323	38.36	6.1	12.20	asthmatic lung	1.27
asthmatic lung ODO3397	29322	37.29	12.16	24.32	asthmatic lung	2.53
asthmatic lung ODO4928	29325	38.01	7.64	15.28	asthmatic lung	1.59
endo cells KC	control	40	0	0.00	endo cells	
endo VEGF KC		40	0	0.00	endo VEGF	0.00
endo bFGF KC		40	0	0.00	endo bFGF	0.00
heart Clontech	normal	37.85	8.49	16.98	heart	
heart ( T-1 ) ischemic	29417	40	0	0.00	heart T-1	-16.98
heart (T-14) non-obstructive DCM	29422	40	0	0.00	heart T-14	-16.98
heart (T-3399) DCM	29426	39.5	2.9	5.80	heart T-3399	-2.93
adenoid GW99-269	26162	40	0	0.00	adenoid	
tonsil GW98-280	22582	36.35	22.46	44.92	tonsil	
T cells PC00314	28453	36.17	25.23	50.46	T cells	
PBMNC		40	0	0.00	PBMNC	
monocyte		40	0.45	0.90	monocyte	
B cells PC00665	28455	40	0.6	1.20	B cells	
dendritic cells 28441		38.07	7.37	14.74	dendritic cells	
neutrophils	28440	32.73	236.09	236.09	neutrophils	

eosinophils	28446	33.68	126.65	253.30	eosinophils	
BM unstim		40	0	0.00	BM unstim	
BM stim		36.52	20.1	20.10	BM stim	20.10
osteo dif		40	0	0.00	osteo dif	0.00
osteo undif		40	0	0.00	osteo undif	
chondrocytes		39.61	2.7	6.75	chondrocytes	
OA Synovium IP12/01	29462	39.91	1.59	1.59	OA Synovium	
OA Synovium NP10/01	29461	38.98	4.07	8.14	OA Synovium	
OA Synovium NP57/00	28464	36.29	23.27	46.54	OA Synovium	
RA Synovium NP03/01	28466	35.81	31.94	63.88	RA Synovium	
RA Synovium NP71/00	28467	34.79	61.79	123.58	RA Synovium	
RA Synovium NP45/00	28475	35.08	51.15	102.30	RA Synovium	
OA bone (biobank)	29217	40	1.12	1.12	OA bone (biobank)	
OA bone Sample 1	J. Emory	36.8	16.77	33.54	OA bone	
OA bone Sample 2	J. Emory	34.72	64.74	129.48	OA bone	
Cartilage (pool)	Normal	37.46	10.93	21.86	Cartilage (pool)	
Cartilage (pool)	OA	40	0	0.00	Cartilage (pool)	-21.86
PBL uninfected	28441	35.05	52.27	104.54	PBL uninfected	
PBL HIV IIIB	28442	37.31	12.04	24.08	PBL HIV IIIB	-4.34
MRC5 uninfected (100%)	29158	40	0	0.00	MRC5 uninfected (100%)	
MRC5 HSV strain F	29178	38.19	6.8	13.60	MRC5 HSV strain F	13.60
W12 cells	29179	40	0	0.00	W12 cells	
Keratinocytes	29180	40	0	0.00	Keratinocytes	
B-actin control	B-actin control	29.77	1604.25			
genomic	genomic	30.5	1001.61			
1.00E+05	1.00E+05	22.95	100000			
1.00E+05	1.00E+05	22.91	100000			
1.00E+04	1.00E+04	26.49	10000			
1.00E+04	1.00E+04	26.66	10000			
1.00E+03	1.00E+03	30.62	1000			
1.00E+03	1.00E+03	30.43	1000			
1.00E+02	1.00E+02	36.12	100			
1.00E+02	1.00E+02	34.73	100			
1.00E+01	1.00E+01	38.58	10			
1.00E+01	1.00E+01	38.82	10			
1.00E-00	1.00E-00	40	0			
1.00E-00	1.00E-00	37.86	1			
NTC	NTC	40	0			

Gene Name sbg995002PIGR

Disease tissues	Fold Change in Disease Population Relative to Normal
colon tumor	1.83

colon tumor	1351.60
colon tumor	3.51
colon tumor	2.76
lung tumor	104.21
lung tumor	-1.64
lung tumor	2.25
lung tumor	1.48
breast tumor	3.89
breast tumor	9.96
breast tumor	0.00
breast tumor	-52.26
brain stage 5 ALZ	-8.95
brain stage 5 ALZ	-8.78
brain stage 5 ALZ	-5.09
brain stage 5 ALZ	-2.36
lung 24	-9.62
lung 28	-9.62
lung 23	-9.62
asthmatic lung	-9.62
asthmatic lung	1.27
asthmatic lung	2.53
asthmatic lung	1.59
endo VEGF	0.00
endo bFGF	0.00
heart T-1	-16.98
heart T-14	-16.98
heart T-3399	-2.93
BM stim	20.10
osteo dif	0.00
Cartilage (pool)	-21.86
PBL HIV IIIB	-4.34
MRC5 HSV strain F	13.60

**Gene Name sbg1033026C1q**

5 Low to moderate overall expression in normal and disease samples. Highest normal expression in the subcutaneous adipocytes, subcutaneous adipose, whole brain, and heart. Highest disease expression in the 3 heart samples. Downregulation in 1 of 4 lung tumor samples and upregulation in 2 of 4 breast tumor samples indicates a role for this gene in cancers of the lung and breast. Upregulation in 2 of 4 AD brain samples suggests an involvement in Alzheimer's disease.

10 Upregulation in 3 of 3 heart samples implies an involvement in cardiovascular diseases such as non-obstructive and obstructive DCM as well as ischemia. Low expression in all of the immune cells. Low to moderate expression in the OA synovium and bone samples as well as in the RA synovium samples.

Sample sbg1033026C1q	Ct (sample 1 and 2)	Mean GOI copies (sample 1)	Mean GOI copies (sample 2)	Average GOI Copies	18S rRNA (ng)	50 ng/18S rRNA (ng)	copies of mRNA detected/50 ng total RNA
Subcutaneous Adipocytes Zenbio	32.32, 31.18	11.99	24.91	18.45	3.06	16.34	301.47
Subcutaneous Adipose Zenbio	34.95, 33.78	2.2	4.69	3.45	0.96	52.36	180.37

Adrenal Gland Clontech	40, 40	0	0	0.00	0.61	81.97	0.00
Whole Brain Clontech	28.5, 28.04	140.11	187.98	164.05	7.24	6.91	1132.91
Fetal Brain Clontech	40, 40	0	0	0.00	0.48	103.95	0.00
Cerebellum Clontech	40, 40	0	0	0.00	2.17	23.04	0.00
Cervix	40, 40	0	0	0.00	2.42	20.66	0.00
Colon	34.82, 38.44	2.39	0.23	1.31	2.71	18.45	24.17
Endometrium	40, 35.09	0	2.01	1.01	0.73	68.21	68.55
Esophagus	40, 40	0	0	0.00	1.37	36.50	0.00
Heart Clontech	32.53, 34.31	10.45	3.32	6.89	1.32	37.88	260.80
Hypothalamus	40, 40	0	0	0.00	0.32	155.28	0.00
Ileum	40, 34.55	0	2.85	1.43	2.58	19.38	27.62
Jejunum	33.04, 34.86	7.51	2.33	4.92	6.60	7.58	37.27
Kidney	40, 40	0	0	0.00	2.12	23.58	0.00
Liver	35.81, 33.92	1.26	4.28	2.77	1.50	33.33	92.33
Fetal Liver Clontech	32.05, 40	14.25	0	7.13	10.40	4.81	34.25
Lung	40, 33.51	0	5.58	2.79	2.57	19.46	54.28
Mammary Gland Clontech	31.05, 30.69	27.02	34.2	30.61	13.00	3.85	117.73
Myometrium	33.29, 35.1	6.42	2	4.21	2.34	21.37	89.96
Omentum	34.44, 40	3.07	0	1.54	3.94	12.69	19.48
Ovary	32.59, 35.04	10.03	2.07	6.05	4.34	11.52	69.70
Pancreas	40, 40	0	0	0.00	0.81	61.80	0.00
Head of Pancreas	40, 40	0	0	0.00	1.57	31.85	0.00
Parotid Gland	34.63, 33.09	2.71	7.29	5.00	5.48	9.12	45.62
Placenta Clontech	32.77, 33.01	8.94	7.7	8.32	5.26	9.51	79.09
Prostate	40, 40	0	0	0.00	3.00	16.67	0.00
Rectum	40, 34.44	0	3.06	1.53	1.23	40.65	62.20
Salivary Gland Clontech	32.96, 40	7.94	0	3.97	7.31	6.84	27.15
Skeletal Muscle Clontech	40, 40	0	0	0.00	1.26	39.68	0.00
Skin	40, 33.46	0.6	5.75	3.18	1.21	41.32	131.20
Small Intestine Clontech	40, 40	0	0	0.00	0.98	51.07	0.00
Spleen	35.65, 35	1.4	2.13	1.77	4.92	10.16	17.94
Stomach	40, 34.73	0	2.54	1.27	2.73	18.32	23.26
Testis Clontech	40, 35.12	0	1.98	0.99	0.57	87.87	86.99
Thymus Clontech	32.44, 31.57	11.11	19.37	15.24	9.89	5.06	77.05
Thyroid	40, 40	0	0	0.00	2.77	18.05	0.00
Trachea Clontech	34.58, 33.56	2.79	5.4	4.10	9.71	5.15	21.09
Urinary Bladder	33.45, 33.34	5.8	6.21	6.01	5.47	9.14	54.89
Uterus	33.19, 32.41	6.82	11.32	9.07	5.34	9.36	84.93
genomic	25.47	981.57					
b-actin	26.87	398.61					
1.00E+05	18.24	100000					
1.00E+05	18.35	100000					
1.00E+04	21.53	10000					
1.00E+04	21.62	10000					

1.00E+03	25.17	1000					
1.00E+03	25.03	1000					
1.00E+02	30.53	100					
1.00E+02	30.49	100					
1.00E+01	30.85	10					
1.00E+01	40	10					
1.00E-00	40	0					
1.00E-00	40	0					
NTC	40	0					
NTC	40	0					

Sample sbg1033026C1q	Reg number (GSK identifier )	Ct	Mean GOI copies	copies of mRNA detec- ted/50 ng total RNA	Sample	Fold Change in Disease Popula- tion
colon normal GW98-167	21941	27.03	397.15	794.30	colon normal	
colon tumor GW98-166	21940	29.53	91.39	182.78	colon tumor	-4.35
colon normal GW98-178	22080	30.3	57.81	115.62	colon normal	
colon tumor GW98-177	22060	29.31	103.84	207.68	colon tumor	1.80
colon normal GW98-561	23514	28.79	140.64	281.28	colon normal	
colon tumor GW98-560	23513	30.18	62.18	124.36	colon tumor	-2.26
colon normal GW98-894	24691	28.31	187.28	374.56	colon normal	
colon tumor GW98-893	24690	28.75	143.93	287.86	colon tumor	-1.30
lung normal GW98-3	20742	28.18	201.78	403.56	lung normal	
lung tumor GW98-2	20741	32.35	17.41	34.82	lung tumor	-11.59
lung normal GW97-179	20677	29.94	71.52	143.04	lung normal	
lung tumor GW97-178	20676	28.76	143.36	286.72	lung tumor	2.00
lung normal GW98-165	21922	28.69	149.49	298.98	lung normal	
lung tumor GW98-164	21921	31.28	32.63	65.26	lung tumor	-4.58
lung normal GW98-282	22584	31.42	30.07	60.14	lung normal	
lung tumor GW98-281	22583	30.33	56.83	113.66	lung tumor	1.89
breast normal GW00-392	28750	28.72	146.7	146.70	breast normal	
breast tumor GW00-391	28746	27.02	398.56	797.12	breast tumor	5.43
breast normal GW00-413	28798	30.95	39.63	39.63	breast normal	
breast tumor GW00-412	28797	30.58	49.03	98.06	breast tumor	2.47
breast normal GW00- 235:238	27592-95	32.53	15.6	15.60	breast normal	
breast tumor GW00- 231:234	27588-91	29.58	88.49	88.49	breast tumor	5.67
breast normal GW98-621	23656	27.5	300.39	600.78	breast normal	
breast tumor GW98-620	23655	29.28	105.43	210.86	breast tumor	-2.85
brain normal BB99-542	25507	30.67	46.59	93.18	brain normal	
brain normal BB99-406	25509	29.54	90.66	181.32	brain normal	
brain normal BB99-904	25546	31.13	35.58	71.16	brain normal	
brain stage 5 ALZ BB99- 874	25502	31.4	30.36	60.72	brain stage 5 ALZ	-1.90

brain stage 5 ALZ BB99-887	25503	28.39	177.94	355.88	brain stage 5 ALZ	3.09
brain stage 5 ALZ BB99-862	25504	28.92	130.19	260.38	brain stage 5 ALZ	2.26
brain stage 5 ALZ BB99-927	25542	28.2	198.98	397.96	brain stage 5 ALZ	3.45
CT lung KC	normal	31.24	33.37	66.74	CT lung	
lung 26 KC	normal	33.59	8.37	8.37	lung 26	
lung 27 KC	normal	37.8	0.7	0.70	lung 27	
lung 24 KC	COPD	34.56	4.73	4.73	lung 24	-4.39
lung 28 KC	COPD	35.39	2.91	2.91	lung 28	-7.13
lung 23 KC	COPD	34.74	4.26	4.26	lung 23	-4.87
lung 25 KC	normal	33.85	7.19	7.19	lung 25	
asthmatic lung ODO3112	29321	35.04	3.57	3.57	asthmatic lung	-5.81
asthmatic lung ODO3433	29323	32.44	16.48	32.96	asthmatic lung	1.59
asthmatic lung ODO3397	29322	29.4	98.44	196.88	asthmatic lung	9.49
asthmatic lung ODO4928	29325	31.1	36.23	72.46	asthmatic lung	3.49
endo cells KC	control	40	0	0.00	endo cells	
endo VEGF KC		40	0	0.00	endo VEGF	0.00
endo bFGF KC		35.4	2.89	2.89	endo bFGF	2.89
heart Clontech	normal	29.05	120.78	241.56	heart	
heart ( T-1 ) ischemic	29417	26.23	633.79	1267.58	heart T-1	5.25
heart (T-14) non-obstructive DCM	29422	25.74	847.85	1695.70	heart T-14	7.02
heart (T-3399) DCM	29426	25.03	1289.37	2578.74	heart T-3399	10.68
adenoid GW99-269	26162	35.24	3.17	6.34	adenoid	
tonsil GW98-280	22582	31	38.35	76.70	tonsil	
T cells PC00314	28453	31.75	24.69	49.38	T cells	
PBMNC		40	0	0.00	PBMNC	
monocyte		40	0	0.00	monocyte	
B cells PC00665	28455	31.35	31.31	62.62	B cells	
dendritic cells 28441		32.81	13.25	26.50	dendritic cells	
neutrophils	28440	31.76	24.51	24.51	neutrophils	
eosinophils	28446	33.08	11.29	22.58	eosinophils	
BM unstim		36.9	1.19	1.19	BM unstim	
BM stim		38.86	0.38	0.38	BM stim	-3.13
osteo dif		37.77	0.72	0.72	osteo dif	0.72
osteo undif		40	0	0.00	osteo undif	
chondrocytes		33.14	10.88	27.20	chondrocytes	
OA Synovium IP12/01	29462	30.61	48.28	48.28	OA Synovium	
OA Synovium NP10/01	29461	27.5	300.97	601.94	OA Synovium	
OA Synovium NP57/00	28464	29.28	105.55	211.10	OA Synovium	
RA Synovium NP03/01	28466	30.18	62.3	124.60	RA Synovium	
RA Synovium NP71/00	28467	29.22	109.5	219.00	RA Synovium	
RA Synovium NP45/00	28475	30.06	66.71	133.42	RA Synovium	
OA bone (biobank)	29217	32.6	14.99	14.99	OA bone (biobank)	
OA bone Sample 1	J. Emory	30.48	52.25	104.50	OA bone	
OA bone Sample 2	J. Emory	32.31	17.76	35.52	OA bone	
Cartilage (pool)	Normal	30.45	53.05	106.10	Cartilage (pool)	

Cartilage (pool)	OA	30.81	43.01	86.02	Cartilage (pool)	-1.23
PBL uninfected	28441	30.19	61.92	123.84	PBL uninfected	
PBL HIV IIIB	28442	31.19	34.35	68.70	PBL HIV IIIB	-1.80
MRC5 uninfected (100%)	29158	30.19	62.02	124.04	MRC5 uninfected (100%)	
MRC5 HSV strain F	29178	31.13	35.48	70.96	MRC5 HSV strain F	-1.75
W12 cells	29179	32	21.32	42.64	W12 cells	
Keratinocytes	29180	33.3	9.92	19.84	Keratinocytes	
B-actin control		26.66	492.23			
genomic		24.83	1443.91			
1.00E+05		18.12	100000			
1.00E+05		18.12	100000			
1.00E+04		21.28	10000			
1.00E+04		21.31	10000			
1.00E+03		24.92	1000			
1.00E+03		24.9	1000			
1.00E+02		29.22	100			
1.00E+02		29.26	100			
1.00E+01		33.13	10			
1.00E+01		34.32	10			
1.00E-00		40	0			
1.00E-00		40	0			
NTC		40	0			

Gene Name sbg1033026C1q

Disease tissues	Fold Change in Disease Population Relative to Normal
colon tumor	-4.35
colon tumor	1.80
colon tumor	-2.26
colon tumor	-1.30
lung tumor	-11.59
lung tumor	2.00
lung tumor	-4.58
lung tumor	1.89
breast tumor	5.43
breast tumor	2.47
breast tumor	5.67
breast tumor	-2.85
brain stage 5 ALZ	-1.90
brain stage 5 ALZ	3.09
brain stage 5 ALZ	2.26
brain stage 5 ALZ	3.45
lung 24	-4.39
lung 28	-7.13
lung 23	-4.87
asthmatic lung	-5.81
asthmatic lung	1.59
asthmatic lung	9.49

asthmatic lung	3.49
endo VEGF	0.00
endo bFGF	2.89
heart T-1	5.25
heart T-14	7.02
heart T-3399	10.68
BM stim	-3.13
osteо dif	0.72
Cartilage (pool)	-1.23
PBL HIV IIIB	-1.80
MRC5 HSV strain F	-1.75

Gene Name sbg1003675Rnase

FAILED

5      Gene Name sbg1015258PLM

Low overall expression in normal and disease samples. Highest normal expression in the endometrium, hypothalamus, liver small intestine, and the testis. Highest disease expression in one of the breast normal/tumor pairs, one of the normal brain samples, two of the Alzheimer's disease brain samples, the B cells and the HSV-infected MRC5 cells. Downregulation in 1 of 4 lung tumor samples is sufficient to claim a role in cancer of the lung. Upregulation in 2 of 4 breast tumor samples indicates an involvement in cancer of the breast. Downregulation in 2 of 3 COPD samples and in 1 of 4 asthmatic lung samples implies a role in chronic obstructive pulmonary disease and asthma. Upregulation in the obstructive DCM heart sample suggests a potential role in cardiovascular disease. Downregulation in the stimulated bone marrow sample. Downregulation in the OA cartilage pool implicates this gene in osteoarthritis. Upregulation in the HSV-infected MRC5 cells suggests that this gene may be a host factor in HSV. Low expression in all immune cells except the B cells which show moderate expression.

10     15

Sample sbg1015258PLM	Ct (sample 1 and 2)	Mean GOI copies (sample 1)	Mean GOI copies (sample 2)	Average GOI Copies	18S rRNA (ng)	50 ng/18S rRNA (ng)	copies of mRNA detected/ 50 ng total RNA
Subcutaneous Adipocytes Zenbio	39.96, 39.32	0.39	0.73	0.56	3.06	16.34	9.15
Subcutaneous Adipose Zenbio	39.61, 37.77	0.62	1.84	1.23	0.96	52.36	64.40
Adrenal Gland Clontech	36.89, 37.65	3.12	1.98	2.55	0.61	81.97	209.02
Whole Brain Clontech	32.77, 33.06	36.18	30.37	33.28	7.24	6.91	229.80
Fetal Brain Clontech	38.01, 37.52	1.6	2.14	1.87	0.48	103.95	194.39
Cerebellum Clontech	38.34, 37.8	1.31	1.81	1.56	2.17	23.04	35.94
Cervix	36.9, 37.17	3.1	2.64	2.87	2.42	20.66	59.30
Colon	35.93, 37.95	5.51	1.66	3.59	2.71	18.45	66.14
Endometrium	34.62, 37.51	12.02	2.15	7.09	0.73	68.21	483.29
Esophagus	35.76, 37.39	6.1	2.31	4.21	1.37	36.50	153.47
Heart Clontech	36.78, 38.53	3.33	1.17	2.25	1.32	37.88	85.23
Hypothalamus	37.12, 36.52	2.71	3.87	3.29	0.32	155.28	510.87
Ileum	36.15, 36.19	4.84	4.72	4.78	2.58	19.38	92.64
Jejunum	34.6, 33.48	12.14	23.65	17.90	6.60	7.58	135.57
Kidney	37.16, 37.9	2.65	1.7	2.18	2.12	23.58	51.30

Liver	34.6, 36.06	12.13	5.11	8.62	1.50	33.33	287.33
Fetal Liver Clontech	34.32, 36.91	14.35	3.07	8.71	10.40	4.81	41.88
Lung	36.94, 35.31	3.02	7.98	5.50	2.57	19.46	107.00
Mammary Gland Clontech	38.03, 36.89	1.58	3.11	2.35	13.00	3.85	9.02
Myometrium	38.44, 38	1.24	1.6	1.42	2.34	21.37	30.34
Omentum	35.41, 35.38	7.51	7.64	7.58	3.94	12.69	96.13
Omentum							
Ovary	34.32, 34.36	14.4	14.07	14.24	4.34	11.52	164.00
Pancreas	36.44, 36.82	4.07	3.25	3.66	0.81	61.80	226.21
Head of Pancreas	37.54, 36.96	2.11	2.98	2.55	1.57	31.85	81.05
Parotid Gland	37.1, 35.46	2.75	7.29	5.02	5.48	9.12	45.80
Placenta Clontech	36.07, 35.36	5.08	7.74	6.41	5.26	9.51	60.93
Prostate	37.4, 37.82	2.3	1.79	2.05	3.00	16.67	34.08
Rectum	36.65, 37.39	3.59	2.32	2.96	1.23	40.65	120.12
Salivary Gland Clontech	38.55, 39.31	1.16	0.74	0.95	7.31	6.84	6.50
Skeletal Muscle Clontech	37.59, 36.87	2.06	3.15	2.61	1.26	39.68	103.37
Skin	38.36, 36.33	1.3	4.34	2.82	1.21	41.32	116.53
Small Intestine Clontech	36.05, 36.76	5.14	3.37	4.26	0.98	51.07	217.31
Spleen	37.62, 35.34	2.02	7.83	4.93	4.92	10.16	50.05
Stomach	35.8, 35.15	5.95	8.76	7.36	2.73	18.32	134.71
Testis Clontech	35.14, 37.08	8.82	2.77	5.80	0.57	87.87	509.23
Thymus Clontech	35.89, 35.06	5.65	9.22	7.44	9.89	5.06	37.59
Thyroid	37.59, 37.2	2.06	2.59	2.33	2.77	18.05	41.97
Trachea Clontech	37.52, 37.95	2.14	1.66	1.90	9.71	5.15	9.78
Urinary Bladder	37.47, 35.44	2.2	7.38	4.79	5.47	9.14	43.78
Uterus	34.17, 34.12	15.66	16.17	15.92	5.34	9.36	149.02
genomic	27.03	1097.52					
b-actin	27.23	974.77					
1.00E+05	19.25	100000					
1.00E+05	19.2	100000					
1.00E+04	22.99	10000					
1.00E+04	22.94	10000					
1.00E+03	27.09	1000					
1.00E+03	27.28	1000					
1.00E+02	31.49	100					
1.00E+02	31.46	100					
1.00E+01	37.86	10					
1.00E+01	35.45	10					
1.00E-00	37.08	1					
1.00E-00	37.4	1					
NTC	36.45	-1					
NTC	36.15	-1					

Sample sbg1015258PLM	Reg number	Ct	Mean GOI	copies of mRNA	Sample	Fold Change in
-------------------------	---------------	----	-------------	-------------------	--------	-------------------

	(GSK identifier )		copies	detected/ 50 ng total RNA		Disease Population
colon normal GW98-167	21941	35.4	9.91	19.82	colon normal	
colon tumor GW98-166	21940	35.13	11.61	23.22	colon tumor	1.17
colon normal GW98-178	22080	34.84	13.83	27.66	colon normal	
colon tumor GW98-177	22060	35	12.59	25.18	colon tumor	-1.10
colon normal GW98-561	23514	35.48	9.4	18.80	colon normal	
colon tumor GW98-560	23513	36.2	6.14	12.28	colon tumor	-1.53
colon normal GW98-894	24691	34.53	16.62	33.24	colon normal	
colon tumor GW98-893	24690	34.29	19.25	38.50	colon tumor	1.16
lung normal GW98-3	20742	34.53	16.69	33.38	lung normal	
lung tumor GW98-2	20741	37.87	2.25	4.50	lung tumor	-7.42
lung normal GW97-179	20677	34.59	16.02	32.04	lung normal	
lung tumor GW97-178	20676	34.45	17.43	34.86	lung tumor	1.09
lung normal GW98-165	21922	33.89	24.39	48.78	lung normal	
lung tumor GW98-164	21921	35.48	9.43	18.86	lung tumor	-2.59
lung normal GW98-282	22584	36.67	4.62	9.24	lung normal	
lung tumor GW98-281	22583	37.87	2.26	4.52	lung tumor	-2.04
breast normal GW00-392	28750	34.17	20.64	20.64	breast normal	
breast tumor GW00-391	28746	33.54	30.09	60.18	breast tumor	2.92
breast normal GW00-413	28798	39.05	1.11	1.11	breast normal	
breast tumor GW00-412	28797	35.01	12.46	24.92	breast tumor	22.45
breast normal GW00-235:238	27592-95	40	0.55	0.55	breast normal	
breast tumor GW00-231:234	27588-91	35.07	12.02	12.02	breast tumor	21.85
breast normal GW98-621	23656	33	41.58	83.16	breast normal	
breast tumor GW98-620	23655	33.05	40.47	80.94	breast tumor	-1.03
brain normal BB99-542	25507	32.73	48.93	97.86	brain normal	
brain normal BB99-406	25509	33.97	23.34	46.68	brain normal	
brain normal BB99-904	25546	37.88	2.24	4.48	brain normal	
brain stage 5 ALZ BB99-874	25502	35.92	7.25	14.50	brain stage 5 ALZ	-3.43
brain stage 5 ALZ BB99-887	25503	31.57	97.99	195.98	brain stage 5 ALZ	3.95
brain stage 5 ALZ BB99-862	25504	36.08	6.57	13.14	brain stage 5 ALZ	-3.78
brain stage 5 ALZ BB99-927	25542	32.66	50.98	101.96	brain stage 5 ALZ	2.05
CT lung KC	normal	37.37	3.04	6.08	CT lung	
lung 26 KC	normal				lung 26	
lung 27 KC	normal	38.52	1.52	1.52	lung 27	
lung 24 KC	COPD	40	0	0.00	lung 24	-3.07
lung 28 KC	COPD	37.4	2.99	2.99	lung 28	-1.03
lung 23 KC	COPD	39.56	0.82	0.82	lung 23	-3.74
lung 25 KC	normal	38.43	1.61	1.61	lung 25	

asthmatic lung ODO3112	29321	39.45	0.88	0.88	asthmatic lung	-3.49
asthmatic lung ODO3433	29323	36.48	5.19	10.38	asthmatic lung	3.38
asthmatic lung ODO3397	29322	35.56	8.99	17.98	asthmatic lung	5.86
asthmatic lung ODO4928	29325	37.06	3.66	7.32	asthmatic lung	2.38
endo cells KC	control	39.29	0.96	0.96	endo cells	
endo VEGF KC		37.65	2.57	2.57	endo VEGF	2.68
endo bFGF KC		40	0.48	0.48	endo bFGF	-2.00
heart Clontech	normal	40	0.68	1.36	heart	
heart ( T-1 ) ischemic	29417	39.29	0.96	1.92	heart T-1	1.41
heart (T-14) non- obstructive DCM	29422	38.21	1.84	3.68	heart T-14	2.71
heart (T-3399) DCM	29426	35.49	9.35	18.70	heart T-3399	13.75
adenoid GW99-269	26162	39.63	0.78	1.56	adenoid	
tonsil GW98-280	22582	34.5	16.92	33.84	tonsil	
T cells PC00314	28453	34.57	16.25	32.50	T cells	
PBMNC		37.32	3.13	3.13	PBMNC	
monocyte		37.74	2.44	4.88	monocyte	
B cells PC00665	28455	33.32	34.36	68.72	B cells	
dendritic cells 28441		37.29	3.19	6.38	dendritic cells	
neutrophils	28440	36.01	6.85	6.85	neutrophils	
eosinophils	28446	35.38	9.98	19.96	eosinophils	
BM unstim		37.44	2.91	2.91	BM unstim	
BM stim		40	0.53	0.53	BM stim	-5.49
osteodif		38.15	1.91	1.91	osteodif	-1.38
osteoundif		37.6	2.64	2.64	osteoundif	
chondrocytes		36.1	6.51	16.28	chondrocytes	
OA Synovium IP12/01	29462	35.58	8.86	8.86	OA Synovium	
OA Synovium NP10/01	29461	35.46	9.54	19.08	OA Synovium	
OA Synovium NP57/00	28464	34.05	22.23	44.46	OA Synovium	
RA Synovium NP03/01	28466	37.92	2.19	4.38	RA Synovium	
RA Synovium NP71/00	28467	35.39	9.92	19.84	RA Synovium	
RA Synovium NP45/00	28475	35.03	12.37	24.74	RA Synovium	
OA bone (biobank)	29217	39.98	0.67	0.67	OA bone (biobank)	
OA bone Sample 1	J. Emory	36.06	6.68	13.36	OA bone	
OA bone Sample 2	J. Emory	39.89	0.67	1.34	OA bone	
Cartilage (pool)	Normal	35.57	8.92	17.84	Cartilage (pool)	
Cartilage (pool)	OA	39.5	0.85	1.70	Cartilage (pool)	-10.49
PBL uninfected	28441	36.65	4.67	9.34	PBL uninfected	
PBL HIV IIIB	28442	36.94	3.92	7.84	PBL HIV IIIB	-1.19
MRC5 uninfected (100%)	29158	37.54	2.74	5.48	MRC5 uninfected (100%)	
MRC5 HSV strain F	29178	33.19	37.18	74.36	MRC5 HSV strain F	13.57
W12 cells	29179	37.23	3.3	6.60	W12 cells	
Keratinocytes	29180	37.18	3.4	6.80	Keratinocytes	

B-actin control		27.26	1296.87			
genomic		27.2	1345.34			
1.00E+05		19.44	100000			
1.00E+05		19.81	100000			
1.00E+04		23.63	10000			
1.00E+04		23.41	10000			
1.00E+03		27.77	1000			
1.00E+03		27.89	1000			
1.00E+02		32.32	100			
1.00E+02		32.3	100			
1.00E+01		36.77	10			
1.00E+01		36.39	10			
1.00E-00		38.06	1			
1.00E-00		37.56	1			
NTC		38.18	-1			

## Gene Name sbg1015258PLM

Disease tissues	Fold Change in Disease Population Relative to Normal
colon tumor	1.17
colon tumor	-1.10
colon tumor	-1.53
colon tumor	1.16
lung tumor	-7.42
lung tumor	1.09
lung tumor	-2.59
lung tumor	-2.04
breast tumor	2.92
breast tumor	22.45
breast tumor	21.85
breast tumor	-1.03
brain stage 5 ALZ	-3.43
brain stage 5 ALZ	3.95
brain stage 5 ALZ	-3.78
brain stage 5 ALZ	2.05
lung 24	-3.07
lung 28	-1.03
lung 23	-3.74
asthmatic lung	-3.49
asthmatic lung	3.38
asthmatic lung	5.86
asthmatic lung	2.38
endo VEGF	2.68
endo bFGF	-2.00

heart T-1	1.41
heart T-14	2.71
heart T-3399	13.75
BM stim	-5.49
osteo dif	-1.38
Cartilage (pool)	-10.49
PBL HIV IIIB	-1.19
MRC5 HSV strain F	13.57

**Gene Name sbg1003328IG (Taqman)**

5 Moderate overall expression. Highest normal expression in whole brain, fetal brain, and cerebellum with slightly lower levels of expression in the colon and mammary gland. Highest disease expression in the colon and lung tumor pairs as well as the normal and Alzheimer's brain. Significant upregulation in 2 of 4 breast tumor samples with slight upregulation in 1 of 4 breast tumor samples implicates this gene in breast cancer. Downregulation in 3 of 3 COPD samples may suggest an involvement in chronic obstructive pulmonary disease. Downregulation in 1 of 4 asthma samples suggests a potential role for this gene in asthma. Downregulation in the HSV-infected 10 MRC5 cells suggests that this gene may play a role in HSV. High expression in 3 of 3 OA synovium samples, 3 of 3 RA synovium samples, 2 of 2 OA bone samples, and corroborating high expression in the T cells and B cells implicates this gene in osteoarthritis and rheumatoid arthritis.

Sample sbg1003328IG	Ct (sample 1 and 2)	Mean GOI copies (sample 1)	Mean GOI copies (sample 2)	Average GOI Copies	18S rRNA (ng)	50 ng/18S rRNA (ng)	copies of mRNA detected /50 ng total RNA
Subcutaneous Adipocytes Zenbio	32.35, 32.1	109.15	127.12	118.14	3.06	16.34	1930.31
Subcutaneous Adipose Zenbio	37.92, 40	3.84	0	1.92	0.96	52.36	100.52
Adrenal Gland Clontech	38.07, 35.73	3.5	14.32	8.91	0.61	81.97	730.33
Whole Brain Clontech	22.72, 23.09	35640.5	28576.52	32108.51	7.24	6.91	221743. 85
Fetal Brain Clontech	33.39, 34.06	58.43	39.04	48.74	0.48	103.95	5066.01
Cerebellum Clontech	31.32, 31.02	202.49	242.95	222.72	2.17	23.04	5131.80
Cervix	36.36, 35.6	9.78	15.49	12.64	2.42	20.66	261.05
Colon	30.74, 32.11	286.9	125.78	206.34	2.71	18.45	3807.01
Endometrium	34.58, 36.01	28.47	12.11	20.29	0.73	68.21	1384.04
Esophagus	37.54, 36.05	4.82	11.78	8.30	1.37	36.50	302.92
Heart Clontech	36.23, 36.85	10.56	7.3	8.93	1.32	37.88	338.26
Hypothalamus	40, 36.96	0	6.81	3.41	0.32	155.28	528.73
Ileum	34.79, 34.48	25.09	30.4	27.75	2.58	19.38	537.69
Jejunum	30.14, 31.02	412.72	242.47	327.60	6.60	7.58	2481.78
Kidney	33.94, 34.61	41.89	28.12	35.01	2.12	23.58	825.59
Liver	36.11, 35.38	11.41	17.61	14.51	1.50	33.33	483.67
Fetal Liver Clontech	30.24, 30.27	388.12	381.28	384.70	10.40	4.81	1849.52
Lung	35.59, 35.09	15.59	20.98	18.29	2.57	19.46	355.74
Mammary Gland Clontech	29.21, 28.52	718.74	1090.18	904.46	13.00	3.85	3478.69

Myometrium	33.7, 34.11	48.42	37.85	43.14	2.34	21.37	921.69
Omentum	33.83, 33.57	44.75	52.27	48.51	3.94	12.69	615.61
Ovary	32.47, 32.34	101.42	109.96	105.69	4.34	11.52	1217.63
Pancreas	38.16, 40	3.31	0	1.66	0.81	61.80	102.29
Head of Pancreas	40, 36.68	0	8.07	4.04	1.57	31.85	128.50
Parotid Gland	31.68, 31.03	162.92	241.11	202.02	5.48	9.12	1843.20
Placenta Clontech	30.48, 30.82	335.37	274.53	304.95	5.26	9.51	2898.76
Prostate	33.39, 32.15	58.39	122.82	90.61	3.00	16.67	1510.08
Rectum	35.95, 35.32	12.5	18.32	15.41	1.23	40.65	626.42
Salivary Gland Clontech	31.25, 30.65	211.88	303.2	257.54	7.31	6.84	1761.56
Skeletal Muscle Clontech	36.61, 37.62	8.44	4.6	6.52	1.26	39.68	258.73
Skin	36.37, 36.08	9.71	11.56	10.64	1.21	41.32	439.46
Small Intestine Clontech	36.74, 34.51	7.79	29.79	18.79	0.98	51.07	959.65
Spleen	34.78, 35.63	25.25	15.18	20.22	4.92	10.16	205.44
Stomach	40, 35.13	0.88	20.56	10.72	2.73	18.32	196.34
Testis Clontech	35.01, 39.68	22.07	1.33	11.70	0.57	87.87	1028.12
Thymus Clontech	29.15, 29.2	749.23	724.61	736.92	9.89	5.06	3725.58
Thyroid	32.02, 32.14	133.23	123.77	128.50	2.77	18.05	2319.49
Trachea Clontech	31.28, 30.17	207.67	405.04	306.36	9.71	5.15	1577.52
Urinary Bladder	33.07, 32.91	70.6	78.07	74.34	5.47	9.14	679.48
Uterus	33.01, 33.15	73.56	67.48	70.52	5.34	9.36	660.30
genomic	29.15	746.77					
b-actin	30.2	397.52					
1.00E+05	21.06	100000					
1.00E+05	20.94	100000					
1.00E+04	25.06	10000					
1.00E+04	24.54	10000					
1.00E+03	28.32	1000					
1.00E+03	28.77	1000					
1.00E+02	33	100					
1.00E+02	32.74	100					
1.00E+01	35.9	10					
1.00E+01	40	0					
1.00E-00	40	0					
1.00E-00	40	0					
NTC	40	0					
NTC	40	0					

Sample sbg1003328IG	Reg number (GSK identifie r)	Ct	Mean GOI copies	copies of mRNA detected/ 50 ng total RNA	Sample	Fold Change in Disease Populati on
colon normal GW98-167	21941	24.26	15509.01	31018.02	colon normal	

colon tumor GW98-166	21940	24.5	13727.44	27454.88	colon tumor	-1.13
colon normal GW98-178	22080	28.01	2276.97	4553.94	colon normal	
colon tumor GW98-177	22060	27.11	3618.2	7236.40	colon tumor	1.59
colon normal GW98-561	23514	24.47	13993.67	27987.34	colon normal	
colon tumor GW98-560	23513	25.32	9040.47	18080.94	colon tumor	-1.55
colon normal GW98-894	24691	24.17	16251.61	32503.22	colon normal	
colon tumor GW98-893	24690	25.15	9872.46	19744.92	colon tumor	-1.65
lung normal GW98-3	20742	24.4	14498.52	28997.04	lung normal	
lung tumor GW98-2	20741	24.66	12640.32	25280.64	lung tumor	-1.15
lung normal GW97-179	20677	24.12	16680.84	33361.68	lung normal	
lung tumor GW97-178	20676	24.69	12468.91	24937.82	lung tumor	-1.34
lung normal GW98-165	21922	25.09	10168.18	20336.36	lung normal	
lung tumor GW98-164	21921	25.49	8296.37	16592.74	lung tumor	-1.23
lung normal GW98-282	22584	26.85	4131.52	8263.04	lung normal	
lung tumor GW98-281	22583	26.59	4702	9404.00	lung tumor	1.14
breast normal GW00-392	28750	25.9	6719.98	6719.98	breast normal	
breast tumor GW00-391	28746	25.04	10402.11	20804.22	breast tumor	3.10
breast normal GW00-413	28798	32.51	226.94	226.94	breast normal	
breast tumor GW00-412	28797	26.37	5261.73	10523.46	breast tumor	46.37
breast normal GW00-235:238	27592-95	34.58	78.63	78.63	breast normal	
breast tumor GW00-231:234	27588-91	28.45	1812.86	1812.86	breast tumor	23.06
breast normal GW98-621	23656	25.26	9289.36	18578.72	breast normal	
breast tumor GW98-620	23655	25.66	7579.13	15158.26	breast tumor	-1.23
brain normal BB99-542	25507	22.52	37845.47	75690.94	brain normal	
brain normal BB99-406	25509	23.07	28574.8	57149.60	brain normal	
brain normal BB99-904	25546	23.85	19214.49	38428.98	brain normal	
brain stage 5 ALZ BB99-874	25502	25.98	6442.51	12885.02	brain stage 5 ALZ	-4.43
brain stage 5 ALZ BB99-887	25503	23.19	26936.06	53872.12	brain stage 5 ALZ	-1.06
brain stage 5 ALZ BB99-862	25504	23.42	23948.83	47897.66	brain stage 5 ALZ	-1.19
brain stage 5 ALZ BB99-927	25542	24.15	16419.33	32838.66	brain stage 5 ALZ	-1.74
CT lung KC	normal	25.63	7714.35	15428.70	CT lung	
lung 26 KC	normal	32.34	247.99	247.99	lung 26	
lung 27 KC	normal	33.71	122.77	122.77	lung 27	
lung 24 KC	COPD	32.47	231.47	231.47	lung 24	-17.21
lung 28 KC	COPD	32.63	213.14	213.14	lung 28	-18.70
lung 23 KC	COPD	31.2	444.95	444.95	lung 23	-8.96
lung 25 KC	normal	33.46	139.4	139.40	lung 25	
asthmatic lung ODO3112	29321	31.6	360.95	360.95	asthmatic lung	-11.04
asthmatic lung ODO3433	29323	28.66	1634.71	3269.42	asthmatic lung	-1.22
asthmatic lung	29322	26.36	5294.26	10588.52	asthmatic lung	2.66

ODO3397						
asthmatic lung	29325	28.23	2033.93	4067.86	asthmatic lung	1.02
ODO4928						
endo cells KC	control	30.68	580.47	580.47	endo cells	
endo VEGF KC		31.08	471.26	471.26	endo VEGF	-1.23
endo bFGF KC		32.25	259.04	259.04	endo bFGF	-2.24
heart Clontech	normal	27.28	3312.82	6625.64	heart	
heart ( T-1 ) ischemic	29417	27.48	2979.22	5958.44	heart T-1	-1.11
heart (T-14) non-obstructive DCM	29422	27.74	2613.8	5227.60	heart T-14	-1.27
heart (T-3399) DCM	29426	26.66	4541.38	9082.76	heart T-3399	1.37
adenoid GW99-269	26162	27.83	2493.31	4986.62	adenoid	
tonsil GW98-280	22582	25.68	7506.04	15012.08	tonsil	
T cells PC00314	28453	27.18	3487.61	6975.22	T cells	
PBMNC		32.6	216.73	216.73	PBMNC	
monocyte		32.27	256.89	513.78	monocyte	
B cells PC00665	28455	27.83	2492.12	4984.24	B cells	
dendritic cells 28441		26.67	4528.97	9057.94	dendritic cells	
neutrophils	28440	28.4	1862.35	1862.35	neutrophils	
eosinophils	28446	31.69	344.59	689.18	eosinophils	
BM unstim		32.04	289.03	289.03	BM unstim	
BM stim		30.59	607.18	607.18	BM stim	2.10
osteo dif		28.43	1831.57	1831.57	osteo dif	3.42
osteo undif		30.83	536	536.00	osteo undif	
chondrocytes		26.74	4368.46	10921.15	chondrocytes	
OA Synovium IP12/01	29462	27.91	2391.03	2391.03	OA Synovium	
OA Synovium NP10/01	29461	27.4	3109.93	6219.86	OA Synovium	
OA Synovium NP57/00	28464	27.05	3729.47	7458.94	OA Synovium	
RA Synovium NP03/01	28466	25.53	8116.96	16233.92	RA Synovium	
RA Synovium NP71/00	28467	26.06	6167.42	12334.84	RA Synovium	
RA Synovium NP45/00	28475	25.35	8888.66	17777.32	RA Synovium	
OA bone (biobank)	29217	30.23	729.87	729.87	OA bone (biobank)	
OA bone Sample 1	J. Emory	27.65	2743.38	5486.76	OA bone	
OA bone Sample 2	J. Emory	28.02	2258.96	4517.92	OA bone	
Cartilage (pool)	Normal	25.82	7006.64	14013.28	Cartilage (pool)	
Cartilage (pool)	OA	27.22	3408.61	6817.22	Cartilage (pool)	-2.06
PBL uninfected	28441	24.24	15680.49	31360.98	PBL uninfected	
PBL HIV IIIB	28442	25.43	8521.98	17043.96	PBL HIV IIIB	-1.84
MRC5 uninfected (100%)	29158	25.58	7922.19	15844.38	MRC5 uninfected (100%)	
MRC5 HSV strain F	29178	32.02	291.12	582.24	MRC5 HSV strain F	-27.21
W12 cells	29179	26.03	6269.24	12538.48	W12 cells	
Keratinocytes	29180	25.43	8538.15	17076.30	Keratinocytes	
B-actin control		29.74	938.61			
genomic		28.79	1522.16			
1.00E+05		20.84	100000			
1.00E+05		21.4	100000			

1.00E+04		24.5	10000				
1.00E+04		25.2	10000				
1.00E+03		28.45	1000				
1.00E+03		29.25	1000				
1.00E+02		35.34	100				
1.00E+02		33.61	100				
1.00E+01		38.95	10				
1.00E+01		40	0				
1.00E-00		40	0				
1.00E-00		40	0				
NTC		40	0				

Gene Name sbg1003328IG

Disease tissues	Fold Change in Disease Population Relative to Normal
colon tumor	-1.13
colon tumor	1.59
colon tumor	-1.55
colon tumor	-1.65
lung tumor	-1.15
lung tumor	-1.34
lung tumor	-1.23
lung tumor	1.14
breast tumor	3.10
breast tumor	46.37
breast tumor	23.06
breast tumor	-1.23
brain stage 5 ALZ	-4.43
brain stage 5 ALZ	-1.06
brain stage 5 ALZ	-1.19
brain stage 5 ALZ	-1.74
lung 24	-17.21
lung 28	-18.70
lung 23	-8.96
asthmatic lung	-11.04
asthmatic lung	-1.22
asthmatic lung	2.66
asthmatic lung	1.02
endo VEGF	-1.23
endo bFGF	-2.24
heart T-1	-1.11
heart T-14	-1.27
heart T-3399	1.37
BM stim	2.10
osteо dif	3.42

Cartilage (pool)	-2.06
PBL HIV IIIB	-1.84
MRC5 HSV strain F	-27.21

**Gene Name sbg1020829SGLT**

5 Low overall expression in normal and disease samples. Highest normal expression in the whole brain, kidney, and thymus. Highest disease expression in the adenoid, tonsil, T cells, B cells, and eosinophils. Highly immune cell specific. Downregulation in 1 of 4 lung tumor samples and upregulation in 1 of 4 breast tumor samples indicates involvement in cancers of the lung and breast. Upregulation in 3 of 4 AD brain samples suggests an involvement in Alzheimer's disease. Downregulation in 3 of 3 COPD samples implies a role in chronic obstructive pulmonary disease. Downregulation in the stimulated bone marrow sample. Upregulation in the differentiated osteoblast sample. Upregulation in the HSV-infected MRC5 cells suggests that this gene may be a host factor in HSV. Moderate to high expression in the OA and RA samples indicates a potential role in osteoarthritis and rheumatoid arthritis.

10

Sample sbg1020829SGLT	Ct (sample 1 and 2)	Mean GOI copies (sample 1)	Mean GOI copies (sample 2)	Average GOI Copies	18S rRNA (ng)	50 ng/18S rRNA (ng)	copies of mRNA detected/50 ng total RNA
Subcutaneous Adipocytes Zenbio	37.07, 40	7.33	0	3.67	3.06	16.34	59.89
Subcutaneous Adipose Zenbio	40, 40	0	0	0.00	0.96	52.36	0.00
Adrenal Gland Clontech	40, 40	0	0	0.00	0.61	81.97	0.00
Whole Brain Clontech	32.13, 32.38	138.5	119.48	128.99	7.24	6.91	890.81
Fetal Brain Clontech	40, 40	0	0	0.00	0.48	103.95	0.00
Cerebellum Clontech	40, 40	0	0	0.00	2.17	23.04	0.00
Cervix	36.13, 40	12.82	0	6.41	2.42	20.66	132.44
Colon	36.93, 36.84	7.97	8.41	8.19	2.71	18.45	151.11
Endometrium	37.45, 37.41	5.84	5.98	5.91	0.73	68.21	403.14
Esophagus	40, 40	0	0	0.00	1.37	36.50	0.00
Heart Clontech	40, 40	0	0	0.00	1.32	37.88	0.00
Hypothalamus	40, 40	0	0	0.00	0.32	155.28	0.00
Ileum	36.53, 35.17	10.09	22.67	16.38	2.58	19.38	317.44
Jejunum	40, 35.73	0	16.2	8.10	6.60	7.58	61.36
Kidney	31.93, 31.01	155.27	269.39	212.33	2.12	23.58	5007.78
Liver	36.1, 35.88	13.05	14.82	13.94	1.50	33.33	464.50
Fetal Liver Clontech	35.06, 34.36	24.26	36.78	30.52	10.40	4.81	146.73
Lung	37.24, 40	6.63	0	3.32	2.57	19.46	64.49
Mammary Gland Clontech	34.25, 34.21	39.27	40.17	39.72	13.00	3.85	152.77
Myometrium	38.48, 35.31	3.16	20.87	12.02	2.34	21.37	256.73
Omentum	40, 38.91	0	2.45	1.23	3.94	12.69	15.55
Ovary	37.87, 37.06	4.56	7.37	5.97	4.34	11.52	68.72
Pancreas	40, 40	0	0	0.00	0.81	61.80	0.00
Head of Pancreas	40, 40	0	0	0.00	1.57	31.85	0.00

Parotid Gland	36.06, 37.07	13.32	7.31	10.32	5.48	9.12	94.11
Placenta Clontech	35.98, 38.73	13.96	2.72	8.34	5.26	9.51	79.28
Prostate	40, 40	0	0	0.00	3.00	16.67	0.00
Rectum	40, 40	0	0	0.00	1.23	40.65	0.00
Salivary Gland Clontech	37.05, 37.06	7.4	7.36	7.38	7.31	6.84	50.48
Skeletal Muscle Clontech	40, 40	0	0	0.00	1.26	39.68	0.00
Skin	40, 40	0	0	0.00	1.21	41.32	0.00
Small Intestine Clontech	40, 40	0	0	0.00	0.98	51.07	0.00
Spleen	35.62, 35.72	17.34	16.35	16.85	4.92	10.16	171.19
Stomach	40, 40	0	1.61	0.81	2.73	18.32	14.74
Testis Clontech	40, 40	0	0	0.00	0.57	87.87	0.00
Thymus Clontech	31.3, 31.09	226.24	257.15	241.70	9.89	5.06	1221.92
Thyroid	40, 40	0	0	0.00	2.77	18.05	0.00
Trachea Clontech	36.6, 36.64	9.68	9.44	9.56	9.71	5.15	49.23
Urinary Bladder	40, 40	0	0	0.00	5.47	9.14	0.00
Uterus	34.64, 36.65	31.06	9.41	20.24	5.34	9.36	189.47
genomic	29.07	853.08					
b-actin	27.08	2793.5					
1.00E+05	20.85	100000					
1.00E+05	21.11	100000					
1.00E+04	24.81	10000					
1.00E+04	24.95	10000					
1.00E+03	28.39	1000					
1.00E+03	28.9	1000					
1.00E+02	34.1	100					
1.00E+02	32.86	100					
1.00E+01	35.52	10					
1.00E+01	40	0					
1.00E-00	40	0					
1.00E-00	40	0					
NTC	40	0					
NTC	40	0					

Sample sbg1020829SGLT	Reg number (GSK identifier )	Ct	Mean GOI copies	copies of mRNA detected/ 50 ng total RNA	Sample	Fold Change in Disease Populat ion
colon normal GW98-167	21941	31.06	206.55	413.10	colon normal	
colon tumor GW98-166	21940	31.18	193.59	387.18	colon tumor	-1.07
colon normal GW98-178	22080	30.74	244.37	488.74	colon normal	
colon tumor GW98-177	22060	30.37	299.28	598.56	colon tumor	1.22
colon normal GW98-561	23514	29.31	527.04	1054.08	colon normal	
colon tumor GW98-560	23513	31.86	134.48	268.96	colon tumor	-3.92

colon normal GW98-894	24691	31.84	135.33	270.66	colon normal	
colon tumor GW98-893	24690	31.9	131.57	263.14	colon tumor	-1.03
lung normal GW98-3	20742	28.81	689.14	1378.28	lung normal	
lung tumor GW98-2	20741	31.91	130.71	261.42	lung tumor	-5.27
lung normal GW97-179	20677	30.04	356.26	712.52	lung normal	
lung tumor GW97-178	20676	29.05	605.73	1211.46	lung tumor	1.70
lung normal GW98-165	21922	28.42	852.41	1704.82	lung normal	
lung tumor GW98-164	21921	30.51	277.13	554.26	lung tumor	-3.08
lung normal GW98-282	22584	31.23	188.34	376.68	lung normal	
lung tumor GW98-281	22583	30.46	285	570.00	lung tumor	1.51
breast normal GW00-392	28750	31.14	197.15	197.15	breast normal	
breast tumor GW00-391	28746	32.15	114.65	229.30	breast tumor	1.16
breast normal GW00-413	28798	34.87	26.64	26.64	breast normal	
breast tumor GW00-412	28797	31.83	136.42	272.84	breast tumor	10.24
breast normal GW00-235:238	27592-95	36.34	12.09	12.09	breast normal	
breast tumor GW00-231:234	27588-91	33.48	56.11	56.11	breast tumor	4.64
breast normal GW98-621	23656	32.39	100.78	201.56	breast normal	
breast tumor GW98-620	23655	31.4	171.82	343.64	breast tumor	1.70
brain normal BB99-542	25507	34.49	32.75	65.50	brain normal	
brain normal BB99-406	25509	34.01	42.2	84.40	brain normal	
brain normal BB99-904	25546	36.17	13.3	26.60	brain normal	
brain stage 5 ALZ BB99-874	25502	31.16	195.23	390.46	brain stage 5 ALZ	6.64
brain stage 5 ALZ BB99-887	25503	31.56	157.33	314.66	brain stage 5 ALZ	5.35
brain stage 5 ALZ BB99-862	25504	32.62	89.2	178.40	brain stage 5 ALZ	3.03
brain stage 5 ALZ BB99-927	25542	33.26	63.43	126.86	brain stage 5 ALZ	2.16
CT lung KC	normal	30.82	234.88	469.76	CT lung	
lung 26 KC	normal	30.21	325.42	325.42	lung 26	
lung 27 KC	normal	36.89	9	9.00	lung 27	
lung 24 KC	COPD	36.17	13.24	13.24	lung 24	-15.84
lung 28 KC	COPD	38.38	4.06	4.06	lung 28	-51.66
lung 23 KC	COPD	35.53	18.67	18.67	lung 23	-11.23
lung 25 KC	normal	34.37	34.83	34.83	lung 25	
asthmatic lung ODO3112	29321	33.65	51.41	51.41	asthmatic lung	-4.08
asthmatic lung ODO3433	29323	30.62	260.95	521.90	asthmatic lung	2.49
asthmatic lung ODO3397	29322	31.31	180.14	360.28	asthmatic lung	1.72
asthmatic lung ODO4928	29325	31.14	197.09	394.18	asthmatic lung	1.88
endo cells KC	control	32.56	92.23	92.23	endo cells	
endo VEGF KC		33.29	62.39	62.39	endo VEGF	-1.48
endo bFGF KC		32.55	92.65	92.65	endo bFGF	1.00
heart Clontech	normal	33.17	66.25	132.50	heart	
heart ( T-1 ) ischemic	29417	33.07	70.16	140.32	heart T-1	1.06
heart (T-14) non-obstructive DCM	29422	34.64	30.13	60.26	heart T-14	-2.20
heart (T-3399) DCM	29426	32.53	93.63	187.26	heart T-3399	1.41

adenoid GW99-269	26162	28.92	650.55	1301.10	adenoid	
tonsil GW98-280	22582	27.11	1719.42	3438.84	tonsil	
T cells PC00314	28453	28.05	1037.04	2074.08	T cells	
PBMNC		36.57	10.71	10.71	PBMNC	
monocyte		33.22	64.68	129.36	monocyte	
B cells PC00665	28455	27.07	1757.79	3515.58	B cells	
dendritic cells 28441		33.77	48.05	96.10	dendritic cells	
neutrophils	28440	30.71	248.56	248.56	neutrophils	
eosinophils	28446	27.3	1549.7	3099.40	eosinophils	
BM unstim		30.06	352.26	352.26	BM unstim	
BM stim		34.14	39.39	39.39	BM stim	-8.94
osteodif		36.29	12.42	12.42	osteodif	12.42
osteoundif		40	0	0.00	osteoundif	
chondrocytes		32.11	117.39	293.48	chondrocytes	
OA Synovium IP12/01	29462	30.17	331.7	331.70	OA Synovium	
OA Synovium NP10/01	29461	32.05	120.98	241.96	OA Synovium	
OA Synovium NP57/00	28464	30.13	339.03	678.06	OA Synovium	
RA Synovium NP03/01	28466	31.28	182.96	365.92	RA Synovium	
RA Synovium NP71/00	28467	29.81	402.34	804.68	RA Synovium	
RA Synovium NP45/00	28475	30.22	324.14	648.28	RA Synovium	
OA bone (biobank)	29217	28.45	837.78	837.78	OA bone (biobank)	
OA bone Sample 1	J. Emory	30.21	325.03	650.06	OA bone	
OA bone Sample 2	J. Emory	29.8	406	812.00	OA bone	
Cartilage (pool)	Normal	31.09	203.28	406.56	Cartilage (pool)	
Cartilage (pool)	OA	32.18	112.77	225.54	Cartilage (pool)	-1.80
PBL uninfected	28441	29.17	567.22	1134.44	PBL uninfected	
PBL HIV IIIB	28442	30.73	246.69	493.38	PBL HIV IIIB	-2.30
MRC5 uninfected (100%)	29158	35.54	18.61	37.22	MRC5 uninfected (100%)	
MRC5 HSV strain F	29178	30.54	272.3	544.60	MRC5 HSV strain F	14.63
W12 cells	29179	32.28	107.25	214.50	W12 cells	
Keratinocytes	29180	34.27	36.84	73.68	Keratinocytes	
B-actin control		27.03	1793.92			
genomic		27.77	1204.8			
1.00E+05		19.84	100000			
1.00E+05		19.86	100000			
1.00E+04		23.46	10000			
1.00E+04		23.8	10000			
1.00E+03		27.45	1000			
1.00E+03		27.94	1000			
1.00E+02		33.86	100			
1.00E+02		31.41	100			
1.00E+01		40	0			
1.00E+01		36.88	10			
1.00E-00		40	0			
1.00E-00		40	0			
NTC		40	0			

## Gene Name sbg1020829SGLT

Disease tissues	Fold Change in Disease Population Relative to Normal
colon tumor	-1.07
colon tumor	1.22
colon tumor	-3.92
colon tumor	-1.03
lung tumor	-5.27
lung tumor	1.70
lung tumor	-3.08
lung tumor	1.51
breast tumor	1.16
breast tumor	10.24
breast tumor	4.64
breast tumor	1.70
brain stage 5 ALZ	6.64
brain stage 5 ALZ	5.35
brain stage 5 ALZ	3.03
brain stage 5 ALZ	2.16
lung 24	-15.84
lung 28	-51.66
lung 23	-11.23
asthmatic lung	-4.08
asthmatic lung	2.49
asthmatic lung	1.72
asthmatic lung	1.88
endo VEGF	-1.48
endo bFGF	1.00
heart T-1	1.06
heart T-14	-2.20
heart T-3399	1.41
BM stim	-8.94
osteo dif	12.42
Cartilage (pool)	-1.80
PBL HIV IIIB	-2.30
MRC5 HSV strain F	14.63

## 5 Gene Name sbg1005450UDPGT

Low to moderate overall expression. Highest normal expression in endometrium, esophagus, and spleen with lower levels of expression in cerebellum, hypothalamus, rectum, and uterus. Highest disease expression in one of the OA synovium samples. Downregulation in 1 of 4 colon tumor samples is sufficient to make a disease claim in cancer of the colon. Upregulation in 1 of 4 lung tumor samples indicates a potential role for this gene in cancer of the lung. Downregulation in 2 of 4 AD brain samples suggests an involvement in Alzheimer's disease. Downregulation in 3 of 3 COPD lung samples and 4 of 4 asthmatic lung samples suggests involvement in chronic obstructive

pulmonary disease and asthma. Upregulation in the HSV-infected MRC5 cells suggests that this gene may be a host factor in HSV. Moderate expression in the B cells and the dendritic cells.

Sample sbg1005450UDPGT	Ct (sample 1 and 2)	Mean GOI copies (sample 1)	Mean GOI copies (sample 2)	Averag e GOI Copies	18S rRNA (ng)	50 ng/18S rRNA (ng)	copies of mRNA detecte d/50 ng total RNA
Subcutaneous Adipocytes Zenbio	40, 40	0.15	0.17	0.16	3.06	16.34	2.61
Subcutaneous Adipose Zenbio	40, 40	0	0	0.00	0.96	52.36	0.00
Adrenal Gland Clontech	40, 40	0	0.14	0.07	0.61	81.97	5.74
Whole Brain Clontech	33.74, 40	12.07	0	6.04	7.24	6.91	41.68
Fetal Brain Clontech	40, 40	0	0	0.00	0.48	103.95	0.00
Cerebellum Clontech	32.07, 33.2	32.85	16.64	24.75	2.17	23.04	570.16
Cervix	40, 40	0	0	0.00	2.42	20.66	0.00
Colon	40, 35.16	0	5.12	2.56	2.71	18.45	47.23
Endometrium	32.73, 31.85	22.19	37.5	29.85	0.73	68.21	2035.81
Esophagus	32.67, 29.39	22.91	165.34	94.13	1.37	36.50	3435.22
Heart Clontech	37.12, 35.03	1.58	5.55	3.57	1.32	37.88	135.04
Hypothalamus	34.08, 40	9.84	0	4.92	0.32	155.28	763.98
Ileum	34.35	8.33		8.33	2.58	19.38	161.43
Jejunum	40, 40	0	0	0.00	6.60	7.58	0.00
Kidney	38.89, 40	0.54	0	0.27	2.12	23.58	6.37
Liver	36.32, 40	2.55	0	1.28	1.50	33.33	42.50
Fetal Liver Clontech	36.96	1.74		1.74	10.40	4.81	8.37
Lung	40, 40	0	0	0.00	2.57	19.46	0.00
Mammary Gland Clontech	40, 40	0	0	0.00	13.00	3.85	0.00
Myometrium	40, 38.22	0	0.82	0.41	2.34	21.37	8.76
Omentum	36.17, 40	2.8	0	1.40	3.94	12.69	17.77
Ovary	40, 40	0	0	0.00	4.34	11.52	0.00
Pancreas	40, 40	0	0	0.00	0.81	61.80	0.00
Head of Pancreas	40, 38.35	0	0.75	0.38	1.57	31.85	11.94
Parotid Gland	40, 40	0	0	0.00	5.48	9.12	0.00
Placenta Clontech	39.06, 35.49	0.49	4.22	2.36	5.26	9.51	22.39
Prostate	38.81, 40	0.57	0	0.29	3.00	16.67	4.75
Rectum	35.22, 33.25	4.94	16.2	10.57	1.23	40.65	429.67
Salivary Gland Clontech	32.56, 34.56	24.55	7.36	15.96	7.31	6.84	109.13
Skeletal Muscle Clontech	40, 40	0	0	0.00	1.26	39.68	0.00
Skin	34.26, 40	8.8	0	4.40	1.21	41.32	181.82
Small Intestine Clontech	40	0	6.23	3.12	0.98	51.07	159.09
Spleen	40, 27.36	0	560.92	280.46	4.92	10.16	2850.20
Stomach	33.49, 39.12	13.98	0.47	7.23	2.73	18.32	132.33

Testis Clontech	40, 40	0	0	0.00	0.57	87.87	0.00
Thymus Clontech	40, 35.33	0	4.64	2.32	9.89	5.06	11.73
Thyroid	37.18, 35.52	1.53	4.13	2.83	2.77	18.05	51.08
Trachea Clontech	40, 40	0	0	0.00	9.71	5.15	0.00
Urinary Bladder	40, 40	0	0.16	0.08	5.47	9.14	0.73
Uterus	30.11	106.94	0	53.47	5.34	9.36	500.66
genomic	35.81	3.47					
b-actin	26.86	757.01					
1.00E+05	18.99	100000					
1.00E+05	19.13	100000					
1.00E+04	22.43	10000					
1.00E+04	22.31	10000					
1.00E+03	25.74	1000					
1.00E+03	25.99	1000					
1.00E+02	31.47	100					
1.00E+02	29.82	100					
1.00E+01	40	0					
1.00E+01	40	0					
1.00E-00	40	0					
1.00E-00	40	0					
NTC	26.02	-1					
NTC	40	0					

Sample sbg1005450UDPGT	Reg number (GSK identifie r)	Ct	Mean GOI copies	copies of mRNA detecte d/50 ng total RNA	Sample	Fold Change in Disease Populati on
colon normal GW98-167	21941	40	0.17	0.34	colon normal	
colon tumor GW98-166	21940	39.88	0.29	0.58	colon tumor	1.71
colon normal GW98-178	22080	40	0	0.00	colon normal	
colon tumor GW98-177	22060	40	0	0.00	colon tumor	0.00
colon normal GW98-561	23514	40	0	0.00	colon normal	
colon tumor GW98-560	23513	40	0	0.00	colon tumor	0.00
colon normal GW98-894	24691	33.84	10.47	20.94	colon normal	
colon tumor GW98-893	24690	40	0	0.00	colon tumor	-20.94
lung normal GW98-3	20742	40	0	0.00	lung normal	
lung tumor GW98-2	20741	40	0	0.00	lung tumor	0.00
lung normal GW97-179	20677	31.67	37.94	75.88	lung normal	
lung tumor GW97-178	20676	33.08	16.47	32.94	lung tumor	-2.30
lung normal GW98-165	21922	40	0	0.00	lung normal	
lung tumor GW98-164	21921	40	0	0.00	lung tumor	0.00
lung normal GW98-282	22584	40	0	0.00	lung normal	
lung tumor GW98-281	22583	35.03	5.16	10.32	lung tumor	10.32
breast normal GW00-392	28750	32.64	21.38	21.38	breast normal	

breast tumor GW00-391	28746	31.67	37.98	75.96	breast tumor	3.55
breast normal GW00-413	28798	32.54	22.63	22.63	breast normal	
breast tumor GW00-412	28797	29.23	161.71	323.42	breast tumor	14.29
breast normal GW00-235:238	27592-95	37.05	1.55	1.55	breast normal	
breast tumor GW00-231:234	27588-91	35.03	5.17	5.17	breast tumor	3.34
breast normal GW98-621	23656	34.12	8.87	17.74	breast normal	
breast tumor GW98-620	23655	40	0	0.00	breast tumor	-17.74
brain normal BB99-542	25507	34.28	8.05	16.10	brain normal	
brain normal BB99-406	25509	40	0	0.00	brain normal	
brain normal BB99-904	25546	40	0	0.00	brain normal	
brain stage 5 ALZ BB99-874	25502	38.8	0.55	1.10	brain stage 5 ALZ	-4.88
brain stage 5 ALZ BB99-887	25503	40	0	0.00	brain stage 5 ALZ	-5.37
brain stage 5 ALZ BB99-862	25504	36.16	2.64	5.28	brain stage 5 ALZ	-1.02
brain stage 5 ALZ BB99-927	25542	40	0	0.00	brain stage 5 ALZ	-5.37
CT lung KC	normal	36.61	2.02	4.04	CT lung	
lung 26 KC	normal				lung 26	
lung 27 KC	normal	40	0	0.00	lung 27	
lung 24 KC	COPD	40	0	0.00	lung 24	-1.35
lung 28 KC	COPD	40	0	0.00	lung 28	-1.35
lung 23 KC	COPD	40	0	0.00	lung 23	-1.35
lung 25 KC	normal	40	0	0.00	lung 25	
asthmatic lung ODO3112	29321	38.19	0.79	0.79	asthmatic lung	-1.70
asthmatic lung ODO3433	29323	36.09	2.76	5.52	asthmatic lung	4.10
asthmatic lung ODO3397	29322	40	0	0.00	asthmatic lung	-1.35
asthmatic lung ODO4928	29325	40	0	0.00	asthmatic lung	-1.35
endo cells KC	control	40	0	0.00	endo cells	
endo VEGF KC		40	0	0.00	endo VEGF	0.00
endo bFGF KC		40	0	0.00	endo bFGF	0.00
heart Clontech	normal	40	0	0.00	heart	
heart ( T-1 ) ischemic	29417	38.36	0.71	1.42	heart T-1	1.42
heart (T-14) non-obstructive DCM	29422	40	0	0.00	heart T-14	0.00
heart (T-3399) DCM	29426	40	0	0.00	heart T-3399	0.00
adenoid GW99-269	26162	38.96	0.5	1.00	adenoid	
tonsil GW98-280	22582	35.44	4.04	8.08	tonsil	
T cells PC00314	28453	38.83	0.54	1.08	T cells	
PBMNC		40	0	0.00	PBMNC	
monocyte		35.1	4.94	9.88	monocyte	
B cells PC00665	28455	33.32	14.31	28.62	B cells	
dendritic cells 28441		32.53	22.85	45.70	dendritic cells	
neutrophils	28440	34.43	7.39	7.39	neutrophils	
eosinophils	28446	40	0	0.00	eosinophils	
BM unstim		40	0	0.00	BM unstim	
BM stim		34.12	8.87	8.87	BM stim	8.87

osteodif		40	0	0.00	osteodif	0.00
osteoundif		40	0	0.00	osteoundif	
chondrocytes		34.51	7.05	17.63	chondrocytes	
OA Synovium IP12/01	29462	40	0	0.00	OA Synovium	
OA Synovium NP10/01	29461	27.21	538.51	1077.02	OA Synovium	
OA Synovium NP57/00	28464	33.5	12.85	25.70	OA Synovium	
RA Synovium NP03/01	28466	39.09	0.46	0.92	RA Synovium	
RA Synovium NP71/00	28467	40	0	0.00	RA Synovium	
RA Synovium NP45/00	28475	40	0	0.00	RA Synovium	
OA bone (biobank)	29217	40	0	0.00	OA bone (biobank)	
OA bone Sample 1	J. Emory	35.23	4.59	9.18	OA bone	
OA bone Sample 2	J. Emory	37.1	1.51	3.02	OA bone	
Cartilage (pool)	Normal	35.45	4.01	8.02	Cartilage (pool)	
Cartilage (pool)	OA	40	0	0.00	Cartilage (pool)	-8.02
PBL uninfected	28441	40	0	0.00	PBL uninfected	
PBL HIV IIIB	28442	40	0	0.00	PBL HIV IIIB	0.00
MRC5 uninfected (100%)	29158	40	0.17	0.34	MRC5 uninfected (100%)	
MRC5 HSV strain F	29178	30.15	93.76	187.52	MRC5 HSV strain F	551.53
W12 cells	29179	40	0	0.00	W12 cells	
Keratinocytes	29180	35.72	3.44	6.88	Keratinocytes	
B-actin control		26.57	788.4			
genomic		25.69	1326.94			
1.00E+05		18.72	100000			
1.00E+05		18.74	100000			
1.00E+04		22.11	10000			
1.00E+04		22.15	10000			
1.00E+03		25.57	1000			
1.00E+03		25.54	1000			
1.00E+02		31.37	100			
1.00E+02		29.65	100			
1.00E+01		40	0			
1.00E+01		40	0			
1.00E-00		40	0			
1.00E-00		40	0			
NTC		40	0			

Gene Name sbg1005450UDPGT

Disease tissues	Fold Change in Disease Population Relative to Normal
colon tumor	1.71
colon tumor	0.00
colon tumor	0.00
colon tumor	-20.94

lung tumor	0.00
lung tumor	-2.30
lung tumor	0.00
lung tumor	10.32
breast tumor	3.55
breast tumor	14.29
breast tumor	3.34
breast tumor	-17.74
brain stage 5 ALZ	-4.88
brain stage 5 ALZ	-5.37
brain stage 5 ALZ	-1.02
brain stage 5 ALZ	-5.37
lung 24	-1.35
lung 28	-1.35
lung 23	-1.35
asthmatic lung	-1.70
asthmatic lung	4.10
asthmatic lung	-1.35
asthmatic lung	-1.35
endo VEGF	0.00
endo bFGF	0.00
heart T-1	1.42
heart T-14	0.00
heart T-3399	0.00
BM stim	8.87
osteo undif	0.00
Cartilage (pool)	-8.02
PBL HIV IIIB	0.00
MRC5 HSV strain F	551.53

**Gene Name sbg1002620Tia**

5 Moderate overall expression. Highest normal expression in the whole brain, endometrium, myometrium, placenta, and rectum. Highest disease expression in the one of the colon normal/tumor pairs, the normal lung samples, one of the asthmatic lung samples, the neutrophils, the eosinophils, and one of the RA synovium samples. Expressed at high levels in all of the samples representative of the GI tract indicating a potential role for this gene in IBS, IBD, and Crohn's disease. Downregulation in 1 of 3 COPD lung samples suggests involvement in chronic obstructive pulmonary disease. Upregulation in 1 of 4 asthmatic lung samples implies a role in asthma. High expression in the OA synovium and bone samples as well as in the RA synovium samples. Also high expression in the chondrocytes. Variable expression in the immune cells with highest expression in the neutrophils and eosinophils and lowest expression in the dendritic cells.

10 Corroborating high expression in B and T cells as well as OA samples implicates this gene in osteoarthritis and rheumatoid arthritis.

15

Sample sbg1002620Tia	Ct (sample 1 and 2)	Mean GOI copies (sample 1)	Mean GOI copies (sample 2)	Average GOI Copies	18S rRNA (ng)	50 ng/18 S rRNA (ng)	copies of mRNA detected/ 50 ng total RNA

Subcutaneous Adipocytes Zenbio	35.04, 34.4	201.66	274.43	238.05	3.06	16.34	3889.62
Subcutaneous Adipose Zenbio	38.03, 38.45	48.67	39.85	44.26	0.96	52.36	2317.28
Adrenal Gland Clontech	38.71, 38.14	35.25	46.23	40.74	0.61	81.97	3339.34
Whole Brain Clontech	29.27, 29.32	3152.23	3071.49	3111.86	7.24	6.91	21490.75
Fetal Brain Clontech	40, 37.57	0	60.7	30.35	0.48	103.95	3154.89
Cerebellum Clontech	39.37, 39.14	25.78	28.75	27.27	2.17	23.04	628.23
Cervix	34.05, 34.32	323.57	285.02	304.30	2.42	20.66	6287.09
Colon	32.64, 32.98	633.12	537.54	585.33	2.71	18.45	10799.45
Endometrium	34.44, 33.84	269.09	357.16	313.13	0.73	68.21	21359.14
Esophagus	35.48, 35.21	163.52	186.15	174.84	1.37	36.50	6380.84
Heart Clontech	38.67, 39.08	35.94	29.52	32.73	1.32	37.88	1239.77
Hypothalamus	40, 40	0	0	0.00	0.32	155.28	0.00
Ileum	33.07, 32.9	516.19	559.94	538.07	2.58	19.38	10427.62
Jejunum	30.58, 30.66	1688.39	1625.61	1657.00	6.60	7.58	12553.03
Kidney	34.9, 33.68	216.07	385.19	300.63	2.12	23.58	7090.33
Liver	37.17, 36.49	73.4	101.31	87.36	1.50	33.33	2911.83
Fetal Liver Clontech	33.99, 34.79	332.15	227.82	279.99	10.40	4.81	1346.08
Lung	34.67, 34.06	240.47	321.54	281.01	2.57	19.46	5467.02
Mammary Gland Clontech	29.3, 29.19	3098.36	3272.39	3185.38	13.00	3.85	12251.44
Myometrium	32.45, 31.79	692.54	946.75	819.65	2.34	21.37	17513.78
Omentum	32.88, 33.43	563.23	434.44	498.84	3.94	12.69	6330.39
Ovary	33.02, 32.92	528.43	553.26	540.85	4.34	11.52	6230.93
Pancreas	37.31, 39.81	68.49	20.84	44.67	0.81	61.80	2760.51
Head of Pancreas	38.5, 39.16	38.99	28.45	33.72	1.57	31.85	1073.89
Parotid Gland	34.48, 34.22	263.15	298.49	280.82	5.48	9.12	2562.23
Placenta Clontech	31.16, 30.91	1280.82	1442.99	1361.91	5.26	9.51	12945.87
Prostate	33.5, 33.11	420.13	506.76	463.45	3.00	16.67	7724.08
Rectum	34.48, 33.88	263.61	350.22	306.92	1.23	40.65	12476.22
Salivary Gland Clontech	34.48, 34.32	263.4	284.18	273.79	7.31	6.84	1872.71
Skeletal Muscle Clontech	40, 39.37	0	25.73	12.87	1.26	39.68	510.52
Skin	35.52, 35.13	160.58	193.62	177.10	1.21	41.32	7318.18
Small Intestine Clontech	36.79, 36.59	87.74	96.5	92.12	0.98	51.07	4704.80
Spleen	34.45, 34.51	267.45	260	263.73	4.92	10.16	2680.13
Stomach	35.16, 33.89	191.03	348.48	269.76	2.73	18.32	4940.57
Testis Clontech	38.19, 37.07	45.22	76.91	61.07	0.57	87.87	5365.99
Thymus Clontech	33.74, 33.57	374.59	406.79	390.69	9.89	5.06	1975.18
Thyroid	34.18, 33.46	304.38	427.57	365.98	2.77	18.05	6606.05
Trachea Clontech	32.67, 31.27	623.94	1213.65	918.80	9.71	5.15	4731.18
Urinary Bladder	32.07, 31.34	830.04	1176.15	1003.10	5.47	9.14	9169.06
Uterus	31.75, 31.37	968.5	1157.09	1062.80	5.34	9.36	9951.26
genomic	31.33	1181.44					
b-actin	28.56	4411.32					
1.00E+05	22.12-	100000					

1.00E+05	22.12	100000					
1.00E+04	26.72	10000					
1.00E+04	26.91	10000					
1.00E+03	31.28	1000					
1.00E+03	31.5	1000					
1.00E+02	36.35	100					
1.00E+02	37.09	100					
1.00E+01	40	10					
1.00E+01	40	10					
1.00E-00	40	1					
1.00E-00	40	0					
NTC	40	0					
NTC	40	0					

Sample sbg1002620T1a	Reg number (GSK identifie r)	Ct	Mean GOI copies	copies of mRNA detected/ 50 ng total RNA	Sample	Fold Change in Disease Populati on
colon normal GW98-167	21941	24.54	22693.01	45386.02	colon normal	
colon tumor GW98-166	21940	24.18	26862.61	53725.22	colon tumor	1.18
colon normal GW98-178	22080	27.08	6895.34	13790.68	colon normal	
colon tumor GW98-177	22060	28.41	3692.19	7384.38	colon tumor	-1.87
colon normal GW98-561	23514	26.58	8698.68	17397.36	colon normal	
colon tumor GW98-560	23513	27.85	4799.22	9598.44	colon tumor	-1.81
colon normal GW98-894	24691	25.9	11972.57	23945.14	colon normal	
colon tumor GW98-893	24690	28.04	4396.4	8792.80	colon tumor	-2.72
lung normal GW98-3	20742	24.25	26016.9	52033.80	lung normal	
lung tumor GW98-2	20741	27.64	5300.37	10600.74	lung tumor	-4.91
lung normal GW97-179	20677	25.1	17476.66	34953.32	lung normal	
lung tumor GW97-178	20676	25.53	14274.54	28549.08	lung tumor	-1.22
lung normal GW98-165	21922	24.62	21917.37	43834.74	lung normal	
lung tumor GW98-164	21921	25.64	13526.49	27052.98	lung tumor	-1.62
lung normal GW98-282	22584	27.08	6884.03	13768.06	lung normal	
lung tumor GW98-281	22583	25.37	15385.8	30771.60	lung tumor	2.23
breast normal GW00-392	28750	26.07	11065.25	11065.25	breast normal	
breast tumor GW00-391	28746	26.87	7611.48	15222.96	breast tumor	1.38
breast normal GW00-413	28798	28.65	3294.68	3294.68	breast normal	
breast tumor GW00-412	28797	28.52	3496.94	6993.88	breast tumor	2.12
breast normal GW00-235:238	27592-95	29.47	2243.69	2243.69	breast normal	
breast tumor GW00-231:234	27588-91	25.83	12385.23	12385.23	breast tumor	5.52
breast normal GW98-621	23656	26.05	11188.07	22376.14	breast normal	
breast tumor GW98-620	23655	26.03	11303.95	22607.90	breast tumor	1.01

brain normal BB99-542	25507	27.68	5198.79	10397.58	brain normal	
brain normal BB99-406	25509	29.81	1909.01	3818.02	brain normal	
brain normal BB99-904	25546	31.84	735.25	1470.50	brain normal	
brain stage 5 ALZ BB99-874	25502	28.43	3650.66	7301.32	brain stage 5 ALZ	1.40
brain stage 5 ALZ BB99-887	25503	29.01	2785.56	5571.12	brain stage 5 ALZ	1.07
brain stage 5 ALZ BB99-862	25504	29.65	2059.62	4119.24	brain stage 5 ALZ	-1.27
brain stage 5 ALZ BB99-927	25542	30.01	1742.3	3484.60	brain stage 5 ALZ	-1.50
CT lung KC	normal	25.49	14553.17	29106.34	CT lung	
lung 26 KC	normal	31.8	749.93	749.93	lung 26	
lung 27 KC	normal	33.35	362.66	362.66	lung 27	
lung 24 KC	COPD	30.67	1275.68	1275.68	lung 24	-6.03
lung 28 KC	COPD	29.25	2490.39	2490.39	lung 28	-3.09
lung 23 KC	COPD	30.11	1661.24	1661.24	lung 23	-4.63
lung 25 KC	normal	32.45	553.75	553.75	lung 25	
asthmatic lung ODO3112	29321	27.3	6215.19	6215.19	asthmatic lung	-1.24
asthmatic lung ODO3433	29323	26.66	8407.3	16814.60	asthmatic lung	2.19
asthmatic lung ODO3397	29322	24.06	28466.73	56933.46	asthmatic lung	7.40
asthmatic lung ODO4928	29325	26.22	10313.71	20627.42	asthmatic lung	2.68
endo cells KC	control	40	0	0.00	endo cells	
endo VEGF KC		40	0	0.00	endo VEGF	0.00
endo bFGF KC		40	0	0.00	endo bFGF	0.00
heart Clontech	normal	27.58	5449.78	10899.56	heart	
heart ( T-1 ) ischemic	29417	28.42	3670.86	7341.72	heart T-1	-1.48
heart (T-14) non- obstructive DCM	29422	27.18	6570.11	13140.22	heart T-14	1.21
heart (T-3399) DCM	29426	26.23	10277.2	20554.40	heart T-3399	1.89
adenoid GW99-269	26162	31.98	688.86	1377.72	adenoid	
tonsil GW98-280	22582	29.31	2421.67	4843.34	tonsil	
T cells PC00314	28453	29.53	2178.21	4356.42	T cells	
PBMNC		33.23	383.88	383.88	PBMNC	
monocyte		31.07	1057.9	2115.80	monocyte	
B cells PC00665	28455	35.97	106.01	212.02	B cells	
dendritic cells 28441		33.56	328.62	657.24	dendritic cells	
neutrophils	28440	22.32	64510.36	64510.36	neutrophils	
eosinophils	28446	24.18	26910.17	53820.34	eosinophils	
BM unstim		30.35	1480.07	1480.07	BM unstim	
BM stim		31.71	782.56	782.56	BM stim	-1.89
osteodif		31.42	895.71	895.71	osteodif	2.03
osteoundif		32.93	440.66	440.66	osteoundif	
chondrocytes		28.98	2820.8	7052.00	chondrocytes	
OA Synovium IP12/01	29462	25.37	15383.84	15383.84	OA Synovium	
OA Synovium NP10/01	29461	27.12	6763.44	13526.88	OA Synovium	

OA Synovium NP57/00	28464	26.48	9130.81	18261.62	OA Synovium	
RA Synovium NP03/01	28466	27.78	4967.23	9934.46	RA Synovium	
RA Synovium NP71/00	28467	24.72	20923.66	41847.32	RA Synovium	
RA Synovium NP45/00	28475	26.15	10658.82	21317.64	RA Synovium	
OA bone (biobank)	29217	28.68	3248.19	3248.19	OA bone (biobank)	
OA bone Sample 1	J. Emory	27.19	6545.82	13091.64	OA bone	
OA bone Sample 2	J. Emory	27.24	6384.92	12769.84	OA bone	
Cartilage (pool)	Normal	26.28	10016.65	20033.30	Cartilage (pool)	
Cartilage (pool)	OA	26.67	8342.92	16685.84	Cartilage (pool)	-1.20
PBL uninfected	28441	31.05	1069.84	2139.68	PBL uninfected	
PBL HIV IIIB	28442	31.7	788.06	1576.12	PBL HIV IIIB	-1.36
MRC5 uninfected (100%)	29158	26.37	9631.13	19262.26	MRC5 uninfected (100%)	
MRC5 HSV strain F	29178	28.38	3747.38	7494.76	MRC5 HSV strain F	-2.57
W12 cells	29179	35.15	155.25	310.50	W12 cells	
Keratinocytes	29180	34.93	172.87	345.74	Keratinocytes	
B-actin control		28.06	4342.74			
genomic		30.54	1356.79			
1.00E+05		21.39	100000			
1.00E+05		21.64	100000			
1.00E+04		26.21	10000			
1.00E+04		26.24	10000			
1.00E+03		30.9	1000			
1.00E+03		30.97	1000			
1.00E+02		36.34	100			
1.00E+02		36.22	100			
1.00E+01		40	10			
1.00E+01		40	0			
1.00E-00		40	0			
1.00E-00		40	0			
NTC		40	0			

Gene Name sbg1002620T1a

5

Disease tissues	Fold Change in Disease Population Relative to Normal
colon tumor	1.18
colon tumor	-1.87
colon tumor	-1.81
colon tumor	-2.72
lung tumor	-4.91
lung tumor	-1.22
lung tumor	-1.62
lung tumor	2.23
breast tumor	1.38

breast tumor	2.12
breast tumor	5.52
breast tumor	1.01
brain stage 5 ALZ	1.40
brain stage 5 ALZ	1.07
brain stage 5 ALZ	-1.27
brain stage 5 ALZ	-1.50
lung 24	-6.03
lung 28	-3.09
lung 23	-4.63
asthmatic lung	-1.24
asthmatic lung	2.19
asthmatic lung	7.40
asthmatic lung	2.68
endo VEGF	0.00
endo bFGF	0.00
heart T-1	-1.48
heart T-14	1.21
heart T-3399	1.89
BM stim	-1.89
osteo dif	2.03
Cartilage (pool)	-1.20
PBL HIV IIIB	-1.36
MRC5 HSV strain F	-2.57

## Gene Name sbg1002620T1b

5 Moderate to high overall expression. Highest normal expression in whole brain, endometrium, jejunum, placenta, thymus, and urinary bladder. Highest disease expression in one of the colon normal/tumor pairs, one of the normal lung samples, one of the asthmatic lung samples, the neutrophils, and the eosinophils. Strong expression in all of the GI tract samples implicates this gene in IBS, IBD, and Crohn's disease. Downregulation in 1 of 4 lung tumor samples is sufficient to make a disease claim in cancer of the lung. Downregulation in 3 of 3 COPD lung samples suggests involvement in chronic obstructive pulmonary disease. Upregulation in 1 of 4 asthmatic lung samples implies a role in asthma. Upregulation in 2 of 3 heart samples suggests this gene may play a role in non-obstructive and obstructive dilated cardiac myopathy. High expression in the RA and OA synovium samples as well as high expression in the chondrocytes and T cells implicates this gene in osteoarthritis and rheumatoid arthritis.

10

15

Sample sbg1002620T1b	Ct (sample 1 and 2)	Mean GOI copies (sample 1)	Mean GOI copies (sample 2)	Averag e GOI Copies	18S rRNA (ng)	50 ng/18S rRNA (ng)	copies of mRNA detected /50 ng total RNA
Subcutaneous Adipocytes Zenbio	31.35, 31.44	58.54	55.11	56.83	3.06	16.34	928.51
Subcutaneous Adipose Zenbio	35.12, 34.21	5	9.05	7.03	0.96	52.36	367.80
Adrenal Gland Clontech	40, 34.29	0	8.61	4.31	0.61	81.97	352.87
Whole Brain Clontech	26.02, 26.06	1897.9	1849.19	1873.55	7.24	6.91	12938.85

Fetal Brain Clontech	40, 36.43	0	2.13	1.07	0.48	103.95	110.71
Cerebellum Clontech	40, 36.05	0	2.74	1.37	2.17	23.04	31.57
Cervix	32.23, 33.04	33.11	19.47	26.29	2.42	20.66	543.18
Colon	30.44, 30.45	105.93	105.29	105.61	2.71	18.45	1948.52
Endometrium	30.86, 30.56	80.75	97.92	89.34	0.73	68.21	6093.79
Esophagus	33.03, 32.34	19.62	30.66	25.14	1.37	36.50	917.52
Heart Clontech	40, 35.05	0	5.26	2.63	1.32	37.88	99.62
Hypothalamus	40, 36.17	0	2.53	1.27	0.32	155.28	196.43
Ileum	31.25, 30.31	62.52	115.58	89.05	2.58	19.38	1725.78
Jejunum	27.75, 27.93	612.01	543.46	577.74	6.60	7.58	4376.78
Kidney	32.59, 31.86	26.03	42.14	34.09	2.12	23.58	803.89
Liver	34.66, 34.5	6.77	7.52	7.15	1.50	33.33	238.17
Fetal Liver Clontech	29.08, 28.58	256.83	356.67	306.75	10.40	4.81	1474.76
Lung	30.74, 30.68	87.44	90.91	89.18	2.57	19.46	1734.92
Mammary Gland Clontech	27.49, 26.81	725.02	1132.42	928.72	13.00	3.85	3572.00
Myometrium	31.2, 30.29	64.54	117.26	90.90	2.34	21.37	1942.31
Omentum	31.19, 30.12	65.05	130.86	97.96	3.94	12.69	1243.08
Ovary	30.24, 30.54	120.95	99.3	110.13	4.34	11.52	1268.72
Pancreas	36.01, 36.55	2.81	1.97	2.39	0.81	61.80	147.71
Head of Pancreas	33.95, 35.73	10.72	3.36	7.04	1.57	31.85	224.20
Parotid Gland	32.16, 33.16	34.51	18.05	26.28	5.48	9.12	239.78
Placenta Clontech	28.42, 28.02	395.01	512.77	453.89	5.26	9.51	4314.54
Prostate	30.61, 31.28	95.23	61.5	78.37	3.00	16.67	1306.08
Rectum	30.5, 30.93	101.73	76.9	89.32	1.23	40.65	3630.69
Salivary Gland Clontech	31.17, 31.07	65.95	70.23	68.09	7.31	6.84	465.73
Skeletal Muscle Clontech	40, 40	0	0	0.00	1.26	39.68	0.00
Skin	34.37, 33.12	8.18	18.53	13.36	1.21	41.32	551.86
Small Intestine Clontech	36.71, 34.96	1.78	5.55	3.67	0.98	51.07	187.18
Spleen	30.54, 31.29	99.47	60.88	80.18	4.92	10.16	814.79
Stomach	32.4, 31.53	29.49	52	40.75	2.73	18.32	746.25
Testis Clontech	34.4, 35.19	8.03	4.79	6.41	0.57	87.87	563.27
Thymus Clontech	27.18, 27.12	888.84	924.29	906.57	9.89	5.06	4583.24
Thyroid	32.17, 30.89	34.36	79.27	56.82	2.77	18.05	1025.54
Trachea Clontech	30.01, 29.25	140.31	230.28	185.30	9.71	5.15	954.15
Urinary Bladder	28.33, 27.87	420.47	565.71	493.09	5.47	9.14	4507.22
Uterus	29.09, 28.81	255.27	308	281.64	5.34	9.36	2637.03
genomic	27.16	900.78					
b-actin	27.4	769.87					
1.00E+05	19.87	100000					
1.00E+05	19.95	100000					
1.00E+04	23.4	10000					
1.00E+04	23.39	10000					
1.00E+03	26.94	1000					
1.00E+03	26.95	1000					
1.00E+02	31.02	100					

1.00E+02	30.96	100					
1.00E+01	33.46	10					
1.00E+01	40	0					
1.00E-00	40	0					
1.00E-00	40	0					
NTC	40	0					
NTC	40	0					

Sample sbg1002620T1b	Reg number (GSK identifier )	Ct	Mean GOI copies	copies of mRNA detected /50 ng total RNA	Sample	Fold Chang e in Diseas e Popula tion
colon normal GW98-167	21941	22.85	18631.2	37262.40	colon normal	
colon tumor GW98-166	21940	22.51	23090.96	46181.92	colon tumor	1.24
colon normal GW98-178	22080	25.49	3620.45	7240.90	colon normal	
colon tumor GW98-177	22060	26.88	1527.3	3054.60	colon tumor	-2.37
colon normal GW98-561	23514	25.37	3901.36	7802.72	colon normal	
colon tumor GW98-560	23513	26.08	2512.21	5024.42	colon tumor	-1.55
colon normal GW98-894	24691	23.78	10441.49	20882.98	colon normal	
colon tumor GW98-893	24690	25.54	3515.48	7030.96	colon tumor	-2.97
lung normal GW98-3	20742	22.6	21810.56	43621.12	lung normal	
lung tumor GW98-2	20741	26.19	2349.32	4698.64	lung tumor	-9.28
lung normal GW97-179	20677	23.38	13423.28	26846.56	lung normal	
lung tumor GW97-178	20676	24.51	6653.03	13306.06	lung tumor	-2.02
lung normal GW98-165	21922	23.68	11120.91	22241.82	lung normal	
lung tumor GW98-164	21921	24.37	7242.32	14484.64	lung tumor	-1.54
lung normal GW98-282	22584	25.05	4745.83	9491.66	lung normal	
lung tumor GW98-281	22583	23.57	11943.28	23886.56	lung tumor	2.52
breast normal GW00-392	28750	24.84	5415.88	5415.88	breast normal	
breast tumor GW00-391	28746	24.98	4973.9	9947.80	breast tumor	1.84
breast normal GW00-413	28798	24.69	5954.77	5954.77	breast normal	
breast tumor GW00-412	28797	26.38	2081.99	4163.98	breast tumor	-1.43
breast normal GW00-235:238	27592-95	25.04	4792.18	4792.18	breast normal	
breast tumor GW00-231:234	27588-91	23.63	11520.86	11520.86	breast tumor	2.40
breast normal GW98-621	23656	23.22	14836.24	29672.48	breast normal	
breast tumor GW98-620	23655	24.24	7879	15758.00	breast tumor	-1.88
brain normal BB99-542	25507	25.16	4447.15	8894.30	brain normal	
brain normal BB99-406	25509	27.05	1377.71	2755.42	brain normal	
brain normal BB99-904	25546	29.35	330.53	661.06	brain normal	
brain stage 5 ALZ BB99-874	25502	27.64	956.16	1912.32	brain stage 5 ALZ	-2.15
brain stage 5 ALZ	25503	27.02	1400.04	2800.08	brain stage 5	-1.47

BB99-887					ALZ	
brain stage 5 ALZ	25504	27.4	1105.21	2210.42	brain stage 5 ALZ	-1.86
<b>BB99-862</b>						
brain stage 5 ALZ	25542	27.1	1336.02	2672.04	brain stage 5 ALZ	-1.54
<b>BB99-927</b>						
CT lung KC	normal	23.52	12295.29	24590.58	CT lung	
lung 26 KC	normal	31.42	91.19	91.19	lung 26	
lung 27 KC	normal	32.34	51.71	51.71	lung 27	
lung 24 KC	COPD	31.27	100.29	100.29	lung 24	-61.80
lung 28 KC	COPD	28.64	511.37	511.37	lung 28	-12.12
lung 23 KC	COPD	30.52	159.17	159.17	lung 23	-38.94
lung 25 KC	normal	32.15	57.91	57.91	lung 25	
asthmatic lung ODO3112	29321	23.19	15086.65	15086.65	asthmatic lung	2.43
asthmatic lung ODO3433	29323	24.76	5706.9	11413.80	asthmatic lung	1.84
asthmatic lung ODO3397	29322	21.71	37760.01	75520.02	asthmatic lung	12.18
asthmatic lung ODO4928	29325	24.16	8255.16	16510.32	asthmatic lung	2.66
endo cells KC	control	37.31	2.36	2.36	endo cells	
endo VEGF KC		40	0	0.00	endo VEGF	-2.36
endo bFGF KC		35.67	6.54	6.54	endo bFGF	2.77
heart Clontech	normal	26.32	2170.24	4340.48	heart	
heart ( T-1 ) ischemic	29417	25.87	2863.04	5726.08	heart T-1	1.32
heart (T-14) non-obstructive DCM	29422	24.62	6200.03	12400.06	heart T-14	2.86
heart (T-3399) DCM	29426	24.06	8775.18	17550.36	heart T-3399	4.04
adenoid GW99-269	26162	29.2	362.88	725.76	adenoid	
tonsil GW98-280	22582	27.24	1222.33	2444.66	tonsil	
T cells PC00314	28453	28.09	723.06	1446.12	T cells	
PBMNC		30.67	145.75	145.75	PBMNC	
monocyte		28.42	587.16	1174.32	monocyte	
B cells PC00665	28455	34.17	16.57	33.14	B cells	
dendritic cells 28441		31.78	72.95	145.90	dendritic cells	
neutrophils	28440	21.46	44297.23	44297.23	neutrophils	
eosinophils	28446	22.79	19332.21	38664.42	eosinophils	
BM unstim		29.22	358.53	358.53	BM unstim	
BM stim		31.27	100.39	100.39	BM stim	-3.57
osteo dif		30.14	202.25	202.25	osteo dif	4.97
osteo undif		32.72	40.67	40.67	osteo undif	
chondrocytes		27.3	1178.3	2945.75	chondrocytes	
OA Synovium IP12/01	29462	23.33	13860.23	13860.23	OA Synovium	
OA Synovium NP10/01	29461	25.3	4080.49	8160.98	OA Synovium	
OA Synovium NP57/00	28464	25.23	4253.8	8507.60	OA Synovium	
RA Synovium NP03/01	28466	25.46	3686.62	7373.24	RA Synovium	
RA Synovium NP71/00	28467	23.31	14036.44	28072.88	RA Synovium	
RA Synovium NP45/00	28475	24.28	7658.52	15317.04	RA Synovium	
OA bone (biobank)	29217	26.48	1958.1	1958.10	OA bone (biobank)	

OA bone Sample 1	J. Emory	25.28	4131.76	8263.52	OA bone	
OA bone Sample 2	J. Emory	25.23	4242.9	8485.80	OA bone	
Cartilage (pool)	Normal	24.05	8829.67	17659.34	Cartilage (pool)	
Cartilage (pool)	OA	24.28	7685.44	15370.88	Cartilage (pool)	-1.15
PBL uninfected	28441	29.33	334.71	669.42	PBL uninfected	
PBL HIV IIIB	28442	29.59	283.96	567.92	PBL HIV IIIB	-1.18
MRC5 uninfected (100%)	29158	23.92	9595.12	19190.24	MRC5 uninfected (100%)	
MRC5 HSV strain F	29178	25.2	4341.36	8682.72	MRC5 HSV strain F	-2.21
W12 cells	29179	30.43	168.9	337.80	W12 cells	
Keratinocytes	29180	29.66	272.9	545.80	Keratinocytes	
B-actin control genomic		27.64 27.35	956.41 1143.39			
1.00E+05		20.14	100000			
1.00E+05		20.26	100000			
1.00E+04		23.6	10000			
1.00E+04		24.02	10000			
1.00E+03		27.49	1000			
1.00E+03		27.5	1000			
1.00E+02		31.66	100			
1.00E+02		31.01	100			
1.00E+01		40	0			
1.00E+01		40	0			
1.00E-00		40	0			
1.00E-00		40	0			
NTC		40	0			

Gene Name sbg1002620T1b

Disease tissues	Fold Change in Disease Population Relative to Normal
colon tumor	1.24
colon tumor	-2.37
colon tumor	-1.55
colon tumor	-2.97
lung tumor	-9.28
lung tumor	-2.02
lung tumor	-1.54
lung tumor	2.52
breast tumor	1.84
breast tumor	-1.43
breast tumor	2.40
breast tumor	-1.88
brain stage 5 ALZ	-2.15
brain stage 5 ALZ	-1.47
brain stage 5 ALZ	-1.86
brain stage 5 ALZ	-1.54
lung 24	-61.80
lung 28	-12.12

lung 23	-38.94
asthmatic lung	2.43
asthmatic lung	1.84
asthmatic lung	12.18
asthmatic lung	2.66
endo VEGF	-2.36
endo bFGF	2.77
heart T-1	1.32
heart T-14	2.86
heart T-3399	4.04
BM stim	-3.57
osteo dif	4.97
Cartilage (pool)	-1.15
PBL HIV IIIB	-1.18
MRC5 HSV strain F	-2.21

**Gene Name sbg102200MCTa**

5 Moderate to low overall expression. Highest normal expression in the subcutaneous adipose tissue, whole brain, fetal brain, cerebellum, and fetal liver. Highest disease expression in 2 of 4 lung tumor samples, one of the normal lung samples, one of the normal breast samples, and the CT lung sample. Downregulation in 1 of 4 breast cancer samples implicates this gene in cancer of the breast.

10 Downregulation in 3 of 3 COPD lung samples suggests involvement in chronic obstructive pulmonary disease. Moderate expression in the OA and RA synovium as well as the PBLs, adenoid, tonsil, T cells, B cells, and the chondrocytes indicates involvement in osteoarthritis and rheumatoid arthritis.

Sample sbg102200MCTa	Ct (sample 1 and 2)	Mean GOI copies (sample 1)	Mean GOI copies (sample 2)	Average GOI Copies	18S rRNA (ng)	50 ng/18S rRNA (ng)	copies of mRNA detecte d/50 ng total RNA
Subcutaneous Adipocytes Zenbio	36.01, 34.76	3.83	8.04	5.94	3.06	16.34	96.98
Subcutaneous Adipose Zenbio	34.85, 33.96	7.63	12.94	10.29	0.96	52.36	538.48
Adrenal Gland Clontech	40, 40	0	0	0.00	0.61	81.97	0.00
Whole Brain Clontech	26.05, 26.18	1434.25	1331.2	1382.73	7.24	6.91	9549.21
Fetal Brain Clontech	40, 34.46	0	9.63	4.82	0.48	103.95	500.52
Cerebellum Clontech	31.7, 32.73	49.65	26.9	38.28	2.17	23.04	881.91
Cervix	40, 40	0	0	0.00	2.42	20.66	0.00
Colon	38.55, 38.57	0.84	0.83	0.84	2.71	18.45	15.41
Endometrium	40, 40	0	0	0.00	0.73	68.21	0.00
Esophagus	35.23, 40	6.09	0	3.05	1.37	36.50	111.13
Heart Clontech	40, 40	0	0	0.00	1.32	37.88	0.00
Hypothalamus	39.8, 40	0.4	0	0.20	0.32	155.28	31.06
Ileum	34.16, 40	11.53	0	5.77	2.58	19.38	111.72
Jejunum	32.82, 33.18	25.46	20.6	23.03	6.60	7.58	174.47
Kidney	34.23, 34.1	11.02	11.9	11.46	2.12	23.58	270.28
Liver	35.35, 37.28	5.65	1.79	3.72	1.50	33.33	124.00
Fetal Liver Clontech	29.45, 28.98	189.89	250.96	220.43	10.40	4.81	1059.74

Lung	34.99, 33.43	7.04	17.81	12.43	2.57	19.46	241.73
Mammary Gland Clontech	31.76, 31.05	48.02	73.18	60.60	13.00	3.85	233.08
Myometrium	34.46, 35.22	9.64	6.12	7.88	2.34	21.37	168.38
Omentum	37.94, 34.13	1.21	11.71	6.46	3.94	12.69	81.98
Ovary	34.03, 33.43	12.44	17.77	15.11	4.34	11.52	174.02
Pancreas	40, 40	0	0	0.00	0.81	61.80	0.00
Head of Pancreas	40, 40	0	0	0.00	1.57	31.85	0.00
Parotid Gland	32.56, 31.81	29.88	46.65	38.27	5.48	9.12	349.13
Placenta Clontech	40, 40	0	0	0.00	5.26	9.51	0.00
Prostate	40, 36.21	0	3.39	1.70	3.00	16.67	28.25
Rectum	40, 39.37	0	0.52	0.26	1.23	40.65	10.57
Salivary Gland Clontech	30.6, 31.77	95.89	47.76	71.83	7.31	6.84	491.28
Skeletal Muscle Clontech	40, 40	0	0	0.00	1.26	39.68	0.00
Skin	34.47, 35.32	9.58	5.75	7.67	1.21	41.32	316.74
Small Intestine Clontech	40, 40	0	0	0.00	0.98	51.07	0.00
Spleen	34.1, 36.49	11.93	2.87	7.40	4.92	10.16	75.20
Stomach	35.17, 36.07	6.3	3.68	4.99	2.73	18.32	91.39
Testis Clontech	37.98, 40	1.19	0	0.60	0.57	87.87	52.28
Thymus Clontech	31.28, 30.4	63.69	108.05	85.87	9.89	5.06	434.13
Thyroid	33.08, 32.96	21.88	23.47	22.68	2.77	18.05	409.30
Trachea Clontech	32.54, 31.34	30.14	61.71	45.93	9.71	5.15	236.48
Urinary Bladder	33.91, 40	13.32	0	6.66	5.47	9.14	60.88
Uterus	33.71, 32.43	15.04	32.13	23.59	5.34	9.36	220.83
genomic	26.3	1237.42					
b-actin	27.49	610.72					
1.00E+05	19.18	100000					
1.00E+05	19.45	100000					
1.00E+04	22.6	10000					
1.00E+04	22.53	10000					
1.00E+03	26.17	1000					
1.00E+03	26.19	1000					
1.00E+02	30.61	100					
1.00E+02	30.53	100					
1.00E+01	40	0					
1.00E+01	34.91	10					
1.00E-00	40	0					
1.00E-00	40	0					
NTC	40	0					
NTC	40	0					

Sample sbg102200MCTa	Reg number (GSK identifier)	Ct	Mean GOI copies	copies of mRNA detecte	Sample	Fold Change in Disease Populatio

				d/50 ng total RNA		n
colon normal GW98-167	21941	28.58	519.72	1039.44	colon normal	
colon tumor GW98-166	21940	30.18	202.86	405.72	colon tumor	-2.56
colon normal GW98-178	22080	31.39	100.15	200.30	colon normal	
colon tumor GW98-177	22060	29.62	282.42	564.84	colon tumor	2.82
colon normal GW98-561	23514	30.36	183.13	366.26	colon normal	
colon tumor GW98-560	23513	30.45	173.87	347.74	colon tumor	-1.05
colon normal GW98-894	24691	30.23	196.98	393.96	colon normal	
colon tumor GW98-893	24690	30.35	183.76	367.52	colon tumor	-1.07
lung normal GW98-3	20742	26.68	1575.72	3151.44	lung normal	
lung tumor GW98-2	20741	28.8	456.47	912.94	lung tumor	-3.45
lung normal GW97-179	20677	27.94	754.47	1508.94	lung normal	
lung tumor GW97-178	20676	26.27	2002.28	4004.56	lung tumor	2.65
lung normal GW98-165	21922	26.87	1411.09	2822.18	lung normal	
lung tumor GW98-164	21921	29.38	325.51	651.02	lung tumor	-4.34
lung normal GW98-282	22584	30	225.32	450.64	lung normal	
lung tumor GW98-281	22583	28.64	502.02	1004.04	lung tumor	2.23
breast normal GW00-392	28750	28.32	602.59	602.59	breast normal	
breast tumor GW00-391	28746	28.05	709.37	1418.74	breast tumor	2.35
breast normal GW00-413	28798	29.56	292.43	292.43	breast normal	
breast tumor GW00-412	28797	30.05	218.89	437.78	breast tumor	1.50
breast normal GW00-235:238	27592-95	30.96	128.91	128.91	breast normal	
breast tumor GW00-231:234	27588-91	30.57	161.3	161.30	breast tumor	1.25
breast normal GW98-621	23656	27.04	1275.81	2551.62	breast normal	
breast tumor GW98-620	23655	31.35	102.26	204.52	breast tumor	-12.48
brain normal BB99-542	25507	28.44	564.32	1128.64	brain normal	
brain normal BB99-406	25509	29.01	402.37	804.74	brain normal	
brain normal BB99-904	25546	29.67	274.03	548.06	brain normal	
brain stage 5 ALZ BB99-874	25502	29.6	284.82	569.64	brain stage 5 ALZ	-1.45
brain stage 5 ALZ BB99-887	25503	27.92	765.16	1530.32	brain stage 5 ALZ	1.85
brain stage 5 ALZ BB99-862	25504	28.74	472.27	944.54	brain stage 5 ALZ	1.14
brain stage 5 ALZ BB99-927	25542	29.3	340.25	680.50	brain stage 5 ALZ	-1.22
CT lung KC	normal	26.69	1569.87	3139.74	CT lung	
lung 26 KC	normal	31.07	120.9	120.90	lung 26	
lung 27 KC	normal	31.17	113.69	113.69	lung 27	
lung 24 KC	COPD	31.8	78.78	78.78	lung 24	-10.98
lung 28 KC	COPD	32.79	44.02	44.02	lung 28	-19.65
lung 23 KC	COPD	31.35	102.33	102.33	lung 23	-8.45
lung 25 KC	normal	31.66	85.57	85.57	lung 25	
asthmatic lung ODO3112	29321	28.76	467.45	467.45	asthmatic lung	-1.85
asthmatic lung ODO3433	29323	27.73	851.21	1702.42	asthmatic lung	1.97
asthmatic lung ODO3397	29322	27.81	812.68	1625.36	asthmatic lung	1.88

asthmatic lung ODO4928	29325	29.42	317.12	634.24	asthmatic lung	-1.36
endo cells KC	control	33.06	37.57	37.57	endo cells	
endo VEGF KC		33.9	22.97	22.97	endo VEGF	-1.64
endo bFGF KC		33.13	36.03	36.03	endo bFGF	-1.04
heart Clontech	normal	31.1	118.18	236.36	heart	
heart ( T-1 ) ischemic	29417	31.16	114.67	229.34	heart T-1	-1.03
heart (T-14) non-obstructive DCM	29422	30.52	166.47	332.94	heart T-14	1.41
heart (T-3399) DCM	29426	30.14	208.3	416.60	heart T-3399	1.76
adenoid GW99-269	26162	29.07	388.9	777.80	adenoid	
tonsil GW98-280	22582	28.29	614.82	1229.64	tonsil	
T cells PC00314	28453	29.78	256.1	512.20	T cells	
PBMNC		33.73	25.44	25.44	PBMNC	
monocyte		33.52	28.71	57.42	monocyte	
B cells PC00665	28455	28.66	495.36	990.72	B cells	
dendritic cells 28441		30.81	140.17	280.34	dendritic cells	
neutrophils	28440	30.17	204.92	204.92	neutrophils	
eosinophils	28446	34.19	19.39	38.78	eosinophils	
BM unstim		35.9	7.11	7.11	BM unstim	
BM stim		35.77	7.7	7.70	BM stim	1.08
osteodif		34.98	12.18	12.18	osteodif	2.55
osteoundif		36.59	4.77	4.77	osteoundif	
chondrocytes		32.91	41.03	102.58	chondrocytes	
OA Synovium IP12/01	29462	29.16	370.33	370.33	OA Synovium	
OA Synovium NP10/01	29461	30.69	151.13	302.26	OA Synovium	
OA Synovium NP57/00	28464	29.51	301.55	603.10	OA Synovium	
RA Synovium NP03/01	28466	30.36	183.35	366.70	RA Synovium	
RA Synovium NP71/00	28467	29.27	346.61	693.22	RA Synovium	
RA Synovium NP45/00	28475	29.13	376.88	753.76	RA Synovium	
OA bone (biobank)	29217	30.47	171.6	171.60	OA bone (biobank)	
OA bone Sample 1	J. Emory	30.05	219.19	438.38	OA bone	
OA bone Sample 2	J. Emory	31.13	116.62	233.24	OA bone	
Cartilage (pool)	Normal	30.65	154.56	309.12	Cartilage (pool)	
Cartilage (pool)	OA	32.01	69.39	138.78	Cartilage (pool)	-2.23
PBL uninfected	28441	27.91	769.91	1539.82	PBL uninfected	
PBL HIV IIIB	28442	28.14	672.12	1344.24	PBL HIV IIIB	-1.15
MRC5 uninfected (100%)	29158	31.66	85.38	170.76	MRC5 uninfected (100%)	
MRC5 HSV strain F	29178	30.08	214.88	429.76	MRC5 HSV strain F	2.52
W12 cells	29179	33.33	32.15	64.30	W12 cells	
Keratinocytes	29180	30.64	155.16	310.32	Keratinocytes	
B-actin control		27.55	946.64			
genomic		26.82	1451.22			
1.00E+05		19.71	100000			
1.00E+05		19.95	100000			
1.00E+04		23.43	10000			
1.00E+04		23.38	10000			

1.00E+03		26.88	1000				
1.00E+03		26.8	1000				
1.00E+02		31.99	100				
1.00E+02		32.15	100				
1.00E+01		34.99	10				
1.00E+01		40	0				
1.00E-00		40	0				
1.00E-00		40	0				
NTC		40	0				

Gene Name sbg102200MCTa

Disease tissues	Fold Change in Disease Population Relative to Normal
colon tumor	-2.56
colon tumor	2.82
colon tumor	-1.05
colon tumor	-1.07
lung tumor	-3.45
lung tumor	2.65
lung tumor	-4.34
lung tumor	2.23
breast tumor	2.35
breast tumor	1.50
breast tumor	1.25
breast tumor	-12.48
brain stage 5 ALZ	-1.45
brain stage 5 ALZ	1.85
brain stage 5 ALZ	1.14
brain stage 5 ALZ	-1.22
lung 24	-10.98
lung 28	-19.65
lung 23	-8.45
asthmatic lung	-1.85
asthmatic lung	1.97
asthmatic lung	1.88
asthmatic lung	-1.36
endo VEGF	-1.64
endo bFGF	-1.04
heart T-1	-1.03
heart T-14	1.41
heart T-3399	1.76
BM stim	1.08
osteo dif	2.55
Cartilage (pool)	-2.23
PBL HIV IIIB	-1.15
MRC5 HSV strain F	2.52

Gene Name sbg102200MCTb

5 High to moderate overall expression. Highest normal expression in the whole brain, liver, fetal liver, and thymus. Highest disease expression in one of the colon normal/tumor pairs, one of the lung normal/tumor pairs, one of the asthmatic lung samples, the dendritic cells, and the uninfected and HIV-infected PBL cells. Upregulation in 2 of 4 breast tumor samples is sufficient to make a disease claim in cancer of the breast. Upregulation in 1 of 4 AD brain samples indicates a potential role in Alzheimer's disease. Downregulation in 3 of 3 COPD lung samples suggests involvement in chronic obstructive pulmonary disease. Upregulation in 1 of 4 asthmatic lung samples indicates a potential role for this gene in lung cancer. High expression in all of the immune cells. Also high to moderate expression in the OA and RA synovium samples, the OA bone samples, and in the chondrocytes suggests an involvement in osteoarthritis and rheumatoid arthritis.

10

Sample sbg102200MCTb	Ct (sample 1 and 2)	Mean GOI copies (sample 1)	Mean GOI copies (sample 2)	Average GOI Copies	18S rRNA (ng)	50 ng/18S rRNA (ng)	copies of mRNA detecte d/50 ng total RNA
Subcutaneous Adipocytes Zenbio	35.66, 34.05	3.76	10.2	6.98	3.06	16.34	114.05
Subcutaneous Adipose Zenbio	40, 36	0.17	3.07	1.62	0.96	52.36	84.82
Adrenal Gland Clontech	40, 40	0	0	0.00	0.61	81.97	0.00
Whole Brain Clontech	26.32, 26.41	1192.66	1124.69	1158.68	7.24	6.91	8001.90
Fetal Brain Clontech	40, 35.84	0	3.38	1.69	0.48	103.95	175.68
Cerebellum Clontech	34.51, 34.28	7.68	8.8	8.24	2.17	23.04	189.86
Cervix	40, 34.34	3.17	8.5	5.84	2.42	20.66	120.56
Colon	33.67, 35.6	12.86	3.91	8.39	2.71	18.45	154.70
Endometrium	35.32, 34.43	4.66	8.05	6.36	0.73	68.21	433.49
Esophagus	34.27, 35.14	8.86	5.19	7.03	1.37	36.50	256.39
Heart Clontech	40, 35.05	0	5.5	2.75	1.32	37.88	104.17
Hypothalamus	40, 40	0	0	0.00	0.32	155.28	0.00
Ileum	35.29, 33.68	4.74	12.8	8.77	2.58	19.38	169.96
Jejunum	31.23, 30.98	57.65	67.22	62.44	6.60	7.58	472.99
Kidney	34.67, 34.21	6.95	9.2	8.08	2.12	23.58	190.45
Liver	30.76, 30.65	77.12	82.56	79.84	1.50	33.33	2661.33
Fetal Liver Clontech	26.8, 27.1	885.14	734.31	809.73	10.40	4.81	3892.91
Lung	40, 40	0	0.17	0.09	2.57	19.46	1.65
Mammary Gland Clontech	31.28, 31.37	56.1	52.95	54.53	13.00	3.85	209.71
Myometrium	34.16, 36.28	9.48	2.57	6.03	2.34	21.37	128.74
Omentum	34.18, 33.42	9.38	15	12.19	3.94	12.69	154.70
Ovary	34.21, 34.18	9.24	9.39	9.32	4.34	11.52	107.32
Pancreas	40, 40	0	0.14	0.07	0.81	61.80	4.33
Head of Pancreas	40, 35.02	0	5.59	2.80	1.57	31.85	89.01
Parotid Gland	31.23, 31.9	57.68	38.33	48.01	5.48	9.12	438.00
Placenta Clontech	31.77, 33.13	41.33	17.94	29.64	5.26	9.51	281.70
Prostate	39.72, 35.03	0.31	5.56	2.94	3.00	16.67	48.92
Rectum	35.36, 34.34	4.53	8.5	6.52	1.23	40.65	264.84
Salivary Gland Clontech	30.52, 30.54	89.5	88.43	88.97	7.31	6.84	608.52

Skeletal Muscle Clontech	40, 40	0	0	0.00	1.26	39.68	0.00
Skin	40, 40	0	0	0.00	1.21	41.32	0.00
Small Intestine Clontech	40, 39.27	0	0.41	0.21	0.98	51.07	10.47
Spleen	34.21, 33.54	9.2	13.91	11.56	4.92	10.16	117.43
Stomach	35.05, 33.62	5.51	13.22	9.37	2.73	18.32	171.52
Testis Clontech	40, 40	0	0	0.00	0.57	87.87	0.00
Thymus Clontech	28.56, 28.44	299.45	322.02	310.74	9.89	5.06	1570.96
Thyroid	31.65, 32.3	44.76	29.81	37.29	2.77	18.05	673.01
Trachea Clontech	32.3, 31.9	29.9	38.28	34.09	9.71	5.15	175.54
Urinary Bladder	34.34, 35.02	8.49	5.59	7.04	5.47	9.14	64.35
Uterus	33.07, 34.56	18.62	7.45	13.04	5.34	9.36	122.05
genomic	25.84	1597.08					
b-actin	27.32	643.56					
1.00E+05	19.22	100000					
1.00E+05	19.33	100000					
1.00E+04	22.48	10000					
1.00E+04	22.95	10000					
1.00E+03	26.19	1000					
1.00E+03	26.37	1000					
1.00E+02	31.23	100					
1.00E+02	30.48	100					
1.00E+01	32.76	10					
1.00E+01	35.02	10					
1.00E-00	40	0					
1.00E-00	40	0					
NTC	40	0					
NTC	40	0					

Sample sgb102200MCTb	Reg number (GSK identifie r)	Ct	Mean GOI copies	copies of mRNA detected /50 ng total RNA	Sample	Fold Change in Disease Populati on
colon normal GW98-167	21941	26.48	1723.59	3447.18	colon normal	
colon tumor GW98-166	21940	26.06	2195.04	4390.08	colon tumor	1.27
colon normal GW98-178	22080	29.03	389.88	779.76	colon normal	
colon tumor GW98-177	22060	27.39	1015.65	2031.30	colon tumor	2.61
colon normal GW98-561	23514	26.74	1478.76	2957.52	colon normal	
colon tumor GW98-560	23513	26.37	1831.8	3663.60	colon tumor	1.24
colon normal GW98-894	24691	25.58	2918.02	5836.04	colon normal	
colon tumor GW98-893	24690	25	4089.75	8179.50	colon tumor	1.40
lung normal GW98-3	20742	24.59	5183.31	10366.62	lung normal	
lung tumor GW98-2	20741	24.94	4232.23	8464.46	lung tumor	-1.22
lung normal GW97-179	20677	25.73	2672.73	5345.46	lung normal	
lung tumor GW97-178	20676	25.36	3307.37	6614.74	lung tumor	1.24
lung normal GW98-165	21922	26.13	2109.28	4218.56	lung normal	

lung tumor GW98-164	21921	25.54	2973.82	5947.64	lung tumor	1.41
lung normal GW98-282	22584	27.08	1212.64	2425.28	lung normal	
lung tumor GW98-281	22583	27.45	979.82	1959.64	lung tumor	-1.24
breast normal GW00-392	28750	26.68	1536.57	1536.57	breast normal	
breast tumor GW00-391	28746	26.58	1626.58	3253.16	breast tumor	2.12
breast normal GW00-413	28798	31.71	81.9	81.90	breast normal	
breast tumor GW00-412	28797	26.57	1632	3264.00	breast tumor	39.85
breast normal GW00-235:238	27592-95	32.52	51.1	51.10	breast normal	
breast tumor GW00-231:234	27588-91	29.67	268.7	268.70	breast tumor	5.26
breast normal GW98-621	23656	26.48	1727.44	3454.88	breast normal	
breast tumor GW98-620	23655	25.65	2793.6	5587.20	breast tumor	1.62
brain normal BB99-542	25507	28.62	494	988.00	brain normal	
brain normal BB99-406	25509	29.45	304.68	609.36	brain normal	
brain normal BB99-904	25546	30.08	211.25	422.50	brain normal	
brain stage 5 ALZ BB99-874	25502	28.75	458.64	917.28	brain stage 5 ALZ	1.36
brain stage 5 ALZ BB99-887	25503	26.86	1383.71	2767.42	brain stage 5 ALZ	4.11
brain stage 5 ALZ BB99-862	25504	28.02	702.59	1405.18	brain stage 5 ALZ	2.09
brain stage 5 ALZ BB99-927	25542	29.57	284.31	568.62	brain stage 5 ALZ	-1.18
CT lung KC	normal	26.58	1624.29	3248.58	CT lung	
lung 26 KC	normal	34.19	19.27	19.27	lung 26	
lung 27 KC	normal	32.45	53.23	53.23	lung 27	
lung 24 KC	COPD	33	38.6	38.60	lung 24	-21.75
lung 28 KC	COPD	32.24	59.95	59.95	lung 28	-14.01
lung 23 KC	COPD	32.87	41.63	41.63	lung 23	-20.17
lung 25 KC	normal	33.04	37.52	37.52	lung 25	
asthmatic lung ODO3112	29321	30.13	205.46	205.46	asthmatic lung	-4.09
asthmatic lung ODO3433	29323	27.82	788.82	1577.64	asthmatic lung	1.88
asthmatic lung ODO3397	29322	25.17	3695.43	7390.86	asthmatic lung	8.80
asthmatic lung ODO4928	29325	27.6	894.3	1788.60	asthmatic lung	2.13
endo cells KC	control	28.2	633.43	633.43	endo cells	
endo VEGF KC		28.86	429.51	429.51	endo VEGF	-1.47
endo bFGF KC		28.97	403.08	403.08	endo bFGF	-1.57
heart Clontech	normal	28.83	437.62	875.24	heart	
heart ( T-1 ) ischemic	29417	28.42	557.54	1115.08	heart T-1	1.27
heart (T-14) non-obstructive DCM	29422	27.72	835.11	1670.22	heart T-14	1.91
heart (T-3399) DCM	29426	28.63	493.01	986.02	heart T-3399	1.13
adenoid GW99-269	26162	27	1269.75	2539.50	adenoid	
tonsil GW98-280	22582	26.33	1876.29	3752.58	tonsil	
T cells PC00314	28453	29.15	363.35	726.70	T cells	
PBMNC		33.05	37.41	37.41	PBMNC	
monocyte		31.49	92.84	185.68	monocyte	
B cells PC00665	28455	26.5	1700.87	3401.74	B cells	
dendritic cells 28441		24.2	6511.17	13022.34	dendritic cells	

neutrophils	28440	27.01	1262.74	1262.74	neutrophils	
eosinophils	28446	29.23	347.08	694.16	eosinophils	
BM unstim		30.85	135.01	135.01	BM unstim	
BM stim		28.68	478.5	478.50	BM stim	3.54
osteо dif		31.03	121.2	121.20	osteо dif	3.93
osteо undif		33.38	30.85	30.85	osteо undif	
chondrocytes		26.63	1579.73	3949.33	chondrocytes	
OA Synovium IP12/01	29462	29.11	371.98	371.98	OA Synovium	
OA Synovium NP10/01	29461	29.45	304.55	609.10	OA Synovium	
OA Synovium NP57/00	28464	27.83	784.87	1569.74	OA Synovium	
RA Synovium NP03/01	28466	27.31	1063.77	2127.54	RA Synovium	
RA Synovium NP71/00	28467	27.08	1217.21	2434.42	RA Synovium	
RA Synovium NP45/00	28475	26.6	1606.41	3212.82	RA Synovium	
OA bone (biobank)	29217	28.65	485.63	485.63	OA bone (biobank)	
OA bone Sample 1	J. Emory	28.78	451.74	903.48	OA bone	
OA bone Sample 2	J. Emory	28.27	607.15	1214.30	OA bone	
Cartilage (pool)	Normal	29.42	310.76	621.52	Cartilage (pool)	
Cartilage (pool)	OA	30.09	209.7	419.40	Cartilage (pool)	-1.48
PBL uninfected	28441	23.85	7997.03	15994.06	PBL uninfected	
PBL HIV IIIB	28442	24.85	4447.34	8894.68	PBL HIV IIIB	-1.80
MRC5 uninfected (100%)	29158	27.02	1258.46	2516.92	MRC5 uninfected (100%)	
MRC5 HSV strain F	29178	29.6	278.84	557.68	MRC5 HSV strain F	-4.51
W12 cells	29179	27.21	1122.77	2245.54	W12 cells	
Keratinocytes	29180	25.64	2815.12	5630.24	Keratinocytes	
B-actin control		27.78	807.72			
genomic		27.04	1246.22			
1.00E+05		19.69	100000			
1.00E+05		20.01	100000			
1.00E+04		23.15	10000			
1.00E+04		23.2	10000			
1.00E+03		27.02	1000			
1.00E+03		26.76	1000			
1.00E+02		31.45	100			
1.00E+02		32.39	100			
1.00E+01		35.72	10			
1.00E+01		34.74	10			
1.00E-00		40	0			
1.00E-00		40	0			
NTC		40	0			

Gene Name sbg102200MCTb

Disease tissues	Fold Change in Disease Population Relative to Normal
colon tumor	1.27
colon tumor	2.61
colon tumor	1.24

colon tumor	1.40
lung tumor	-1.22
lung tumor	1.24
lung tumor	1.41
lung tumor	-1.24
breast tumor	2.12
breast tumor	39.85
breast tumor	5.26
breast tumor	1.62
brain stage 5 ALZ	1.36
brain stage 5 ALZ	4.11
brain stage 5 ALZ	2.09
brain stage 5 ALZ	-1.18
lung 24	-21.75
lung 28	-14.01
lung 23	-20.17
asthmatic lung	-4.09
asthmatic lung	1.88
asthmatic lung	8.80
asthmatic lung	2.13
endo VEGF	-1.47
endo bFGF	-1.57
heart T-1	1.27
heart T-14	1.91
heart T-3399	1.13
BM stim	3.54
osteo dif	3.93
Cartilage (pool)	-1.48
PBL HIV IIIB	-1.80
MRCS HSV strain F	-4.51

**Gene Name sbg1020380LYG**

**Failed**

5

**Gene Name sbg1007026SGLT**

Good to moderate overall expression. The highest normal expression is seen in the whole brain, cerebellum, hypothalamus, jejunum, fetal liver, rectum, and uterus. This gene shows system specific expression in samples representing the central nervous system, the female reproductive organs, and the GI tract. The expression seen in the disease samples confirms that seen in the normal samples with the highest levels of expression seen in the normal and Alzheimer's brain samples.

10 Upregulation in 1 of 4 colon tumor samples and 2 of 4 breast tumor samples as well as downregulation in 1 of 4 lung tumors poses a potential role for this gene in cancers of the colon and breast. Downregulation in 2 of 4 Alzheimer's brain samples implies involvement in Alzheimer's disease. Downregulation in 3 of 3 COPD samples and upregulation in 2 of 4 asthmatic lung samples suggests a potential role for this gene in chronic obstructive pulmonary disorder. Upregulation in the VEGF-treated endothelial cell line implicates a possible role for this gene in angiogenesis.

15 Downregulated in the stimulated bone marrow sample. High expression in the RA and OA synovium samples, the OA bone samples, and the chondrocytes with corroborating high expression in the T cells, B cells, neutrophils, and eosinophils implicates this gene in osteoarthritis and rheumatoid arthritis.

20

Sample sbg1007026SGLT	Ct (sample 1 and 2)	Mean GOI	Mean GOI	Average GOI	18S rRNA	50 ng/18	copies of mRNA
--------------------------	------------------------	-------------	-------------	----------------	-------------	-------------	-------------------

		copies (sample 1)	copies (sample 2)	Copies	(ng)	S rRNA (ng)	detected/ 50 ng total RNA
Subcutaneous Adipocytes Zenbio	40, 40	0	0	0.00	3.06	16.34	0.00
Subcutaneous Adipose Zenbio	40, 40	0	0.1	0.05	0.96	52.36	2.62
Adrenal Gland Clontech	40, 38.76	0	0.31	0.16	0.61	81.97	12.70
Whole Brain Clontech	23.01, 22.63	3438.45	4301.69	3870.07	7.24	6.91	26727.00
Fetal Brain Clontech	35.91, 39.16	1.66	0.24	0.95	0.48	103.95	98.75
Cerebellum Clontech	34.55, 32.7	3.71	11.08	7.40	2.17	23.04	170.39
Cervix	34.21, 34.61	4.54	3.58	4.06	2.42	20.66	83.88
Colon	33.44, 33.7	7.16	6.14	6.65	2.71	18.45	122.69
Endometrium	34.88, 40	3.05	0.1	1.58	0.73	68.21	107.44
Esophagus	40, 40	0	0.1	0.05	1.37	36.50	1.82
Heart Clontech	39.63, 39.53	0.18	0.19	0.19	1.32	37.88	7.01
Hypothalamus	40, 35.34	0	2.33	1.17	0.32	155.28	180.90
Ileum	40, 40	0	0	0.00	2.58	19.38	0.00
Jejunum	30.1, 30.34	51.59	44.92	48.26	6.60	7.58	365.57
Kidney	33.49, 40	6.96	0	3.48	2.12	23.58	82.08
Liver	40, 33.7	0	6.15	3.08	1.50	33.33	102.50
Fetal Liver Clontech	29.58, 29.41	70.26	77.58	73.92	10.40	4.81	355.38
Lung	35.61, 37.83	1.98	0.53	1.26	2.57	19.46	24.42
Mammary Gland Clontech	33.05, 34.04	9.02	5.03	7.03	13.00	3.85	27.02
Myometrium	33.63, 34.13	6.38	4.77	5.58	2.34	21.37	119.12
Omentum	40, 40	0	0	0.00	3.94	12.69	0.00
Ovary	35.38, 37.6	2.27	0.61	1.44	4.34	11.52	16.59
Pancreas	40, 37.1	0	0.82	0.41	0.81	61.80	25.34
Head of Pancreas	35.45, 36.72	2.18	1.03	1.61	1.57	31.85	51.11
Parotid Gland	36.88, 40	0.94	0	0.47	5.48	9.12	4.29
Placenta Clontech	33.84, 38.46	5.66	0.37	3.02	5.26	9.51	28.66
Prostate	38.76, 37.12	0.31	0.81	0.56	3.00	16.67	9.33
Rectum	36.18, 33.82	1.42	5.7	3.56	1.23	40.65	144.72
Salivary Gland Clontech	38.36, 39.93	0.39	0.12	0.26	7.31	6.84	1.74
Skeletal Muscle Clontech	35.69, 36.23	1.9	1.38	1.64	1.26	39.68	65.08
Skin	39.51, 40	0.2	0.09	0.15	1.21	41.32	5.99
Small Intestine Clontech	40, 36.04	0.1	1.53	0.82	0.98	51.07	41.62
Spleen	33.51, 38.51	6.87	0.36	3.62	4.92	10.16	36.74
Stomach	34.14, 34.19	4.73	4.59	4.66	2.73	18.32	85.35
Testis Clontech	35.81, 40	1.76	0.11	0.94	0.57	87.87	82.16
Thymus Clontech	33.26, 32.49	7.96	12.55	10.26	9.89	5.06	51.85
Thyroid	40, 39.9	0.08	0.16	0.12	2.77	18.05	2.17
Trachea Clontech	34.25, 33.8	4.42	5.77	5.10	9.71	5.15	26.24
Urinary Bladder	39.95, 36.54	0.1	1.14	0.62	5.47	9.14	5.67
Uterus	33, 31.23	9.3	26.52	17.91	5.34	9.36	167.70
genomic	24.72	1251.19					

b-actin	25.89	625.04					
1.00E+05	17.54	100000					
1.00E+05	17.65	100000					
1.00E+04	21.03	10000					
1.00E+04	20.92	10000					
1.00E+03	24.87	1000					
1.00E+03	24.96	1000					
1.00E+02	29.1	100					
1.00E+02	29.04	100					
1.00E+01	32.05	10					
1.00E+01	33.51	10					
1.00E-00	36.41	1					
1.00E-00	37.41	1					
NTC	40	0					
NTC	40	-1					

Sample sbg1007026SGLT	Reg number (GSK identifier )	Ct	Mean GOI copies	copies of mRNA detected/ 50 ng total RNA	Sample	Fold Change in Disease Populati on
colon normal GW98-167	21941	29.22	127.1	254.20	colon normal	
colon tumor GW98-166	21940	31.07	44.11	88.22	colon tumor	-2.88
colon normal GW98-178	22080	38.41	0.65	1.30	colon normal	
colon tumor GW98-177	22060	31.17	41.5	83.00	colon tumor	63.85
colon normal GW98-561	23514	31.21	40.69	81.38	colon normal	
colon tumor GW98-560	23513	33.06	14.04	28.08	colon tumor	-2.90
colon normal GW98-894	24691	29.63	100.41	200.82	colon normal	
colon tumor GW98-893	24690	32.22	22.7	45.40	colon tumor	-4.42
lung normal GW98-3	20742	29.8	91.46	182.92	lung normal	
lung tumor GW98-2	20741	34.26	7.02	14.04	lung tumor	-13.03
lung normal GW97-179	20677	29.59	103.13	206.26	lung normal	
lung tumor GW97-178	20676	29.84	89.09	178.18	lung tumor	-1.16
lung normal GW98-165	21922	29.6	102.46	204.92	lung normal	
lung tumor GW98-164	21921	30.8	51.53	103.06	lung tumor	-1.99
lung normal GW98-282	22584	32.53	18.97	37.94	lung normal	
lung tumor GW98-281	22583	32.29	21.8	43.60	lung tumor	1.15
breast normal GW00-392	28750	28.77	164.85	164.85	breast normal	
breast tumor GW00-391	28746	30.64	56.21	112.42	breast tumor	-1.47
breast normal GW00-413	28798	34.49	6.17	6.17	breast normal	
breast tumor GW00-412	28797	30.37	65.97	131.94	breast tumor	21.38
breast normal GW00- 235:238	27592-95	32.87	15.66	15.66	breast normal	
breast tumor GW00- 231:234	27588-91	29.8	91.07	91.07	breast tumor	5.82
breast normal GW98-621	23656	28.95	149.19	298.38	breast normal	
breast tumor GW98-620	23655	29.62	101.25	202.50	breast tumor	-1.47
brain normal BB99-542	25507	24.5	1917.28	3834.56	brain normal	

brain normal BB99-406	25509	21.35	11736.92	23473.84	brain normal	
brain normal BB99-904	25546	25.25	1248.68	2497.36	brain normal	
brain stage 5 ALZ BB99-874	25502	27.29	386.81	773.62	brain stage 5 ALZ	-12.84
brain stage 5 ALZ BB99-887	25503	23.61	3196.37	6392.74	brain stage 5 ALZ	-1.55
brain stage 5 ALZ BB99-862	25504	25.56	1045.09	2090.18	brain stage 5 ALZ	-4.75
brain stage 5 ALZ BB99-927	25542	24.45	1976.24	3952.48	brain stage 5 ALZ	-2.51
CT lung	normal	31.07	44.03	88.06	CT lung Nml	
lung 26	normal	24.93	1496.87		lung 26 Nml	
lung 27	normal	34.06	7.92	7.92	lung 27 Nml	
lung 24	COPD	34.58	5.87	5.87	lung 24 COPD	-5.45
lung 28	COPD	40	0	0.00	lung 28 COPD	-31.99
lung 23	COPD	40	0	0.00	lung 23 COPD	-31.99
lung 25	normal	40	0	0.00	lung 25 Nml	
asthmatic lung ODO3112	29321	33.19	13.04	13.04	asthmatic lung	-2.45
asthmatic lung ODO3433	29323	30.61	57.38	114.76	asthmatic lung	3.59
asthmatic lung ODO3397	29322	29.2	129.16	258.32	asthmatic lung	8.07
asthmatic lung ODO4928	29325	30.32	67.67	135.34	asthmatic lung	4.23
endo cells	control	35.09	4.37	4.37	endo cells	
endo VEGF		32.22	22.7	22.70	endo VEGF	5.19
endo bFGF		33.23	12.7	12.70	endo bFGF	2.91
heart Clontech	normal	33.53	10.71	21.42	heart	
heart ( T-1 ) ischemic	29417	33.43	11.37	22.74	heart ( T-1 ) ischemic	1.06
heart (T-14) non-obstructive DCM	29422	34.45	6.32	12.64	heart (T-14) non-obstructive DCM	-1.69
heart (T-3399) DCM	29426	31.98	26.02	52.04	heart (T-3399) DCM	2.43
adenoid GW99-269	26162	29.56	104.93	209.86	adenoid	
tonsil GW98-280	22582	29	144.55	289.10	tonsil	
T cells PC00314	28453	32.03	25.34	50.68	T cells	
PBMNC		37.71	0.97	0.97	PBMNC	
monocyte		37.49	1.1	2.20	monocyte	
B cells PC00665	28455	27.18	410.49	820.98	B cells	
dendritic cells	28441	33.7	9.73	19.46	dendritic cells	
neutrophils	28440	32.48	19.6	19.60	neutrophils	
eosinophils	28446	32.44	20.08	40.16	eosinophils	
BM unstim		33.8	9.17	9.17	BM unstim	
BM stim	treated	38.89	0.49	0.49	BM stim	-18.71
osteо dif	treated	37.26	1.26	1.26	osteо dif	1.26
osteо undif		40	0	0.00	osteо undif	
chondrocytes		32.07	24.82	62.05	chondrocytes	
OA Synovium IP12/01	29462	30.31	68.26	68.26	OA Synovium	
OA Synovium NP10/01	29461	30.74	53.26	106.52	OA Synovium	
OA Synovium NP57/00	28464	31.3	38.48	76.96	OA Synovium	
RA Synovium NP03/01	28466	31.08	43.89	87.78	RA Synovium	
RA Synovium NP71/00	28467	31.35	37.58	75.16	RA Synovium	

RA Synovium NP45/00	28475	30.74	53.21	106.42	RA Synovium	
OA bone (biobank)	29217	30.47	61.99	61.99	OA bone (biobank)	
OA bone Sample 1	J. Emory	29.92	85.09	170.18	OA bone	
OA bone Sample 2	J. Emory	30.91	48.27	96.54	OA bone	
Cartilage (pool)	Normal	31.34	37.68	75.36	Nml Cartilage (pool)	
Cartilage (pool)	OA	31.72	30.35	60.70	OA Cartilage (pool)	-1.24
PBL uninfected	28441	30.8	51.54	103.08	PBL uninfected	
PBL HIV IIIB	28442	32.03	25.38	50.76	PBL HIV IIIB	-2.03
MRC5 uninfected (100%)	29158	32.29	21.85	43.70	MRC5 uninfected (100%)	
MRC5 HSV strain F	29178	31.21	40.73	81.46	MRC5 HSV strain F	1.86
W12 cells	29179	33.12	13.52	27.04	W12 cells	
Keratinocytes	29180	32.35	21.06	42.12	Keratinocytes	
B-actin control		25.63	1002.01			
genomic		25.19	1290.48			
1.00E+05		17.86	100000			
1.00E+05		17.85	100000			
1.00E+04		21.44	10000			
1.00E+04		21.51	10000			
1.00E+03		25.33	1000			
1.00E+03		25.26	1000			
1.00E+02		29.62	100			
1.00E+02		30.55	100			
1.00E+01		32.93	10			
1.00E+01		33.46	10			
1.00E-00		38.18	1			
1.00E-00		40	0			
NTC		38.28	-1			
*lung 26 Normal has been omitted due to multiple amplification failures from that sample						

Gene Name sbg1007026SGLT

Disease tissues	Fold Change in Disease Population Relative to Normal
colon tumor	-2.88
colon tumor	63.85
colon tumor	-2.90
colon tumor	-4.42
Jung tumor	-13.03
lung tumor	-1.16
lung tumor	-1.99
lung tumor	1.15
breast tumor	-1.47
breast tumor	21.38

breast tumor	5.82
breast tumor	-1.47
brain stage 5 ALZ	-12.84
brain stage 5 ALZ	-1.55
brain stage 5 ALZ	-4.75
brain stage 5 ALZ	-2.51
lung 24	-5.45
lung 28	-31.99
lung 23	-31.99
asthmatic lung	-2.45
asthmatic lung	3.59
asthmatic lung	8.07
asthmatic lung	4.23
endo VEGF	5.19
endo bFGF	2.91
heart T-1	1.06
heart T-14	-1.69
heart T-3399	2.43
BM stim	-18.71
osteo dif	1.26
Cartilage (pool)	-1.24
PBL HIV IIIB	-2.03
MRC5 HSV strain F	1.86

**Gene Name sbg1012732GLUT**

5 High to moderate overall expression. This gene is expressed fairly ubiquitously in all normal samples analyzed with highest levels of expression seen in the whole brain, fetal brain cerebellum, kidney, fetal liver, and the placenta. This gene is also expressed fairly ubiquitously in the disease samples. Downregulation in 3 of 3 COPD samples suggests a potential role for this gene in chronic obstructive pulmonary disorder. Upregulation in 3 of 3 disease heart samples implies an involvement in cardiovascular diseases such as non-obstructive and obstructive DCM and ischemia. Downregulation in the HSV-infected MRC5 cells suggests that this gene may play a role in HSV. Upregulated in the differentiated osteoblasts. High expression in the RA and OA synovium samples, the OA bone samples, and the chondrocytes with corroborating high expression in the T cells, B cells, dendritic cells, neutrophils, and eosinophils implicates this gene in osteoarthritis and rheumatoid arthritis.

10

Sample sbg1012732GLUT	Ct (sample 1 and 2)	Mean GOI copies (sample 1)	Mean GOI copies (sample 2)	Average GOI Copies	18S rRNA (ng)	50 ng/18S rRNA (ng)	copies of mRNA detected/ 50 ng total RNA
Subcutaneous Adipocytes Zenbio	30.84, 30.49	46.76	57.63	52.20	3.06	16.34	852.86
Subcutaneous Adipose Zenbio	34.89, 35.19	4.31	3.62	3.97	0.96	52.36	207.59
Adrenal Gland Clontech	33.79, 32.74	8.27	15.31	11.79	0.61	81.97	966.39
Whole Brain Clontech	22.02, 21.91	8374.61	8944.05	8659.33	7.24	6.91	59802.00
Fetal Brain Clontech	32.03, 32.85	23.23	14.34	18.79	0.48	103.95	1952.70
Cerebellum Clontech	28.2, 28.26	221.12	213.07	217.10	2.17	23.04	5002.19
Cervix	32.91, 34.54	13.81	5.31	9.56	2.42	20.66	197.52
Colon	30.88, 32.48	45.58	17.87	31.73	2.71	18.45	585.33
Endometrium	36.13, 32.5	2.08	17.6	9.84	0.73	68.21	671.21

Esophagus	32.19, 33.5	21.15	9.77	15.46	1.37	36.50	564.23
Heart Clontech	31.93, 31.73	24.67	27.76	26.22	1.32	37.88	992.99
Hypothalamus	40, 32.77	0	15.04	7.52	0.32	155.28	1167.70
Ileum	30.94, 30.52	44.17	56.37	50.27	2.58	19.38	974.22
Jejunum	30.04, 29.34	75.03	113.25	94.14	6.60	7.58	713.18
Kidney	29.72, 29.18	90.58	124.19	107.39	2.12	23.58	2532.67
Liver	34.81, 32.2	4.52	21.05	12.79	1.50	33.33	426.17
Fetal Liver Clontech	26.6, 26.85	567.46	488.36	527.91	10.40	4.81	2538.03
Lung	31.61, 30.52	29.69	56.54	43.12	2.57	19.46	838.81
Mammary Gland Clontech	28.06, 27.59	239.58	316.2	277.89	13.00	3.85	1068.81
Myometrium	30.44, 29.88	59.31	82.52	70.92	2.34	21.37	1515.28
Omentum	31.7, 30.82	28.2	47.35	37.78	3.94	12.69	479.38
Ovary	30.92, 31.56	44.74	30.55	37.65	4.34	11.52	433.70
Pancreas	33.08, 32.66	12.54	16.03	14.29	0.81	61.80	882.88
Head of Pancreas	33.98, 34.1	7.36	6.89	7.13	1.57	31.85	226.91
Parotid Gland	29.5, 30.55	102.86	55.41	79.14	5.48	9.12	722.03
Placenta Clontech	25.63, 25.87	1002.18	869.55	935.87	5.26	9.51	8896.06
Prostate	30.23, 31.17	67.04	38.48	52.76	3.00	16.67	879.33
Rectum	31.29, 31.15	35.89	38.94	37.42	1.23	40.65	1520.93
Salivary Gland Clontech	28.82, 28.83	153.9	152.53	153.22	7.31	6.84	1047.98
Skeletal Muscle Clontech	33.23, 32.66	11.48	16.02	13.75	1.26	39.68	545.63
Skin	32.62, 32.57	16.46	16.96	16.71	1.21	41.32	690.50
Small Intestine Clontech	34.63; 32.82	5.03	14.62	9.83	0.98	51.07	501.79
Spleen	31.45, 32.71	32.66	15.56	24.11	4.92	10.16	245.02
Stomach	32.38, 32.43	18.93	18.41	18.67	2.73	18.32	341.94
Testis Clontech	32.32, 32.27	19.58	20.17	19.88	0.57	87.87	1746.49
Thymus Clontech	27.24, 26.75	388.32	518.55	453.44	9.89	5.06	2292.39
Thyroid	30.48, 29.44	57.86	106.5	82.18	2.77	18.05	1483.39
Trachea Clontech	29.96, 30.29	78.48	64.81	71.65	9.71	5.15	368.92
Urinary Bladder	30.59, 30.1	54.25	72.45	63.35	5.47	9.14	579.07
Uterus	30.62, 29.73	53.18	89.72	71.45	5.34	9.36	669.01
genomic	25.15	1330.24					
b-actin	26.01	800.58					
1.00E+05	18.01	100000					
1.00E+05	18.19	100000					
1.00E+04	21.35	10000					
1.00E+04	21.3	10000					
1.00E+03	25.59	1000					
1.00E+03	25.51	1000					
1.00E+02	29.95	100					
1.00E+02	29.37	100					
1.00E+01	34.05	10					
1.00E+01	33.22	10					
1.00E-00	37.19	1					
1.00E-00	40	0					
NTC	40	0					

NTC	40	0					
-----	----	---	--	--	--	--	--

Sample sbg1012732GLUT	Reg number (GSK identifier )	Ct	Mean GOI copies	copies of mRNA detected/ 50 ng total RNA	Sample	Fold Change in Disease Populati on
colon normal GW98-167	21941	25.38	1695.47	3390.94	colon normal	
colon tumor GW98-166	21940	25.51	1576.91	3153.82	colon tumor	-1.08
colon normal GW98-178	22080	26.8	765.5	1531.00	colon normal	
colon tumor GW98-177	22060	25.86	1297.34	2594.68	colon tumor	1.69
colon normal GW98-561	23514	26.12	1120.64	2241.28	colon normal	
colon tumor GW98-560	23513	26.12	1121.89	2243.78	colon tumor	1.00
colon normal GW98-894	24691	24.85	2283.56	4567.12	colon normal	
colon tumor GW98-893	24690	24.37	2989.5	5979.00	colon tumor	1.31
lung normal GW98-3	20742	24.37	2984.11	5968.22	lung normal	
lung tumor GW98-2	20741	25.38	1691.06	3382.12	lung tumor	-1.76
lung normal GW97-179	20677	25.07	2020.52	4041.04	lung normal	
lung tumor GW97-178	20676	24.61	2607.03	5214.06	lung tumor	1.29
lung normal GW98-165	21922	24.92	2195.85	4391.70	lung normal	
lung tumor GW98-164	21921	25.36	1712.62	3425.24	lung tumor	-1.28
lung normal GW98-282	22584	26.24	1049.97	2099.94	lung normal	
lung tumor GW98-281	22583	25.94	1241.8	2483.60	lung tumor	1.18
breast normal GW00-392	28750	25.26	1813.7	1813.70	breast normal	
breast tumor GW00-391	28746	24.87	2259.54	4519.08	breast tumor	2.49
breast normal GW00-413	28798	25.4	1672.46	1672.46	breast normal	
breast tumor GW00-412	28797	25.21	1864.18	3728.36	breast tumor	2.23
breast normal GW00- 235:238	27592-95	25.68	1435.2	1435.20	breast normal	
breast tumor GW00- 231:234	27588-91	24.08	3510.78	3510.78	breast tumor	2.45
breast normal GW98-621	23656	24.16	3363.26	6726.52	breast normal	
breast tumor GW98-620	23655	24.19	3300.23	6600.46	breast tumor	-1.02
brain normal BB99-542	25507	22.64	7880.57	15761.14	brain normal	
brain normal BB99-406	25509	23.32	5357.05	10714.10	brain normal	
brain normal BB99-904	25546	23.66	4436.27	8872.54	brain normal	
brain stage 5 ALZ BB99- 874	25502	24.7	2474.23	4948.46	brain stage 5 ALZ	-2.38
brain stage 5 ALZ BB99- 887	25503	23.22	5674.88	11349.76	brain stage 5 ALZ	-1.04
brain stage 5 ALZ BB99- 862	25504	23.5	4868.6	9737.20	brain stage 5 ALZ	-1.21
brain stage 5 ALZ BB99- 927	25542	23.17	5843.2	11686.40	brain stage 5 ALZ	-1.01
CT lung	normal	25.61	1486.99	2973.98	CT lung Nml	
lung 26	normal	26.55	879.91		lung 26 Nml	
lung 27	normal	29.44	174.3	174.30	lung 27 Nml	

lung 24	COPD	29.99	128.5	128.50	lung 24 COPD	-8.67
lung 28	COPD	29.56	163.34	163.34	lung 28 COPD	-6.82
lung 23	COPD	29.59	160.67	160.67	lung 23 COPD	-6.94
lung 25	normal	29.24	194.83	194.83	lung 25 Nml	
asthmatic lung ODO3112	29321	27.22	604.38	604.38	asthmatic lung	-1.84
asthmatic lung ODO3433	29323	26.46	923.43	1846.86	asthmatic lung	1.66
asthmatic lung ODO3397	29322	26.16	1094.36	2188.72	asthmatic lung	1.96
asthmatic lung ODO4928	29325	25.51	1576.72	3153.44	asthmatic lung	2.83
endo cells	control	29.09	211.78	211.78	endo cells	
endo VEGF		30.07	122.67	122.67	endo VEGF	-1.73
endo bFGF		29.93	132.63	132.63	endo bFGF	-1.60
heart Clontech	normal	27.35	561.26	1122.52	heart	
heart ( T-1 ) ischemic	29417	23.82	4053.65	8107.30	heart ( T-1 ) ischemic	7.22
heart (T-14) non-obstructive DCM	29422	23.96	3746.25	7492.50	heart (T-14) non-obstructive DCM	6.67
heart (T-3399) DCM	29426	23.35	5282.35	10564.70	heart (T-3399) DCM	9.41
adenoid GW99-269	26162	25.71	1405.41	2810.82	adenoid	
tonsil GW98-280	22582	23.97	3725.77	7451.54	tonsil	
T cells PC00314	28453	25.03	2062.68	4125.36	T cells	
PBMNC		30.16	116.69	116.69	PBMNC	
monocyte		30.15	117.05	234.10	monocyte	
B cells PC00665	28455	23.22	5673.63	11347.26	B cells	
dendritic cells	28441	25.74	1385.65	2771.30	dendritic cells	
neutrophils	28440	27.14	631.86	631.86	neutrophils	
eosinophils	28446	28.27	335.66	671.32	eosinophils	
BM unstim		30.08	122.25	122.25	BM unstim	
BM stim	treated	29.57	162.71	162.71	BM stim	1.33
osteo dif	treated	29.07	214.84	214.84	osteo dif	2.91
osteo undif		30.98	73.85	73.85	osteo undif	
chondrocytes		25.41	1667.28	4168.20	chondrocytes	
OA Synovium IP12/01	29462	24.65	2554.39	2554.39	OA Synovium	
OA Synovium NP10/01	29461	25.72	1399	2798.00	OA Synovium	
OA Synovium NP57/00	28464	25.24	1828.2	3656.40	OA Synovium	
RA Synovium NP03/01	28466	25.69	1422.61	2845.22	RA Synovium	
RA Synovium NP71/00	28467	25.25	1818.15	3636.30	RA Synovium	
RA Synovium NP45/00	28475	25.22	1857.13	3714.26	RA Synovium	
OA bone (biobank)	29217	26.19	1074.74	1074.74	OA bone (biobank)	
OA bone Sample 1	J. Emory	26.71	805.65	1611.30	OA bone	
OA bone Sample 2	J. Emory	26.96	700.88	1401.76	OA bone	
Cartilage (pool)	Normal	26.38	968.45	1936.90	Nml Cartilage (pool)	
Cartilage (pool)	OA	28.07	376.23	752.46	OA Cartilage (pool)	-2.57
PBL uninfected	28441	25.09	1997.75	3995.50	PBL uninfected	
PBL HIV IIIB	28442	25.36	1710.81	3421.62	PBL HIV IIIB	-1.17
MRC5 uninfected (100%)	29158	25.28	1788.71	3577.42	MRC5 uninfected (100%)	

MRC5 HSV strain F	29178	30.17	116.17	232.34	MRC5 HSV strain F	-15.40
W12 cells	29179	27.6	489.01	978.02	W12 cells	
Keratinocytes	29180	26.4	959.61	1919.22	Keratinocytes	
B-actin control		25.62	1482.86			
genomic		25.42	1657.68			
1.00E+05		18.49	100000			
1.00E+05		18.49	100000			
1.00E+04		21.94	10000			
1.00E+04		21.98	10000			
1.00E+03		25.34	1000			
1.00E+03		25.39	1000			
1.00E+02		30.59	100			
1.00E+02		30.9	100			
1.00E+01		32.51	10			
1.00E+01		39.12	10			
1.00E-00		39.07	1			
1.00E-00		36.71	1			
NTC		39.63	-1			
*lung 26 Normal has been omitted due to multiple amplification failures from that sample						

Gene Name sbg1012732GLUT

Disease tissues	Fold Change in Disease Population Relative to Normal
colon tumor	-1.08
colon tumor	1.69
colon tumor	1.00
colon tumor	1.31
lung tumor	-1.76
lung tumor	1.29
lung tumor	-1.28
lung tumor	1.18
breast tumor	2.49
breast tumor	2.23
breast tumor	2.45
breast tumor	-1.02
brain stage 5 ALZ	-2.38
brain stage 5 ALZ	-1.04
brain stage 5 ALZ	-1.21
brain stage 5 ALZ	-1.01
lung 24	-8.67
lung 28	-6.82
lung 23	-6.94
asthmatic lung	-1.84
asthmatic lung	1.66
asthmatic lung	1.96
asthmatic lung	2.83
endo VEGF	-1.73

endo bFGF	-1.60
heart T-1	7.22
heart T-14	6.67
heart T-3399	9.41
BM stim	1.33
osteо dif	2.91
Cartilage (pool)	-2.57
PBL HIV IIIB	-1.17
MRC5 HSV strain F	-15.40

**Gene Name sbg1012732GLUTb**

The same as sbg1012732GLUT.

5

**Gene Name sbg1018172CSP**

10 Moderate to low overall expression. Highest normal expression is seen in the whole brain, kidney, thyroid, and uterus. This gene is expressed in all of the samples representing the female reproductive system. Highest disease expression is seen in many of the normal/tumor lung samples and the asthmatic lung samples. Downregulation in 2 of 4 lung tumor samples and upregulation in 2 of 4 breast tumor samples suggests an involvement in cancers of the lung and breast.

15 Downregulation in 3 of 3 COPD samples suggests a potential role for this gene in chronic obstructive pulmonary disorder. Upregulation in 2 of 4 asthmatic lung samples implies an involvement in asthma. Upregulation in 1 of 3 disease heart samples implies an involvement in cardiovascular disease such as obstructive DCM. Downregulation in the OA cartilage pool with corroborating low expression in the immune cells (T and B cells in particular) implicates this gene in osteoarthritis and rheumatoid arthritis. Upregulation in the HSV-infected MRC5 cells suggests that this gene may be a host factor in HSV.

20

Sample sbg1018172CSP	Ct (sample 1 and 2)	Mean GOI copies (sample 1)	Mean GOI copies (sample 2)	Average GOI Copies	18S rRNA (ng)	50 ng/18S rRNA (ng)	copies of mRNA detected/50 ng total RNA
Subcutaneous Adipocytes Zenbio	35.54, 34.87	7.65	11.21	9.43	3.06	16.34	154.08
Subcutaneous Adipose Zenbio	40, 40	0.4	0	0.20	0.96	52.36	10.47
Adrenal Gland Clontech	40, 40	0	0	0.00	0.61	81.97	0.00
Whole Brain Clontech	25.71, 25.78	1950.98	1867.58	1909.28	7.24	6.91	13185.64
Fetal Brain Clontech	40, 40	0	0	0.00	0.48	103.95	0.00
Cerebellum Clontech	36.32, 35.16	4.95	9.48	7.22	2.17	23.04	166.24
Cervix	36.76, 36.16	3.85	5.42	4.64	2.42	20.66	95.76
Colon	36.52, 36.41	4.41	4.7	4.56	2.71	18.45	84.04
Endometrium	36.4, 35.92	4.73	6.19	5.46	0.73	68.21	372.44
Esophagus	40, 40	0	0	0.00	1.37	36.50	0.00
Heart Clontech	40, 40	0	0	0.00	1.32	37.88	0.00
Hypothalamus	40, 40	0	0	0.00	0.32	155.28	0.00
Ileum	40, 40	0	0	0.00	2.58	19.38	0.00
Jejunum	36.53, 33.22	4.38	28.28	16.33	6.60	7.58	123.71

Kidney	32.81, 32.45	35.74	43.67	39.71	2.12	23.58	936.44
Liver	35.92, 36.2	6.19	5.29	5.74	1.50	33.33	191.33
Fetal Liver Clontech	31.57, 30.46	71.69	134.34	103.02	10.40	4.81	495.26
Lung	33.35, 36.86	26.32	3.65	14.99	2.57	19.46	291.54
Mammary Gland Clontech	32.99, 32.17	32.23	51.27	41.75	13.00	3.85	160.58
Myometrium	34.99, 40	10.44	0	5.22	2.34	21.37	111.54
Omentum	35.61, 40	7.37	0	3.69	3.94	12.69	46.76
Ovary	35.83, 35.54	6.53	7.67	7.10	4.34	11.52	81.80
Pancreas	35.86, 40	6.39	0	3.20	0.81	61.80	197.47
Head of Pancreas	40, 40	0	0	0.00	1.57	31.85	0.00
Parotid Gland	34.26, 34.03	15.73	17.96	16.85	5.48	9.12	153.70
Placenta Clontech	32.64, 33.16	39.34	29.26	34.30	5.26	9.51	326.05
Prostate	35.71, 40	6.95	0	3.48	3.00	16.67	57.92
Rectum	33.84, 34.42	19.99	14.41	17.20	1.23	40.65	699.19
Salivary Gland Clontech	40, 40	0	0	0.00	7.31	6.84	0.00
Skeletal Muscle Clontech	34.2, 40	16.33	0	8.17	1.26	39.68	324.01
Skin	35.02, 40	10.31	0.48	5.40	1.21	41.32	222.93
Small Intestine Clontech	40, 40	0	0	0.29	0.98	51.07	14.81
Spleen	40, 35.31	0	8.71	4.36	4.92	10.16	44.26
Stomach	40, 35.4	0	8.3	4.15	2.73	18.32	76.01
Testis Clontech	40, 37.31	0	2.82	1.41	0.57	87.87	123.90
Thymus Clontech	30.9, 31.1	104.45	93.52	98.99	9.89	5.06	500.43
Thyroid	31.62, 31.57	69.89	71.93	70.91	2.77	18.05	1279.96
Trachea Clontech	34.19, 34.08	16.41	17.49	16.95	9.71	5.15	87.28
Urinary Bladder	40, 34.4	0	14.55	7.28	5.47	9.14	66.50
Uterus	30.63, 30.6	122.13	123.57	122.85	5.34	9.36	1150.28
genomic	26.58	1190.6					
b-actin	27.38	758.43					
1.00E+05	19.07	100000					
1.00E+05	19.35	100000					
1.00E+04	22.57	10000					
1.00E+04	22.59	10000					
1.00E+03	26.24	1000					
1.00E+03	26.31	1000					
1.00E+02	30.18	100					
1.00E+02	31.64	100					
1.00E+01	35.9	10					
1.00E+01	40	0					
1.00E-00	40	0					
1.00E-00	40	0					
NTC	40	0					
NTC	40	0					

Sample sbg1018172CSP	Reg number	Ct	Mean GOI	copies of mRNA	Sample	Fold Change
-------------------------	---------------	----	-------------	-------------------	--------	----------------

	(GSK identifier )		copies	detected/ 50 ng total RNA		in Disease Population
colon normal GW98-167	21941	27.29	1064.89	2129.78	colon normal	
colon tumor GW98-166	21940	26.18	2023.11	4046.22	colon tumor	1.90
colon normal GW98-178	22080	30.45	168.68	337.36	colon normal	
colon tumor GW98-177	22060	29.33	324.49	648.98	colon tumor	1.92
colon normal GW98-561	23514	30.36	177.62	355.24	colon normal	
colon tumor GW98-560	23513	32.27	58.7	117.40	colon tumor	-3.03
colon normal GW98-894	24691	30.71	145.57	291.14	colon normal	
colon tumor GW98-893	24690	32.3	57.43	114.86	colon tumor	-2.53
lung normal GW98-3	20742	24.82	4478.67	8957.34	lung normal	
lung tumor GW98-2	20741	33.61	26.86	53.72	lung tumor	-166.74
lung normal GW97-179	20677	26.31	1874.25	3748.50	lung normal	
lung tumor GW97-178	20676	24.52	5311.72	10623.44	lung tumor	2.83
lung normal GW98-165	21922	24.99	4042.28	8084.56	lung normal	
lung tumor GW98-164	21921	27.19	1127.26	2254.52	lung tumor	-3.59
lung normal GW98-282	22584	25.51	2990.53	5981.06	lung normal	
lung tumor GW98-281	22583	26.67	1522.51	3045.02	lung tumor	-1.96
breast normal GW00-392	28750	32.25	59.17	59.17	breast normal	
breast tumor GW00-391	28746	30.48	165.82	331.64	breast tumor	5.60
breast normal GW00-413	28798	34.58	15.31	15.31	breast normal	
breast tumor GW00-412	28797	30.05	213.4	426.80	breast tumor	27.88
breast normal GW00-235:238	27592-95	34.41	16.85	16.85	breast normal	
breast tumor GW00-231:234	27588-91	33.52	28.31	28.31	breast tumor	1.68
breast normal GW98-621	23656	28.22	618.19	1236.38	breast normal	
breast tumor GW98-620	23655	32.02	67.94	135.88	breast tumor	-9.10
brain normal BB99-542	25507	29.11	367.88	735.76	brain normal	
brain normal BB99-406	25509	28.05	682.39	1364.78	brain normal	
brain normal BB99-904	25546	29.06	379.07	758.14	brain normal	
brain stage 5 ALZ BB99-874	25502	30.06	211.81	423.62	brain stage 5 ALZ	-2.25
brain stage 5 ALZ BB99-887	25503	26.97	1280.13	2560.26	brain stage 5 ALZ	2.69
brain stage 5 ALZ BB99-862	25504	29.85	239.03	478.06	brain stage 5 ALZ	-1.99
brain stage 5 ALZ BB99-927	25542	28.13	652.56	1305.12	brain stage 5 ALZ	1.37
CT lung	normal	26.97	1280.81	2561.62	CT lung Nml	
lung 26	normal	32.21	60.75		lung 26 Nml	
lung 27	normal	34	21.39	21.39	lung 27 Nml	
lung 24	COPD	32.11	64.11	64.11	lung 24 COPD	-13.87
lung 28	COPD	33.01	38.18	38.18	lung 28 COPD	-23.29
lung 23	COPD	32.84	42.15	42.15	lung 23 COPD	-21.10
lung 25	normal	31.63	84.78	84.78	lung 25 Nml	
asthmatic lung ODO3112	29321	29.4	310.75	310.75	asthmatic lung	-2.86
asthmatic lung ODO3433	29323	27.02	1242.79	2485.58	asthmatic lung	2.80

asthmatic lung ODO3397	29322	25.97	2289.74	4579.48	asthmatic lung	5.15
asthmatic lung ODO4928	29325	26.84	1380.5	2761.00	asthmatic lung	3.10
endo cells	control	40	0	0.00	endo cells	
endo VEGF		40	0	0.00	endo VEGF	0.00
endo bFGF		40	1.01	1.01	endo bFGF	1.01
heart Clontech	normal	33.02	37.93	75.86	heart	
heart ( T-1 ) ischemic	29417	34.34	17.51	35.02	heart ( T-1 ) ischemic	-2.17
heart (T-14) non-obstructive DCM	29422	34.85	13.07	26.14	heart (T-14) non-obstructive DCM	-2.90
heart (T-3399) DCM	29426	29.74	254.69	509.38	heart (T-3399) DCM	6.71
adenoid GW99-269	26162	35.07	11.5	23.00	adenoid	
tonsil GW98-280	22582	40	0	0.00	tonsil	
T cells PC00314	28453	36.12	6.22	12.44	T cells	
PBMNC		40	0	0.00	PBMNC	
monocyte		40	0	0.00	monocyte	
B cells PC00665	28455	40	0	0.00	B cells	
dendritic cells	28441	40	0	0.00	dendritic cells	
neutrophils	28440	35.43	9.3	9.30	neutrophils	
eosinophils	28446	40	1.32	2.64	eosinophils	
BM unstim		40	0	0.00	BM unstim	
BM stim	treated	40	0	0.00	BM stim	0.00
osteo dif	treated	40	0	0.00	osteo dif	0.00
osteo undif		40	0	0.00	osteo undif	
chondrocytes		33.23	33.49	83.73	chondrocytes	
OA Synovium IP12/01	29462	34.9	12.68	12.68	OA Synovium	
OA Synovium NP10/01	29461	28.55	510.63	1021.26	OA Synovium	
OA Synovium NP57/00	28464	34	21.41	42.82	OA Synovium	
RA Synovium NP03/01	28466	40	0	0.00	RA Synovium	
RA Synovium NP71/00	28467	36.2	5.96	11.92	RA Synovium	
RA Synovium NP45/00	28475	36.38	5.34	10.68	RA Synovium	
OA bone (biobank)	29217	35.58	8.52	8.52	OA bone (biobank)	
OA bone Sample 1	J. Emory	33.54	27.91	55.82	OA bone	
OA bone Sample 2	J. Emory	34.92	12.54	25.08	OA bone	
Cartilage (pool)	Normal	33.88	22.98	45.96	Nml Cartilage (pool)	
Cartilage (pool)	OA	40	0	0.00	OA Cartilage (pool)	-45.96
PBL uninfected	28441	30.74	142.65	285.30	PBL uninfected	
PBL HIV IIIB	28442	32.47	52.13	104.26	PBL HIV IIIB	-2.74
MRC5 uninfected (100%)	29158	40	0	0.00	MRC5 uninfected (100%)	
MRC5 HSV strain F	29178	30.06	211.88	423.76	MRC5 HSV strain F	423.76
W12 cells	29179	39.65	0.8	1.60	W12 cells	
Keratinocytes	29180	33.76	24.58	49.16	Keratinocytes	
B-actin control		27.17	1140.82			
genomic		26.81	1405.46			

1.00E+05		19.68	100000				
1.00E+05		19.63	100000				
1.00E+04		23.15	10000				
1.00E+04		23.27	10000				
1.00E+03		27.1	1000				
1.00E+03		27.33	1000				
1.00E+02		31.34	100				
1.00E+02		32.04	100				
1.00E+01		35.09	10				
1.00E+01		40	10				
1.00E-00		40	0				
1.00E-00		40	0				
NTC		40	0				
*lung 26 Normal has been omitted due to multiple amplification failures from that sample							

Gene Name sbg1018172CSP

Disease tissues	Fold Change in Disease Population Relative to Normal
colon tumor	1.90
colon tumor	1.92
colon tumor	-3.03
colon tumor	-2.53
lung tumor	-166.74
lung tumor	2.83
lung tumor	-3.59
lung tumor	-1.96
breast tumor	5.60
breast tumor	27.88
breast tumor	1.68
breast tumor	-9.10
brain stage 5 ALZ	-2.25
brain stage 5 ALZ	2.69
brain stage 5 ALZ	-1.99
brain stage 5 ALZ	1.37
lung 24	-13.87
lung 28	-23.29
lung 23	-21.10
asthmatic lung	-2.86
asthmatic lung	2.80
asthmatic lung	5.15
asthmatic lung	3.10
endo VEGF	0.00
endo bFGF	1.01
heart T-1	-2.17
heart T-14	-2.90
heart T-3399	6.71
BM stim	0.00
osteо dif	0.00
Cartilage (pool)	-45.96

PBL HIV IIIB	-2.74
MRC5 HSV strain F	423.76

**Gene Name sbg1004570ERGIC**

5 Moderate to low overall expression. This gene is expressed fairly ubiquitously in all normal samples analyzed with highest levels of expression seen in the whole brain, hypothalamus, pancreas, and head of pancreas. This pattern of expression suggests that this gene may be involved in diabetes or other metabolic diseases. Highest disease expression is seen in the colon, breast, and lung normal/tumor pairs as well as the Alzheimer's brain samples and the T cells, B cells, dendritic cells, and eosinophils. Upregulation in 2 of 4 breast tumor samples suggests a role for this gene in breast cancer. Upregulation in 2 of 4 Alzheimer's brain samples implies an involvement in 10 Alzheimer's disease. Downregulation in 3 of 3 COPD samples and 4 of 4 asthmatic lung samples suggests a potential role for this gene in chronic obstructive pulmonary disorder and asthma. Upregulated in the stimulated bone marrow sample.

Sample sbg1004570ERGIC	Ct (sample 1 and 2)	Mean GOI copies (sample 1)	Mean GOI copies (sample 2)	Average GOI Copies	18S rRNA (ng)	50 ng/18S rRNA (ng)	copies of mRNA detected /50 ng total RNA
Subcutaneous Adipocytes Zenbio	40, 40	0	0	0.00	3.06	16.34	0.00
Subcutaneous Adipose Zenbio	39.46, 35.22	0.08	1.37	0.73	0.96	52.36	37.96
Adrenal Gland Clontech	36.91, 36.21	0.43	0.7	0.57	0.61	81.97	46.31
Whole Brain Clontech	26.46, 30.31	547.02	39.49	293.26	7.24	6.91	2025.24
Fetal Brain Clontech	36.04, 36.66	0.78	0.51	0.65	0.48	103.95	67.05
Cerebellum Clontech	35.46, 34.63	1.16	2.06	1.61	2.17	23.04	37.10
Cervix	35.63, 36.28	1.04	0.67	0.86	2.42	20.66	17.67
Colon	35.38, 34.57	1.23	2.13	1.68	2.71	18.45	31.00
Endometrium	40, 35.24	0.06	1.35	0.71	0.73	68.21	48.09
Esophagus	35.02, 36.31	1.57	0.65	1.11	1.37	36.50	40.51
Heart Clontech	37.16, 35.48	0.36	1.15	0.76	1.32	37.88	28.60
Hypothalamus	35.15, 36.01	1.44	0.8	1.12	0.32	155.28	173.91
Ileum	35.04, 35.5	1.55	1.13	1.34	2.58	19.38	25.97
Jejunum	35.14, 34.88	1.45	1.73	1.59	6.60	7.58	12.05
Kidney	35.81, 37.16	0.91	0.36	0.64	2.12	23.58	14.98
Liver	36.19, 34.39	0.71	2.42	1.57	1.50	33.33	52.17
Fetal Liver Clontech	32.94, 33.1	6.51	5.85	6.18	10.40	4.81	29.71
Lung	34.54, 35.16	2.18	1.43	1.81	2.57	19.46	35.12
Mammary Gland Clontech	34.45, 34.76	2.33	1.88	2.11	13.00	3.85	8.10
Myometrium	34.08, 34.61	2.98	2.09	2.54	2.34	21.37	54.17
Omentum	35.22, 36.18	1.37	0.71	1.04	3.94	12.69	13.20
Ovary	34.52, 34.83	2.21	1.78	2.00	4.34	11.52	22.98
Pancreas	34.45, 33.99	2.32	3.18	2.75	0.81	61.80	169.96
Head of Pancreas	33.24, 33.63	5.32	4.06	4.69	1.57	31.85	149.36
Parotid Gland	33.22, 33.08	5.38	5.9	5.64	5.48	9.12	51.46
Placenta Clontech	36.02, 35.39	0.79	1.22	1.01	5.26	9.51	9.55

Prostate	35.98, 35.07	0.81	1.51	1.16	3.00	16.67	19.33
Rectum	36.71, 37.13	0.49	0.37	0.43	1.23	40.65	17.48
Salivary Gland Clontech	33.51, 34.22	4.41	2.71	3.56	7.31	6.84	24.35
Skeletal Muscle Clontech	35.53, 34.52	1.11	2.21	1.66	1.26	39.68	65.87
Skin	36.02, 36.07	0.79	0.77	0.78	1.21	41.32	32.23
Small Intestine Clontech	35.02, 37.21	1.57	0.35	0.96	0.98	51.07	49.03
Spleen	35.64, 35.27	1.03	1.33	1.18	4.92	10.16	11.99
Stomach	35.08, 35.41	1.51	1.2	1.36	2.73	18.32	24.82
Testis Clontech	35.48, 38.1	1.15	0.19	0.67	0.57	87.87	58.88
Thymus Clontech	32.15, 31.72	11.16	14.98	13.07	9.89	5.06	66.08
Thyroid	35.61, 35.09	1.05	1.49	1.27	2.77	18.05	22.92
Trachea Clontech	35.04, 34.75	1.55	1.89	1.72	9.71	5.15	8.86
Urinary Bladder	36.11, 36.24	0.74	0.68	0.71	5.47	9.14	6.49
Uterus	35.59, 35.68	1.06	1	1.03	5.34	9.36	9.64
genomic	24.29	2416.83					
b-actin	26.09	706.6					
1.00E+05	20.09	100000					
1.00E+05	19.53	100000					
1.00E+04	21.72	10000					
1.00E+04	21.68	10000					
1.00E+03	24.13	1000					
1.00E+03	24.18	1000					
1.00E+02	29.13	100					
1.00E+02	30.16	100					
1.00E+01	31.7	10					
1.00E+01	33.16	10					
1.00E-00	36.93	1					
1.00E-00	34.75	1					
NTC	36	-1					
NTC	35.85	-1					

Sample sbg1004570ERGIC	Reg number (GSK identifier )	Ct	Mean GOI copies	copies of mRNA detecte d/50 ng total RNA	Sample	Fold Change in Disease Populati on
colon normal GW98-167	21941	30.51	38.25	76.50	colon normal	
colon tumor GW98-166	21940	31.28	23.13	46.26	colon tumor	-1.65
colon normal GW98-178	22080	31.79	16.57	33.14	colon normal	
colon tumor GW98-177	22060	31.3	22.86	45.72	colon tumor	1.38
colon normal GW98-561	23514	30.71	33.5	67.00	colon normal	
colon tumor GW98-560	23513	31.18	24.73	49.46	colon tumor	-1.35
colon normal GW98-894	24691	30.16	48.2	96.40	colon normal	
colon tumor GW98-893	24690	29.96	55	110.00	colon tumor	1.14
lung normal GW98-3	20742	30.1	50.19	100.38	lung normal	
lung tumor GW98-2	20741	32.86	8.15	16.30	lung tumor	-6.16

lung normal GW97-179	20677	31.65	18.14	36.28	lung normal	
lung tumor GW97-178	20676	31.05	26.89	53.78	lung tumor	1.48
lung normal GW98-165	21922	30.44	40.16	80.32	lung normal	
lung tumor GW98-164	21921	30.72	33.36	66.72	lung tumor	-1.20
lung normal GW98-282	22584	31.83	16.13	32.26	lung normal	
lung tumor GW98-281	22583	32.09	13.61	27.22	lung tumor	-1.19
breast normal GW00-392	28750	32.76	8.73	8.73	breast normal	
breast tumor GW00-391	28746	30.68	34.38	68.76	breast tumor	7.88
breast normal GW00-413	28798	37.11	0.5	0.50	breast normal	
breast tumor GW00-412	28797	30.8	31.72	63.44	breast tumor	126.88
breast normal GW00-235:238	27592-95	38.8	0.17	0.17	breast normal	
breast tumor GW00-231:234	27588-91	37.36	0.43	0.43	breast tumor	2.53
breast normal GW98-621	23656	31.67	17.86	35.72	breast normal	
breast tumor GW98-620	23655	32.59	9.8	19.60	breast tumor	-1.82
brain normal BB99-542	25507	33.66	4.83	9.66	brain normal	
brain normal BB99-406	25509	33.24	6.37	12.74	brain normal	
brain normal BB99-904	25546	33.2	6.54	13.08	brain normal	
brain stage 5 ALZ BB99-874	25502	33.1	6.97	13.94	brain stage 5 ALZ	1.18
brain stage 5 ALZ BB99-887	25503	30.93	29.17	58.34	brain stage 5 ALZ	4.93
brain stage 5 ALZ BB99-862	25504	31.44	20.73	41.46	brain stage 5 ALZ	3.51
brain stage 5 ALZ BB99-927	25542	32.93	7.83	15.66	brain stage 5 ALZ	1.32
CT lung	normal	32.62	9.6	19.20	CT lung Nml	
lung 26	normal				lung 26 Nml	
lung 27	normal	40	0	0.00	lung 27 Nml	
lung 24	COPD	39.15	0.13	0.13	lung 24 COPD	-49.46
lung 28	COPD	40	0.08	0.08	lung 28 COPD	-80.38
lung 23	COPD	38.59	0.19	0.19	lung 23 COPD	-33.84
lung 25	normal	40	0.09	0.09	lung 25 Nml	
asthmatic lung ODO3112	29321	40	0	0.00	asthmatic lung	-6.43
asthmatic lung ODO3433	29323	38.47	0.2	0.40	asthmatic lung	-16.08
asthmatic lung ODO3397	29322	38.01	0.28	0.56	asthmatic lung	-11.48
asthmatic lung ODO4928	29325	38.13	0.26	0.52	asthmatic lung	-12.37
endo cells	control	36.24	0.89	0.89	endo cells	
endo VEGF		39.8	0.09	0.09	endo VEGF	-9.89
endo bFGF		37.19	0.47	0.47	endo bFGF	-1.89
heart Clontech	normal	35.52	1.43	2.86	heart	
heart ( T-1 ) ischemic	29417	33.79	4.43	8.86	heart ( T-1 ) ischemic	3.10
heart ( T-14 ) non-obstructive DCM	29422	34.81	2.27	4.54	heart ( T-14 ) non-obstructive DCM	1.59
heart ( T-3399 ) DCM	29426	34.11	3.59	7.18	heart ( T-3399 ) DCM	2.51
adenoid GW99-269	26162	34.97	2.05	4.10	adenoid	
tonsil GW98-280	22582	33.05	7.23	14.46	tonsil	

T cells PC00314	28453	31.09	26.2	52.40	T cells	
PBMNC		38.01	0.28	0.28	PBMNC	
monocyte		36.29	0.86	1.72	monocyte	
B cells PC00665	28455	32.13	13.23	26.46	B cells	
dendritic cells	28441	31.94	14.96	29.92	dendritic cells	
neutrophils	28440	34.08	3.66	3.66	neutrophils	
eosinophils	28446	32.23	12.37	24.74	eosinophils	
BM unstim		39.73	0.09	0.09	BM unstim	
BM stim	treated	37.03	0.53	0.53	BM stim	5.89
osteodif	treated	36.8	0.61	0.61	osteodif	0.61
osteoundif		40	0	0.00	osteoundif	
chondrocytes		31.85	15.9	39.75	chondrocytes	
OA Synovium IP12/01	29462	38.61	0.19	0.19	OA Synovium	
OA Synovium NP10/01	29461	33.11	6.96	13.92	OA Synovium	
OA Synovium NP57/00	28464	33.81	4.39	8.78	OA Synovium	
RA Synovium NP03/01	28466	33.11	6.96	13.92	RA Synovium	
RA Synovium NP71/00	28467	32.03	14.14	28.28	RA Synovium	
RA Synovium NP45/00	28475	32.47	10.55	21.10	RA Synovium	
OA bone (biobank)	29217	35.25	1.7	1.70	OA bone (biobank)	
OA bone Sample 1	J. Emory	34.54	2.72	5.44	OA bone	
OA bone Sample 2	J. Emory	36.28	0.87	1.74	OA bone	
Cartilage (pool)	Normal	35.24	1.71	3.42	Nml Cartilage (pool)	
Cartilage (pool)	OA	34.45	2.87	5.74	OA Cartilage (pool)	1.68
PBL uninfected	28441	32.53	10.19	20.38	PBL uninfected	
PBL HIV IIIB	28442	31.77	16.79	33.58	PBL HIV IIIB	1.65
MRC5 uninfected (100%)	29158	33.12	6.87	13.74	MRC5 uninfected (100%)	
MRC5 HSV strain F	29178	33.76	4.54	9.08	MRC5 HSV strain F	-1.51
W12 cells	29179	33.1	6.96	13.92	W12 cells	
Keratinocytes	29180	32.67	9.29	18.58	Keratinocytes	
B-actin control		26.03	726.55			
genomic		24.63	1825.58			
1.00E+05		19.96	100000			
1.00E+05		19.27	100000			
1.00E+04		21.83	10000			
1.00E+04		21.45	10000			
1.00E+03		23.86	1000			
1.00E+03		23.84	1000			
1.00E+02		28.42	100			
1.00E+02		29.35	100			
1.00E+01		33.3	10			
1.00E+01		35.09	10			
1.00E-00		35.16	1			
1.00E-00		36.05	1			
NTC		38.24	-1			
*lung 26 Normal has						

been omitted due to multiple amplification failures from that sample						
--	--	--	--	--	--	--

Gene Name sbg1004570ERGIC

Disease tissues	Fold Change in Disease Population Relative to Normal
colon tumor	-1.65
colon tumor	1.38
colon tumor	-1.35
colon tumor	1.14
lung tumor	-6.16
lung tumor	1.48
lung tumor	-1.20
lung tumor	-1.19
breast tumor	7.88
breast tumor	126.88
breast tumor	2.53
breast tumor	-1.82
brain stage 5 ALZ	1.18
brain stage 5 ALZ	4.93
brain stage 5 ALZ	3.51
brain stage 5 ALZ	1.32
lung 24	-49.46
lung 28	-80.38
lung 23	-33.84
asthmatic lung	-6.43
asthmatic lung	-16.08
asthmatic lung	-11.48
asthmatic lung	-12.37
endo VEGF	-9.89
endo bFGF	-1.89
heart T-1	3.10
heart T-14	1.59
heart T-3399	2.51
BM stim	5.89
osteo dif	0.61
Cartilage (pool)	1.68
PBL HIV IIIB	1.65
MRC5 HSV strain F	-1.51

Gene Name sbg1016995IGBrecpt

5 Moderate to low overall expression. Highest normal expression is seen in the whole brain in lung with slightly lower levels of expression in the endometrium, ileum, rectum, and skin. High level of expression in the skin may suggest a possible role for this gene in psoriasis and Lupus. The patterns of expression in the samples on the disease plate indicate that this gene is highly specific to the adenoid and tonsil. Downregulation in 2 of 4 lung tumor samples and upregulation in 2 of 4 breast tumor samples suggests an involvement in cancers of the lung and breast.

10 Downregulation in 3 of 3 COPD samples suggests a potential role for this gene in chronic obstructive pulmonary disorder. Upregulated in the stimulated bone marrow sample. Downregulated in the differentiated osteoblast. Upregulated in the HIV-infected PBL cells suggests that this gene may be a host factor in HIV.

15

Sample	Ct (sample)	Mean	Mean	Average	18S	50	copies of
--------	-------------	------	------	---------	-----	----	-----------

sgb1016995IGBrect	1 and 2)	GOI copies (sample 1)	GOI copies (sample 2)	GOI Copies	rRNA (ng)	ng/18S rRNA (ng)	mRNA detected/ 50 ng total RNA
Subcutaneous Adipocytes Zenbio	40, 40	0.61	0.61	0.61	3.06	16.34	9.97
Subcutaneous Adipose Zenbio	40, 40	0.59	0.56	0.58	0.96	52.36	30.10
Adrenal Gland Clontech	39.89, 39.79	0.54	0.57	0.56	0.61	81.97	45.49
Whole Brain Clontech	30.69, 30.76	108.67	104.35	106.51	7.24	6.91	735.57
Fetal Brain Clontech	39.41, 40	0.71	0.62	0.67	0.48	103.95	69.13
Cerebellum Clontech	39.33, 37.82	0.74	1.78	1.26	2.17	23.04	29.03
Cervix	36.12, 36.58	4.73	3.62	4.18	2.42	20.66	86.26
Colon	35.23, 38.35	7.9	1.31	4.61	2.71	18.45	84.96
Endometrium	35.51, 40	6.73	0	3.37	0.73	68.21	229.54
Esophagus	37.22, 38.18	2.5	1.45	1.98	1.37	36.50	72.08
Heart Clontech	40, 40	0	0	0.00	1.32	37.88	0.00
Hypothalamus	40, 40	0	0	0.00	0.32	155.28	0.00
Ileum	34.65, 34.11	11.04	15.09	13.07	2.58	19.38	253.20
Jejunum	34.84, 34.04	9.91	15.72	12.82	6.60	7.58	97.08
Kidney	38.2, 39.11	1.43	0.84	1.14	2.12	23.58	26.77
Liver	34.47, 38.59	12.26	1.14	6.70	1.50	33.33	223.33
Fetal Liver Clontech	33.51, 33.07	21.26	27.43	24.35	10.40	4.81	117.04
Lung	27.32, 37.11	755.31	2.68	379.00	2.57	19.46	7373.44
Mammary Gland Clontech	36.31, 36.4	4.24	4.03	4.14	13.00	3.85	15.90
Myometrium	40, 38.7	0.7	1.07	0.89	2.34	21.37	18.91
Omentum	35.44, 36.14	6.98	4.68	5.83	3.94	12.69	73.98
Ovary	38.76, 35.49	1.03	6.82	3.93	4.34	11.52	45.22
Pancreas	40, 38.56	0.48	1.16	0.82	0.81	61.80	50.68
Head of Pancreas	40, 40	0	0	0.00	1.57	31.85	0.00
Parotid Gland	36.8, 35.45	3.2	6.98	5.09	5.48	9.12	46.44
Placenta Clontech	35.63, 35.11	6.27	8.47	7.37	5.26	9.51	70.06
Prostate	37.4, 37.5	2.26	2.14	2.20	3.00	16.67	36.67
Rectum	35.45, 35.25	6.94	7.81	7.38	1.23	40.65	299.80
Salivary Gland Clontech	37.3, 37.06	2.4	2.75	2.58	7.31	6.84	17.61
Skeletal Muscle Clontech	40, 39.34	0	0.74	0.37	1.26	39.68	14.68
Skin	38.84, 34.56	0.98	11.63	6.31	1.21	41.32	260.54
Small Intestine Clontech	40, 40	0	0.63	0.32	0.98	51.07	16.09
Spleen	34.37, 34.89	13	9.6	11.30	4.92	10.16	114.84
Stomach	39.73, 35.52	0.59	6.67	3.63	2.73	18.32	66.48
Testis Clontech	38.91, 40	0.94	0	0.47	0.57	87.87	41.30
Thymus Clontech	31.96, 32.96	52.16	29.2	40.68	9.89	5.06	205.66
Thyroid	35.53, 40	6.66	0	3.33	2.77	18.05	60.11
Trachea Clontech	37.99, 37.69	1.61	1.91	1.76	9.71	5.15	9.06

Urinary Bladder	39.69, 39.02	0.6	0.89	0.75	5.47	9.14	6.81
Uterus	34.41, 33.56	12.67	20.75	16.71	5.34	9.36	156.46
genomic	26.31	1359.1					
b-actin	27.2	812.88					
1.00E+05	19.24	100000					
1.00E+05	19.38	100000					
1.00E+04	22.67	10000					
1.00E+04	22.67	10000					
1.00E+03	26.31	1000					
1.00E+03	26.28	1000					
1.00E+02	30.17	100					
1.00E+02	31.02	100					
1.00E+01	36.17	10					
1.00E+01	34.46	10					
1.00E-00	40	0					
1.00E-00	40	1					
NTC	40	-1					
NTC	40	-1					

Sample sbg1016995IGBrectp	Reg number (GSK identifier )	Ct	Mean GOI copies	copies of mRNA detected /50 ng total RNA	Sample	Fold Change in Disease Populati on
colon normal GW98-167	21941	29.45	174.86	349.72	colon normal	
colon tumor GW98-166	21940	32.1	33.44	66.88	colon tumor	-5.23
colon normal GW98-178	22080	31.77	41.07	82.14	colon normal	
colon tumor GW98-177	22060	32.66	23.5	47.00	colon tumor	-1.75
colon normal GW98-561	23514	29.15	211.24	422.48	colon normal	
colon tumor GW98-560	23513	31.25	56.95	113.90	colon tumor	-3.71
colon normal GW98-894	24691	30.68	81.3	162.60	colon normal	
colon tumor GW98-893	24690	31.33	54.12	108.24	colon tumor	-1.50
lung normal GW98-3	20742	31.86	38.92	77.84	lung normal	
lung tumor GW98-2	20741	34.55	7.25	14.50	lung tumor	-5.37
lung normal GW97-179	20677	28.38	342.07	684.14	lung normal	
lung tumor GW97-178	20676	32.1	33.52	67.04	lung tumor	-10.20
lung normal GW98-165	21922	32.2	31.46	62.92	lung normal	
lung tumor GW98-164	21921	30.5	90.8	181.60	lung tumor	2.89
lung normal GW98-282	22584	29.82	138.8	277.60	lung normal	
lung tumor GW98-281	22583	32.72	22.64	45.28	lung tumor	-6.13
breast normal GW00-392	28750	31.5	48.65	48.65	breast normal	
breast tumor GW00-391	28746	31.9	37.84	75.68	breast tumor	1.56
breast normal GW00-413	28798	34.37	8.07	8.07	breast normal	
breast tumor GW00-412	28797	29.97	126.73	253.46	breast tumor	31.41
breast normal GW00-	27592-95	35.08	5.2	5.20	breast normal	

235:238						
breast tumor GW00-231:234	27588-91	32.3	29.54	29.54	breast tumor	5.68
breast normal GW98-621	23656	31.11	61.96	123.92	breast normal	
breast tumor GW98-620	23655	31.27	56.22	112.44	breast tumor	-1.10
brain normal BB99-542	25507	33.3	15.82	31.64	brain normal	
brain normal BB99-406	25509	33.02	18.83	37.66	brain normal	
brain normal BB99-904	25546	33.93	10.62	21.24	brain normal	
brain stage 5 ALZ BB99-874	25502	32.36	28.38	56.76	brain stage 5 ALZ	1.88
brain stage 5 ALZ BB99-887	25503	31.79	40.66	81.32	brain stage 5 ALZ	2.69
brain stage 5 ALZ BB99-862	25504	32.04	34.76	69.52	brain stage 5 ALZ	2.30
brain stage 5 ALZ BB99-927	25542	31.79	40.51	81.02	brain stage 5 ALZ	2.68
CT lung	normal	33.32	15.63	31.26	CT lung Nml	
lung 26	normal	29.8	140.4		lung 26 Nml	
lung 27	normal	38.71	0.54	0.54	lung 27 Nml	
lung 24	COPD	39.31	0.37	0.37	lung 24 COPD	-29.00
lung 28	COPD	37.09	1.48	1.48	lung 28 COPD	-7.25
lung 23	COPD	38.02	0.83	0.83	lung 23 COPD	-12.93
lung 25	normal	39.22	0.39	0.39	lung 25 Nml	
asthmatic lung ODO3112	29321	37.96	0.86	0.86	asthmatic lung	-12.48
asthmatic lung ODO3433	29323	31.15	60.54	121.08	asthmatic lung	11.28
asthmatic lung ODO3397	29322	33.74	12.01	24.02	asthmatic lung	2.24
asthmatic lung ODO4928	29325	31.59	46.09	92.18	asthmatic lung	8.59
endo cells	control	36.98	1.58	1.58	endo cells	
endo VEGF		39.28	0.38	0.38	endo VEGF	-4.16
endo bFGF		37.3	1.3	1.30	endo bFGF	-1.22
heart Clontech	normal	35.73	3.45	6.90	heart	
heart ( T-1 ) ischemic	29417	34.7	6.58	13.16	heart ( T-1 ) ischemic	1.91
heart (T-14) non-obstructive DCM	29422	37.5	1.15	2.30	heart (T-14) non-obstructive DCM	-3.00
heart (T-3399) DCM	29426	35.15	4.96	9.92	heart (T-3399) DCM	1.44
adenoid GW99-269	26162	25.98	1528.07	3056.14	adenoid	
tonsil GW98-280	22582	24.6	3626.43	7252.86	tonsil	
T cells PC00314	28453	34.49	7.5	15.00	T cells	
PBMNC		37.58	1.09	1.09	PBMNC	
monocyte		37.4	1.22	2.44	monocyte	
B cells PC00665	28455	31.68	43.59	87.18	B cells	
dendritic cells	28441	35.05	5.28	10.56	dendritic cells	
neutrophils	28440	35.68	3.57	3.57	neutrophils	
eosinophils	28446	35.07	5.23	10.46	eosinophils	
BM unstim		38.19	0.75	0.75	BM unstim	
BM stim	treated	34.27	8.61	8.61	BM stim	11.48
osteodif	treated	40	0.09	0.09	osteodif	-5.78
osteoundif		40	0.52	0.52	osteoundif	

chondrocytes		32.86	20.79	51.98	chondrocytes	
OA Synovium IP12/01	29462	31.85	38.99	38.99	OA Synovium	
OA Synovium NP10/01	29461	34.76	6.33	12.66	OA Synovium	
OA Synovium NP57/00	28464	31.39	51.96	103.92	OA Synovium	
RA Synovium NP03/01	28466	31.1	62.3	124.60	RA Synovium	
RA Synovium NP71/00	28467	31.95	36.76	73.52	RA Synovium	
RA Synovium NP45/00	28475	32.43	27.14	54.28	RA Synovium	
OA bone (biobank)	29217	35.84	3.22	3.22	OA bone (biobank)	
OA bone Sample 1	J. Emory	35.43	4.18	8.36	OA bone	
OA bone Sample 2	J. Emory	34.86	5.95	11.90	OA bone	
Cartilage (pool)	Normal	34.79	6.21	12.42	Nml Cartilage (pool)	
Cartilage (pool)	OA	36.55	2.07	4.14	OA Cartilage (pool)	-3.00
PBL uninfected	28441	30.02	122.76	245.52	PBL uninfected	
PBL HIV IIIB	28442	28.17	388.59	777.18	PBL HIV IIIB	3.17
MRC5 uninfected (100%)	29158	34.6	7.01	14.02	MRC5 uninfected (100%)	
MRC5 HSV strain F	29178	33.27	16.13	32.26	MRC5 HSV strain F	2.30
W12 cells	29179	34.43	7.8	15.60	W12 cells	
Keratinocytes	29180	35.04	5.31	10.62	Keratinocytes	
B-actin control		27	808.77			
genomic		26.18	1353.11			
1.00E+05		19.37	100000			
1.00E+05		19.59	100000			
1.00E+04		22.75	10000			
1.00E+04		22.8	10000			
1.00E+03		26.43	1000			
1.00E+03		26.17	1000			
1.00E+02		30.09	100			
1.00E+02		30.21	100			
1.00E+01		35.27	10			
1.00E+01		35.55	10			
1.00E-00		39.31	1			
1.00E-00		34.53	1			
NTC		40	-1			
*lung 26 Normal has been omitted due to multiple amplification failures from that sample						

Gene Name sbg1016995IGBrecpt

Disease tissues	Fold Change in Disease Population Relative to Normal
colon tumor	-5.23
colon tumor	-1.75
colon tumor	-3.71
colon tumor	-1.50

lung tumor	-5.37
lung tumor	-10.20
lung tumor	2.89
lung tumor	-6.13
breast tumor	1.56
breast tumor	31.41
breast tumor	5.68
breast tumor	-1.10
brain stage 5 ALZ	1.88
brain stage 5 ALZ	2.69
brain stage 5 ALZ	2.30
brain stage 5 ALZ	2.68
lung 24	-29.00
lung 28	-7.25
lung 23	-12.93
asthmatic lung	-12.48
asthmatic lung	11.28
asthmatic lung	2.24
asthmatic lung	8.59
endo VEGF	-4.16
endo bFGF	-1.22
heart T-1	1.91
heart T-14	-3.00
heart T-3399	1.44
BM stim	11.48
osteo dif	-5.78
Cartilage (pool)	-3.00
PBL HIV IIIB	3.17
MRC5 HSV strain F	2.30

## Gene Name sbg1151bSREC

5 Highest overall expression in normal and disease samples. Fairly ubiquitously expressed but highest normal expression in adipocytes, adipose, whole brain, fetal brain, and endometrium. Highest disease expression in one of the colon tumor samples, one of the normal lung samples, chondrocytes, and the uninfected MRC5. There are no significant changes in brains from patients with Alzheimer's disease. Downregulation in 1 of 4 lung tumors suggests possible implication in lung cancer. Upregulation in 1 of 4 breast tumor samples is sufficient to claim a role in cancer of the breast. Upregulation in 1 of 4 asthma lungs implies a role in asthma. Downregulation in HSV 10 implicates involvement in herpes simplex virus as a potential host factor. High expression in immune cells. High expression in cartilage and bone samples from patients with OA as well as high expression in chondrocytes possible involvement in osteoarthritis and rheumatoid arthritis. Additionally, the corroborating expression in immune cells (particularly B and T cells) provides 15 additional evidence for a role in RA/OA.

Sample sbg1151bSREC	Ct (sample 1 and 2)	Mean GOI copies (sample 1)	Mean GOI copies (sample 2)	Average GOI Copies	18S rRNA (ng)	50 ng/18S rRNA (ng)	copies of mRNA detected /50 ng total RNA
Subcutaneous Adipocytes Zenbio	28.31, 28.35	477.04	466.02	471.53	3.06	16.34	7704.74
Subcutaneous Adipose Zenbio	30.79, 30.22	122.3	166.95	144.63	0.96	52.36	7571.99
Adrenal Gland Clontech	33.96, 33.47	21.39	27.97	24.68	0.61	81.97	2022.95
Whole Brain Clontech	24.07, 23.98	4889.28	5123.8	5006.54	7.24	6.91	34575.55

Fetal Brain Clontech	31.1, 32.29	103.16	53.55	78.36	0.48	103.95	8145.01
Cerebellum Clontech	31.03, 31.99	107.02	63.18	85.10	2.17	23.04	1960.83
Cervix	31.22, 30.06	96.6	182.64	139.62	2.42	20.66	2884.71
Colon	30.68, 30.53	129.52	140.99	135.26	2.71	18.45	2495.48
Endometrium	30.59, 30.44	136.06	147.8	141.93	0.73	68.21	9681.45
Esophagus	33.11, 32.17	34.08	57.32	45.70	1.37	36.50	1667.88
Heart Clontech	33.19, 32.41	32.68	50.11	41.40	1.32	37.88	1567.99
Hypothalamus	34.34, 40	17.4	0	8.70	0.32	155.28	1350.93
Ileum	31.29, 30.13	92.84	174.99	133.92	2.58	19.38	2595.25
Jejunum	29.7, 29.48	221.9	251.05	236.48	6.60	7.58	1791.48
Kidney	31.03, 30.17	107.15	171.45	139.30	2.12	23.58	3285.38
Liver	32.89, 33.16	38.61	33.17	35.89	1.50	33.33	1196.33
Fetal Liver Clontech	28.05, 28.15	550.64	518.95	534.80	10.40	4.81	2571.13
Lung	29.39, 28.63	263.85	398.99	331.42	2.57	19.46	6447.86
Mammary Gland Clontech	27.56, 27.39	717.67	789.94	753.81	13.00	3.85	2899.25
Myometrium	29.08, 28.93	312.86	339.46	326.16	2.34	21.37	6969.23
Omentum	30.72, 29.32	126.7	273.04	199.87	3.94	12.69	2536.42
Ovary	28.89, 28.68	346.91	388.02	367.47	4.34	11.52	4233.47
Pancreas	35.24, 35.75	10.59	8.02	9.31	0.81	61.80	575.09
Head of Pancreas	35.25, 33.21	10.57	32.34	21.46	1.57	31.85	683.28
Parotid Gland	28.46, 27.84	438.62	615.36	526.99	5.48	9.12	4808.30
Placenta Clontech	28.67, 28.66	391.9	393.15	392.53	5.26	9.51	3731.23
Prostate	30.55, 31.46	139.05	84.64	111.85	3.00	16.67	1864.08
Rectum	31.28, 31.43	93.33	85.92	89.63	1.23	40.65	3643.29
Salivary Gland Clontech	31.13, 30.57	101.46	138.16	119.81	7.31	6.84	819.49
Skeletal Muscle Clontech	34.05, 35.24	20.38	10.59	15.49	1.26	39.68	614.48
Skin	31.53, 31.2	81.49	97.36	89.43	1.21	41.32	3695.25
Small Intestine Clontech	34.81, 33.82	13.41	23.18	18.30	0.98	51.07	934.37
Spleen	31.01, 30.44	108.41	147.9	128.16	4.92	10.16	1302.39
Stomach	32.01, 31.1	62.6	102.97	82.79	2.73	18.32	1516.21
Testis Clontech	31.74, 32.29	72.49	53.45	62.97	0.57	87.87	5533.39
Thymus Clontech	28.84, 28.53	356.64	421.44	389.04	9.89	5.06	1966.84
Thyroid	30.12, 30.04	176.76	184.5	180.63	2.77	18.05	3260.47
Trachea Clontech	28.48, 28.38	434.3	459.42	446.86	9.71	5.15	2301.03
Urinary Bladder	29.63, 29.55	230.25	241.15	235.70	5.47	9.14	2154.48
Uterus	28.69, 28.37	387.47	461.07	424.27	5.34	9.36	3972.57
genomic	26.24	1487.44					
b-actin	27.28	839.2					
1.00E+05	18.96	100000					
1.00E+05	19.34	100000					
1.00E+04	22.64	10000					
1.00E+04	22.84	10000					
1.00E+03	26.22	1000					
1.00E+03	26.04	1000					
1.00E+02	31.04	100					

1.00E+02	30.1	100					
1.00E+01	33.33	10					
1.00E+01	39.08	10					
1.00E-00	40	0					
1.00E-00	40	1					
NTC	40	0					
NTC	40	0					

Sample sbg1151bSREC	Reg number (GSK identifie r)	Ct	Mean GOI copies	copies of mRNA detected /50 ng total RNA	Sample	Fold Change in Disease Populatio n
colon normal GW98-167	21941	24.55	5357.25	10714.50	colon normal	
colon tumor GW98-166	21940	22.61	19769.94	39539.88	colon tumor	3.69
colon normal GW98-178	22080	26.71	1252.3	2504.60	colon normal	
colon tumor GW98-177	22060	26.13	1854.49	3708.98	colon tumor	1.48
colon normal GW98-561	23514	26.82	1165.06	2330.12	colon normal	
colon tumor GW98-560	23513	25.75	2390.26	4780.52	colon tumor	2.05
colon normal GW98-894	24691	26.06	1948.57	3897.14	colon normal	
colon tumor GW98-893	24690	26.59	1362.55	2725.10	colon tumor	-1.43
lung normal GW98-3	20742	22.77	17753	35506.00	lung normal	
lung tumor GW98-2	20741	26.17	1803.8	3607.60	lung tumor	-9.84
lung normal GW97-179	20677	25.24	3370.88	6741.76	lung normal	
lung tumor GW97-178	20676	24.14	7057.92	14115.84	lung tumor	2.09
lung normal GW98-165	21922	23.87	8442.49	16884.98	lung normal	
lung tumor GW98-164	21921	24.08	7339.83	14679.66	lung tumor	-1.15
lung normal GW98-282	22584	25.51	2804.42	5608.84	lung normal	
lung tumor GW98-281	22583	24.2	6787.31	13574.62	lung tumor	2.42
breast normal GW00-392	28750	25.7	2480.5	2480.50	breast normal	
breast tumor GW00-391	28746	25.77	2364.2	4728.40	breast tumor	1.91
breast normal GW00-413	28798	26.06	1948.1	1948.10	breast normal	
breast tumor GW00-412	28797	27.21	894.11	1788.22	breast tumor	-1.09
breast normal GW00- 235:238	27592-95	26.64	1317.83	1317.83	breast normal	
breast tumor GW00- 231:234	27588-91	23.91	8225.11	8225.11	breast tumor	6.24
breast normal GW98-621	23656	24.46	5693.73	11387.46	breast normal	
breast tumor GW98-620	23655	23.91	8218.73	16437.46	breast tumor	1.44
brain normal BB99-542	25507	26.39	1553.13	3106.26	brain normal	
brain normal BB99-406	25509	26.63	1325.63	2651.26	brain normal	
brain normal BB99-904	25546	27.05	1001.6	2003.20	brain normal	
brain stage 5 ALZ BB99- 874	25502	26.97	1052.15	2104.30	brain stage 5 ALZ	-1.23
brain stage 5 ALZ BB99- 887	25503	25.28	3289.99	6579.98	brain stage 5 ALZ	2.54
brain stage 5 ALZ BB99- 862	25504	26.24	1725.06	3450.12	brain stage 5 ALZ	1.33
brain stage 5 ALZ BB99- 874	25542	26.12	1864.26	3728.52	brain stage 5 ALZ	1.44

927						
CT lung KC	normal	24.74	4711.99	9423.98	CT lung	
lung 26 KC	normal	27.78	611.36	611.36	lung 26	
lung 27 KC	normal	28.27	439.19	439.19	lung 27	
lung 24 KC	COPD	26.92	1091.11	1091.11	lung 24	-2.56
lung 28 KC	COPD	26.93	1085.65	1085.65	lung 28	-2.57
lung 23 KC	COPD	27.19	909.68	909.68	lung 23	-3.07
lung 25 KC	normal	27.62	678.79	678.79	lung 25	
asthmatic lung ODO3112	29321	25.33	3173.52	3173.52	asthmatic lung	1.14
asthmatic lung ODO3433	29323	25.36	3106.89	6213.78	asthmatic lung	2.23
asthmatic lung ODO3397	29322	23.81	8809.42	17618.84	asthmatic lung	6.32
asthmatic lung ODO4928	29325	24.76	4649.98	9299.96	asthmatic lung	3.34
endo cells KC	control	26	2021.13	2021.13	endo cells	
endo VEGF KC		25.78	2343.21	2343.21	endo VEGF	1.16
endo bFGF KC		26.7	1264.03	1264.03	endo bFGF	-1.60
heart Clontech	normal	26.62	1330.64	2661.28	heart	
heart ( T-1 ) ischemic	29417	27.07	984.33	1968.66	heart T-1	-1.35
heart (T-14) non-obstructive DCM	29422	26.11	1877.75	3755.50	heart T-14	1.41
heart (T-3399) DCM	29426	26.34	1608.79	3217.58	heart T-3399	1.21
adenoid GW99-269	26162	27.64	670.25	1340.50	adenoid	
tonsil GW98-280	22582	27.61	684.15	1368.30	tonsil	
T cells PC00314	28453	25.95	2098.64	4197.28	T cells	
PBMNC		31.16	63.19	63.19	PBMNC	
monocyte		31.32	56.63	113.26	monocyte	
B cells PC00665	28455	26.34	1609.52	3219.04	B cells	
dendritic cells 28441		28.25	444.68	889.36	dendritic cells	
neutrophils	28440	26.11	1874.13	1874.13	neutrophils	
eosinophils	28446	26.39	1553.82	3107.64	eosinophils	
BM unstim		31.45	51.76	51.76	BM unstim	
BM stim		31.28	58.37	58.37	BM stim	1.13
osteо dif		24.62	5118.74	5118.74	osteо dif	1.70
osteо undif		25.41	3015.6	3015.60	osteо undif	
chondrocytes		22.12	27351.89	68379.73	chondrocytes	
OA Synovium IP12/01	29462	24.5	5551.61	5551.61	OA Synovium	
OA Synovium NP10/01	29461	25.1	3711.29	7422.58	OA Synovium	
OA Synovium NP57/00	28464	24.5	5537.1	11074.20	OA Synovium	
RA Synovium NP03/01	28466	26.45	1492.95	2985.90	RA Synovium	
RA Synovium NP71/00	28467	24.44	5783.96	11567.92	RA Synovium	
RA Synovium NP45/00	28475	25.94	2112.54	4225.08	RA Synovium	
OA bone (biobank)	29217	26.16	1811.72	1811.72	OA bone (biobank)	
OA bone Sample 1	J. Emory	24.54	5399.31	10798.62	OA bone	
OA bone Sample 2	J. Emory	26.07	1931.94	3863.88	OA bone	
Cartilage (pool)	Normal	25.09	3730.42	7460.84	Cartilage (pool)	
Cartilage (pool)	OA	25.79	2328.66	4657.32	Cartilage (pool)	-1.60
PBL uninfected	28441	26.95	1068.16	2136.32	PBL uninfected	
PBL HIV IIIB	28442	28.41	401.86	803.72	PBL HIV IIIB	-2.66

MRC5 uninfected (100%)	29158	22.28	24694.87	49389.74	MRC5 uninfected (100%)	
MRC5 HSV strain F	29178	29.07	256.64	513.28	MRC5 HSV strain F	-96.22
W12 cells	29179	28.37	410.68	821.36	W12 cells	
Keratinocytes	29180	29.12	249.25	498.50	Keratinocytes	
B-actin control		27.53	721.15			
genomic		26.92	1091.74			
1.00E+05		19.96	100000			
1.00E+05		20.19	100000			
1.00E+04		23.43	10000			
1.00E+04		23.34	10000			
1.00E+03		26.64	1000			
1.00E+03		26.8	1000			
1.00E+02		31.34	100			
1.00E+02		31.48	100			
1.00E+01		34.9	10			
1.00E+01		34.19	10			
1.00E-00		40	0			
1.00E-00		35.53	1			
NTC		40	0			

Gene Name sbg1151bSREC

Disease tissues	Fold Change in Disease Population Relative to Normal
colon tumor	3.69
colon tumor	1.48
colon tumor	2.05
colon tumor	-1.43
lung tumor	-9.84
lung tumor	2.09
lung tumor	-1.15
lung tumor	2.42
breast tumor	1.91
breast tumor	-1.09
breast tumor	6.24
breast tumor	1.44
brain stage 5 ALZ	-1.23
brain stage 5 ALZ	2.54
brain stage 5 ALZ	1.33
brain stage 5 ALZ	1.44
lung 24	-2.56
lung 28	-2.57
lung 23	-3.07
asthmatic lung	1.14
asthmatic lung	2.23
asthmatic lung	6.32
asthmatic lung	3.34
endo VEGF	1.16
endo bFGF	-1.60
heart T-1	-1.35

heart T-14	1.41
heart T-3399	1.21
BM stim	1.13
osteо dif	1.70
Cartilage (pool)	-1.60
PBL HIV IIIB	-2.66
MRC5 HSV strain F	-96.22

**Gene Name sbg1399854ANK**

5 Low overall expression. Highest normal expression is seen in the whole brain, fetal brain, and liver. Good levels of expression are seen in all of the samples representing the female reproductive system. Highest disease expression is seen in the normal and Alzheimer's brain samples as well as in the dendritic cells. Upregulation in 2 of 4 colon tumor samples and in 2 of 4 breast tumor samples as well as downregulation in 2 of 4 lung tumor samples implicates this gene in cancers of the colon, breast, and lung. Downregulation in 3 of 3 COPD samples and in 2 of 4 asthmatic lung samples suggests a potential role for this gene in chronic obstructive pulmonary disorder and asthma. Downregulation in the OA cartilage sample as well as corroborating low expression in the normal chondrocytes and many of the immune cells suggests involvement in osteoarthritis.

10 Upregulation in the HSV-infected MRC5 cells suggests that this gene may be a host factor in HSV.

Sample sbg1399854ANK	Ct (sample 1 and 2)	Mean GOI copies (sample 1)	Mean GOI copies (sample 2)	Average GOI Copies	18S rRNA (ng)	50 ng/18S rRNA (ng)	copies of mRNA detec- ted/50 ng total RNA
Subcutaneous Adipocytes Zenbio	40, 40	0	0	0.00	3.06	16.34	0.00
Subcutaneous Adipose Zenbio	40, 40	1.83	1.77	1.80	0.96	52.36	94.24
Adrenal Gland Clontech	40, 40	1.75	0	0.88	0.61	81.97	71.72
Whole Brain Clontech	28.57, 28.35	944.29	1058.09	1001.19	7.24	6.91	6914.30
Fetal Brain Clontech	36.57, 34.65	14.38	39.28	26.83	0.48	103.95	2788.98
Cerebellum Clontech	37.21, 36.71	10.3	13.37	11.84	2.17	23.04	272.70
Cervix	36.3, 40	16.52	0	8.26	2.42	20.66	170.66
Colon	36.17, 35.71	17.73	22.5	20.12	2.71	18.45	371.13
Endometrium	40, 36.1	0	18.41	9.21	0.73	68.21	627.90
Esophagus	40, 40	0	1.58	0.79	1.37	36.50	28.83
Heart Clontech	40, 40	0	0	0.00	1.32	37.88	0.00
Hypothalamus	40, 40	0	0	0.00	0.32	155.28	0.00
Ileum	40, 40	0	0	0.00	2.58	19.38	0.00
Jejunum	34.07, 34.37	53.18	45.33	49.26	6.60	7.58	373.14
Kidney	37.55, 40	8.58	0	4.29	2.12	23.58	101.18
Liver	36.53, 35.62	14.69	23.59	19.14	1.50	33.33	638.00
Fetal Liver Clontech	34.56, 34.61	41.04	40.04	40.54	10.40	4.81	194.90
Lung	40, 40	0	0	0.00	2.57	19.46	0.00
Mammary Gland Clontech	39.07, 39.45	3.89	3.18	3.54	13.00	3.85	13.60
Myometrium	39.5, 35.37	3.1	26.93	15.02	2.34	21.37	320.83
Omentum	40, 36.18	0	17.61	8.81	3.94	12.69	111.74
Ovary	35.87, 34.34	20.75	46.22	33.49	4.34	11.52	385.77

Pancreas	40, 40	0	0	0.00	0.81	61.80	0.00
Head of Pancreas	40, 39.79	0	2.66	1.33	1.57	31.85	42.36
Parotid Gland	35.2, 38.6	29.46	4.97	17.22	5.48	9.12	157.07
Placenta Clontech	40, 38.14	0	6.32	3.16	5.26	9.51	30.04
Prostate	40, 40	0	0	0.00	3.00	16.67	0.00
Rectum	40, 39.2	0	3.63	1.82	1.23	40.65	73.78
Salivary Gland Clontech	40, 39.19	2.19	3.64	2.92	7.31	6.84	19.94
Skeletal Muscle Clontech	40, 39.37	0	3.32	1.66	1.26	39.68	65.87
Skin	40, 40	0	2.09	1.05	1.21	41.32	43.18
Small Intestine Clontech	40, 40	1.44	0	0.72	0.98	51.07	36.77
Spleen	35.36, 40	27.05	1.84	14.45	4.92	10.16	146.80
Stomach	40, 37.03	1.93	11.29	6.61	2.73	18.32	121.06
Testis Clontech	40, 37.99	0	6.82	3.41	0.57	87.87	299.65
Thymus Clontech	38.47, 35.55	5.32	24.52	14.92	9.89	5.06	75.43
Thyroid	40, 40	0	2.15	1.08	2.77	18.05	19.40
Trachea Clontech	35.37, 36.67	26.97	13.66	20.32	9.71	5.15	104.61
Urinary Bladder	39.07, 40	3.89	1.42	2.66	5.47	9.14	24.27
Uterus	36.01, 33.41	19.29	75.06	47.18	5.34	9.36	441.71
genomic	29.57	558.84					
b-actin	27.57	1592.66					
1.00E+05	19.91	100000					
1.00E+05	20.08	100000					
1.00E+04	23.79	10000					
1.00E+04	24.06	10000					
1.00E+03	27.72	1000					
1.00E+03	28.29	1000					
1.00E+02	31.95	100					
1.00E+02	33.62	100					
1.00E+01	39.75	10					
1.00E+01	35.41	10					
1.00E-00	40	0					
1.00E-00	40	0					
NTC	40	-1					
NTC	40	-1					

Sample sbg1399854ANK	Reg number (GSK identifier )	Ct	Mean GOI copies	copies of mRNA detected/50 ng total RNA	Sample	Fold Change in Disease Populati on
colon normal GW98-167	21941	35.32	22.34	44.68	colon normal	
colon tumor GW98-166	21940	34.14	47.5	95.00	colon tumor	2.13
colon normal GW98-178	22080	36.16	13.07	26.14	colon normal	
colon tumor GW98-177	22060	35.58	18.93	37.86	colon tumor	1.45

colon normal GW98-561	23514	36.58	10.03	20.06	colon normal	
colon tumor GW98-560	23513	32.61	126.48	252.96	colon tumor	12.61
colon normal GW98-894	24691	35.61	18.62	37.24	colon normal	
colon tumor GW98-893	24690	33.24	84.75	169.50	colon tumor	4.55
lung normal GW98-3	20742	34.77	31.8	63.60	lung normal	
lung tumor GW98-2	20741	33.63	66.03	132.06	lung tumor	2.08
lung normal GW97-179	20677	34.76	32.04	64.08	lung normal	
lung tumor GW97-178	20676	34.44	39.23	78.46	lung tumor	1.22
lung normal GW98-165	21922	35.18	24.44	48.88	lung normal	
lung tumor GW98-164	21921	37.99	4.06	8.12	lung tumor	-6.02
lung normal GW98-282	22584	33.64	65.37	130.74	lung normal	
lung tumor GW98-281	22583	37.3	6.34	12.68	lung tumor	-10.31
breast normal GW00-392	28750	36.29	12.08	12.08	breast normal	
breast tumor GW00-391	28746	36.14	13.29	26.58	breast tumor	2.20
breast normal GW00-413	28798	37.08	7.29	7.29	breast normal	
breast tumor GW00-412	28797	33.26	83.58	167.16	breast tumor	22.93
breast normal GW00-235:238	27592-95	38.93	2.24	2.24	breast normal	
breast tumor GW00-231:234	27588-91	36.57	10.08	10.08	breast tumor	4.50
breast normal GW98-621	23656	34.9	29.32	58.64	breast normal	
breast tumor GW98-620	23655	36.11	13.51	27.02	breast tumor	-2.17
brain normal BB99-542	25507	29.6	866.9	1733.80	brain normal	
brain normal BB99-406	25509	31.93	194.87	389.74	brain normal	
brain normal BB99-904	25546	30.38	526.58	1053.16	brain normal	
brain stage 5 ALZ BB99-874	25502	32.7	119.57	239.14	brain stage 5 ALZ	-4.43
brain stage 5 ALZ BB99-887	25503	30.08	634.97	1269.94	brain stage 5 ALZ	1.20
brain stage 5 ALZ BB99-862	25504	29.7	809.22	1618.44	brain stage 5 ALZ	1.53
brain stage 5 ALZ BB99-927	25542	29.93	700.82	1401.64	brain stage 5 ALZ	1.32
CT lung	normal	35.1	25.82	51.64	CT lung Nml	
lung 26	normal	36.74	9.07		lung 26 Nml	
lung 27	normal	40	0	0.00	lung 27 Nml	
lung 24	COPD	40	2.5	2.50	lung 24 COPD	-7.11
lung 28	COPD	40	0	0.00	lung 28 COPD	-17.77
lung 23	COPD	40	0	0.00	lung 23 COPD	-17.77
lung 25	normal	39.39	1.67	1.67	lung 25 Nml	
asthmatic lung ODO3112	29321	40	0	0.00	asthmatic lung	-17.77
asthmatic lung ODO3433	29323	37	7.68	15.36	asthmatic lung	-1.16
asthmatic lung ODO3397	29322	36.08	13.8	27.60	asthmatic lung	1.55
asthmatic lung ODO4928	29325	40	0	0.00	asthmatic lung	-17.77
endo cells	control	40	0	0.00	endo cells	
endo VEGF		40	0	0.00	endo VEGF	0.00
endo bFGF		35.68	17.77	17.77	endo bFGF	17.77
heart Clontech	normal	35.03	26.95	53.90	heart	
heart ( T-1 ) ischemic	29417	36.36	11.53	23.06	heart ( T-1 ) ischemic	-2.34

heart (T-14) non-obstructive DCM	29422	34.57	36.11	72.22	heart (T-14) non-obstructive DCM	1.34
heart (T-3399) DCM	29426	36.25	12.37	24.74	heart (T-3399) DCM	-2.18
adenoid GW99-269	26162	38.51	2.92	5.84	adenoid	
tonsil GW98-280	22582	35.05	26.54	53.08	tonsil	
T cells PC00314	28453	35.5	19.98	39.96	T cells	
PBMNC		40	0	0.00	PBMNC	
monocyte		40	0	0.00	monocyte	
B cells PC00665	28455	33.78	59.82	119.64	B cells	
dendritic cells	28441	29.33	1026.14	2052.28	dendritic cells	
neutrophils	28440	31.3	292.56	292.56	neutrophils	
eosinophils	28446	35.97	14.79	29.58	eosinophils	
BM unstim		35.56	19.16	19.16	BM unstim	
BM stim	treated	34.79	31.48	31.48	BM stim	1.64
osteodif	treated	40	2.59	2.59	osteodif	2.59
osteoundif		40	0	0.00	osteoundif	
chondrocytes		37.11	7.15	17.88	chondrocytes	
OA Synovium IP12/01	29462	35.95	14.93	14.93	OA Synovium	
OA Synovium NP10/01	29461	35.74	17.17	34.34	OA Synovium	
OA Synovium NP57/00	28464	39.09	2.02	4.04	OA Synovium	
RA Synovium NP03/01	28466	38.03	3.97	7.94	RA Synovium	
RA Synovium NP71/00	28467	35.08	26.03	52.06	RA Synovium	
RA Synovium NP45/00	28475	37.11	7.13	14.26	RA Synovium	
OA bone (biobank)	29217	33.76	60.54	60.54	OA bone (biobank)	
OA bone Sample 1	J. Emory	33.35	78.68	157.36	OA bone	
OA bone Sample 2	J. Emory	34.15	47.2	94.40	OA bone	
Cartilage (pool)	Normal	35.05	26.63	53.26	Nml Cartilage (pool)	
Cartilage (pool)	OA	37.42	5.87	11.74	OA Cartilage (pool)	-4.54
PBL uninfected	28441	33.95	53.63	107.26	PBL uninfected	
PBL HIV IIIB	28442	33.3	81.2	162.40	PBL HIV IIIB	1.51
MRC5 uninfected (100%)	29158	39.41	1.64	3.28	MRC5 uninfected (100%)	
MRC5 HSV strain F	29178	35.73	17.22	34.44	MRC5 HSV strain F	10.50
W12 cells	29179	35.08	26.08	52.16	W12 cells	
Keratinocytes	29180	36.69	9.33	18.66	Keratinocytes	
B-actin control		28.13	2213.67			
genomic		29.03	1240.79			
1.00E+05		22.03	100000			
1.00E+05		22.36	100000			
1.00E+04		25.68	10000			
1.00E+04		25.78	10000			
1.00E+03		29.01	1000			
1.00E+03		28.67	1000			
1.00E+02		33.46	100			
1.00E+02		40	100			

1.00E+01		38.75	10			
1.00E+01		40	10			
1.00E-00		40	0			
1.00E-00		38.6	1			
NTC		40	0			
*lung 26 Normal has been omitted due to multiple amplification failures from that sample						

Gene Name sbg1399854ANK

Disease tissues	Fold Change in Disease Population Relative to Normal
colon tumor	2.13
colon tumor	1.45
colon tumor	12.61
colon tumor	4.55
lung tumor	2.08
lung tumor	1.22
lung tumor	-6.02
lung tumor	-10.31
breast tumor	2.20
breast tumor	22.93
breast tumor	4.50
breast tumor	-2.17
brain stage 5 ALZ	-4.43
brain stage 5 ALZ	1.20
brain stage 5 ALZ	1.53
brain stage 5 ALZ	1.32
lung 24	-7.11
lung 28	-17.77
lung 23	-17.77
asthmatic lung	-17.77
asthmatic lung	-1.16
asthmatic lung	1.55
asthmatic lung	-17.77
endo VEGF	0.00
endo bFGF	17.77
heart T-1	-2.34
heart T-14	1.34
heart T-3399	-2.18
BM stim	1.64
osteо dif	2.59
Cartilage (pool)	-4.54
PBL HIV IIIB	1.51
MRC5 HSV strain F	10.50

**Table V. Additional diseases based on mRNA expression in specific tissues**

Tissue Expression	Additional Diseases
Brain	Neurological and psychiatric diseases, including Alzheimers, parasupranuclear palsey, Huntington's disease, myotonic dystrophy, anorexia, depression, schizophrenia, headache, amnesias, anxiety disorders, sleep disorders, multiple sclerosis
Heart	Cardiovascular diseases, including congestive heart failure, dilated cardiomyopathy, cardiac arrhythmias, Hodgson's Disease, myocardial infarction, cardiac arrhythmias
Lung	Respiratory diseases, including asthma, Chronic Obstructive Pulmonary Disease, cystic fibrosis, acute bronchitis, adult respiratory distress syndrome
Liver	Dyslipidemia, hypercholesterolemia, hypertriglyceridemia, cirrhosis, hepatic encephalopathy, fatty hepatocirrhosis, viral and nonviral hepatitis, Type II Diabetes Mellitis, impaired glucose tolerance
Kidney	Renal diseases, including acute and chronic renal failure, acute tubular necrosis, cystinuria, Fanconi's Syndrome, glomerulonephritis, renal cell carcinoma, renovascular hypertension
Skeletal muscle	Eulenburg's Disease, hypoglycemia, obesity, tendinitis, periodic paralyses, malignant hyperthermia, paramyotonia congenita, myotonia congenita
Intestine	Gastrointestinal diseases, including Myotonia congenita, Ileus, Intestinal Obstruction, Tropical Sprue, Pseudomembranous Enterocolitis
Spleen/lymph	Lymphangiectasia, hypersplenism, angiomas, ankylosing spondylitis, Hodgkin's Disease, macroglobulinemia, malignant lymphomas, rheumatoid arthritis
Placenta	Choriocarcinoma, hydatidiform mole, placenta previa
Testis	Testicular cancer, male reproductive diseases, including low testosterone and male infertility
Pancreas	Diabetic ketoacidosis, Type 1 & 2 diabetes, obesity, impaired glucose tolerance

**What is claimed is:**

1. An isolated polypeptide selected from the group consisting of:
  - 5 (a) an isolated polypeptide encoded by a polynucleotide comprising a sequence set forth in Table I;
  - (b) an isolated polypeptide comprising a polypeptide sequence set forth in Table I; and
  - (c) a polypeptide sequence of a gene set forth in Table I.
- 10 2. An isolated polynucleotide selected from the group consisting of:
  - (a) an isolated polynucleotide comprising a polynucleotide sequence set forth in Table I;
  - (b) an isolated polynucleotide of a gene set forth in Table I;
  - (c) an isolated polynucleotide comprising a polynucleotide sequence encoding a polypeptide set forth in Table I;
- 15 (d) an isolated polynucleotide encoding a polypeptide set forth in Table I;
  - (e) a polynucleotide which is an RNA equivalent of the polynucleotide of (a) to (d); or a polynucleotide sequence complementary to said isolated polynucleotide.
- 20 3. An expression vector comprising a polynucleotide capable of producing a polypeptide of claim 1 when said expression vector is present in a compatible host cell.
4. A process for producing a recombinant host cell which comprises the step of introducing an expression vector comprising a polynucleotide capable of producing a polypeptide of claim 1 into a cell such that the host cell, under appropriate culture conditions, produces said polypeptide.
- 25 5. A recombinant host cell produced by the process of claim 4.
6. A membrane of a recombinant host cell of claim 5 expressing said polypeptide.
- 30 7. A process for producing a polypeptide which comprises culturing a host cell of claim 5 under conditions sufficient for the production of said polypeptide and recovering said polypeptide from the culture.

## SEQUENCE LISTING

<110> SMITHKLINE BEECHAM CORPORATION  
 SMITHKLINE BEECHAM p.l.c.  
 GLAXO GROUP, LIMITED

<120> NOVEL COMPOUNDS

<130> GP50034

<140> TO BE ASSIGNED  
 <141> 2001-09-13

<150> 60/232,463  
 <151> 2000-09-13

<150> 60/232,455  
 <151> 2000-09-13

<150> 60/237,293  
 <151> 2000-10-02

<150> 60/246,269  
 <151> 2000-11-07

<150> 60/252,049  
 <151> 2000-11-20

<160> 88

<170> FastSEQ for Windows Version 4.0

<210> 1  
 <211> 1707  
 <212> DNA  
 <213> Homo sapiens

<400> 1

atgaaggaaag	cagagatgga	cggtgaggca	gtccgcttct	gcacagataa	ccagtgtgtc	60
tccctgcacc	cccaagaggt	ggactctgtg	gcaatggctc	ctgcagcccc	caagataccg	120
aggctcgttc	aggctacccc	ggcatttatg	gctgtgacct	tggttttctc	tcttgtgact	180
ctctttgtag	tgggtaagcc	cccagtcaa	cagcagacaa	gacctgttcc	gaaggctgtg	240
caagccgtaa	ttctgggaga	caacattact	gggcattttac	cttttgaacc	caacaatcat	300
caccactttg	gcagggaggc	agaaatgcga	gagcttatcc	agacatttaa	aggccacatg	360
gagaattcca	gtgcctgggt	agtagaaatc	catgttga	agtgcagagt	ggacaatgtc	420
aattcgcagc	tccaggtgt	cggtgatcat	ctgggaaaaca	ccaatgtga	catccagatg	480
gtaaaaaggag	ttctaaagga	tgcactaca	ttgagtttgc	agacacagat	gttaaggagt	540
tccctggagg	gaaccaatgc	tgagatccag	aggctcaagg	aagaccttga	aaaggcagat	600
gctttaactt	tccagacgct	gaattttcta	aaaagcaggat	tagaaaaacac	cagcattgag	660
ctccacgtgc	taagcagagg	cttagaaaaat	gcaaaactctg	aaattcagat	gttgaatgcc	720
agagccaaatg	ctgagatcca	gggactaaag	gaaaatttgc	agaacacaaa	tgctttaaac	780
tcccagaccc	aggcctttt	aaaaaagcagt	tttgacaaca	ctagtgctga	gatccagttc	840
ttaagagggtc	atttggaaaag	agctggtgat	gaaattcacg	tgtttaaaag	ggatttgaaa	900
atggtcacag	cccagaccca	aaaagcaaat	ggccgtctgg	accagacaga	tactcagatt	960
caggtattca	agtcagagat	ggaaaaatgt	aataccttaa	atgcccagat	tcaaggtctta	1020
aatggtcata	tgaaaaatgc	cagcagagag	atacagaccc	taaaaacaagg	aatgaagaat	1080
gcttcagcct	taacttcca	gaccagatg	ttagacagca	atctgcagaa	ggccagtgc	1140
gagatccaga	ggttaagagg	ggatctagag	aacacccaaag	ctctaaccat	gaaaatccag	1200
caggagcaga	gtcgctgaa	gaccctccat	gtggtcattta	ttcacagga	acagctacaa	1260

agaacccaaa	gtcagctct	ccagatggc	ctgcaaggct	ggaagttcaa	tggtggaaagc	1320
ttatattatt	tttctagtgt	caagaagtct	tggcatgagg	ctgagcagtt	ctgcgtgtcc	1380
cagggagccc	atctggcata	tgtggctcc	aaggaggagc	aggcatttct	gttagagttc	1440
acaagtaaaag	tgtactactg	gatcgtctc	actgacaggg	gcacagaggg	ctctggcgc	1500
tggacagatg	ggacaccatt	caacgccc	cagaacaaag	cccctgtgt	cttcgggttt	1560
tggaaaaga	atcgtctga	caactggcg	cacaagaatg	ggcagactga	agactgtgtc	1620
caaattcagc	agaagtggaa	tgacatgacc	tgtgacacc	cctatcagtg	ggtgtgcaag	1680
aagccatgg	gccagggtgt	ggcctga				1707

<210> 2  
 <211> 1095

<212> DNA  
 <213> Homo sapiens

<400> 2						
atgtcgagac	aaggaaaatt	atttctgt	tttggagtgg	gttgttgt	aacggcaggc	60
ttgccaagg	acgataaac	tcctagcacc	attgcggatg	tgcacaatgg	ttatacgtat	120
aatgttgtag	agcaagtct	aaaggatgt	tttgtgttat	tttcccagg	aacactttgt	180
gattttccaa	aaatacacca	tggattctg	tatgtatgaag	aagattataa	ccctttttcc	240
caagttccta	caggggaagt	tttctattac	tcctgtgaat	ataattttgt	gttccttca	300
aaatcctttt	ggactcgcata	aacatgcaca	gaagaaggat	ggtcaccac	accgaagtgt	360
ctcagaatgt	gttccttcc	ttttgtaaa	aatggtcatt	ctgaatcttc	aggactaata	420
catctggaaag	gtgatactgt	acaattatt	tgcaacacag	gatacgcct	tcaaaaacaat	480
gagaaaaaca	ttcgtgtgt	agaacggggc	tggtccactc	ctcccatatg	cagcttcact	540
atgaaaacat	gtggatacat	acctgaactc	gagtacggtt	atgttcagcc	gtctgtccct	600
ccctatcaac	atggagttc	agtgcagggt	aattgcagaa	atgaatatgc	aatgatttgg	660
aataacatga	ttacctgtat	taatggaaa	tggacagagc	ttcctatgtg	tgttgagtct	720
actgcattt	gtggggcccc	tccatctatt	aacaatggag	ataccacctc	attcccattt	780
tcaaatatc	ctccagggtc	aacagtgcac	taccgttgc	agtccttcta	taaaactccag	840
ggctctgtaa	ctgtAACATG	cagaaaataaa	cagtggtcag	aaccaccaag	atgccttagat	900
ccatgtgtgg	tatctgaaga	aaacatgaac	aaaaataaca	tacagttaaa	atggagaaac	960
gatggaaaac	tctatgcaaa	aacaggggat	gctgttgaat	tccagtgtaa	attcccacat	1020
aaagcgtat	tatcatcacc	accatttcga	gcaatctgtc	aggaagggaa	atttgaatat	1080
cctatatgt	aatga					1095

<210> 3  
 <211> 984  
 <212> DNA  
 <213> Homo sapiens

<400> 3						
atgttgcct	tattcagtgt	aatcctaatac	tcatggtat	ccactgttgg	gggagaaggaa	60
acactttgt	atttccaaa	aatacaccat	ggatttctgt	atgatgaaga	agattataaac	120
ccttttccc	aatccctac	agggaaagt	ttctattact	cctgtgaata	taattttgtg	180
tcccttcaa	aatcccttgc	gactcgcata	acatgcacag	aagaaggatg	gtcaccacaa	240
ccgaaagtgc	tcaaatgt	ttcccttctt	tttgtgaaa	atggtcattt	tgaatcttca	300
ggactaatac	atctggaaagg	tgatactgt	caaattattt	gcaacacagg	atacagcctt	360
caaaaacat	agaaaaacat	ttcgtgtgt	gaacggggct	ggtccactcc	tcccatatgc	420
agcttcacta	tggaaaacat	tggatacatca	cctgaactcg	agtacgggtt	tgttcagccg	480
tctgtccctc	cctatcaaca	tggatttca	gtcgagggtg	attgcagaaa	tgaatatgc	540
atgattggaa	ataacatgt	tacctgtatt	aatggaaat	ggacagagct	tcctatgtgt	600
gttgagtcta	ctgcatttt	tggccccct	ccatctattt	acaatggaga	taccacctca	660
ttccattat	cagttatatcc	tccagggtca	acagtgcac	accgttgc	gtccttctat	720
aaactccagg	gctctgtaa	tgttaacatgc	agaaataaa	agtggcaga	accaccaaga	780
tgccttagatc	catgtgtgtt	atctgaagaa	aaatgcaca	aaaataacat	acagttaaaa	840
tggagaaacg	atggaaaact	ctatgcaaaa	acaggggatg	ctgttgaatt	ccagtgtaaa	900
ttcccacata	aagcgatgt	atcatcacca	ccatttcgag	caatctgtca	ggaagggaaa	960
tttgaatata	ctatatgt	atga				984

<210> 4  
 <211> 465  
 <212> DNA  
 <213> Homo sapiens

<400> 4  
 atggcaccgg ccagagcagg atgctgcccc ctgctgctgc tgcttctggg gctgtgggtg 60  
 gcagagggtcc tagtcagagc caagcccaag gacatgacat catctcagtg gtttaaaact 120  
 cagcatgtgc agcccagccc tcaagcatgc aactcagcca tgagcatcat caataagtac 180  
 acagaacggt gcaaagacct caaacaccc ctgcacggc ccttctccag tgtggccatc 240  
 acctgcccaga ccccaacat agcctgcaag aatagctgt aaaaactgcca ccagagccac 300  
 gggccatgt ccctgaccat gggtaggctc acctcaggga agtacccaaa ctgcaggta 360  
 aaagagaaggc acctgaacac accttacata gtggcctgtg accctccaca acagggtgac 420  
 ccagggtacc cacttgttcc tgtgcacttg gataaaagttt tctaa 465

<210> 5  
 <211> 1509  
 <212> DNA  
 <213> Homo sapiens

<400> 5  
 atgcgcgcgc tgggagggtc tctccgcccc cccgcgcggg cccacggggc cgagcctctc 60  
 cccagtgcgc tggggccctg cgctgggggt gaccgggacc tgggtcgggg aaccccccgg 120  
 tgggagccca ggccgcgcag ggtccccatc cacgagcagg tcgacccccc gcgagagggg 180  
 ccccacccct tccagaaacct cctgccttc ctgtgggccc tgctgaactg tggtttgggg 240  
 gtcagtgcgc agggtccggg cgagtggacc ccgtgggtgt cctggaccccg ctgctccagc 300  
 tcctgcgggc gtggcgcttc tgcgcgcagc cggcgctgcc tccggcttcc tggggaaagaa 360  
 ccgtgcgtggg gagactccca tgagtaccgc ctctgcctgt tgccagactg ccccccagg 420  
 gctgtgcctt tccgagaccc acagtgtgcc ctgtacaatg gccgcctgt cctgggcacc 480  
 cagaagaccc accagtgggt gcccctccat ggggcgcaca accagtgcga cctcaactgc 540  
 ctggctgagg ggcacgcctt ctaccacagc ttccggccgcg tcctggacgg caccgcctgc 600  
 agcccccgggt cccaggggggt ctgcgtggct ggccgcgtgcc tttaggcgcgg ctgtgatggg 660  
 ttgttgggct cgggtgcctt cgaggaccgc tgcgtggccgt gcggaggcgc caacgactcg 720  
 tgccctttcg tgcagcgcgt gtttgcgtac gcccggcgt tcgcgtggta ctggAACgtg 780  
 accctgatcc cccaggccgc cagacacatc cgcgtggac acaggagccg caaccacctg 840  
 ggtatccctag gatcaactgat gggggggcgt gggcgctacg tgcttaatgg gcactgggtg 900  
 gtcagcccac caggaccta cgaggccgc ggcacgcgt tggtctacac ccgagacaca 960  
 gggccccagg agacattgca agcagccggg cccacccccc atgacccgtc cctacaggtc 1020  
 ctcctgcagg agcccaaccc tggcatcgag tttgagttt ggctccctcg ggagcgctac 1080  
 agccccctcc aggctcggt gcaaggccctg ggctggccccc tgaggcagcc tcagccccgg 1140  
 ggggtggagc ctcagccccc cgcagccccc gctgtcaccc ctgcacagac cccaaacgcgt 1200  
 gccccagttt tccaggcccg agtgcgtggc caccaccacc aggcccagg gacccgtat 1260  
 gaggtgcgc tccagctcg tctacaagaac cgcgcgcac tgcgggcacg cgagtacgtg 1320  
 tgggcgcagg gccactgccc ctggcccgat ctggcaccccc accgggacta cctgatggct 1380  
 gtcccgacgtc ttgtcagccc cgaacggcaca caggaccagg tgctgcgtcc ccacgcggc 1440  
 taaccccccgc cctggagcccc tgccggaggac agccgcatac gctgcactgc ccggcgctgt 1500  
 cctggctga 1509

<210> 6  
 <211> 1356  
 <212> DNA  
 <213> Homo sapiens

<400> 6  
 atggactcgcc cccctctgtt ccccaaggcccc cacctttcc agaacccctt gctttccctg 60  
 tggccctgc tgaactgtgg tttgggggtc agtgctcagg gtccgggcga gtggaccccg 120  
 tgggtgtccct ggacccgcgt ctcacgcgtcc tgccggccgtg gctgtctgt ggcgcagccgg 180  
 cgcgcctcc ggcttcctgg ggaagaacccg tgctggggag actcccatga gtaccgcctc 240  
 tgccagttgc cagactgccc cccaggccgt tgcccttcc gagacccatac gtgtgcctcg 300

tacaatggcc	gccctgtcct	gggcacccag	aagacctacc	agtgggtgcc	cttccatggg	360
gcccacaacc	agtgcgacct	caactgcctg	gctgaggggc	acgccttcta	ccacagcttc	420
ggccgcgtcc	tggacggcac	cgcctgcage	ccgggtgccc	agggggctcg	cgtggctggc	480
cgtgcctta	gcccggctg	tgatgggtt	ttgggctcg	gtgcctcga	gjaccgctgt	540
ggccgctg	gaggcgccaa	cgactcg	ctttcg	agcgcgtgtt	tcgtgacg	600
gtgcctcg	ctgggtactg	gaacgtgacc	ctgatccccg	agggcgccag	acacatccgc	660
gttgaacaca	ggagccgca	ccacctgggt	atccttagat	cactatggg	ggcgatggg	720
cgtacgtc	ttaatggca	ctgggtggc	agcccacccag	ggacatcga	ggcggccggc	780
acgcatgtgg	tctacacccg	agacacagg	ccccaggaga	cattgcaagc	agccggggccc	840
accccccatt	acctgtcct	acaggtcct	ctgcaggagc	ccaaccctgg	cattcgagttt	900
gagttctggc	tccctcg	gjcgtacagc	cccttccagg	ctcg	gtgc	960
tggcccctga	ggcagcc	gccccgggg	gtggagcc	agccccccgc	agccccctgct	1020
gtcaccctgt	cacagaccc	aacgtggc	ccagtgttcc	aggccc	gagt	1080
caccaccagg	cccaggagac	ccgctatg	gtgcgcatec	agctcgtcta	caagaaccgc	1140
tcgcccactgc	gggcacgcg	gtacgtgtt	gcccagg	actgccc	ctcgatgctg	1200
gcacccacc	gggactac	gatggctgc	cagcgtctt	tcagcc	ccggcacacag	1260
gaccagctgc	tgctgcccc	cgccgctac	gccccccct	ggagcc	ctgc	ggaggacagc
cgcat	actgcccc	gjcgtcct	ggctga			1320
						1356

&lt;210&gt; 7

&lt;211&gt; 1296

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 7

atgatccgga	ccccattgtc	ggcctctg	catgcctgc	tcctcccagg	ctcccgccgg	60
cgaccccccgc	gcaacatgca	gcccacgggc	cgcgagggtt	cccg	cgct	120
tatctgcggc	gtctgctgt	cctgtactg	ctgctgctgc	tgccggcagcc	cgtaacc	180
gcccggacca	cgccggccgc	ccccagagcc	ctctccacgc	tgggtcccc	cagcctcttc	240
accacgcccgg	gtgtccccag	ccgcctcact	accccagggc	teactacg	ccaggac	300
aaaaccctgg	acccctgggg	tcgcgcg	gccc	tgatgc	ggagtttccc	360
gggtatgtag	gtctgaacag	ctctcaaaag	ctggcctg	tcattggcgt	ggaggggtgg	420
cactcactgg	acagcagcc	ctctgtgt	cgcagtttct	atgtgt	gggtgcgtac	480
ctgacactta	ccttcac	cagtacacca	tggcagaga	gttccac	aa	540
cacatgtaca	ccaa	cgatcg	cg	gattgaca	gtcttgg	600
aaccgcctgg	gcat	gtatgat	agatttgc	tatgc	atcc	660
ctggaaatgt	ctcagg	gttgc	tcc	actc	actcg	720
aatttgt	atgttcc	tgat	atcc	tcg	cc	780
atgg	tgtcc	atgg	tg	caac	ctgc	840
gcagat	cgaa	atcg	ctcg	ttg	ctt	900
ggaaat	acgg	actgg	ccgg	catt	ggat	960
gtctgtat	agg	gttgc	tcgg	gttgc	atgtgt	1020
cgtggaaacc	tgct	cg	ttc	caac	ttc	1080
cag	tgg	ggc	atc	gcac	cc	1140
ctcgcc	act	ccag	ct	atc	cc	1200
cgg	ggag	gtc	ccat	acc	tt	1260
gccaccatcc	caac	ttc	ccag	ttc	gt	1296

&lt;210&gt; 8

&lt;211&gt; 1443

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 8

atgcagcc	ccggcctcg	gggtccggc	acgtttggc	ggtggcct	gtcgagtct	60
ctgctc	tcgt	ctgt	ccag	cc	ac	120
agaccc	ccac	gctgg	cccc	ccac	cc	180
tcgacc	tca	ctgt	cagc	ccag	cc	240
cggact	cgct	cg	gac	cc	tt	300

cagaaaaggcc	tacaggatgt	taacctgcgc	aatttcagct	acggccagac	cagccctggac	360
aggcttagag	atggcctcg	gggcgc	ttctggtcag	cctatgtgcc	atgccagacc	420
caggaccggg	atgc	cctcaccctg	gagcagattg	acctcatacg	ccgc	480
gcctcctatt	ctgagctgga	gctt	tcggctaaag	gtctgaacag	ctct	540
ctggcctgc	tcatt	ggagggtgg	cactca	acagc	cct	600
cgcagttct	atgt	gg	ctac	c	ctctgt	660
tgggcagaga	gttcc	gtt	cacatgtaca	c	ac	720
agcttttgt	agaa	ag	agaggagtt	aacc	gtat	780
tatgcatcg	acac	aaga	gggtc	ctgg	gtat	840
tcccactcg	ctgg	ctgg	aa	ttgtt	ttc	900
cagcttcg	aga	aga	acac	atgg	tgat	960
tgcaacctgc	ttgt	gtcc	atgt	tg	atc	1020
attggatctg	agtt	act	gc	gat	tc	1080
gggctggagg	atgt	ttgt	ttgt	gg	cc	1140
agcgaggaag	agtc	ttct	ggaa	act	cc	1200
aaaaaggtga	gag	ggac	ccct	gt	ct	1260
caactgagca	cat	ccc	gtgc	gg	act	1320
ctggaggtga	cca	acc	cctg	gtc	c	1380
tactttgtc	cagg	c	gtgc	cc	tc	1440
tga						1443

<210> 9  
<211> 1116  
<212> DNA  
<213> Homo

<400> 9	atggatgcag	ccacagctcc	aaagcaagcc	tggcccccatt	ggccccccgt	ctttttccctc	60
	ctccctctac	ctggagggag	cggtggcagc	tgcctctgtg	tgtgtgactg	caccccccag	120
	ccccaggctg	tgctctgtgg	ccacaggccaa	ctggaggctg	tacctggagg	actcccaactg	180
	gacactgagc	tcctggacct	gagtggaaac	cgcctcccgaa	aggctcagcc	cctgggtcggg	240
	ctccaggagc	tacgcctgtc	agggggcatgc	ctcacctcca	ttgctgccc	tgcctccat	300
	ggcttactg	ccttccaccc	cctggatgtg	gcagataacg	cccttcagac	actagaggaa	360
	acagcttcc	cttctccaga	caaactggtc	accttgaggc	tgtctggcaa	ccccctaacc	420
	tgtactgccc	gcctctctg	gctgctccgg	ctccgcacc	tggactttgg	catgtcccccc	480
	cctgcctgtg	ctggccccca	tcatgtccag	ggaaagagcc	tgaaggagtt	ttcagacatc	540
	ctgcctccag	ggcacttcac	ctgcaaaacca	gccctgatcc	aaaagtccgg	gcctcgatgg	600
	gtcattgcag	aggagggcgg	gcatgcgggt	ttctctgtc	ctggagatgg	agaccagcc	660
	cccactgtct	cctggatgag	gcctcatggg	gcttggctgg	gcagggctgg	gagagtaagg	720
	gtcttagagg	atggacact	ggagatccgc	tcagtgcagc	tacgggacag	aggggcctat	780
	gtctgtgtgg	ttagcaatgt	cgctggaaat	gactccctga	ggacctggct	ggaagtcatc	840
	cagggtggaa	cacccaaacgg	cacactttt	gaccccaaca	tcaccgtgcc	agggatccca	900
	gggccttttt	ttctggatag	cagaggtgtg	gccatggtgc	tggcagtcgg	cttccccc	960
	ttcttcacct	cagtggaccct	ctgcttggc	ctgattgccc	tttggagcaa	gggc当地gg	1020
	cgggtcaaac	atcacatgac	cttgacttt	gtggcacctc	ggccctctgg	ggataaaaac	1080
	tctgggggta	accgggtcac	tgccaagctc	ttctgt			1116

<210> 10  
<211> 1779  
<212> DNA  
<213> Homo

```

<400> 10
atggatgcag ccacagctcc aaagcaagcc tggcccccatt gccccccgct ctttttcctc 60
ctcccttac ctggagggag cggtggcagc tgccctgtcg tgtgtgactg caccccccag 120
ccccaggctg tgctctgtgg ccacaggcaa ctggaggctg tacctggagg actcccaactg 180
gacactgagc tcctggacct gagtgggAAC cgccctgtggg ggctccagaca ggaaatgctc 240
tcccccttga gcctgtctca ggaattggac ctcagctaca accagctctc aaccctttag 300
cctggggcct tccatggct acaaaggcta ctcacccctga ggctgcagggg caatcggtc 360

```

agaatcatgg	ggcctgggt	cttctcaggc	ctctctgtc	tgaccctgtc	ggacccctccgc	420
ctcaaccaga	ttgttcttctt	cctagatgg	gcttttgggg	agcttaggcag	cctccagaag	480
ctggagggtt	gggacaacca	cctggtattt	gtggctccgg	gggccttgc	agggctagcc	540
aagttgagca	ccctcaccc	ggagcgctgc	aacctcagca	cagtgcctgg	cctagccctt	600
gcccgtctcc	cggcaactgt	ggccctaagg	cttagagaaac	tggatattgg	gaggctgcca	660
gctggggccc	tgccggggct	gggcagctc	aaggagctgg	agatccacct	ctggccatct	720
ctggaggctc	tggaccctgg	gagcctgggt	gggctcaatc	tcagcagcct	ggccatcaact	780
cgttcaatc	ttagctcggt	gccctccaa	gcaactgtacc	acctcagctt	cctcagggtc	840
ctggatctgt	cccagaatcc	catctcagcc	atccccagccc	gaaggctcag	ccccctgggt	900
cggctccagg	agctacgcct	gtcagggca	tgcctcaact	ccattgtctgc	ccatgccttc	960
catggcttga	ctgccttcca	cctcctggat	gtggcagata	acgccttca	gacactagag	1020
gaaacagctt	tcccttctcc	agacaaactg	gtcaccttga	ggctgtctgg	caacccccccta	1080
acctgtact	gcccctctt	ctggctgtc	cggctccggc	acctggactt	ttggatgtcc	1140
ccccctgcct	gtgctggccc	ccatcatgtc	caggggaaaga	gcctgaagga	gttttcagac	1200
atccctgcctc	cagggcaatt	cacccgtcaaa	ccagccctga	tccggaaagtc	ggggcctcga	1260
tgggtcattt	cagaggaggg	cgggcatgca	gttttctctt	gctctggaga	ttggagaccca	1320
gcccccaactg	tctcctggat	gaggcctcat	ggggcttggc	ttggcagggc	ttggagagata	1380
agggtcctag	aggatggac	actggagatc	cgctcagtc	agctacggga	cagaggggccc	1440
tatgtctgt	tggtagcaa	tgtcgctggg	aatgactccc	tgaggacctg	gctggaaagtc	1500
atccagggtgg	aaccacccaaa	cggcacactt	tctgacccca	acatcaccgt	gccagggtac	1560
ccagggcctt	tttttcttga	tagcagaggt	gtggccatgg	tgctggcagt	gggcttcctc	1620
cccttcctca	cctcagtgac	cctctgttt	ggcctgattt	ccctttggag	caagggcaaa	1680
ggtcgggtca	aacatcacat	gaccttgcac	tttgcggcac	ctcgccctc	tgggataaaa	1740
aactctgggg	gttaaccgggt	cactgccaag	ctttcttgc			1779

&lt;210&gt; 11

&lt;211&gt; 429

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 11

atggccaggt	acatgctgct	gctgctcctg	gccccatggg	tgctgaccgg	ggagctgtgg	60
ccgggagctg	aggccccggc	agcgccttac	ggggctcagcc	tttgcggccg	agaattcatc	120
cgagcagtca	tcttcacctg	cggggctcc	cgggtggagac	gatcagacat	cctggcccac	180
gaggctatgg	gagataccctt	cccgatgca	gatgctgtat	aagacagtct	ggcaggcggag	240
ctggatgagg	ccatggggctc	cagcgagtgg	ctggccctga	ccaagtcacc	ccaggccttt	300
tacagggggc	gaccaggctg	gcaaggaaacc	cctggggttc	ttcggggcag	ccgagatgtc	360
ctggctggcc	tttccagcag	ctgctgcaag	tgggggtgt	gcaaaaagtga	aatcagtagc	420
ctttcttag						429

&lt;210&gt; 12

&lt;211&gt; 692

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 12

atgtctgaag	aagtgaccta	cgcgacactc	acatttcagg	attctgtctgg	agcaaggaat	60
aaccgagatg	gaaataaacct	aagaaaaaga	gggcattccag	ctccatctcc	catttggcgt	120
catgctgctc	tgggtctggt	aactcttgc	ctgatgttgc	tgattgggct	ggtgacgttg	180
gggatgatgt	ttttgcagat	atctaatttgc	attaacttgc	atttcaggaaa	atttgagtcaa	240
cttcagaaaa	ccatccaaca	gcagcaggat	aacttatccc	agcaactggg	caactccaac	300
aacttgcaca	tggaggagga	atttttcaag	tcacagatct	ccagtcact	gaagaggcag	360
gaacaaaatgg	ccatcaaact	gtgccaagag	ctaatcatcc	atacttcaga	ccacagatgt	420
aatccatgtc	ctaagatgt	gcaatggatc	aaaaatagg	gctacttattt	tacaacaaaat	480
gaggagaaaa	cctgggctaa	cagtagaaag	gactgcata	acaagaactc	caccctagtg	540
aagatagaca	gttttggaaaga	aaaggatttt	cttatgtcac	agccattact	catgtttcg	600
ttcttttggc	tgggattatc	atgggactcc	tctggcagaa	gttgggtctg	ggaagatggc	660
tctgttccct	ctccatcttcc	gtacgtctc	aa			692

<210> 13  
 <211> 585  
 <212> DNA  
 <213> Homo sapiens

<400> 13  
 atgtggctgt ccccagctct gctgcttctc atcctccag gttactccat tgccgctaaa 60  
 atcaactggtc caacaacagt gaatggctcg gagcagggtct cattgactgt gcagtgtgct 120  
 tatggctcag gctgggagac ctacttgaag tggcgggtgtc aaggagctga ttggaaattac 180  
 ttaacatcc ttgttaaaaac aaatggatca gagcaggagg taaaagaagaa tcgagtttc 240  
 atcaggagaca atcagaaaaaa ccacatgttc accgtgacca tggagaatct caaaagagat 300  
 gatgctgaca gttattgggtg tggactgag agacctggaa ttgatcttgg ggtcaaaagtt 360  
 caagtgacca ttaacccagg cacacaaact gcagtctcag aatggacaac cacaacagca 420  
 agcctggctt tcacagctgc agccacccag aagaccagca gccccctcac caggtccccg 480  
 ctcagagca cccacttcc tttctgttc ctctggagc tgcctctgtc cctgagcatg 540  
 ctggggaccg tcctctgggt gaacagacca caaagaaggt cttga 585

<210> 14  
 <211> 1002  
 <212> DNA  
 <213> Homo sapiens

<400> 14  
 atgaggatct ggtggcttct gcttgccatt gaaatctgca cagggAACat aaactcacag 60  
 gacacctgca ggcaagggtca cccttggaaatc cctgggaaacc ccgggtcacaa tggctgcct 120  
 ggaagagatg gacgagacgg agcgaagggt gacaaaggcg atgcaggaga accaggacgt 180  
 cctggcagcc cggggaaagga tggacgagt ggagagaagg gagaacgagg agcagatgga 240  
 aaagttgaag caaaaggcat caaagggtat caaggctcaa gaggatcccc agggaaacat 300  
 gggcccaagg ggcttgcagg gcccattggga gagaaggccc tccgaggaga gactgggcct 360  
 caggggcaga aggggaataa gggtgacgt ggtcccactg gtcctgaggg gccaaggggc 420  
 aacattgggc ctttgggccc aactggttt ccggggccca tggggccctat tggaaagcct 480  
 ggtcccaaag gagaagctgg acccacgggg ccccagggtg agccaggagt cggggaaata 540  
 agaggctgga aaggagatcg aggagagaaa gggaaaatcg gtgagactct agtcttgcca 600  
 aaaagtgtctt tcactgtggg gctcacgggt ctgagcaagt ttcccttctc agatatgccc 660  
 attaaatttg ataagatctt gtataacgaa ttcaaccatt atgatacagc agcggggaaa 720  
 ttacacgtgcc acattgtctgg ggtcttattac ttcacctacc acatcactgt tttctccaga 780  
 aatgttcagg tgcctttgtt caaaatgga gtaaaaatac tgcacaccaa agatgtttac 840  
 atgagctctg aggaccaggc ctctggcggc attgtcttc agctgaagct cggggatgag 900  
 gtgtggctgc aggtgacagg aggagagagg ttcaatggct tgtttgcgtga tgaggacgt 960  
 gacacaactt tcacagggtt cttctgttc agcagccctgt ga 1002

<210> 15  
 <211> 678  
 <212> DNA  
 <213> Homo sapiens

<400> 15  
 atgaggatct ggtggcttct gcttgccatt gaaatctgca cagggAACat aaactcacag 60  
 gacacctgca ggcaagggtca cccttggaaatc cctgggaaacc ccgggtcacaa tggctgcct 120  
 ggaagagatg gacgagacgg agcgaagggt gacaaaggcg atgcaggaga agctggacc 180  
 acggggccccc agggtgagcc aggagtccgg ggaataagag gctggaaagg agatcgagga 240  
 gagaagggtca aatcggtga gactcttagtc ttggccaaaaa gtgccttcac tgcggggctc 300  
 acgggtctga gcaagttcc ttcttcagat atgcccattt aatttgcataa gatcctgttat 360  
 aacgaattca accattatgta tacagcagcg gggaaaattca cgtgccacat tgctgggtc 420  
 tattacttca cctaccat cactgttttc tccagaaatg ttcaggtgtc tttgtcaaa 480  
 aatggagtaa aaatactgca caccaaaatg gcttacatgta gctctgagga ccaggccctc 540  
 ggcggcattt tcctgcagct gaagctcggtt gatgaggtgtt ggctgcaggt gacaggagga 600  
 gagaggttca atggcttgcgtt tgctgtatgag gacgtatgaca caactttcac agggttccctt 660  
 ctgttgcgtca gcccgtga 678

<210> 16  
 <211> 618  
 <212> DNA  
 <213> Homo sapiens

<400> 16  
 atgatgagaa ctctcatcac cacacaccca ctgccccctgc ttcttattgcc gcagcagctg 60  
 ctgcagctgg tgcagtttca agaggtggat acagattttg atttcccaga agaagataaa 120  
 aaagaagaat ttgaagagt tttggaaaaaa ttttttagta cagggccccgc cagaccacct 180  
 accaaagaaa aagtcaaaag acgtgtcctt attgaacctg gaatgccact aaatcatata 240  
 gactactgta accatgaaat catggaaaaa aatgtttact acaaacacccg ttgggtggca 300  
 gaacattact tccttcttatt gcaatatgac gagctccaaa aaatctgtta caacagattt 360  
 gtccatgtta agaatggaaat taggaaatgt aacaggagca aaggctttgtt agaaggagtg 420  
 tatttgtaatt taacagaagc atttggaaata ccagcgtgtt aatacgaatc actttatagg 480  
 aagggtctacg tccttattcac ttgttcatgg caaaatggaaa tgcaaaaaacg tattcctcat 540  
 actataatg atctcggtt gccacctgaa cacagaagtt tcctcagtta ggatgggtgc 600  
 ttgtcatat cgcccttag 618

<210> 17  
 <211> 288  
 <212> DNA  
 <213> Homo sapiens

<400> 17  
 atggagggtgg tgctgatctt tctatgcagc ctgttggccc acattgtcct gcccgatgca 60  
 gttgagaggg agaaggcaaat tgaccctttt cattatgact accagaccct gaggattagg 120  
 gggttggat gtgctgtgggt cctttctcc attgggatcc tccttattcct aggttgcaga 180  
 tgcaagtgcg gtttcaatca gaagcccagg accccaggag aggaggaagc ccaggtggag 240  
 aacctcatca ctgcaaatgc aacaaagctc cagaaagcag agagctga 288

<210> 18  
 <211> 1788  
 <212> DNA  
 <213> Homo sapiens

<400> 18  
 atggagggtgg gaatgggatg ctgggccccgg gaggtgctgg tccccgaggg gcccttgcac 60  
 cgcgtggctg gcacagctgt ctccatctcc tgcaatgtga ccggctatga gggccctgccc 120  
 cagcagaact tcgagtgtt cctgtatagg cccgaggccc cagatactgc actgggcatt 180  
 gtcagtacca aggataccca gttctccat gctgtcttca agtcccagt ggtggcgggt 240  
 gaggtgcagg tgcagcgcct acaaggatgat gccgtggcgc tcaagattgc cccctgcag 300  
 gcccaggatg ccggcatatta ttagtgcac accccctcca ctgataccgg ctacctgggc 360  
 agtacacgcg gcaagggtgg gctgagagtt cttccagatg tcctccagggt gtctgtgc 420  
 ccccccaggcc cccgaggccc ccaggcccca acctcaccccc cacgcacatgc ggtgcatgag 480  
 gggcaggagc tggcaactggg ctgcctggcagg aggacaagca cacagaagca cacacacctg 540  
 gcaatgtcct ttggcgcata tggcccgag gcaccaggat ggcgggtcaac tctgcaggaa 600  
 gtgggtggaa tccggtcaga cttggccgtg gaggctggag ctccctatgc tgagcgattt 660  
 gctgcagggg agcttcgtct gggcaaggaa gggaccgatc ggtaccgcatt gtagtaggg 720  
 ggtgcccagg caggggacgc aggacacccatc cactgcactg ccgtcgatgt gattcaggat 780  
 cctgtatggca gctggggcca gattgcagag aaaaggccgg tcctggccca cgtggatgtg 840  
 cagacgctgt ccagccagct ggcagtgaca gtggggccctg gtgaacgtcg gatggccca 900  
 ggggagccct tggaaactgtc gtgcaatgtg tcagggccac ttccccccatc aggccgtcat 960  
 gctgcatact ctgttaggtt gggatggca cctgcggggc acctggggcc cggccgcctg 1020  
 gtagcccatgc tggacacaga ggggtggc agcctggggc ctggctatga gggccgacac 1080  
 attgccatgg agaagggtggc atccagaaca taccggctac ggctagaggc tgccaggcc 1140  
 ggtgatgcgg gcacctaccg ctgcctcgcc aaaggctatg ttgcagggtc tgggaccgg 1200  
 cttcgtaag cagccagtgc ccgttcccg gctctccctg tacatgtgcg ggaggaaggt 1260  
 gtgggtctgg aggctgtggc atgcttagca ggaggcacag tgcaccggg ggagactgc 1320  
 tccctgctgt gcaacatctc tggcgggtt ggcggccacag gactgcggct ggccgcac 1380

tgggggtgg	agcgaccaga	ggacggagag	ctcagctctg	tccctgccc	gctgggtgggt	1440
ggcgtaggcc	aggatgggt	ggcagagctg	ggagtccggc	ctggaggagg	ccctgtcagc	1500
gtagagctgg	tggggccccc	aagccatcg	ctgagactac	acagcttggg	gcccggaggat	1560
gaaggcgtgt	accactgtgc	ccccagcgcc	tgggtgcagc	atgcccacta	cagctggtac	1620
caggcggggca	gtgcccgtc	agggcctgtt	acagtctacc	cctacatgca	tgcctggac	1680
accctatttg	tgcctctgct	ggtgggtaca	ggggtggccc	tagtcaactgg	tgccactgtc	1740
cttggtacca	tcacttgctg	cttcatgaag	aggcttcgaa	aacggtga		1788

&lt;210&gt; 19

&lt;211&gt; 1842

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 19

atggggcggcc	tcaggcccac	gtctgctggc	ccttcgctgc	cgctgtctgt	gctgctaatg	60
cttaggaatgg	gatgctggc	ccgggagggt	ctgggtcccc	agggggccctt	gtaccgcgtg	120
gtctggcacag	ctgtctccat	ctcctgcaat	gtgaccggct	atgagggccc	tgcccagcag	180
aacttcgagt	gttccctgta	taggcccag	gccccagata	ctgcaactggg	cattgtcagt	240
accaaggata	cccagttctc	ctatgctgc	ttcaagtccc	gagtgggtgg	gggtgaggtg	300
caggtgcagc	gcctacaagg	tgatgccgt	gtgctcaaga	ttgcccgcct	gcaggccca	360
gatgccggca	tttatgagtg	ccacaccccc	tccactgata	cccgctaccc	gggcagctac	420
agccggcaagg	tggagctgag	agttcttcca	gatgtcctcc	aggtgtctgc	tgccccccca	480
ggggcccccag	gcccgcaggc	cccaacctca	cccccacgca	tgacggtgca	tgaggggcag	540
gagctggcac	tgggctgcct	ggcaggagaca	agcacacaga	agcacacaca	cctggcagtg	600
tcctttgggc	gatctgtgcc	cgaggcacca	gttggggcgt	caactctgca	ggaagtggtg	660
ggaatccgggt	cagacttggc	cgtggaggct	ggagctccct	atgctgagcg	attggctgca	720
ggggagcttc	gtctgggcaa	ggaagggacc	gatcggtacc	gcatggtagt	aggggggtgcc	780
caggcaggggg	acgcaggcac	ctaccactgc	actggcgtc	agtggattca	ggatcctgat	840
ggcagctgggg	cccagattgc	agagaaaagg	gccgtcctgg	cccacgtgga	tgtcagacg	900
ctgtccagcc	agctggcagt	gacagtgggg	cctggtaac	gtcggatcgg	cccaggggag	960
cccttggaaac	tgctgtgcaa	tgtgtcaggg	gcacttcccc	cagcaggccc	tcatgctgca	1020
tactctgttag	gttgggagat	ggcacctcgc	ggggcacctg	ggcccccggc	cctggtagcc	1080
cagctggaca	cagagggtgt	ggcagccctg	ggccctggct	atgagggccc	acacattgccc	1140
atggagaagg	tggcatccag	aacataccgg	ctacggctag	aggctgcccag	gcctgggtat	1200
gcggggcacct	accgctgcct	cgccaaagcc	tatgttcgag	ggtctgggac	ccggcttcgt	1260
gaagcagcca	gtgcccgttc	ccggccctc	cctgtacatg	tgccggagga	aggtgtggtg	1320
ctggaggcgt	tggcatggct	agcaggaggg	acagtgtacc	gcccggagac	tgcctccctg	1380
ctgtgcaaca	tctctgtgcg	gggtggccccc	ccaggactgc	ggctggccgc	cagctgggtgg	1440
gtggagcgcac	cagaggacgg	agagctcage	tctgtccctg	cccagctgtt	gggtggcgta	1500
ggccaggatg	gtgtggcaga	gctggggatc	cggcctggag	gaggccctgt	cagcgttagag	1560
ctgtgtgggc	cccgaaagcca	tggctgaga	ctacacagct	tgggggccca	ggtatgaaggc	1620
gtgttaccat	gtgccccccag	cggctgggtg	cagcatgcg	actacagctg	gtaccaggcg	1680
ggcagtgtccc	gctcaggggcc	tgttacagtc	tacccctaca	tgcatgcct	ggacacccta	1740
tttgcctc	tgctgggtgg	tacaggggtg	gccctagtca	ctggtgcac	tgcctttgggt	1800
accatcaatt	gctgtttcat	gaagaggctt	cgaaaacgggt	ga		1842

&lt;210&gt; 20

&lt;211&gt; 1791

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 20

atggccgcca	actccaccag	cgacctccac	actccggga	cgcagctgag	cgtggctgac	60
atcatcgta	tcactgtgt	ttttgcctg	aacgtggccg	tgggcatatg	gtcctttgt	120
cggcccgat	ggaacacgg	gaatggctac	ttcctggcag	gccgggacat	gacgtgggt	180
cggattggag	cctcccttct	cgccagcagc	gagggctctg	gcctttcat	tggactggcg	240
ggctcaggcg	cgccaggagg	tctggccgt	gcaggcttcg	agtggaaatgc	cacgtacgt	300
ctgctggcac	tggcatgggt	gttcgtgccc	atctacatct	cctcagagat	cgtcacctt	360
cctgagataca	ttcagaagcg	ctacggggcc	cagcgatcc	gatgtaccc	gtctgtcctg	420

tccctgtcac	tgtctgtctt	caccaagata	tcgctggacc	tgtacgcggg	ggctctgttt	480
gtgcacatct	gcctggctg	gaacttctac	ctctccaccá	tcctcacegt	cgccatcaca	540
gcccgttaca	ccatcgcagg	gggcctggct	gctgtaatct	acacggacgc	cctgcagacg	600
ctcatcatgg	tggtggggc	tgtcatctg	acaatcaaag	cttttgacca	gatcggtggt	660
tacgggcage	tggaggcagc	ctacgcccag	gccattccct	ccaggaccat	tgccaaacacc	720
acctggcacc	tgccacgtac	agacgcctg	cacatgttgc	gagaccccca	cacaggggac	780
ctgcccgttga	ccgggatgac	ctttggctg	accatcatgg	ccacctggta	ctggtgacacc	840
gaccagggtca	tcgtgcacgc	atcatgtca	gcccgggacc	tgaaccatgc	caaggcgggc	900
tccatcttgg	ccagctacct	caagatgtc	ccccatgggg	tgatcataat	gccccggcatg	960
atcagccgcg	cattgttccc	agatgtatgt	ggctgcgtgg	tgccgtccga	gtgcctgcgg	1020
gcctgccccgg	ccgagggtcgg	ctgtccaaac	atcgccctacc	ccaagctgtt	catggaactg	1080
atgcccatacg	gtctgcgggg	gctgtatgtc	gcagtgtatgc	tggcggcgct	catgtcgtcg	1140
ctgacccatcca	tcttcaaacag	cagcagcacc	ctttcaacta	tggacatctg	gaggcggctg	1200
cgtcccccgct	ccggcgagcg	ggagctccctg	ctgggtggac	ggctggatcat	agtggcactc	1260
atcggcgtga	gtgtggcctg	gatccccgtc	ctgcaggact	ccaacagcgg	gcaactcttc	1320
atctacatgc	agtcagtgac	cagtcctctg	gccccaccag	tgactgcagt	ctttgtctg	1380
ggcgtcttct	ggcgtcttct	ggcgtcttct	ggggccttct	ggggcctgtat	agcaggcgtg	1440
gtgggtgggg	ccacgaggt	ggtcctggaa	ttcctgaacc	cagccccacc	gtgcggagag	1500
ccagacacgc	ggccagccgt	cctggggagc	atccactacc	tgcacttgc	tgcacttgc	1560
tttgcactca	gtgggtctgt	tgtgggtggct	ggaagcctgc	tgaccccacc	cccacagagt	1620
gtccagatgt	agaaccttac	ctggtggacc	ctggctcaagg	atgtgccctt	gsgaactaaa	1680
gcaggtgatg	gccaacacacc	ccagaaaacac	gccttctggg	cccggtctgt	tggtttcaat	1740
ccatccctcc	tcatgtgt	caacatattc	ttttatgcct	acttcgcctg	a	1791

&lt;210&gt; 21

&lt;211&gt; 1182

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 21

atggattcct	taaagaatga	gaactatgtat	ctggtatttg	ttgaagcatt	tgatttctgt	60
tctttcttga	ttgctgagaa	gcttgtaaa	ccatttgtgg	ccatttctcc	caccacattc	120
ggctctttgg	attttggct	accaagcccc	ttgtcttattg	ttccagttatt	cccttccttg	180
ctgactgatc	acatggacatt	ctggggccga	gtgaagaatt	ttctgtatgtt	cttttagtttc	240
tccaggagcc	aatggacat	gcagtcatac	tttgacaaca	ccatcaagga	gcatttccca	300
gaaggctcta	ggccagtttt	gtctcatctt	ctactgaag	cagagggtgt	gtttgttaac	360
tctgattttg	ccttgcattt	tgccggcccc	ctgcttccca	acactgttta	tattggaggc	420
ttgatggaaa	aacctattaa	accagtacca	caagacttgg	acaacttcat	tgccaacttt	480
ggggatgcag	ggttgtcct	tgtggcctt	ggctccatgt	tgaacacccca	tcagtccttc	540
gaagtccctca	agaagatgc	caatgcctt	gcccacccccc	ctcaaggagt	gatatggaca	600
tgtcagagtt	ctcattggcc	cagagatgtt	catttggcca	caaatgtgaa	aattgtggac	660
tggcttccctc	agagtgcac	cctggctcac	cccagcatcc	gtctttttgt	cactcatgtt	720
ggcagaacaaca	gcgtaatgg	ggccatccgt	catgggtgtc	ccatgggtgg	attaccagtc	780
aatggagacc	agcatggaaa	catggtccga	gtatgtgcca	aaaattatgg	tgtctctatc	840
cgggtgaatc	aggtcacacgc	cgacacactg	acacttacaa	tgaacaaga	catagaagac	900
aagaggatca	agtcggcagt	gttggcagcc	agtgtatctc	tgcacttgc	gcccctgagc	960
ccgcacacgc	ggctgggtgg	ctggatcgac	cacatcctcc	agactggggg	agcgacgcac	1020
ctcaaggccct	atgccttcca	gcagccttgg	catgagcagt	acctcattga	tgtctttgt	1080
tttctgtctgg	ggctcactct	gggcactatg	tggctttgtg	ggaagctgt	gggtgtgg	1140
cccaagggtgc	tgcgtggggc	caggaagggt	aagaagacat	ga		1182

&lt;210&gt; 22

&lt;211&gt; 1572

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 22

atgggtgggc	agcggtgtct	gcttctagtg	gccttccttc	tttctgggg	cctgctctca	60
gaggctgcca	aaatcctgac	aatatctaca	ctgggtggaa	gccattacct	actgttggac	120

cgggtgtctc	agattcttca	agagcatgg	cataatgtga	ctatgttca	ttagactgga	180
aagttttga	tcccagatat	taaaggagg	aaaaaatcat	accaagttat	caggtgg	240
tcacctaag	atcatcaaa	aagaattaag	aagcatttt	atagctacat	agaaacagca	300
ttggatggca	gaaaagaatc	tgaagccct	gtaaagctaa	tggaaatatt	tggactcaa	360
tgttagttatt	tgctaaggcag	aaaggatata	atggattct	taaagaatga	gaactatgat	420
ctggtatttg	ttgaaggcatt	tgatttctgt	tcttcctga	ttgctgagaa	gcttgtgaaa	480
ccatttgtgg	ccattcttcc	caccacattc	ggctctttgg	attttggct	accaagcccc	540
ttgtcttatg	ttccagtatt	cccttccttg	ctgactgatc	acatggactt	ctggggccga	600
gtgaaagaatt	ttctgtatgtt	ctttagttc	tccaggagcc	aatggacat	gcagtctaca	660
tttgacaaca	ccatcaagga	gcatttccca	gaaggctcta	ggccagttt	gtctcatctt	720
ctactaaag	cagagttgt	gtttgttaac	tctgatttt	ccttgcattt	tgcccgcccc	780
ctgcttccca	acaatgttta	tattggagc	ttgatggaaa	aacctattaa	accagtacca	840
caagacttgg	acaacttcat	tgccaactt	ggggatgcag	ggtttgtcct	tgtggcctt	900
ggccatgt	tgaacaccca	tcagtcctt	gaagtctca	agaagatgca	caatgcctt	960
gcccaccc	ctcaaggagt	gatatggaca	tgtcagagg	ctcattggcc	cagagatgtt	1020
catttggcca	caaatgtgaa	aatttggac	tggcttcctc	agagtgcac	cctggctcac	1080
cccagcatcc	gtcttttgc	cactatgg	gggcagaaca	gcgtatgg	ggccatccgt	1140
catggtgtgc	ccatgggtgg	attaccagtc	aatggagacc	agcatggaaa	catggtccga	1200
gttagtagcca	aaaattatgg	tgtctctatc	cggttgaatc	aggtcacagc	cgacacactg	1260
acacttacaa	tgaaaacaagt	catagaagac	aagaggtaca	agtcggcagt	ggtggcagcc	1320
agtgtcatcc	tgcactctca	gcccctgagc	ccgcacagc	ggctgggtgg	ctggatcgac	1380
cacatcctcc	agactgggg	agcgacgcac	ctcaaggcct	atgccttcca	gcagccttgg	1440
catagcagt	acctcatgta	tgtctttgt	tttctgtgg	ggctcaactct	gggcactatg	1500
tggcttgg	ggaagctgct	gggtgtgg	gccaggtggc	tgcgtggggc	caggaagg	1560
aagaagacat	ga					1572

&lt;210&gt; 23

&lt;211&gt; 759

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 23

atgagctgcg	tcctgggtgg	tgtcatcccc	ttggggctgc	tgttctgg	ctgcggatcc	60
caaggctacc	tcctgccaa	cgtcaactctc	ttagaggagc	tgctcagcaa	ataccagcac	120
aacgagtctc	actcccggt	ccgcagagcc	atcccaggg	aggacaagga	ggagatcctc	180
atgctgcaca	acaagctcg	gggcagggt	cagcctcagg	cctccaaat	ggagtacatg	240
acctggatg	acgaactgga	gaagtctgt	gcagcgtgg	ccagtcagt	catctggag	300
cacgggccc	ccagtctgt	ggtgtccatc	gggcagaacc	tggcgctca	ctggggcagg	360
tatcgctctc	cgggttcca	tgtcagttcc	ttgtatgacg	aggtgaagga	ctacacctac	420
ccctacccga	gcgagtgca	ccccgtgt	ccagagagg	gctcgcc	catgtgcac	480
cactacacac	agatagttt	ggccaccacc	aacaagatcg	tttgcgtgt	gaacacctgc	540
cggaaagatga	ctgtctgggg	agaagtttgg	gagaacgcgg	tctactttgt	ctgcaattat	600
tctccaaagg	ggaactggat	tggagaagcc	ccctacaaga	atggccggcc	ctgctctgag	660
tgcacccacca	gctatggagg	cagctgcagg	aacaacttgc	gttaccgagg	taggaaattt	720
actcccaaca	cttttgcata	gaatttgc	cc	tcagtctga		759

&lt;210&gt; 24

&lt;211&gt; 1494

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 24

atgagctgcg	tcctgggtgg	tgtcatcccc	ttggggctgc	tgttctgg	ctgcggatcc	60
caaggctacc	tcctgccaa	cgtcaactctc	ttagaggagc	tgctcagcaa	ataccagcac	120
aacgagtctc	actcccggt	ccgcagagcc	atcccaggg	aggacaagga	ggagatcctc	180
atgctgcaca	acaagctcg	gggcagggt	cagcctcagg	cctccaaat	ggagtacatg	240
acctggatg	acgaactgga	gaagtctgt	gcagcgtgg	ccagtcagt	catctggag	300
cacgggccc	ccagtctgt	ggtgtccatc	gggcagaacc	tggcgctca	ctggggcagg	360
tatcgctctc	cgggttcca	tgtcagttcc	ttgtatgacg	aggtgaagga	ctacacctac	420

ccctacccga	gcgagtgcaa	cccctggtgt	ccagagaggt	gctcggggcc	catgtgcacg	480
cactacacac	agatagttg	ggccaccacc	aacaagatcg	gttgtgctgt	gaacacctgc	540
cggaaagatga	ctgtctgggg	agaagtttgg	gagaacgcgg	tctactttgt	ctgcaattat	600
tctccaaagg	ggaactggat	tggagaagcc	ccctacaaga	atggccggcc	ctgctctgag	660
tgcccaccca	gctatggagg	cagctgcagg	aacaacttgt	gttaccgaga	agaaacctac	720
actccaaaac	ctgaaacgga	cgagatgaat	gagggtggaaa	cggtcccat	tcctgaagaa	780
aaccatgtt	ggctccaacc	gagggtgatg	agacccacca	agcccaagaa	aacctctgcg	840
gtcaactaca	tgacccaagt	cgtcagatgt	gacaccaaga	tgaaggacag	gtgcaaagg	900
tccacgtgta	acaggtacca	gtgcccagca	ggctgcctga	accacaaggc	gaagatcttt	960
ggaactctgt	tctatgaaag	ctcgctcagc	atatgcccgg	cgcccatcaca	ctacgggatc	1020
ctggatgaca	aggggggcct	gggtggatatc	accaggaacg	ggaaggtccc	cttcttcgtg	1080
aagtctgaga	gacacggcgt	gcagtcctc	agcaaataca	aaccttccag	ctcattcatg	1140
gtgtcaaaag	tgaaaagtgca	ggatttggac	tgctacacga	ccgttgcgtca	gctgtgcccc	1200
tttggaaaagc	cagcaactca	ctgccccaga	atccattgtc	cggcacactg	caaagacgaa	1260
ccttcctact	gggctcccggt	gttttggaaacc	aacatctatg	cagatacctc	aagcatctgc	1320
aagacagccg	tgcacgcggg	agtcatcagc	aacgagagtg	gggggtgacgt	ggacgtgatg	1380
ccctggata	aaaagaagac	ctacgtgggc	tcgctcagga	atggagttca	gtctgaaagc	1440
ctggggactc	ctcggatgg	aaaggccttc	cgatctttg	ctgtcaggca	gtga	1494

&lt;210&gt; 25

&lt;211&gt; 1315

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 25

batgctgcac	aacaaggcttc	ggggccaggt	gcagcctcag	gcctccaaca	tggagtacat	60
gacctggat	gacgaactgg	agaagtctgc	tcgcagcgtgg	gccagtcagt	gcatctggga	120
gcacggggcc	accagtctgc	tgggttccat	cgggcagaac	ctggcgctc	actggggca	180
gtatcgctct	ccgggggttcc	atgtcagtc	ctggtatgac	gaggtgaagg	actacaccta	240
cccttacccg	agcgagtgca	accctggtg	tccagagagg	tgctcggggc	ccatgtgcac	300
gcactacaca	cagatagttt	gggcccaccac	caacaagatc	ggttgcgtg	tgaacacactg	360
ccggaagatg	actgtctggg	gagaagtttgc	ggagaacgcg	gtctactttg	tctgcaatta	420
ttctccaaag	gggaacttgg	ttggagaagc	cccttacaag	aatggccggc	cctgctctga	480
gtgcccaccc	agctatggag	gcagctgcag	gaacaacttg	tgttaccgag	aagaaaccta	540
cactccaaaa	cctgaaacgg	acgagatgaa	tgaggtggaa	acggctccca	ttcctgaaaga	600
aaaccatgtt	tggctccaaac	cgagggtgat	gagacccacc	aagcccaaga	aaacctctgc	660
ggtcaactac	atgaccaaaag	tcgtcagatg	tgacaccaag	atgaaggaca	ggtgcaaagg	720
gtccacgtgt	aacaggtacc	agtgcacgc	aggctgcctg	aaccacaaagg	cgaagatctt	780
tggaactctg	ttctatgaaa	gctcgctctag	catatgcgc	gcccgcattcc	actacgggat	840
cctggatgac	aaggggggcc	tgggtgatat	caccaggaa	gggaaggtcc	cttcttcgt	900
gaagtctgag	agacacgcgc	tgcagtcct	cagcaaatac	aaaccttcca	gctcattcat	960
gtgtcaaaag	tgaaaagtgc	aggatttgg	ctgctacacg	accgttgcct	agctgtgccc	1020
gtttggaaaag	ccagcaactc	actgcccac	aatccattgt	cgccacact	gaaaagacga	1080
accttcctac	tgggtctccgg	tgtttggaaac	caacatctat	gcagatacct	caagcatctg	1140
caagacagcc	gtgcacgcgg	gagtcatcag	caacgagat	gggggtgacg	tggacgtgat	1200
ccctggggat	aaaagaaga	cctacgtgg	tcgctcagg	aatggagttc	agtctgaaag	1260
cctggggactc	ctcggatgg	gaaaggcctt	cgatctttt	ctgtcaggc	agtga	1315

&lt;210&gt; 26

&lt;211&gt; 927

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 26

atgggttgggg	gcgtcctcgc	ctcgctgggc	ttcgctttct	cggtttcgc	cagcgatctg	60
ctgcatctct	acctcgccct	gggcctcctc	gctggcttgc	gttggccct	ggttgcgc	120
ccgcgcctag	gcacccctctc	gcgttacttc	tcccgcgc	gagtcttggc	ggtggggctg	180
gcgcgtcaccg	gcaacggggc	ctctcgctg	ctcctggggc	ccgccttgca	gcttcttc	240
gatactttcg	gctggcgcccc	cgctctgctc	ctcctcgccg	cgatcaccct	ccacccatc	300

ccctgtggcg ccctgctgct acccctggtc	cttcctggag	acccccagc	cccaccgcgt	360
atccccctag ctggccctcgg	cctgagtcgt	ttcacacgccc	gggccttc	420
ctaggcacag ccctgggttgg	gggggggtac	ttcggttc	acgtgcactt	480
gcttagacc gggggcttggg	gggatacgg	gcagcgctgg	tggtggccgt	540
ggggatgcgg	ggccccggct	ggtctgcggg	accaggctg	600
cccggtgc	tggccgtatt	cggggctctg	ggctgtgggt	660
gtggccgtgg	tggggcggcga	agagagctgg	gggggtcccc	720
tatgggctga	gcgcggggag	ttacgccccg	ctggtttccg	780
ggcgtcggag	gtgtgggtca	ggccacagg	ctggtgatga	840
ctcctgggcc	ctccccctg	aggtaaggac	ctgagctcac	900
tctgccccctg	gggttcgagg	cttctaa		927

&lt;210&gt; 27

&lt;211&gt; 1344

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 27

atgacccccc agccgcgg acccccgat	gggggctggg	gctgggtgg	ggcgccgcga	60
gccttcgcga taaacgggt	gtccatcg	ctgctgcgt	cgctgggc	120
gacccgtccg	agcacttga	ccgaagcgcc	caggacactg	180
ctggccgtgc	agcaggc	cagccccgtg	ggcagcgc	240
cgccccgtgg	tatgggtgg	ggggtc	gcctcgctgg	300
gccagcgatc	tgctgcac	ctacctcg	ctgggc	360
ctgggttgc	ccccgcct	aggcacc	tcgcgttact	420
gccccgtggc	tggcg	ccgg	tctccgc	480
cagcttcttc	tcgataactt	cggctgg	tgctctcg	540
ctccaccta	ccccgtgg	cgcctgt	tcacccctgg	600
gccccaccgc	gtagtc	ccct	tcgcgttact	660
tcaatctttg	ctctagg	ccgc	tctccacac	720
ttggctcccc	acgctt	ccgg	ccggc	780
gtggctgcga	tggggatgc	ggggccc	ctgg	840
tgggtgc	tcccgc	gtcgg	tgactgg	900
gtgggtgggc	tgg	gg	ggggctgtgg	960
gcggctgtgg	cctatgg	gagc	gggggtcc	1020
cccggtgtgg	tgggc	agg	cctgctggc	1080
agccctgggg	ggct	ccct	gatgtgtat	1140
tccaccgc	ctt	ctgt	ccggcag	1200
gggttgc	gggc	ctc	catctacata	1260
gagacggggg	agct	cc	ctccagccac	1320
tccactctgg	acacc	ctt	ggggcctggc	1344

&lt;210&gt; 28

&lt;211&gt; 1375

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 28

batggcg	aggacag	ccccgac	gggctggg	tgggtgg	tgctctc	60
gttctcc	tcggcg	ttt	tttgggt	tcttc	tttgggt	120
gtttgtggcg	gcgtt	agc	ggc	tc	ccat	180
cgcgg	cag	ccg	cg	tc	tc	240
gcccgtgt	atgact	gc	tc	tg	tc	300
tactcctt	acccac	ctt	cg	cg	tc	360
gac	cc	ctt	gg	gg	gg	420
cac	cc	ctt	gg	gg	gg	480
gtggctgc	agcc	ctt	gg	gg	gg	540
ccac	cc	ctt	gg	gg	gg	600
gggtggccc	aggccc	ac	cc	cc	cc	660

tgttgcctc	accctgatca	acactggcta	cttcattccc	tacctecacc	ttgtggccca	720
tctccaggac	ctggattggg	acccactacc	tgctgccttc	ctactctcag	ttgttgcata	780
ttctgacctc	gtggggcggt	tggctccgg	atggctggga	gatgcagtcc	cagggcctgt	840
gacacgactc	ctgatgcct	ggaccacatt	gactgggggt	tcactagccc	tttccctgt	900
agctcaggt	cccacagccc	tgggtgtct	ggtgtggcc	tacggttca	catcaggggc	960
tctggccca	ctggccttc	ccgtgctgcc	tgaactaata	gggactagaa	ggatttactg	1020
tgcctggga	ctgttgcaga	tgtatagagag	catcgggggg	ctgctggggc	ctcctctc	1080
agctacctc	cgggatgtgt	caggcaacta	cacggcttct	tttgggtgg	ctggggcctt	1140
ccttcttca	gggagtggca	ttctcctcac	cctggcccaac	ttcttctgtct	tctcaactac	1200
tacctccggg	cctcaggacc	ttgtAACAGA	agcactagat	actaaAGTTC	ccctacccaa	1260
ggaggggctg	gaaggaggac	tgaactccac	agagtcaggc	ccagaaaAGCC	aaagcttgac	1320
agctccaggt	cttctcttgc	cacgtcttgg	tctccacaga	accacagtgc	cttaa	1375

&lt;210&gt; 29

&lt;211&gt; 510

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 29

atgaccatga	agacctctgg	ggccacttgt	gatgcaaaca	gtgtgatgaa	ctgcgggatc	60
cgcgggtctg	aaatgttgc	ttagatggat	tttagggcca	taaaacctta	ccagactctg	120
atcaaaaaag	tcgggcagag	acattgcgtg	gaccctgcgt	tcatcgcagc	catcatctcc	180
agggaaagcc	atgggggatc	tgtcctgcaa	gacggctggg	accacagggg	acttaaattt	240
ggcttgatgc	agcttgataa	acaaacgtac	caccctgtcg	gtgcctggg	tagcaaagag	300
caccccccac	aggctactgg	gattctaaca	gagagaatta	aggcaatcca	aaaaaaattc	360
cccacgtgga	gtgttgccta	gcacctcaaa	ggtaggtctct	cagctttaa	gtcaggaatt	420
gaagcgattt	ccaccccatc	ggacatagac	aatgacttcg	tcaatgatat	cattgctcga	480
gctaagttct	ataaaaagaca	aagcttctag				510

&lt;210&gt; 30

&lt;211&gt; 561

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 30

atgaaggcctc	acctacatcc	acggctgtac	cacggctgt	atggggacat	catgaccatg	60
aagacctctg	ggccacttg	tgtgcaaac	agtgtgatga	actgcgggat	ccgcgggtct	120
gaaatgtttg	ctgagatgg	ttttagggcc	ataaaacctt	accagactct	gatcaaaaaaa	180
gtcgggcaga	gacattgcgt	ggacccctgt	gtcatcgcag	ccatcatctc	cagggaaagc	240
catggggat	ctgtcctgca	agacggctgg	gaccacaggg	gacttaaattt	ttggcttgatg	300
cagcttgata	acaaaacgt	ccaccctgtc	ggtaggtctgg	atagcaaaga	gcaccccttca	360
caggctactg	ggattcttac	agagagaattt	aggcaatcc	aaaaaaattt	ccccacgtgg	420
agtgttgc	agcacctcaa	aggtaggtctc	tcagctttta	agtcaggaat	tgaagcgatt	480
gccaccccat	cgacataga	caatgacttc	gtcaatgata	tcatgtcg	agctaagttc	540
tataaaagac	aaagcttctca	g				561

&lt;210&gt; 31

&lt;211&gt; 2028

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 31

atggagagcg	gcaccagcg	ccctcagcct	ccacagttag	atcccctgg	tgcggtttccc	60
cagaagggct	tggagctgg	ggacatcg	gtgctagttc	tgtacttct	ctttgtctcg	120
gctgttggac	tatggtccac	agtgaagacc	aaaagagaca	cagtggaaagg	ctacttc	180
gctggaggggg	acatgggtgt	gtggccagt	ggtagcatct	tgtttggcc	caatgttgg	240
agtggacatt	tcattggcct	ggcagggtca	ggtagctgt	cgggcatttc	tgtatcagct	300
tatgaactta	atggcttgg	ttctgtgt	atgttggcct	ggatcttc	acccatctac	360
attgctggc	aggcaccac	gtgccagaa	tacctacgg	agcgcttc	tggtcatcaga	420

atccccatca	tcctggctgt	actctaccta	tttatctaca	tcttcaccaa	gatctcggt	480
gacatgtatg	caggtgccat	cttcatccag	cagtcttgc	acctggatct	gtacctggcc	540
atagttggc	tactggccat	cactgctgt	tacacgggt	ctggggcct	ggctgctgt	600
atctacacgg	atgcccctgca	gacgtgtac	atgcttata	gagcgtcac	cttgatggc	660
tacagttcg	ccgcgggtgg	tggatggaa	ggactgaagg	agaagtaact	cttggccctg	720
gctagcaacc	ggagtgagaa	cacagctgc	gggctgccc	ggsaagatgc	cttccatatt	780
ttccgagatc	cgctgacatc	tgatctccc	tggccgggg	tcctatttg	aatgtccatc	840
ccatccctct	ggtactgggt	cacggatcag	gtgattgtcc	agcggactct	ggctgccaag	900
aacctgtccc	atgccaaagg	agggtgtct	atggctgtat	acctgaaggt	gctggccctc	960
ttcataatgg	tgtccctgg	gatggtcagc	cgcacatct	tccagatca	agtggccctgt	1020
gcagatccag	agatctgcca	gaagatctgc	agcaacccct	caggctgttc	ggacatcgcg	1080
tatcccaaac	tcgtgctgg	actctgccc	acagggctcc	gtgggctgtat	gatggctgt	1140
atggtggcgg	ctctcatgtc	ctccctcacc	tccatcttta	acagtgcag	caccatcttc	1200
accatggacc	tctggaaatca	cctccggcc	cgggcatctg	agaaggagct	catgattgt	1260
ggcagggtgt	ttgtgctgt	gctggctctg	gtctccatcc	tctggatccc	tgtggtccag	1320
gccagccagg	gcggccagct	tttcatctat	atccagtcca	tcagctctta	cctgcagccg	1380
cctgtggcgg	tggctttcat	catggatgt	ttctggaa	ggaccaatga	aaagggtgcc	1440
ttctggggcc	tgatctcggg	cctgctcctg	ggcttggtt	ggctggctt	gactttatt	1500
tacgtgcagc	ctcgatgcga	ccagccagat	gagcgcgg	tcctggtaa	gagcatttcac	1560
tacctctact	tctccatgtat	cctgtccacg	gtcaccctca	tcactgtctc	caccgtgagc	1620
tggttcacag	agccacccctc	caaggagatg	gtcagccacc	tgacctggtt	tactcgta	1680
gaccgggtgg	tccagaagga	acaagcacca	ccagcagctc	ccttgtct	taccctctc	1740
cagaacggga	tgccagagggc	cagcagcagc	agcagcgtcc	agttcgagat	gttcaagaa	1800
aacacgtcta	aaacccacag	ctgtgacatg	accccaaagc	agtccaaagt	gttgaaggcc	1860
atccctgtggc	tctgtggaa	acaggagaag	ggcaaggaag	agctccggc	cagagcagaa	1920
gccatcatag	tttccctgg	agaaaacccc	ttggtaa	ccctccctgg	cgtcaacctc	1980
atttctgcg	tgagctgcgc	catcttatac	tggggctatt	ttgcttag		2028

&lt;210&gt; 32

&lt;211&gt; 1458

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 32

atggagccct	gttggggaga	aggctgttt	catctagcac	ccccacgcca	ccatccccag	60
aaggctgact	ggcatttc	tccacagcac	attcaggaat	tcaccaatga	gacatggcag	120
gcgcgtactg	gagagccact	gcccgtac	ctagtcc	ttatgtggc	cctcatcg	180
tctctgtatc	ccctgggagg	cctcttgg	gca	cagg	ccct	240
ctgggaa	agaagtc	cctgtgt	tttgc	ttgtgt	tcag	300
tttggattca	gccc	aaagc	aggcc	gatgt	tgctgg	360
ggagtcaat	ttgtgt	gatgt	catgt	ggatgt	actgt	420
aaggagctcc	ggggatgt	ggccatgt	tcagccat	ttacgg	cttgc	480
atgggacagg	ttgtcg	actc	ctagg	ggcc	ctc	540
ctggccagct	gcctgg	gccc	cag	ctcg	cc	600
agccgcgt	acct	ctcat	tgact	gtgg	tcgt	660
cggctccggg	gttccggg	cttgc	gac	ccgg	cct	720
gcctgccc	gttccgg	gggg	gat	ccgg	ccgt	780
agacaggtga	caagc	ctgt	gttct	ggat	gtact	840
gtgtacgc	acgc	ctct	gtgttcc	ggat	gtgt	900
tacgcatca	tcggg	acttgg	ggatgt	ggatgt	ggatgt	960
atcgagaggg	tgggt	cggt	atcggt	acag	ctgt	1020
gggagcatct	tcact	gtgg	ctgt	ccat	gtgt	1080
gccatggcc	gcat	cttt	tc	ttgg	ccgt	1140
gggatcc	ccac	agat	gtt	ccagg	ccgt	1200
ggggcgctca	tgt	ggat	cat	gtc	ccgt	1260
gcctgtccc	actt	cct	tc	ttgg	ccgt	1320
actggcc	tcct	tct	gtt	gtgt	ccgt	1380
cacagactca	actt	cccc	tttgc	ggat	ccgt	1440
cagtcaacag	aact	ccat	gtgttcc	ggatgtt	ccgt	1458

<210> 33  
 <211> 1491  
 <212> DNA  
 <213> Homo sapiens

<400> 33

atgagagcgc	tccgaagact	gattcagggc	aggatcctgc	tcctgaccat	ctgcgctgcc	60
ggcattggtg	ggactttca	gttggctat	aacctctcta	tcatcaatgc	ccgcacccat	120
cacattcagg	aattcaccaa	tgagacatgg	caggcgcgt	ctggagagcc	actgcggat	180
cacctagtcc	tgcttatgt	gtccctcata	gtgtctctgt	atcccctgg	aggcctcttt	240
ggagcactgc	ttgcagggtcc	cttggccatc	acgctggaa	ggaagaagtc	cctcctggtg	300
aataacatct	ttgtgggtgc	agcagcaatc	ctgtttggat	tcagccgaa	agcaggctcc	360
ttttagatga	tcatgctggg	aagactgctc	gtgggagtc	atgcagggt	gagcatgaac	420
atccagccca	tgtacctggg	ggagagcgc	cctaaggagc	tccgaggagc	tgtggccat	480
agctcagcca	tcttacggc	tctggggatc	gtatgggac	agggtggcgg	actcaggag	540
cctcttaggt	gcccctcaggc	ctggccctgt	ctgctggcca	gctgcctgg	gcccggggcg	600
cuccagctcg	cctccctgtcc	tctgctccct	gaaagccgc	gctacccct	cattgactgt	660
ggagacaccg	aggcctgcct	ggcagacta	cggcggctcc	ggggctccgg	gacttggca	720
ggggagctgg	aggagctgg	ggaggagcgc	gctgcctgg	agggtgcgg	tgccggcgc	780
ccatgggagc	tgttccagca	tcggccctgt	aggagacagg	tgacaagcct	cgtggttctg	840
ggcagtgc	tggagctctg	cggaaatgac	tcgggtgtac	cctacgcctc	ctccgtgttc	900
cggaggcag	gagtgcgg	agcgaagatc	cagtacgcga	tcatcggac	ttgggagctgc	960
gagctgctca	cgccgggtgt	tagttgtgt	gtaatcgaga	gggtgggtcg	gcgcgtgctg	1020
ctcatcggt	ggtacagct	gatgacctgc	tgggggagca	tcttactgt	gcccctgtgc	1080
ctgcagagct	ccttccctgt	gacactctac	ctggccatgg	cctgcacat	tgccttcatc	1140
ctcagcttg	gcattggccc	tgccggagtg	acggggatcc	tggccacaga	gctgtttgac	1200
cagatggcca	ggcctgctgc	ctgcatggc	tgcggggcgc	tcatgtggat	catgctcatc	1260
ctggtcggcc	tggatttcc	cttatacatg	gaggccttgt	cccacttcct	ctatgtccct	1320
ttccttggtg	tctgtgtctg	tggggccatc	tacactggc	tgttccccc	tgagaccaa	1380
ggcaagacct	tccaagagat	ctccaaggaa	ttacacagac	tcaacttccc	caggcgggccc	1440
cagggcccca	cgtggaggag	cctggaggtt	atccagtcaa	cagaactcta	g	1491

<210> 34  
 <211> 1501  
 <212> DNA  
 <213> Homo sapiens

<400> 34

batgctccac	gccctcctgc	gatctagaat	gattcagggc	aggatcctgc	tcctgaccat	60
ctgcgctgcc	ggcattggtg	ggactttca	gttggctat	aacctctcta	tcatcaatgc	120
cccgacccat	cacattcagg	aattcaccaa	tgagacatgg	caggcgcgt	ctggagagcc	180
actgcggat	cacctagtcc	tgcttatgt	gtccctcata	gtgtctctgt	atcccctgg	240
aggccttctt	ggagcactgc	ttgcagggtcc	cttggccatc	acgctggaa	ggaagaagtc	300
cctcctggtg	aataacatct	ttgtgggtgc	agcagcaatc	ctgtttggat	tcagccgaa	360
agcaggctcc	tttgagatga	tcatgctggg	aagactgctc	gtgggagtc	atgcagggt	420
gagcatgaac	atccagccca	tgtacctggg	ggagagcgc	cctaaggagc	tccgaggagc	480
tgtggccatg	agctcagcca	tcttacggc	tctggggatc	gtatgggac	agggtggcgg	540
actcagggag	ctccttaggt	gcccctcaggc	ctggccctgt	ctgctggcca	gctgcctgg	600
gcccggggcg	ctccagctcg	cctccctgtcc	tctgctccct	gaaagccgc	gctacccct	660
cattgactgt	ggagacaccg	aggcctgcct	ggcagcaacta	cggcggctcc	ggggctccgg	720
ggacttggca	ggggagctgg	aggagctgg	ggaggagcgc	gctgcctgccc	agggtgcgg	780
tgcccggcgc	ccatgggagc	tgttccagca	tcggccctgt	aggagacagg	tgacaagcct	840
cgtggttctg	ggcagtgc	tggagctctg	cgggaaatgac	tcgggtgtac	cctacgcctc	900
ctccgtgttc	cggaaggcag	gagtgcgg	agcgaagatc	cagtacgcga	tcatcggac	960
tgggagctgc	gagctgctca	cggcgggtgt	tagttgtgt	gtaatcgaga	gggtgggtcg	1020
gcgcgtctg	ctcatcggt	ggtacagct	gatgacctgc	tggggagca	tcttactgt	1080
gcccctgtgc	ctgcagagct	cctccctgt	gacactctac	ctggccatgg	cctgcacat	1140
tgcccttcata	ctcagcttg	gcattggccc	tgccggagtg	acggggatcc	tggccacaga	1200
gctgtttgac	cagatggcca	ggcctgctgc	ctgcacatgg	tgcggggcgc	tcatgtggat	1260

catgctcate	ctggtcggcc	tgggatttcc	ctttatcatg	gaggccttgt	cccaacttcc	1320
ctatgtccct	ttccttggtg	tctgtgtctg	tggggccatc	tacactggcc	tgttccttcc	1380
ttagacaaaa	ggcaagaccc	tccaagagat	ctccaaggaa	ttacacagac	tcaacttccc	1440
caggcgggccc	cagggcccc	cgtggaggag	cctggagggtt	atccagtcaa	cagaactctca	1500
g						1501

&lt;210&gt; 35

&lt;211&gt; 4077

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 35

atggtagtgg	tgaagccat	gaacacaatg	gctccggtgg	tcacccggaa	taccggtctt	60
attctctatg	agggtcagtc	tcggccctc	acaggccctg	caggcagtgg	tccgcaaaac	120
ttggtcatca	gcgatgagga	tgacctagaa	gcagtgcggc	tagaggtgg	ggctgggctc	180
cggcatggtc	accttgtcat	tctgggtct	tccagtggca	gctctgctcc	caagagcttt	240
acagtggctg	agctggcagc	cggccaggt	gtctaccago	atgatgacag	agacggctcg	300
ctgagcgaca	acctgggtct	tcgcattgggt	gatggaggag	gcaggcacca	gttacagttt	360
ctgttcccca	tcaccttagt	gcctgtggat	gaccagccac	ctgttctcaa	tgccaaacacg	420
gggctgacac	tggcagaggg	tgaaacagtg	cccattcctc	ccctttccct	gagtgcact	480
gacatggatt	cagatgattc	tctgtgtctt	tttggctgg	agtcaccctt	cttaactacag	540
gggcattctgc	ttctccgcca	aactcaccct	ccccatgaga	agcaggaact	tctcagaggc	600
ctttggagga	aggagggggc	attttatgag	cgaacagtga	cagagtggca	gcagcaggac	660
ataacagagg	gcaggctgtt	ctatagacac	tctggggccc	atagtcctgg	gccagtcaca	720
gaccaggttca	catttagagt	ccaggataac	catgaccctc	ctaattcagtc	ccccgtacag	780
cggtttgtga	ttcgtatcca	tcctgtggat	cgcctccctc	cggagctggg	cagtggctgt	840
cccccttcgt	ttggtggata	ggaatcccag	ctcacaccac	tgaggaagaa	gtggctgcgc	900
tacactgacc	tggacacaga	tgaccgagaa	ctacgttaca	cagtactca	gtccccccaca	960
gacacagacg	aaaatcacct	gccagcccc	ctgggtaccc	ttgttcttgc	tgacaaccccc	1020
tcagtcgtgg	tgaccctattt	taccaagcc	cagatcaacc	atcataaaat	tgcttacaga	1080
ccccccgggtc	aagaacttggg	cgtggctact	cgagtggccc	agttccagtt	ccaggtggaa	1140
gaccgagctg	ggaatgtggc	tccaggtacc	tttacccttt	acttgcattcc	cgtggacaac	1200
cagccacctg	agatcctcaa	caccggcttc	actattcagg	agaagggtca	ccacatcctg	1260
agtgagacag	agttgcacgt	gaatgatgt	gacactgtat	ttgcccataat	ctctttcact	1320
ctcactcagg	cacccaaaca	tggccacatg	agagtgtctg	gacagatcct	gcatgttaggg	1380
ggtcttttcc	acttggagga	cataaaacag	ggccgagttt	cctatgccc	taatggggac	1440
aagtccctga	ctgatagctg	ctccctggaa	gtcagtgaca	gacatcatgt	ggtgcccattc	1500
actcttcagag	taaatgtccg	gccagtgat	gatgaagtgc	ccataactgag	ccatcctact	1560
ggcaactctgg	agtcctatct	agatgtctt	gaaaatgggg	ctactgaaat	cactgccaat	1620
gttattaagg	ggaccaatga	ggaactgtat	gacttgatgt	tgactttctt	cttggaaagat	1680
ccacccctgt	atggggaaat	cttggtcaat	ggcattccag	cagagcagtt	tactcaaagg	1740
gacatcttgg	agggctctgt	tgtatatacc	cacaccagt	gtgagatagg	cctattgcct	1800
aaagcggatt	cttttaaccc	gagtcgtca	gatatgtctc	aagaatggag	aattgggtggc	1860
aatactatcc	aaggaggta	tatatgggt	accatcctgc	ctgttgatag	ccaggccccca	1920
gaaatctttg	taggtgaaca	gttgatagta	atggaagggt	ataaaagtgt	tataacatca	1980
gtgcatataa	gtgctgaaga	tgtcactcc	ctgaatgtat	acatcttgc	cactatagtt	2040
attcagccata	cttcagggtt	ttttggaaaac	atttctccag	caccaggctc	tgagaaatca	2100
agagcaggga	ttgccataag	tgcttcaac	tttggaaaatc	tcaggcagg	ccacataaaac	2160
tatgtccaga	gtgtccataa	agggggtggaa	cctgtggagg	accgatttgc	atttcgttgc	2220
tctgtatggca	ttaactttt	agagagacag	ttttttccca	ttgtatcat	tcccaccaat	2280
gatgaacagc	cagagatgtt	tatgagagaa	ttttatgggt	tggaaaggat	gagtctggta	2340
attgatacac	ccattctcaa	tgctgtgtat	gctgtatgtc	ccctggatga	ttaactttc	2400
actattaccc	aattccccac	tcatggtcac	atcatgaatc	agctgataaa	tggcacgggt	2460
ttggtcgaaa	gcttcaccc	ggatcagatc	atagagatgt	ccagcattat	ttatgagcat	2520
gatgactccg	agacccagga	agacagttt	tgatggataac	taacagatgg	gaagcactct	2580
gtggaaaaga	cggtcctcat	tatagttatc	cctgttgatg	atgagacgccc	cagaatgact	2640
atcaataatg	gacttagaaat	agaaattggg	gataccaaga	ttatcaacaa	caaaatatta	2700
atggcaacag	attttagattc	agaagacaaa	tctttggttt	atattattcg	ttatggggca	2760
ggacatggct	tattacagag	acgaaaaccc	actggtgcc	ttgaaaatat	cacactgggc	2820

atgaatttta	cccaggatga	agtagacaga	aacttaattc	agtatgtcca	tttggggcaa	2880
gagggcattc	gggacctaatt	taaatttgc	gtgactgatg	gaataaaatcc	cctcatagat	2940
cgttactttt	atgtgtccat	cgggagcatt	gacattgtct	tccctgatgt	gataagtaag	3000
ggagtgtcct	tgaaaagaagg	tggcaaagtc	actcttacaa	cagacctact	aagcactagt	3060
gacttgaaca	gtcctgtatg	aaacttggtt	tttaccatca	ccagggctcc	catgcgaggt	3120
caccttggaaat	gcacggatca	gcctgggtg	tccatcacgt	ctttcactca	gctgcaactg	3180
gctggaaaaca	aaatctacta	catccacaca	gctgatgatg	aagtaaaaat	ggacagtttt	3240
gagtttcaag	tcaccgtatgg	acgtaaccct	gtcttcggaa	cattccgtat	ctccattagc	3300
gatgtggaca	ataaaaagcc	agttgtcacc	atccacaagg	tggttgcag	tgaaaagtgaa	3360
aacaagctga	ttactccctt	tgagctca	gtcgaagaca	gagatactcc	tgacaagctc	3420
ctgaaaattca	ctatcaccca	ggtgccattt	catggccatc	tcctattcaa	caataccaga	3480
cctgtcatgg	tttttaccaa	gcaagacttg	aatgaaaact	taatcagcta	caaacatgat	3540
ggcactgagt	caagtgaaga	tagttctcc	ttcacagtg	ctgatggcac	ccatacagac	3600
ttctatgttt	ttcctgatac	gggtttgaa	acaaggagac	cccaagtgtat	gaagatccag	3660
gtcttggctg	ttgacaacag	tgtccccca	atcgca	atagggggc	ctctacactt	3720
cgcactctag	ccactggcca	cttgggggttc	atgatcacaa	gaaaatatt	gaaagtggag	3780
gacagagaca	gcttacacat	ttcttctaga	tttacgtga	cagaggcccc	tcaacatgga	3840
tatcttctca	acctggacaa	aggcaaccac	agcatca	agttcacaca	agctgacatt	3900
gatgacatga	aaatatgtct	tgtttaaga	gaaggggcta	atgcaca	agtgatgttc	3960
tatTTTgcag	ttgaagatgg	tggtaagtat	tcccctctcc	ttgttagtgac	cgcaaggaga	4020
gacgcttttc	ttgggtgctc	tctgtatgaca	ttattacaag	aagtcttcat	caagtaa	4077

&lt;210&gt; 36

&lt;211&gt; 9318

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

<400> 36						
atggcacgt	cttggctcac	tgcaacctcc	acctccggc	ccgctgcctt	cgccaggcg	60
ttgctgtccc	ctggctcgc	ggggctgca	ggggctccotg	ctgaggaggc	catagtgctg	120
gcgaaccgcg	gactccgggt	gccttcggc	cgtgaagtct	ggctggatcc	cctgcatgac	180
ctgggtgtgc	aggtgcagcc	cggggaccgc	tgcgccgtt	cgtactaga	caacgacgca	240
ctggcccgac	gaccggggcg	cctgagttcc	aagcgttcc	cgtgcgactt	tggccctggc	300
gaggtgcgct	actctcacct	gggcgcgcgc	agccgcgtc	gggaccgcgt	ccggctgcag	360
ctgcgcgtatg	acgcgcggcg	agggcagta	gtgctaccac	ttgtactgg	gttggagggt	420
gtcttcaccc	agctggaggt	tgtgactcgg	aacttgcctc	ttgtcggtgg	agaactgctg	480
gggaccagca	atgcccctgg	cgcgcggagc	ctggagttcg	ccttcagcc	cgagacagag	540
gagtgcgcgc	tgggcatct	gtccggcttg	ggcgcgtc	ctcgctatgg	agaactcctc	600
cactaccgc	aggtccctgg	aggagccaga	gaggggaggcg	ccccggagac	tctcctgtatg	660
gactgcaaag	cttccagga	actaggcgtg	cgctatcgc	acacagccgc	cagtgcgtca	720
ccaaacaggg	actggatacc	catgggtgt	gagctgcgtt	cacgggggc	tcctgtgggc	780
agccctgc	tgaaacgcga	gcacttccag	tttctggta	ggatccgagg	agggggccgag	840
aacactgcac	ccaagccca	tttcgtggcc	atgatgtatg	ttggaggtgg	ccagtttgc	900
ctgacggccc	tgacccca	catgctggca	gccgaggatg	ctgagttcc	ctctgacctg	960
ttgatcttca	accttaettc	tccatccag	cctggccagg	gctacttgg	gagcaccgat	1020
gatgcagcc	tgccttctt	ctccctact	cagagggtat	tgccggctt	gaagattgccc	1080
taccagccccc	cttctgaaga	ctctgaccag	gagccctt	ttgaactgg	attggaggta	1140
gtggatctag	aaggagcagc	ttcagaccct	tttgccttca	ttgttagtgg	gaagcccatg	1200
aacacaatgg	ctccgggtgt	cacccggaa	accggcttta	ttctctatg	gggtcagtct	1260
cggccccccta	caggccctgc	aggcagtgtt	ccgcacaaact	ttgtcatcag	cgtgaggat	1320
gacctagaag	cagtgcgcgt	agaggtgggt	gctgggcctt	ggcatggtca	ccttgcatt	1380
ctgggtgtctt	ccagtggcag	ctctgtcc	aagagcttta	cagtggctga	gctggcagcc	1440
ggccagggtgg	tctaccagca	tgatgacaga	gacggctgc	tgagcgcacaa	cctggtgctt	1500
cgcacgtgtgg	atggaggagg	caggcaccag	gtacagttt	tttccccat	caccttagtg	1560
cctgtggatg	accagccacc	tgttctcaat	gccaacacgg	ggctgacact	ggcagagggt	1620
gaaacagtgc	ccatcctgc	ccttccctg	agtgcactg	acatggattc	agatgattct	1680
ctgctgtttt	ttgtgcttga	gtcacccctc	ttaactacgg	ggcattctgt	tctccgcca	1740
actcaccctc	cccatgagaa	gcaggaactt	ctcagaggcc	tttggaggaa	ggagggggca	1800
ttttatgagc	gaacagtgc	agagtggcag	cagcaggaca	taacagaggg	caggctgttc	1860

tatagacact	ctggggccca	tagtccctggg	ccagtcacag	accagttcac	attagagtc	1920
caggataacc	atgaccctcc	taatcagtcc	gggctacagc	ggtttgtat	tcgttatccat	1980
cctgtggatc	gcctccctcc	ggagctgggc	agtggctgtc	cccttcgtat	ggtggtacag	2040
gaatcccacg	tcacaccact	gaggaagaag	tggctgcgtt	acactgacct	ggacacagat	2100
gaccgagaac	tacgttacac	agtgactcag	ccccccacag	acacagacga	aaatcacctg	2160
ccagccccac	tgggtacett	ggtcttgcact	gacaaccctt	cagtcgttgt	gaccatttt	2220
acccaagccc	agatcaacca	tcataaaaatt	gcttacagac	ccccgggtca	agaactggc	2280
gtggctactc	gagtggccca	gttccagttc	caggtggaaag	accgagctgg	aatgtggct	2340
ccaggtacct	ttaccctta	cttgcatccc	gtggacaacc	agccacctga	gatcctcaac	2400
accggcttca	ctattcagga	gaagggtcac	cacatcctga	gtgagacaga	gttgcacgtg	2460
aatgatgttag	acactgtatgt	tgcccatatc	tctttcactc	tcactcaggc	acccaaacat	2520
ggccacatga	gagtgtctgg	acagatcctg	catgttaggg	gtctcttcca	cttggaggac	2580
ataaaaacagg	gcccgttcc	ctatgcccatt	aatggggaca	agtccctgac	tgatagctgc	2640
tccttggaaag	tcagtgcacag	acatcatgtg	gtgcccattca	ctctcagagt	aaatgtccgg	2700
ccagtggatg	atgaagtgcc	catactgagc	catcctactg	gcactctgg	gtccttatcta	2760
gatgtcttag	aaaatggggc	tactgaaaatc	actgccaatg	ttattaaggg	gaccaatgag	2820
gaaactgtatg	acttgcattt	gactttccctc	ttggaaagatc	caccttgcata	ttggggaaatc	2880
ttggtcaatg	gcattccagc	agagcagttt	actcaaaggg	acatcttgg	gggctctgtt	2940
gtatatacc	acaccagtgg	tgagataggc	ctattgccta	aagggattc	tttaaacctg	3000
agtcgttcag	ataagtctca	agaatggaga	attggtgccca	atactatcca	aggagttact	3060
atatgggtga	ccatcctgcc	tgttgatgc	caggccccag	aatctctgt	aggtaacag	3120
ttgatagtaa	ttggaaaggta	taaaagtgtt	ataacatcag	tgcatataag	tgctgaagat	3180
gtcgcactccc	tgaatgtatg	catcttgc	actatagtta	ttcagccctac	ttcaggttat	3240
gttggaaaaca	tttctccagc	accaggctct	gagaaatcaa	gagcaggat	tgccataaagt	3300
gcttcaact	tgaaagatct	caggcaggc	cacataaaact	atgtccagag	tgtccataaa	3360
gggggtggaaac	ctgtggagga	ccgatttgc	tttcgttgtt	ctgatggcat	taactttca	3420
gagagacagt	tcttccccat	tgtaatcatt	cccaccaatg	atgaacagcc	agagatgttt	3480
atgagagaat	ttatggtgc	ggaaggcatg	agtctggtaa	ttgatacacc	cattctcaat	3540
gctgctgtatg	ctgatgttcc	cctggatgt	ttaactttca	ctattaccca	attccccact	3600
catggtcaca	tcatgaatca	gctgataaaat	ggcacggttt	ttgtcggaaag	cttcacccctt	3660
gatcagatca	tagagagttc	cagcattatt	tatgagcatg	atgactccga	gaccaggaa	3720
gacagttttg	tgattaaact	aacagatggg	aagcactctg	tggaaaagac	ggtcctcatt	3780
atagttatcc	ctgttgatga	tgagacgccc	agaatgacta	tcaataatgg	actagaaata	3840
gaaattgggg	ataccaagat	tatcaacaac	aaaatattaa	ttggcaacaga	tttagattca	3900
gaagacaaat	ctttggttt	tattattcgt	tatggccag	gacatggctt	attacagaga	3960
cgaaaacacta	ctggtgccct	tgaaaatatac	acactgggc	tgaattttac	ccaggatgaa	4020
gtagacagaa	acttaattca	gtatgtccat	ttggggcaag	agggcattcg	ggacctaatt	4080
aaatttgcgt	tgactgtatgg	aataatccc	ctcatagatc	gttactttt	tgtgtccatc	4140
gggagcatttgc	acattgtctt	ccctgtatgt	ataagtaagg	gagtgtcctt	gaaaagaagg	4200
ggcaaagtca	ctcttacaaac	agacactata	agcactagtg	acttgcacag	tcctgtatgaa	4260
aacttggttt	ttaccatcac	caggctccc	atgcgagg	acctggatg	cacggatcag	4320
cctggtgtgt	ccatcacgtc	tttactcag	ctgcaactgg	ctggaaacaa	aatctactac	4380
atccacacag	ctgatgtatg	agtaaaaatg	gacagttttt	agtttcaatg	caccgatgga	4440
cgtaaccctg	tcttcggac	atccgtatc	tccattagcg	atgtggacaa	taaaaaagcca	4500
gtgggtcacca	tccacaagct	ggttgtcagt	gaaagtggaaa	acaagctgat	tactcctttt	4560
gagtcactg	tgcgaaagac	agatatactct	gacaagctcc	tgaaatttcac	tatcaccacca	4620
gtgcctattc	atggccatct	ccttattcaac	aataccagac	ctgtcatgg	ttttaccaag	4680
caagacttga	atgaaaactt	aatcagctac	aaacatgatg	gcactgagtc	aatgtgaagat	4740
agcttctcc	tcacagtgc	tgatggcacc	catacagact	tctatgttt	tcctgatacg	4800
gtgtttgaaa	caaggagacc	ccaaatgtatg	aagatccagg	tcttggctgt	tgacaacagt	4860
gtccccccaaa	tcgcagtgaa	taagggggcc	tctacacttc	gcactctagc	cactggccac	4920
ttgggggttca	tgatcacaag	caaaatattt	aaagtggagg	acagagacag	cttacacatt	4980
tctcttagat	ttatcgatgc	agaggcccc	caacatggat	atcttctcaa	cctggacaaa	5040
ggcaaccaca	gcatcactca	gttacaccaa	gctgacattt	atgacatgaa	aatatgtat	5100
gtcttaagag	aaggggctaa	tgccacaagt	gatatgttt	attttgcagt	tgaagatgg	5160
ggtggaaaca	agttaacgt	ccagaatttt	cgtctgaatt	ggcgtatgg	ctcctttgaa	5220
aaggaatatt	acctggtcaa	tgaggactcc	aaatttctag	atgttgcatt	taaactgtaga	5280
ggttacttgg	gagaaacttc	ttttataatgt	attggcaca	gagacagaac	tgcagaaaa	5340
gacaaagact	tcaagggcaa	agcacagaaa	caagtgcagt	tcaacccagg	ccagaccagg	5400

gccacatggc	gagtgcggat	cctgagtgtat	ggggagcatg	agcagtctga	aacctttcag	5460
gtggtactct	cagagcccg	gctggctgcc	ttggattcc	ccacagtgc	caactgttag	5520
atcggtgatc	caggagatga	gccaactgtg	tttattcccc	agtccaaata	ctccgttga	5580
gaagatgtt	gtgagctgtt	cattccatc	aggaggagcg	gagatgtgag	ccaggagtt	5640
atggtgttct	gttataccca	acaaggaaca	gcaactggaa	ctgtccgac	ttccgtgttg	5700
tcttactctg	attacatatac	caggccttag	gaccacacca	gtgttgc	cccttgacaaa	5760
gatgaacggg	agaaactgtg	tcggatagtc	ataattgtat	actcttgc	cgaggaggag	5820
gaaaccttcc	atgtccttct	gagcatgccc	atggggggaa	gaatcggatc	agagttccca	5880
ggggctcaag	ttacaatctg	tcctgacaaa	gatgtggc	catctgat	caaatttaat	5940
gttgctgaga	actacagttt	actgccttc	acctgtttc	aaggtagcat	agccacggca	6000
gaggcagcca	cccaggagg	gggacgc	accagacaag	tagctgc	caaaaaaagac	6060
aaagacttca	agggcaaagc	acagaaacaa	gtcagttca	acccaggcca	gaccaggccc	6120
acatggcgag	tgccgatctt	gagtgtatgg	gagcatgagc	agtctgaaa	ctttcagggt	6180
gtactctcag	agcccgtct	ggctgcctt	gaattccca	cagtgc	ccatgtgatc	6240
gttgatccag	gagatgc	ccatgggggg	gaagaatcgg	atcagat	ccaggggctc	6300
aagttacaat	cgttcctgac	aaagatgtat	gtgagacta	atttacttga	aaattcttt	6360
tcccgggaaag	atcaacatca	ggaacaactt	tctagacaga	aaaaatggga	atctaaaaca	6420
atgataat	acacattat	tttatgtgag	acagaaaagc	cctgcattt	tgagctgat	6480
gacgatgtgc	tctatgagga	ggttagaggag	ctccgcctt	tactcggc	tccacaaagc	6540
aactctccct	ttggggctgc	agtttggtaa	caaaatgaaa	ctctcataa	gatccgagat	6600
gatgctgata	agactgttat	taaatttgg	gaaaccaa	ttagtg	tcacccaaa	6660
gaacctggag	agtcgggtgt	tataagaatt	ccagtgat	gccaaggaga	cacttcaaag	6720
gttccattt	tgagagtcc	caccaaggat	ggctcg	ccctctggaga	agactaccac	6780
cctgtgtcag	aagaaattga	gtttaaggaa	ggggaaaccc	agcagtggt	tgaatcgaa	6840
gttaccttgc	acgggggtgag	agagatgaga	gaggccttca	ctgttccac	aaaacctgt	6900
gaaaatatga	tagcagagat	gcagcttcc	aacttgc	tcaccctc	ccctgatggc	6960
acaagagttt	gaaaccacaa	gtgtccaaac	ctcctggatt	atactga	gaagactcat	7020
tatggtttct	tgactgtgc	taccaaaaaat	ccagaaataa	ttggagagac	atatccttac	7080
cagtacagct	tgtccatcag	aggttccact	accttgc	tctaccggaa	cctgaaaccta	7140
gaggcctgtt	tatggagtt	cgttagctac	tatgacat	cagaactc	tgctgactgc	7200
agatcagtgt	tgaatgc	cataatttcat	gagatggc	ctgaaggaaa	gcaaaagtaaa	7260
tgcttggtaa	attctactt	atactctatt	ttggatgtc	atgagagc	tccaaactt	7320
tgcatttgc	cattaaggat	ggggaaatgg	agaaaaataa	aaagcaaacc	atcagcacag	7380
actccatgt	ctcagaggt	tcgtggttt	attgaccacc	ccagggaaaca	gcccctgc	7440
caagccatgt	ctgaccagg	catgtcccc	gtgatctca	ctagagagc	ttccaactt	7500
gagtcaccc	tcagccctga	tggcacaaga	gttggaaacc	acaagtgc	caacctc	7560
gattatactg	aagtgaagac	tcattatgg	ttcttgact	atgctacaa	aaatccgaa	7620
ataattggag	agacatatcc	ttaccatgt	agctgtc	tcagagg	tcactacc	7680
cgttctacc	ggaacctgaa	cctagaggcc	tggttatgg	agttcg	ttactatgac	7740
atgtcagaac	tccttgc	ctgtggggc	accattggaa	cagatgg	ggtcctaaac	7800
ctagtgc	cctatgt	ccttcg	cctctgtat	tttccat	gttccattc	7860
ccctgggggg	taggggt	gcagat	tttttttt	gacttga	tttttttt	7920
gtgtacgaca	ccgccc	atgtt	gatgtt	tttttttt	tttttttt	7980
caaggttctc	tctatccaa	cacgtgc	atcggtat	tttttttt	tttttttt	8040
ttcaagacag	aggctca	ccatggctt	tttgc	tttttttt	tttttttt	8100
agtcagtgt	tcatgt	tgatcatca	ggcctg	tttttttt	tttttttt	8160
agtgaaccaa	cctataacca	gccag	tttttttt	tttttttt	tttttttt	8220
cgttactact	cagg	actgt	tttttttt	tttttttt	tttttttt	8280
gaataccg	tgcc	ctgc	tttttttt	tttttttt	tttttttt	8340
cgattccaa	agg	tc	tttttttt	tttttttt	tttttttt	8400
ctgtctct	aga	ttt	tttttttt	tttttttt	tttttttt	8460
gatgttgc	tttgc	tttgc	tttttttt	tttttttt	tttttttt	8520
aatctgggt	actc	ctgc	tttttttt	tttttttt	tttttttt	8580
ggctatgtt	cca	tttgc	tttttttt	tttttttt	tttttttt	8640
tcactctt	atagattt	aaatgtgg	tttttttt	tttttttt	tttttttt	8700
tttggaaat	tcctt	tttgc	tttttttt	tttttttt	tttttttt	8760
gtgaatc	ctggat	tttgc	tttttttt	tttttttt	tttttttt	8820
ctaggcc	aatgg	tttgc	tttttttt	tttttttt	tttttttt	8880
cgaggtattt	gcaaa	tttgc	tttttttt	tttttttt	tttttttt	8940

tccaccacca	agagccggaa	gaagagagag	atcaggagca	caccctcact	ggcatggag	9000
atgggtctg	aaaacagtcg	aggaacaaac	atccagcaca	ttgccttgg	ccgcaccaag	9060
aggcagatcc	cccatgggg	agcacctcca	gatggcatcc	tcccctgg	gctcaacagc	9120
cccaagctctg	cagtca	ggta	gtgggaggca	ccacggtagg	ttta	9180
atctgcctca	ctgtcat	gtgt	tgcaggggca	aggaaagt	ttt	9240
gatgccccga	aaggctccag	cagc	cccatggtgc	cccc	acagag	9300
gacagctcag	aagt	tttga				9318

&lt;210&gt; 37

&lt;211&gt; 1374

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 37

atggggtta	gtggagcctg	gggcttgagc	tgccttgc	cacagacgcc	atcctggcc	60
tggaggaaga	tgcggacgcc	atccatgagg	aaccggagtg	gcccgtgt	gagcagggcc	120
tctgtccccct	tctctgcctg	ggaagttagag	gtcagatga	gggtgacggg	actggggcgc	180
cggggagccc	agggcattgc	cgtgtgtac	acccggggca	ggggccatgt	aggctctgtc	240
cttggggggc	tggcttcgt	ggacggcatc	gggatcttct	ttgactctcc	gca	300
actcaggaca	gtcctgcct	ccgtgtgt	gccagcgcac	ggcacatccc	ctctgagcag	360
cctggggatg	gagctagcca	aggctgggc	tcctgtcatt	gggacttccg	gaaccggcoa	420
caccccttca	gagcacggat	cacca	ggcagaggc	tgcgc	tttgcac	480
ggcctca	ccagtgtatcc	agg	tgtgtggatg	tggggcc	gttgg	540
cctggagggtt	tctttgggt	ctc	acccggcaccc	tggcagatga	tcatgtgtc	600
ctgtccttcc	tgaccttc	cctg	cccagccca	agg	tttcc	660
ctggagatgc	agcacgtcc	cctggcgagg	cagcttgg	ggctgtggc	aaaggctggc	720
ttgggaccca	gggaggatgt	aactccaaa	tcagacttgc	aagctcaagg	agaaggggaa	780
aggctcttgc	acctggagga	gac	agacaccgc	ggatcctgca	ggctctgcgg	840
ggtctctcca	agcagctggc	ccaggctgag	agacaatgg	agaagcagct	ggccccccag	900
gccaagccag	gcctgacgga	ggctggggat	gcagctgtcc	gcatggctgc	agaagcccag	960
gtctcctacc	tgcctgtgg	cattgagcat	catttcttgc	agctggacca	cattcctggc	1020
ctcctgcagg	aggagcttc	gggcccggc	aaggcagcag	ccaaggcccc	ccgcccaccc	1080
ggccagcccc	caagggcctc	ctcgtgcct	cagcctggca	tcttcctgtt	ctacctcctc	1140
attcagactg	taggcttctt	cggctacgt	cacttcaggc	gcccgtgt	ccggccggog	1200
aagaccatgg	cgttcatgtt	gaagaccatg	gtggggcc	agctgaagaa	cctca	1260
agcctgggag	gcggcgagga	taagggagat	ggggaca	cgccagccga	agctcagg	1320
atgagccggg	aggagtacga	ggagtatc	aagcaactcg	tggaa	agagaa	1374

&lt;210&gt; 38

&lt;211&gt; 1581

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 38

atccggccgg	tca	gtgtcc	agg	ttctgccttc	tc	cctggacc	60
cacagccctg	agacgggg	ttc	tc	cgcagg	ttt	agtacaagct	120
ggcccaaggc	tggcatt	ttgg	gg	atacccttct	gg	gacgc	180
atccctggcc	tggag	ggt	gg	ccatccat	gg	aaaccggag	240
tggagcaggg	cctctgt	ttt	gg	tggaa	gt	aggcagat	300
ggactggggc	gcccggg	gg	gg	ggcgtgt	gt	acacc	360
gtaggctctg	tccttgggg	gct	gg	tggacgg	tc	ggatctt	420
ccggcagagg	atactc	agg	gg	atccgtgt	tc	ggccagc	480
ccctctgagc	agcctggg	tt	gg	caagg	gt	cctgtca	540
cggaaaccggc	cacacc	cc	gg	atcac	tt	ggacttc	600
tccttgaaca	gtggc	c	cc	ccagg	tc	tgtgggccc	660
ctgctttgg	ccc	ttt	tt	gtctc	cc	accggcac	720
gatcatgtt	gtt	ttt	tt	agcct	tc	tttccc	780
cctcagccct	tc	ttt	tt	ggc	tc	ggctgtgg	840
gcaaggctgg	gtt	ttt	tt	ggc	tc	ggatccaa	900
gcttgggcac	cagg	ttt	tt	ggc	tc	aatcagactc	
caggaggat	gt	ttt	tt	ggc	tc	tgaagctcaa	

ggagaagggg	aaaggctctt	tgacctggag	gagacgctgg	gcagacacccg	ccggatcctg	960
caggctctgc	gggtctctc	caagcagctg	gcccaggctg	agagacaatg	gaagaagca	1020
ctggggccccc	caggccaa	caggctgac	ggaggctggg	ccctggatgc	tccctgcca	1080
attccatcca	ccccagggag	gggtggcac	ctctccatgt	caactaataa	ggactctgcc	1140
aaggctgg	ccctgcttca	tggacagtgg	actctctcc	aggccctgca	agagatgagg	1200
atgcagctg	tccgcattgc	tgcagaagcc	caggctctc	acctgcctgt	gggcattgag	1260
catcattct	tagagcttga	ccacatcctg	ggcctctgc	aggaggagct	tcggggcccg	1320
gccaaggcag	cagccaa	ccccggccca	cctggccagc	ccccaaaggc	ctcctcg	1380
ctgcagctgc	gcatcttct	gttctaccc	ctcattcaga	ctgttaggett	tttcggctac	1440
gtcacttca	ggcaggagct	gaacaagagc	cttcaggagt	gtctgtccac	aggcagcc	1500
cctctgggtc	ctgcaccaca	caccccccagg	gccctgggga	ttctgaggag	gcagcc	1560
cctgccagca	tgcc	tgcc	tgcc	tgcc	tgcc	1581

&lt;210&gt; 39

&lt;211&gt; 2715

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 39

atgctcttgg	ctctatgttc	atctctggct	cttatttttgc	cagctctgt	cagtggacag	60
cttgaggcatt	cagggaacta	ctactgcaca	gctgacaatg	gctttggccc	ccagcacagt	120
gaggtggta	gtctctctgt	caactgtccct	gtgtctcatc	ctgtcc	ctcagctct	180
gctgaggccc	tgacttttga	aggagccact	gtgacacttc	actcttc	gtcgtc	240
gctccacttt	ctgtgttga	aggagacttc	gtgggtctga	ggtgcggg	aaaggcggaa	300
gtaacactga	atactatgt	caagaatgg	aacgtcc	cattc	ttaaagctct	360
gacttccata	ttcatcacgc	aagtctcaaa	gacaatgg	catatcactt	tactggattt	420
aacggaa	at	tttctgt	tttccaa	atagtcaaaa	tccaa	480
ctgccccagt	gttctctgaa	ggcacctgt	cccactgtgg	cccttagtga	gatattctca	540
gtcaatagag	gtccacttct	gacaggcaca	ggctccc	ggag	ttatgactcc	600
ttccctactg	aggactggaa	cttacttct	atcccatt	ctgtgg	tgcttgc	660
aggccttgc	ctc	ctc	tc	tttggaa	tttggaa	720
cagcagaagg	ggaacc	cctgctcat	ggcc	tttgc	tttgc	780
atcacacttt	tttgcacat	ggcagg	tttgc	tttgc	tttgc	840
aaagatgcat	tatttgttac	aggaaatgaa	agcaga	agc	atcattgg	900
agccttgc	gtggg	caaga	agcagat	aaat	tttgc	960
caggatattt	tcatatata	cagacaagg	gagagt	gttgc	tttgc	1020
caggtctaca	gacgg	ctgc	tggagg	tttgc	tttgc	1080
agggtgata	gtt	cg	ggact	tttgc	tttgc	1140
ctccagtctg	tgg	acaat	ctt	tttgc	tttgc	1200
aagttagtgc	cctt	cctt	ggc	tttgc	tttgc	1260
gcaaagaaga	gtct	at	tttgc	tttgc	tttgc	1320
gac	tttgc	tttgc	tttgc	tttgc	tttgc	1380
gctgcacaca	aa	cc	tttgc	tttgc	tttgc	1440
agagtactc	tgact	tgca	tttgc	tttgc	tttgc	1500
catcg	act	ggg	ggg	ggg	ggg	1560
gatctggac	tgt	ac	agg	ggg	ggg	1620
ctt	ttt	ttt	ttt	ttt	ttt	1680
actccaatgt	cc	agg	gg	gg	gg	1740
cctgctctga	gact	cg	act	ttt	ttt	1800
acattgg	tt	gat	gg	ttt	ttt	1860
tgg	aa	at	ttt	ttt	ttt	1920
agg	aa	at	ttt	ttt	ttt	1980
at	aa	at	ttt	ttt	ttt	2040
acc	gg	cc	ttt	ttt	ttt	2100
gct	gg	gg	ttt	ttt	ttt	2160
gg	gg	gg	ttt	ttt	ttt	2220
cat	gg	gg	ttt	ttt	ttt	2280
ctg	aa	at	ttt	ttt	ttt	2340
act	gg	gg	ttt	ttt	ttt	2400

cggaggaagt cagtacaccc caaaaaggga gatttggtat actctgagat ccagactact	2460
cagctggag aagaagagga agggaaatcat ggcaataaaaa atcaagaact agaacttgtt	2520
aatgttaggag agagttttc tcacagggca tgcatatgga gtactcta at gggaaacttgc	2580
caaacaatcg ggggtgcata tacctccagg acacttctag aggataagga tgtctcagtt	2640
gtctactctg aggtaaagac aacaacacca gataacttag ctggaaagat cagctctaag	2700
gatgaagaaa gttaa	2715

<210> 40  
 <211> 1548  
 <212> DNA  
 <213> Homo sapiens

<400> 40	
atgctgtgt gggcgtcctt gctggcctt gctccagttt gtggacaatc tgcagctgca	60
cacaaacctg tgatccgt ccacccctca tggaccacat tcttcaaagg agagagatgt	120
actctgactt gcaatggatt tcagttctat gcaacagaga aaacaacatg gtatcatcg	180
cactactggg gagaaaaattt gaccctgacc ccagggaaaca ccctcgaggt tcggaaatct	240
ggactgtaca gatgccaggc ccggggctcc ccacgaagta accctgtgc cttgtcttt	300
tcttcagact ccttaatctt gcaggccca tattctgtgt ttgaaggta cacattgggt	360
ctgagatgcc acagaagaag gaaagagaaa ttgactgtg tgaaatatac ttggaaatgga	420
aacattctt ccatttctaa taaaagctgg gatcttctta tcccacaagc aagttcaaat	480
aacaatggca attatcgatg cattggatattt ggagatgaga atgatgtatt tagatcaaat	540
ttcaaaataa taaaattca agaactattt ccacatccag agctgaaagc tacagactct	600
cagcctacag agggaaattt tgtaaacctg agctgtgaaa cacagcttcc tccagagcgg	660
tcagacaccc cacttcactt caacttcttcc agagatggcg aggtcatcct gtcagactgg	720
agcacgtacc cgaaacttcca gctcccaacc gtctggagag aaaactcagg atcctattgg	780
tgtgggtctg aaacagttag gggtaacatc cacaaggcaca gtccctcgct acagatccat	840
gtcagccggc tccctgtgtc tgggtgtctc ctggagaccc agccctcagg gggccaggct	900
gttgaagggg agatgtgtt ccttgtctgc tccgtggctg aaggcacagg ggataaccaca	960
ttctcctggc accgagagga catcgaggag agtctgggaa gggaaactca gcgttccctg	1020
agagcagagc tggagctccc tgccatcaga cagagccatg cagggggata ctactgtaca	1080
gcagacaaca gctacggccc tgccctggc acatgtgtca atgtactgt gagagagacc	1140
ccaggcaaca gagatggctt tgccggcccg ggagccactg gaggctgct cagtgtctt	1200
ctccctggctg tggccctgtc gtttcaactgc tggcgtcggg ggaagtcagg agttggtttc	1260
ttgggagacg aaaccaggtt ccctcccgct ccaggccccag gagagtcctc ccattccatc	1320
tgcctggccc aggtggagct tcagtcgttg tatgttgatg tacaccccaa aaagggagat	1380
ttggtatact ctgagatcca gactactcg ctggagaaag aagaggaagc taatacctcc	1440
aggacacttc tagaggataa ggatgtctca gttgtctact ctggaggtaaa gacacaacac	1500
ccagataact cagctggaaa gatcagctct aaggatgaag aaagttaa	1548

<210> 41  
 <211> 2494  
 <212> DNA  
 <213> Homo sapiens

<400> 41	
batggctgtg ggaggaggac acaaaggagt tagatgtcctt ccctctgctc gcagctccca	60
gggtccccacg tgctgcgtg gctggaggca gcaaggggac gagtgtgggaa ttgcgggtgt	120
cgaaggcaac tccacgtgtc cagagaacca ggtgtgcgtg aggctggcg agtgcgcgt	180
ccgcccacggc tacttcgtgtt ccaactgcga caccaggatc ccgcgcctgt tctggggccc	240
cgactgcaag gagctgtgtc gctggccaccc acacgggcacg tgcgaggacg tgacaggcca	300
gtgtacttgtt cacgcgcggc gctggggcgc ggcgtgcgtg catgcgtgcc agtgcgcgt	360
cggcacgtgc caccggggca gcccggcggtt ccgcgtgtt gcccgttggt gggccgcgc	420
gtgcgcgcgc gctgtgtactt gcaaggccac gtcgcgtgc gaccacacaga ccggccgcct	480
cctgtgcccac gcaggctgtt gggccgcacg ctgcacaaac cagtcgcctt gcaactcg	540
tccctgcgag cagcagacgc gcccgtgtca gtgcgcgcac gtcgtgttgc ggcgcgcgt	600
cgatcgctac tgccagttgtc tcccgccggc ctgcacccctt gtggacggca cgtgtgcct	660
cgagccgggc taccggcgca agtactgtcg cgagccgtgc cccggggct tctacggctt	720
gggctgtcgc cgccgggtgtt gccagtgca gggccagcag ccgtgcacgg tggccgaggg	780

ccgctgcttg	acgtgcgagc	ccggctggaa	cggaaccaaag	tgcgaccagc	cttgcgccac	840
cggtttctat	ggcgagggct	gcagccacgg	ctgtccgcaca	tgccgcgacg	gcatgcctg	900
taaccatgtc	accggcaagt	gtacgcgtg	caacgcgggc	tggatcgccg	accgggtgcga	960
gaccaagtgt	agcaatggca	cttacggcga	ggactgcgccc	tgcgtgtgcg	ccgactgcgg	1020
cagcggacac	tgcgacttcc	agtcggggcg	ctgcctgtgc	agccctggcg	ccacacgggc	1080
ccactgtaac	gtgacgtgcc	cgccggact	ccacggcgcg	gactgtgc	aggcctgcag	1140
ctgcccacgag	gacacgtgcg	accgggtcac	tggtcctgc	cacctagaaa	ccaaccagcg	1200
caagggcgtg	atgggcgcgg	gcccgcgtct	cgtccctgc	gtctgcctgc	tgctctcgct	1260
gctcggctgc	tgctgcgtt	gcccggcga	ggaccctacg	cgccgacccc	gccccccgcag	1320
ggagcttcg	tttggagga	agaaggcgcc	gcaccgacta	tgcgggcgct	ttagtgcac	1380
cagcatgaag	ctgccccgg	tcccgctccg	gaggcagaaa	ctacccaaag	tcgttagtggc	1440
ccaccacgac	ctggataaaca	cactcaactg	cagttcctg	gagccaccct	cagggctgga	1500
gcagccctca	ccatccttgtt	cctctcgcc	cteccc	tcgtttgaca	ccactgtatga	1560
aggccctgtg	tactgtgtac	ccatgagga	ggcaccagcg	gagagccggg	accccgaaagt	1620
ccccactgtc	cctgcccgg	cgccggcgcc	gtccccctgt	cccttgcacca	cgccagccctc	1680
cggcggaggag	gcgataaccc	tcccgccgtc	ctccgcacagc	gagcgggtcg	cgtccagcg	1740
ggagggggccc	ggaggggctc	tgtacgcgc	cgtggcccg	cgccgaggccc	ggccggccccc	1800
ggcccccggc	gagattgggg	gcctgtcgct	gtcgccatcg	cccgagcgca	ggaaaccgccc	1860
gccacctgac	cccgccacca	agcctaaggt	gtcctggatc	cacggcaagc	acagcgccgc	1920
tgca	ctggcgcct	caccaccgc	gccaggctcc	gaggccgcgc	ccagccccag	1980
caagaggaaa	cgacgc	gcgacaaaatc	ggcgcataacg	gtcgaacacg	gcagccccccg	2040
gaccgcgac	ccaa	ccgcgc	gccccccgg	gctgcccggag	gaggcgcacag	2100
gcctcgccg	ccc	aggggccc	gagcgcgc	cgccgc	cccttggag	2160
ccggcgggtcc	ccc	gcga	gcgcgc	tcgc	ttggccgtcg	2220
caagactcgc	agc	ctggggcc	gcgcgc	ggcc	gcgcaggccc	2280
gcccggc	ccac	agaaaag	ccaa	gcgc	ccagggaaaa	2340
ccca	ggc	ggcc	cc	gcgc	cccgccgc	2400
ccccccggaa	aa	gaccccca	tccagaagcc	gcgc	caag	2460
cgagctggc	agggcggc	caccaccc	gtag			2494

&lt;210&gt; 42

&lt;211&gt; 2614

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 42

batggagggc	gcagggccccc	ggggggccgg	gccggcgcgg	cgccggggag	cgggggggcc	60
gcgcgtcaccg	ctgtgcctgt	cgctgtgt	gctgtgcgt	ctctggatgc	tgccggacac	120
cgtggcgcct	caggaactga	accctcgccg	ccgcaacgtg	tgccgtgc	ccggctccca	180
ggtgtccacg	tgctgcgt	gctggaggca	gcaaggggac	gagtgtggga	ttgcgggtgt	240
cgaaggcaac	tccacgtct	cagagaacac	ggtgtgcgt	aggcctggcg	agtgcgcgt	300
ccgcacacggc	tacttcgg	ccaa	gtgc	ccgcgc	tctggggccc	360
cgactgcaag	gagctgtgt	gctgc	ccac	ccgcgc	tgacaggc	420
gtgtacttgt	cacgcgc	gctggggc	g	cgctgc	catgcgtgc	480
cggcacgtgc	cacccccc	g	ccgtgt	tccggctgg	ggggcgc	540
gtgcgc	cgcgt	g	tcgc	gacc	ccggcc	600
cctgtccac	gcagg	gtt	gtgc	gacc	ccggcc	660
tccctgcgag	cagc	gag	ccgc	gtac	ccgt	720
cgatcgctac	tgcc	actgt	ccgc	gtgg	acggca	780
cgagccggc	tacc	gcgc	tgcc	acgg	cggtgc	840
gggtctgtc	cgcc	gggt	ccgc	gttgc	gacc	900
ccgctgc	acgt	gcgc	ccgc	ccgt	ccgt	960
cggttctat	ggcg	aggg	ccgc	ccgc	ccgc	1020
taaccatgtc	accgg	caagt	gtac	ccgc	ccgc	1080
gaccaagtgt	agca	atgg	ccgc	ccgc	ccgc	1140
cagcggacac	tgc	actt	ccgc	ccgc	ccgc	1200
ccactgtaac	gtg	acgtgc	ccac	ccgc	ccgc	1260
ctgcccacgag	gacac	gtgc	cccg	ccgc	ccgc	1320
caagggcgtg	atgggcgc	gcgc	ccgc	ccgc	ccgc	1380

gctcggctgc	tgctgcgtt	gccgcggcaa	ggaccctacg	cgccgacccc	gcccccgca	1440
ggagctttcg	cttggggagga	agaaggcgcc	gcaccgacta	tgcgggcgct	tcagtcgcat	1500
cagcatgaag	ctgccccgga	tcccgcctcg	gaggcagaaa	ctacccaaag	tcgttagtggc	1560
ccacccacgac	ctggataaca	cactcaactg	cagcttcctg	gagccacccct	cagggcttgg	1620
gcagccctca	ccatcctgtt	ccttcgggc	ctccctctcc	tcgtttgaca	ccactgtatga	1680
aggccctgtg	tactgtgtac	cccatgagga	ggcaccagcg	gagagccggg	accccgaaagt	1740
ccccactgtc	cctggcgagg	cgccggcgcc	gtccctgtg	cccttgacca	cgccagcctc	1800
cgccgaggag	gcgataaccc	tcccccgtc	ctccgacagc	gagcggtcgg	cggtccagcgt	1860
ggagggggccc	ggaggggttc	tgtacgcgcg	cgtggccca	cgcgaggcccc	ggccggggccc	1920
ggcccgggggc	gagatggggg	gcctgtcgct	gtcgccatcg	cccggacgc	ggaaaccgc	1980
gccacactgac	cccgcacca	agccctaaatg	gtcctggatc	cacggcaagc	acagcgccgc	2040
tgcaactggc	cgtgcgcct	caccacggcc	gccaggctcc	gaggccgc	ccagccccag	2100
caagaggaaa	cggaacgc	gcgacaaaatc	ggcgcataacg	gtcgaacacag	gcagcccccc	2160
gaccggcgac	ccaacgcgc	gccccccggg	gtcgcccgag	gaggcgacag	ccctcgctgc	2220
gcctcgccg	cccaggggcc	gagcgcgc	cgccgggggg	cctttggag	cccacggacg	2280
ccggcggtcc	cccgcgaage	cgccgcgggc	tgcctccatg	ttggccgctg	acgtgcgc	2340
caagactgc	agcctgggc	gcccggaggt	ggccctggc	gcccggggcc	ccagggaaaa	2400
gccggcgccc	ccacagaaaag	ccaacgc	cgtgccc	gcctcgccc	cccgcgc	2460
cccacgcacc	gaaaccccg	ggccctgagaa	ggcggcgacc	gacttgc	ccctgagac	2520
ccccccggaaag	aagacccca	tccagaagcc	gccgcgcaag	aagagccggg	aggcggcg	2580
cgagctggc	agggcg	cgaccaccc	gtag			2614

&lt;210&gt; 43

&lt;211&gt; 402

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 43

atcgactgcc	gcgcggagca	ggccgtacg	ccgctcatgg	tggccgtgg	gtgcggac	60
cccgcgctgc	gcgcgcgtt	cgtcggtg	ctgctcgagc	aggggtgtc	agtgaac	120
cgagacgagc	gcggccgcac	cgcactcagc	ctggcgtcg	agcgaggcca	cctggacgc	180
gtcagactgc	tggcgtcgtt	cagcgtgtac	cccggaggcg	ccgactctgc	ggcaacagc	240
ccgggtatgt	gggcggcg	ctgcggccac	ggggcggtc	tgcagttcc	gtgcgg	300
ttccgcgc	taggcctgc	cctcgaccgc	accaaccgt	cggggctc	cgcgctg	360
ctggccgc	cccgcg	ccggacctgt	gtcaggccc	tc		402

&lt;210&gt; 44

&lt;211&gt; 975

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 44

atgctcaaac	ccaaggac	gtgccccca	gcggggacgc	gcacccct	ggaggccat	60
caggcg	aagtgc	actt	ggcccgttc	gtgttgat	cgctggacc	120
gactgcgcg	cggagc	agg	ccgtacgc	ctcatgg	ccgtggg	180
gctgtcg	cgcg	cttc	cggtcg	ctcg	gagg	240
gacgacgcg	ccgc	actc	cgatgc	gcgtgc	gaggccac	300
cagctgtgg	tgc	atct	cggt	gagg	ggacgc	360
gtgatgtgg	cg	ccgc	ccgt	gagg	ccgc	420
ccggcctag	cc	cg	cg	gg	ccgc	480
gccgcgc	cc	cg	cc	cc	cc	540
ggcaagaatt	cc	cc	cc	cc	cc	600
atgagcctgg	ct	ct	cc	cc	cc	660
ctgatggccc	tac	ccaa	cc	cc	cc	720
gtgctggagg	gag	cc	cc	cc	cc	780
gagggcg	cc	cc	cc	cc	cc	840
cccacgc	tc	cc	cc	cc	cc	900
ctgtctgt	cg	cc	cc	cc	cc	960
cgtgtc	cc	cc	cc	cc	cc	975

<210> 45  
 <211> 568  
 <212> PRT  
 <213> homo sapiens

<400> 45  
 Met Lys Glu Ala Glu Met Asp Gly Glu Ala Val Arg Phe Cys Thr Asp  
 1 5 10 15  
 Asn Gln Cys Val Ser Leu His Pro Gln Glu Val Asp Ser Val Ala Met  
 20 25 30  
 Ala Pro Ala Ala Pro Lys Ile Pro Arg Leu Val Gln Ala Thr Pro Ala  
 35 40 45  
 Phe Met Ala Val Thr Leu Val Phe Ser Leu Val Thr Leu Phe Val Val  
 50 55 60  
 Gly Lys Pro Pro Val Gln Gln Gln Thr Arg Pro Val Pro Lys Pro Val  
 65 70 75 80  
 Gln Ala Val Ile Leu Gly Asp Asn Ile Thr Gly His Leu Pro Phe Glu  
 85 90 95  
 Pro Asn Asn His His Phe Gly Arg Glu Ala Glu Met Arg Glu Leu  
 100 105 110  
 Ile Gln Thr Phe Lys Gly His Met Glu Asn Ser Ser Ala Trp Val Val  
 115 120 125  
 Glu Ile Gln Met Leu Lys Cys Arg Val Asp Asn Val Asn Ser Gln Leu  
 130 135 140  
 Gln Val Leu Gly Asp His Leu Gly Asn Thr Asn Ala Asp Ile Gln Met  
 145 150 155 160  
 Val Lys Gly Val Leu Lys Asp Ala Thr Thr Leu Ser Leu Gln Thr Gln  
 165 170 175  
 Met Leu Arg Ser Ser Leu Glu Gly Thr Asn Ala Glu Ile Gln Arg Leu  
 180 185 190  
 Lys Glu Asp Leu Glu Lys Ala Asp Ala Leu Thr Phe Gln Thr Leu Asn  
 195 200 205  
 Phe Leu Lys Ser Ser Leu Glu Asn Thr Ser Ile Glu Leu His Val Leu  
 210 215 220  
 Ser Arg Gly Leu Glu Asn Ala Asn Ser Glu Ile Gln Met Leu Asn Ala  
 225 230 235 240  
 Arg Ala Asn Ala Glu Ile Gln Gly Leu Lys Glu Asn Leu Gln Asn Thr  
 245 250 255  
 Asn Ala Leu Asn Ser Gln Thr Gln Ala Phe Ile Lys Ser Ser Phe Asp  
 260 265 270  
 Asn Thr Ser Ala Glu Ile Gln Phe Leu Arg Gly His Leu Glu Arg Ala  
 275 280 285  
 Gly Asp Glu Ile His Val Leu Lys Arg Asp Leu Lys Met Val Thr Ala  
 290 295 300  
 Gln Thr Gln Lys Ala Asn Gly Arg Leu Asp Gln Thr Asp Thr Gln Ile  
 305 310 315 320  
 Gln Val Phe Lys Ser Glu Met Glu Asn Val Asn Thr Leu Asn Ala Gln  
 325 330 335  
 Ile Gln Val Leu Asn Gly His Met Lys Asn Ala Ser Arg Glu Ile Gln  
 340 345 350  
 Thr Leu Lys Gln Gly Met Lys Asn Ala Ser Ala Leu Thr Ser Gln Thr  
 355 360 365  
 Gln Met Leu Asp Ser Asn Leu Gln Lys Ala Ser Ala Glu Ile Gln Arg  
 370 375 380  
 Leu Arg Gly Asp Leu Glu Asn Thr Lys Ala Leu Thr Met Glu Ile Gln  
 385 390 395 400  
 Gln Glu Gln Ser Arg Leu Lys Thr Leu His Val Val Ile Thr Ser Gln  
 405 410 415

Glu Gln Leu Gln Arg Thr Gln Ser Gln Leu Leu Gln Met Val Leu Gln  
 420 425 430  
 Gly Trp Lys Phe Asn Gly Gly Ser Leu Tyr Tyr Phe Ser Ser Val Lys  
 435 440 445  
 Lys Ser Trp His Glu Ala Glu Gln Phe Cys Val Ser Gln Gly Ala His  
 450 455 460  
 Leu Ala Ser Val Ala Ser Lys Glu Glu Gln Ala Phe Leu Val Glu Phe  
 465 470 475 480  
 Thr Ser Lys Val Tyr Tyr Trp Ile Gly Leu Thr Asp Arg Gly Thr Glu  
 485 490 495  
 Gly Ser Trp Arg Trp Thr Asp Gly Thr Pro Phe Asn Ala Ala Gln Asn  
 500 505 510  
 Lys Ala Pro Val Val Phe Gly Phe Trp Glu Lys Asn Gln Ser Asp Asn  
 515 520 525  
 Trp Arg His Lys Asn Gly Gln Thr Glu Asp Cys Val Gln Ile Gln Gln  
 530 535 540  
 Lys Trp Asn Asp Met Thr Cys Asp Thr Pro Tyr Gln Trp Val Cys Lys  
 545 550 555 560  
 Lys Pro Met Gly Gln Gly Val Ala  
 565 .

<210> 46  
 <211> 364  
 <212> PRT  
 <213> homo sapiens

<400> 46  
 Met Ser Arg Gln Gly Lys Leu Phe Ser Ala Phe Gly Val Gly Cys Cys  
 1 5 10 15  
 Val Thr Ala Gly Leu Pro Lys Asp Asp Asn Thr Pro Ser Thr Ile Ala  
 20 25 30  
 Asp Val His Asn Gly Tyr Thr Met Asn Val Val Glu Gln Val Leu Lys  
 35 40 45  
 Asp Ser Phe Val Leu Phe Phe Pro Gly Thr Leu Cys Asp Phe Pro Lys  
 50 55 60  
 Ile His His Gly Phe Leu Tyr Asp Glu Glu Asp Tyr Asn Pro Phe Ser  
 65 70 75 80  
 Gln Val Pro Thr Gly Glu Val Phe Tyr Tyr Ser Cys Glu Tyr Asn Phe  
 85 90 95  
 Val Ser Pro Ser Lys Ser Phe Trp Thr Arg Ile Thr Cys Thr Glu Glu  
 100 105 110  
 Gly Trp Ser Pro Thr Pro Lys Cys Leu Arg Met Cys Ser Phe Pro Phe  
 115 120 125  
 Val Lys Asn Gly His Ser Glu Ser Ser Gly Leu Ile His Leu Glu Gly  
 130 135 140  
 Asp Thr Val Gln Ile Ile Cys Asn Thr Gly Tyr Ser Leu Gln Asn Asn  
 145 150 155 160  
 Glu Lys Asn Ile Ser Cys Val Glu Arg Gly Trp Ser Thr Pro Pro Ile  
 165 170 175  
 Cys Ser Phe Thr Met Lys Thr Cys Gly Tyr Ile Pro Glu Leu Glu Tyr  
 180 185 190  
 Gly Tyr Val Gln Pro Ser Val Pro Pro Tyr Gln His Gly Val Ser Val  
 195 200 205  
 Glu Val Asn Cys Arg Asn Glu Tyr Ala Met Ile Gly Asn Asn Met Ile  
 210 215 220  
 Thr Cys Ile Asn Gly Ile Trp Thr Glu Leu Pro Met Cys Val Glu Ser  
 225 230 235 240  
 Thr Ala Tyr Cys Gly Pro Pro Ser Ile Asn Asn Gly Asp Thr Thr

245	250	255
Ser Phe Pro Leu Ser Val Tyr Pro Pro	Gly Ser Thr Val Thr Tyr Arg	
260	265	270
Cys Gln Ser Phe Tyr Lys Leu Gln Gly Ser Val Thr Val Thr Cys Arg		
275	280	285
Asn Lys Gln Trp Ser Glu Pro Pro Arg Cys Leu Asp Pro Cys Val Val		
290	295	300
Ser Glu Glu Asn Met Asn Lys Asn Ile Gln Leu Lys Trp Arg Asn		
305	310	315
Asp Gly Lys Leu Tyr Ala Lys Thr Gly Asp Ala Val Glu Phe Gln Cys		
325	330	335
Lys Phe Pro His Lys Ala Met Ile Ser Ser Pro Pro Phe Arg Ala Ile		
340	345	350
Cys Gln Glu Gly Lys Phe Glu Tyr Pro Ile Cys Glu		
355	360	

<210> 47  
 <211> 327  
 <212> PRT  
 <213> homo sapiens

<400> 47

Met Leu Leu Leu Phe Ser Val Ile Leu Ile Ser Trp Val Ser Thr Val			
1	5	10	15
Gly Gly Glu Gly Thr Leu Cys Asp Phe Pro Lys Ile His His Gly Phe			
20	25	30	
Leu Tyr Asp Glu Glu Asp Tyr Asn Pro Phe Ser Gln Val Pro Thr Gly			
35	40	45	
Glu Val Phe Tyr Tyr Ser Cys Glu Tyr Asn Phe Val Ser Pro Ser Lys			
50	55	60	
Ser Phe Trp Thr Arg Ile Thr Cys Thr Glu Glu Gly Trp Ser Pro Thr			
65	70	75	80
Pro Lys Cys Leu Arg Met Cys Ser Phe Pro Phe Val Lys Asn Gly His			
85	90	95	
Ser Glu Ser Ser Gly Leu Ile His Leu Glu Gly Asp Thr Val Gln Ile			
100	105	110	
Ile Cys Asn Thr Gly Tyr Ser Leu Gln Asn Asn Glu Lys Asn Ile Ser			
115	120	125	
Cys Val Glu Arg Gly Trp Ser Thr Pro Pro Ile Cys Ser Phe Thr Met			
130	135	140	
Lys Thr Cys Gly Tyr Ile Pro Glu Leu Glu Tyr Gly Tyr Val Gln Pro			
145	150	155	160
Ser Val Pro Pro Tyr Gln His Gly Val Ser Val Glu Val Asn Cys Arg			
165	170	175	
Asn Glu Tyr Ala Met Ile Gly Asn Asn Met Ile Thr Cys Ile Asn Gly			
180	185	190	
Ile Trp Thr Glu Leu Pro Met Cys Val Glu Ser Thr Ala Tyr Cys Gly			
195	200	205	
Pro Pro Pro Ser Ile Asn Asn Gly Asp Thr Thr Ser Phe Pro Leu Ser			
210	215	220	
Val Tyr Pro Pro Gly Ser Thr Val Thr Tyr Arg Cys Gln Ser Phe Tyr			
225	230	235	240
Lys Leu Gln Gly Ser Val Thr Val Thr Cys Arg Asn Lys Gln Trp Ser			
245	250	255	
Glu Pro Pro Arg Cys Leu Asp Pro Cys Val Val Ser Glu Glu Asn Met			
260	265	270	
Asn Lys Asn Asn Ile Gln Leu Lys Trp Arg Asn Asp Gly Lys Leu Tyr			
275	280	285	

Ala Lys Thr Gly Asp Ala Val Glu Phe Gln Cys Lys Phe Pro His Lys  
 290 295 300  
 Ala Met Ile Ser Ser Pro Pro Phe Arg Ala Ile Cys Gln Glu Gly Lys  
 305 310 315 320  
 Phe Glu Tyr Pro Ile Cys Glu  
 325

<210> 48  
 <211> 154  
 <212> PRT  
 <213> homo sapiens

<400> 48  
 Met Ala Pro Ala Arg Ala Gly Cys Cys Pro Leu Leu Leu Leu Leu  
 1 5 10 15  
 Gly Leu Trp Val Ala Glu Val Leu Val Arg Ala Lys Pro Lys Asp Met  
 20 25 30  
 Thr Ser Ser Gln Trp Phe Lys Thr Gln His Val Gln Pro Ser Pro Gln  
 35 40 45  
 Ala Cys Asn Ser Ala Met Ser Ile Ile Asn Lys Tyr Thr Glu Arg Cys  
 50 55 60  
 Lys Asp Leu Asn Thr Phe Leu His Glu Pro Phe Ser Ser Val Ala Ile  
 65 70 75 80  
 Thr Cys Gln Thr Pro Asn Ile Ala Cys Lys Asn Ser Cys Lys Asn Cys  
 85 90 95  
 His Gln Ser His Gly Pro Met Ser Leu Thr Met Gly Glu Leu Thr Ser  
 100 105 110  
 Gly Lys Tyr Pro Asn Cys Arg Tyr Lys Glu Lys His Leu Asn Thr Pro  
 115 120 125  
 Tyr Ile Val Ala Cys Asp Pro Pro Gln Gln Gly Asp Pro Gly Tyr Pro  
 130 135 140  
 Leu Val Pro Val His Leu Asp Lys Val Val  
 145 150

<210> 49  
 <211> 502  
 <212> PRT  
 <213> homo sapiens

<400> 49  
 Met Arg Gln Leu Gly Gly Ser Leu Arg Pro Pro Arg Ala Ala His Gly  
 1 5 10 15  
 Ala Glu Pro Leu Pro Ser Ala Leu Gly Pro Cys Ala Gly Gly Asp Arg  
 20 25 30  
 Asp Leu Gly Arg Gly Thr Pro Gly Trp Glu Pro Arg Arg Ala Arg Val  
 35 40 45  
 Pro Ile His Glu Gln Val Asp Pro Pro Arg Glu Gly Pro His Leu Phe  
 50 55 60  
 Gln Asn Leu Leu Leu Phe Leu Trp Ala Leu Leu Asn Cys Gly Leu Gly  
 65 70 75 80  
 Val Ser Ala Gln Gly Pro Gly Glu Trp Thr Pro Trp Val Ser Trp Thr  
 85 90 95  
 Arg Cys Ser Ser Ser Cys Gly Arg Gly Val Ser Val Arg Ser Arg Arg  
 100 105 110  
 Cys Leu Arg Leu Pro Gly Glu Pro Cys Trp Gly Asp Ser His Glu  
 115 120 125  
 Tyr Arg Leu Cys Gln Leu Pro Asp Cys Pro Pro Gly Ala Val Pro Phe

130	135	140
Arg Asp Leu Gln Cys Ala Leu Tyr Asn Gly Arg Pro Val Leu Gly Thr		
145	150	155
Gln Lys Thr Tyr Gln Trp Val Pro Phe His Gly Ala Pro Asn Gln Cys		160
165	170	175
Asp Leu Asn Cys Leu Ala Glu Gly His Ala Phe Tyr His Ser Phe Gly		
180	185	190
Arg Val Leu Asp Gly Thr Ala Cys Ser Pro Gly Ala Gln Gly Val Cys		
195	200	205
Val Ala Gly Arg Cys Leu Ser Ala Gly Cys Asp Gly Leu Leu Gly Ser		
210	215	220
Gly Ala Leu Glu Asp Arg Cys Gly Arg Cys Gly Gly Ala Asn Asp Ser		
225	230	235
Cys Leu Phe Val Gln Arg Val Phe Arg Asp Ala Gly Ala Phe Ala Gly		240
245	250	255
Tyr Trp Asn Val Thr Leu Ile Pro Glu Gly Ala Arg His Ile Arg Val		
260	265	270
Glu His Arg Ser Arg Asn His Leu Gly Ile Leu Gly Ser Leu Met Gly		
275	280	285
Gly Asp Gly Arg Tyr Val Leu Asn Gly His Trp Val Val Ser Pro Pro		
290	295	300
Gly Thr Tyr Glu Ala Ala Gly Thr His Val Val Tyr Thr Arg Asp Thr		
305	310	315
Gly Pro Gln Glu Thr Leu Gln Ala Ala Gly Pro Thr Ser His Asp Leu		320
325	330	335
Leu Leu Gln Val Leu Leu Gln Glu Pro Asn Pro Gly Ile Glu Phe Glu		
340	345	350
Phe Trp Leu Pro Arg Glu Arg Tyr Ser Pro Phe Gln Ala Arg Val Gln		
355	360	365
Ala Leu Gly Trp Pro Leu Arg Gln Pro Gln Pro Arg Gly Val Glu Pro		
370	375	380
Gln Pro Pro Ala Ala Pro Ala Val Thr Pro Ala Gln Thr Pro Thr Leu		
385	390	395
Ala Pro Val Phe Gln Ala Arg Val Leu Gly His His His Gln Ala Gln		400
405	410	415
Glu Thr Arg Tyr Glu Val Arg Ile Gln Leu Val Tyr Lys Asn Arg Ser		
420	425	430
Pro Leu Arg Ala Arg Glu Tyr Val Trp Ala Pro Gly His Cys Pro Cys		
435	440	445
Pro Met Leu Ala Pro His Arg Asp Tyr Leu Met Ala Val Gln Arg Leu		
450	455	460
Val Ser Pro Asp Gly Thr Gln Asp Gln Leu Leu Leu Pro His Ala Gly		
465	470	475
Tyr Ala Arg Pro Trp Ser Pro Ala Glu Asp Ser Arg Ile Arg Leu Thr		480
485	490	495
Ala Arg Arg Cys Pro Gly		
500		

<210> 50  
 <211> 451  
 <212> PRT  
 <213> homo sapiens

<400> 50  
 Met Asp Ser Ala Pro Leu Phe Pro Arg Pro His Leu Phe Gln Asn Leu  
 1 5 10 15  
 Leu Leu Phe Leu Trp Ala Leu Leu Asn Cys Gly Leu Gly Val Ser Ala  
 20 25 30

Gln Gly Pro Gly Glu Trp Thr Pro Trp Val Ser Trp Thr Arg Cys Ser  
 35 40 45  
 Ser Ser Cys Gly Arg Gly Val Ser Val Arg Ser Arg Arg Cys Leu Arg  
 50 55 60  
 Leu Pro Gly Glu Glu Pro Cys Trp Gly Asp Ser His Glu Tyr Arg Leu  
 65 70 75 80  
 Cys Gln Leu Pro Asp Cys Pro Pro Gly Ala Val Pro Phe Arg Asp Leu  
 85 90 95  
 Gln Cys Ala Leu Tyr Asn Gly Arg Pro Val Leu Gly Thr Gln Lys Thr  
 100 105 110  
 Tyr Gln Trp Val Pro Phe His Gly Ala Pro Asn Gln Cys Asp Leu Asn  
 115 120 125  
 Cys Leu Ala Glu Gly His Ala Phe Tyr His Ser Phe Gly Arg Val Leu  
 130 135 140  
 Asp Gly Thr Ala Cys Ser Pro Gly Ala Gln Gly Val Cys Val Ala Gly  
 145 150 155 160  
 Arg Cys Leu Ser Ala Gly Cys Asp Gly Leu Leu Gly Ser Gly Ala Leu  
 165 170 175  
 Glu Asp Arg Cys Gly Arg Cys Gly Gly Ala Asn Asp Ser Cys Leu Phe  
 180 185 190  
 Val Gln Arg Val Phe Arg Asp Ala Gly Ala Phe Ala Gly Tyr Trp Asn  
 195 200 205  
 Val Thr Leu Ile Pro Glu Gly Ala Arg His Ile Arg Val Glu His Arg  
 210 215 220  
 Ser Arg Asn His Leu Gly Ile Leu Gly Ser Leu Met Gly Gly Asp Gly  
 225 230 235 240  
 Arg Tyr Val Leu Asn Gly His Trp Val Val Ser Pro Pro Gly Thr Tyr  
 245 250 255  
 Glu Ala Ala Gly Thr His Val Val Tyr Thr Arg Asp Thr Gly Pro Gln  
 260 265 270  
 Glu Thr Leu Gln Ala Ala Gly Pro Thr Ser His Asp Leu Leu Leu Gln  
 275 280 285  
 Val Leu Leu Gln Glu Pro Asn Pro Gly Ile Glu Phe Glu Phe Trp Leu  
 290 295 300  
 Pro Arg Glu Arg Tyr Ser Pro Phe Gln Ala Arg Val Gln Ala Leu Gly  
 305 310 315 320  
 Trp Pro Leu Arg Gln Pro Gln Pro Arg Gly Val Glu Pro Gln Pro Pro  
 325 330 335  
 Ala Ala Pro Ala Val Thr Pro Ala Gln Thr Pro Thr Leu Ala Pro Val  
 340 345 350  
 Phe Gln Ala Arg Val Leu Gly His His His Gln Ala Gln Glu Thr Arg  
 355 360 365  
 Tyr Glu Val Arg Ile Gln Leu Val Tyr Lys Asn Arg Ser Pro Leu Arg  
 370 375 380  
 Ala Arg Glu Tyr Val Trp Ala Pro Gly His Cys Pro Cys Pro Met Leu  
 385 390 395 400  
 Ala Pro His Arg Asp Tyr Leu Met Ala Val Gln Arg Leu Val Ser Pro  
 405 410 415  
 Asp Gly Thr Gln Asp Gln Leu Leu Leu Pro His Ala Gly Tyr Ala Arg  
 420 425 430  
 Pro Trp Ser Pro Ala Glu Asp Ser Arg Ile Arg Leu Thr Ala Arg Arg  
 435 440 445  
 Cys Pro Gly  
 450

<210> 51  
 <211> 431  
 <212> PRT

&lt;213&gt; homo sapiens

&lt;400&gt; 51

Met Ile Arg Thr Pro Leu Ser Ala Ser Ala His Arg Leu Leu Pro  
 1 5 10 15  
 Gly Ser Arg Gly Arg Pro Pro Arg Asn Met Gln Pro Thr Gly Arg Glu  
 20 25 30  
 Gly Ser Arg Ala Leu Ser Arg Arg Tyr Leu Arg Arg Leu Leu Leu  
 35 40 45  
 Leu Leu Leu Leu Leu Arg Gln Pro Val Thr Arg Ala Glu Thr Thr  
 50 55 60  
 Pro Gly Ala Pro Arg Ala Leu Ser Thr Leu Gly Ser Pro Ser Leu Phe  
 65 70 75 80  
 Thr Thr Pro Gly Val Pro Ser Ala Leu Thr Thr Pro Gly Leu Thr Thr  
 85 90 95  
 Pro Gly Thr Pro Lys Thr Leu Asp Leu Arg Gly Arg Ala Gln Ala Leu  
 100 105 110  
 Met Arg Ser Phe Pro Leu Val Asp Gly Tyr Val Gly Leu Asn Ser Ser  
 115 120 125  
 Gln Lys Leu Ala Cys Leu Ile Gly Val Glu Gly Gly His Ser Leu Asp  
 130 135 140  
 Ser Ser Leu Ser Val Leu Arg Ser Phe Tyr Val Leu Gly Val Arg Tyr  
 145 150 155 160  
 Leu Thr Leu Thr Phe Thr Cys Ser Thr Pro Trp Ala Glu Ser Ser Thr  
 165 170 175  
 Lys Phe Arg His His Met Tyr Thr Asn Val Ser Gly Leu Thr Ser Phe  
 180 185 190  
 Gly Glu Lys Val Val Glu Glu Leu Asn Arg Leu Gly Met Met Ile Asp  
 195 200 205  
 Leu Ser Tyr Ala Ser Asp Thr Leu Ile Arg Arg Val Leu Glu Val Ser  
 210 215 220  
 Gln Ala Pro Val Ile Phe Ser His Ser Ala Ala Arg Ala Val Cys Asp  
 225 230 235 240  
 Asn Leu Leu Asn Val Pro Asp Asp Ile Leu Gln Leu Leu Lys Lys Asn  
 245 250 255  
 Gly Gly Ile Val Met Val Thr Leu Ser Met Gly Val Leu Gln Cys Asn  
 260 265 270  
 Leu Leu Ala Asn Val Ser Thr Val Ala Asp Asp Ser Asn Arg Cys Ser  
 275 280 285  
 Val Pro Val Ile Gly Ser Glu Phe Ile Gly Ile Gly Gly Asn Tyr Asp  
 290 295 300  
 Gly Thr Gly Arg Phe Pro Gln Gly Leu Glu Asp Val Ser Thr Tyr Pro  
 305 310 315 320  
 Val Leu Ile Glu Glu Leu Leu Ser Arg Ser Trp Ser Glu Glu Leu  
 325 330 335  
 Gln Gly Val Leu Arg Gly Asn Leu Leu Arg Val Phe Arg Gln Val Glu  
 340 345 350  
 Lys Val Arg Glu Glu Ser Arg Ala Gln Ser Pro Val Glu Ala Glu Phe  
 355 360 365  
 Pro Tyr Gly Gln Leu Ser Thr Ser Cys His Ser His Leu Val Pro Gln  
 370 375 380  
 Asn Gly His Gln Ala Thr His Leu Glu Val Thr Lys Gln Pro Thr Asn  
 385 390 395 400  
 Arg Val Pro Trp Arg Ser Ser Asn Ala Ser Pro Tyr Leu Val Pro Gly  
 405 410 415  
 Leu Val Ala Ala Ala Thr Ile Pro Thr Phe Thr Gln Trp Leu Cys  
 420 425 430

<210> 52  
 <211> 480  
 <212> PRT  
 <213> homo sapiens

<400> 52  
 Met Gln Pro Ser Gly Leu Glu Gly Pro Gly Thr Phe Gly Arg Trp Pro  
 1 5 10 15  
 Leu Leu Ser Leu Leu Leu Leu Leu Leu Gln Pro Val Thr Cys  
 20 25 30  
 Ala Tyr Thr Thr Pro Gly Pro Pro Arg Ala Leu Thr Thr Leu Gly Ala  
 35 40 45  
 Pro Arg Ala His Thr Met Pro Gly Thr Tyr Ala Pro Ser Thr Thr Leu  
 50 55 60  
 Ser Ser Pro Ser Thr Gln Gly Leu Gln Glu Gln Ala Arg Ala Leu Met  
 65 70 75 80  
 Arg Asp Phe Pro Leu Val Asp Gly His Asn Asp Leu Pro Leu Val Leu  
 85 90 95  
 Arg Gln Val Tyr Gln Lys Gly Leu Gln Asp Val Asn Leu Arg Asn Phe  
 100 105 110  
 Ser Tyr Gly Gln Thr Ser Leu Asp Arg Leu Arg Asp Gly Leu Val Gly  
 115 120 125  
 Ala Gln Phe Trp Ser Ala Tyr Val Pro Cys Gln Thr Gln Asp Arg Asp  
 130 135 140  
 Ala Leu Arg Leu Thr Leu Glu Gln Ile Asp Leu Ile Arg Arg Met Cys  
 145 150 155 160  
 Ala Ser Tyr Ser Glu Leu Glu Leu Val Thr Ser Ala Lys Gly Leu Asn  
 165 170 175  
 Ser Ser Gln Lys Leu Ala Cys Leu Ile Gly Val Glu Gly Gly His Ser  
 180 185 190  
 Leu Asp Ser Ser Leu Ser Val Leu Arg Ser Phe Tyr Val Leu Gly Val  
 195 200 205  
 Arg Tyr Leu Thr Leu Thr Phe Thr Cys Ser Thr Pro Trp Ala Glu Ser  
 210 215 220  
 Ser Thr Lys Phe Arg His His Met Tyr Thr Asn Val Ser Gly Leu Thr  
 225 230 235 240  
 Ser Phe Gly Glu Lys Val Val Glu Glu Leu Asn Arg Leu Gly Met Met  
 245 250 255  
 Ile Asp Leu Ser Tyr Ala Ser Asp Thr Leu Ile Arg Arg Val Leu Glu  
 260 265 270  
 Val Ser Gln Ala Pro Val Ile Phe Ser His Ser Ala Ala Arg Ala Val  
 275 280 285  
 Cys Asp Asn Leu Leu Asn Val Pro Asp Asp Ile Leu Gln Leu Leu Lys  
 290 295 300  
 Lys Asn Gly Gly Ile Val Met Val Thr Leu Ser Met Gly Val Leu Gln  
 305 310 315 320  
 Cys Asn Leu Leu Ala Asn Val Ser Thr Val Ala Asp His Phe Asp His  
 325 330 335  
 Ile Arg Ala Val Ile Gly Ser Glu Phe Ile Gly Ile Gly Gly Asn Tyr  
 340 345 350  
 Asp Gly Thr Gly Arg Phe Pro Gln Gly Leu Glu Asp Val Ser Thr Tyr  
 355 360 365  
 Pro Val Leu Ile Glu Glu Leu Leu Ser Arg Ser Trp Ser Glu Glu Glu  
 370 375 380  
 Leu Gln Gly Val Leu Arg Gly Asn Leu Leu Arg Val Phe Arg Gln Val  
 385 390 395 400  
 Glu Lys Val Arg Glu Glu Ser Arg Ala Gln Ser Pro Val Glu Ala Glu  
 405 410 415  
 Phe Pro Tyr Gly Gln Leu Ser Thr Ser Cys His Ser His Leu Val Pro

420	425	430
Gln Asn Gly His Gln Ala Thr His Leu Glu Val Thr Lys Gln Pro Thr		
435	440	445
Asn Arg Val Pro Trp Arg Ser Ser Asn Ala Ser Pro Tyr Leu Val Pro		
450	455	460
Gly Leu Val Ala Ala Ala Thr Ile Pro Thr Phe Thr Gln Trp Leu Cys		
465	470	475
		480

<210> 53  
 <211> 371  
 <212> PRT  
 <213> homo sapiens

<400> 53			
Met Asp Ala Ala Thr Ala Pro Lys Gln Ala Trp Pro Pro Trp Pro Pro			
1	5	10	15
Leu Leu Phe Leu Leu Leu Pro Gly Gly Ser Gly Ser Cys Pro			
20	25	30	
Ala Val Cys Asp Cys Thr Ser Gln Pro Gln Ala Val Leu Cys Gly His			
35	40	45	
Arg Gln Leu Glu Ala Val Pro Gly Gly Leu Pro Leu Asp Thr Glu Leu			
50	55	60	
Leu Asp Leu Ser Gly Asn Arg Leu Pro Lys Ala Gln Pro Leu Val Arg			
65	70	75	80
Leu Gln Glu Leu Arg Leu Ser Gly Ala Cys Leu Thr Ser Ile Ala Ala			
85	90	95	
His Ala Phe His Gly Leu Thr Ala Phe His Leu Leu Asp Val Ala Asp			
100	105	110	
Asn Ala Leu Gln Thr Leu Glu Glu Thr Ala Phe Pro Ser Pro Asp Lys			
115	120	125	
Leu Val Thr Leu Arg Leu Ser Gly Asn Pro Leu Thr Cys Asp Cys Arg			
130	135	140	
Leu Leu Trp Leu Leu Arg Leu Arg His Leu Asp Phe Gly Met Ser Pro			
145	150	155	160
Pro Ala Cys Ala Gly Pro His His Val Gln Gly Lys Ser Leu Lys Glu			
165	170	175	
Phe Ser Asp Ile Leu Pro Pro Gly His Phe Thr Cys Lys Pro Ala Leu			
180	185	190	
Ile Arg Lys Ser Gly Pro Arg Trp Val Ile Ala Glu Glu Gly Gly His			
195	200	205	
Ala Val Phe Ser Cys Ser Gly Asp Gly Asp Pro Ala Pro Thr Val Ser			
210	215	220	
Trp Met Arg Pro His Gly Ala Trp Leu Gly Arg Ala Gly Arg Val Arg			
225	230	235	240
Val Leu Glu Asp Gly Thr Leu Glu Ile Arg Ser Val Gln Leu Arg Asp			
245	250	255	
Arg Gly Ala Tyr Val Cys Val Val Ser Asn Val Ala Gly Asn Asp Ser			
260	265	270	
Leu Arg Thr Trp Leu Glu Val Ile Gln Val Glu Pro Pro Asn Gly Thr			
275	280	285	
Leu Ser Asp Pro Asn Ile Thr Val Pro Gly Ile Pro Gly Pro Phe Phe			
290	295	300	
Leu Asp Ser Arg Gly Val Ala Met Val Leu Ala Val Gly Phe Leu Pro			
305	310	315	320
Phe Leu Thr Ser Val Thr Leu Cys Phe Gly Leu Ile Ala Leu Trp Ser			
325	330	335	
Lys Gly Lys Gly Arg Val Lys His His Met Thr Phe Asp Phe Val Ala			
340	345	350	

Pro	Arg	Pro	Ser	Gly	Asp	Lys	Asn	Ser	Gly	Gly	Asn	Arg	Val	Thr	Ala
355						360						365			
Lys	Leu	Phe													
370															

<210>	54
<211>	592
<212>	PRT
<213>	homo sapiens

<400>	54														
Met	Asp	Ala	Ala	Thr	Ala	Pro	Lys	Gln	Ala	Trp	Pro	Pro	Trp	Pro	Pro
1							5			10			15		
Leu	Leu	Phe	Leu	Leu	Leu	Leu	Pro	Gly	Gly	Ser	Gly	Gly	Ser	Cys	Pro
							20			25			30		
Ala	Val	Cys	Asp	Cys	Thr	Ser	Gln	Pro	Gln	Ala	Val	Leu	Cys	Gly	His
							35			40			45		
Arg	Gln	Leu	Glu	Ala	Val	Pro	Gly	Gly	Leu	Pro	Leu	Asp	Thr	Glu	Leu
							50			55			60		
Leu	Asp	Leu	Ser	Gly	Asn	Arg	Leu	Trp	Gly	Leu	Gln	Gln	Gly	Met	Leu
							65			70			75		80
Ser	Arg	Leu	Ser	Leu	Leu	Gln	Glu	Leu	Asp	Leu	Ser	Tyr	Asn	Gln	Leu
							85			90			95		
Ser	Thr	Leu	Glu	Pro	Gly	Ala	Phe	His	Gly	Leu	Gln	Ser	Leu	Leu	Thr
							100			105			110		
Leu	Arg	Leu	Gln	Gly	Asn	Arg	Leu	Arg	Ile	Met	Gly	Pro	Gly	Val	Phe
							115			120			125		
Ser	Gly	Leu	Ser	Ala	Leu	Thr	Leu	Leu	Asp	Leu	Arg	Leu	Asn	Gln	Ile
							130			135			140		
Val	Leu	Phe	Leu	Asp	Gly	Ala	Phe	Gly	Glu	Leu	Gly	Ser	Leu	Gln	Lys
							145			150			155		160
Leu	Glu	Val	Gly	Asp	Asn	His	Leu	Val	Phe	Val	Ala	Pro	Gly	Ala	Phe
							165			170			175		
Ala	Gly	Leu	Ala	Lys	Leu	Ser	Thr	Leu	Thr	Leu	Glu	Arg	Cys	Asn	Leu
							180			185			190		
Ser	Thr	Val	Pro	Gly	Leu	Ala	Leu	Ala	Arg	Leu	Pro	Ala	Leu	Val	Ala
							195			200			205		
Leu	Arg	Leu	Arg	Glu	Leu	Asp	Ile	Gly	Arg	Leu	Pro	Ala	Gly	Ala	Leu
							210			215			220		
Arg	Gly	Leu	Gly	Gln	Leu	Lys	Glu	Leu	Glu	Ile	His	Leu	Trp	Pro	Ser
							225			230			235		240
Leu	Glu	Ala	Leu	Asp	Pro	Gly	Ser	Leu	Val	Gly	Leu	Asn	Leu	Ser	Ser
							245			250			255		
Leu	Ala	Ile	Thr	Arg	Cys	Asn	Leu	Ser	Ser	Val	Pro	Phe	Gln	Ala	Leu
							260			265			270		
Tyr	His	Leu	Ser	Phe	Leu	Arg	Val	Leu	Asp	Leu	Ser	Gln	Asn	Pro	Ile
							275			280			285		
Ser	Ala	Ile	Pro	Ala	Arg	Arg	Leu	Ser	Pro	Leu	Val	Arg	Leu	Gln	Glu
							290			295			300		
Leu	Arg	Leu	Ser	Gly	Ala	Cys	Leu	Thr	Ser	Ile	Ala	Ala	His	Ala	Phe
							305			310			315		320
His	Gly	Leu	Thr	Ala	Phe	His	Leu	Leu	Asp	Val	Ala	Asp	Asn	Ala	Leu
							325			330			335		
Gln	Thr	Leu	Glu	Glu	Thr	Ala	Phe	Pro	Ser	Pro	Asp	Lys	Leu	Val	Thr
							340			345			350		
Leu	Arg	Leu	Ser	Gly	Asn	Pro	Leu	Thr	Cys	Asp	Cys	Arg	Leu	Leu	Trp
							355			360			365		
Leu	Leu	Arg	Leu	Arg	His	Leu	Asp	Phe	Gly	Met	Ser	Pro	Pro	Ala	Cys

370	375	380													
Ala	Gly	Pro	His	His	Val	Gln	Gly	Lys	Ser	Leu	Lys	Glu	Phe	Ser	Asp
385					390			395							400
Ile	Leu	Pro	Pro	Gly	His	Phe	Thr	Cys	Lys	Pro	Ala	Leu	Ile	Arg	Lys
					405			410							415
Ser	Gly	Pro	Arg	Trp	Val	Ile	Ala	Glu	Glu	Gly	Gly	His	Ala	Val	Phe
					420			425							430
Ser	Cys	Ser	Gly	Asp	Gly	Asp	Pro	Ala	Pro	Thr	Val	Ser	Trp	Met	Arg
					435			440							445
Pro	His	Gly	Ala	Trp	Leu	Gly	Arg	Ala	Gly	Arg	Val	Arg	Val	Leu	Glu
					450			455							460
Asp	Gly	Thr	Leu	Glu	Ile	Arg	Ser	Val	Gln	Leu	Arg	Asp	Arg	Gly	Ala
465					470				475						480
Tyr	Val	Cys	Val	Val	Ser	Asn	Val	Ala	Gly	Asn	Asp	Ser	Leu	Arg	Thr
					485				490						495
Trp	Leu	Glu	Val	Ile	Gln	Val	Glu	Pro	Pro	Asn	Gly	Thr	Leu	Ser	Asp
					500			505							510
Pro	Asn	Ile	Thr	Val	Pro	Gly	Ile	Pro	Gly	Pro	Phe	Phe	Leu	Asp	Ser
					515			520							525
Arg	Gly	Val	Ala	Met	Val	Leu	Ala	Val	Gly	Phe	Leu	Pro	Phe	Leu	Thr
					530			535							540
Ser	Val	Thr	Leu	Cys	Phe	Gly	Leu	Ile	Ala	Leu	Trp	Ser	Lys	Gly	Lys
545					550				555						560
Gly	Arg	Val	Lys	His	His	Met	Thr	Phe	Asp	Phe	Val	Ala	Pro	Arg	Pro
					565				570						575
Ser	Gly	Asp	Lys	Asn	Ser	Gly	Gly	Asn	Arg	Val	Thr	Ala	Lys	Leu	Phe
					580			585							590

<210> 55  
 <211> 142  
 <212> PRT  
 <213> homo sapiens

<400> 55															
Met	Ala	Arg	Tyr	Met	Leu	Leu	Leu	Leu	Leu	Ala	Val	Trp	Val	Leu	Thr
1				5				10							15
Gly	Glu	Leu	Trp	Pro	Gly	Ala	Glu	Ala	Arg	Ala	Ala	Pro	Tyr	Gly	Val
				20				25							30
Arg	Leu	Cys	Gly	Arg	Glu	Phe	Ile	Arg	Ala	Val	Ile	Phe	Thr	Cys	Gly
				35				40							45
Gly	Ser	Arg	Trp	Arg	Arg	Ser	Asp	Ile	Leu	Ala	His	Glu	Ala	Met	Gly
				50				55							60
Asp	Thr	Phe	Pro	Asp	Ala	Asp	Ala	Asp	Glu	Asp	Ser	Leu	Ala	Gly	Glu
65					70				75						80
Leu	Asp	Glu	Ala	Met	Gly	Ser	Ser	Glu	Trp	Leu	Ala	Leu	Thr	Lys	Ser
				85				90							95
Pro	Gln	Ala	Phe	Tyr	Arg	Gly	Arg	Pro	Ser	Trp	Gln	Gly	Thr	Pro	Gly
				100				105							110
Val	Leu	Arg	Gly	Ser	Arg	Asp	Val	Leu	Ala	Gly	Leu	Ser	Ser	Ser	Cys
				115				120							125
Cys	Lys	Trp	Gly	Cys	Ser	Lys	Ser	Glu	Ile	Ser	Ser	Leu	Cys		
				130				135							140

<210> 56  
 <211> 230  
 <212> PRT  
 <213> homo sapiens

&lt;400&gt; 56

Met Ser Glu Glu Val Thr Tyr Ala Thr Leu Thr Phe Gln Asp Ser Ala  
 1 5 10 15  
 Gly Ala Arg Asn Asn Arg Asp Gly Asn Asn Leu Arg Lys Arg Gly His  
 20 25 30  
 Pro Ala Pro Ser Pro Ile Trp Arg His Ala Ala Leu Gly Leu Val Thr  
 35 40 45  
 Leu Cys Leu Met Leu Leu Ile Gly Leu Val Thr Leu Gly Met Met Phe  
 50 55 60  
 Leu Gln Ile Ser Asn Asp Ile Asn Ser Asp Ser Glu Lys Leu Ser Gln  
 65 70 75 80  
 Leu Gln Lys Thr Ile Gln Gln Gln Asp Asn Leu Ser Gln Gln Leu  
 85 90 95  
 Gly Asn Ser Asn Asn Leu Ser Met Glu Glu Glu Phe Leu Lys Ser Gln  
 100 105 110  
 Ile Ser Ser Leu Leu Lys Arg Gln Glu Gln Met Ala Ile Lys Leu Cys  
 115 120 125  
 Gln Glu Leu Ile Ile His Thr Ser Asp His Arg Cys Asn Pro Cys Pro  
 130 135 140  
 Lys Met Trp Gln Trp Tyr Gln Asn Ser Cys Tyr Tyr Phe Thr Thr Asn  
 145 150 155 160  
 Glu Glu Lys Thr Trp Ala Asn Ser Arg Lys Asp Cys Ile Asp Lys Asn  
 165 170 175  
 Ser Thr Leu Val Lys Ile Asp Ser Leu Glu Glu Lys Asp Phe Leu Met  
 180 185 190  
 Ser Gln Pro Leu Leu Met Phe Ser Phe Phe Trp Leu Gly Leu Ser Trp  
 195 200 205  
 Asp Ser Ser Gly Arg Ser Trp Phe Trp Glu Asp Gly Ser Val Pro Ser  
 210 215 220  
 Pro Ser Leu Tyr Val Ser  
 225 230

&lt;210&gt; 57

<211> 194  
 <212> PRT  
 <213> homo sapiens

&lt;400&gt; 57

Met Trp Leu Ser Pro Ala Leu Leu Leu Ile Leu Pro Gly Tyr Ser  
 1 5 10 15  
 Ile Ala Ala Lys Ile Thr Gly Pro Thr Thr Val Asn Gly Ser Glu Gln  
 20 25 30  
 Gly Ser Leu Thr Val Gln Cys Ala Tyr Gly Ser Gly Trp Glu Thr Tyr  
 35 40 45  
 Leu Lys Trp Arg Cys Gln Gly Ala Asp Trp Asn Tyr Cys Asn Ile Leu  
 50 55 60  
 Val Lys Thr Asn Gly Ser Glu Gln Glu Val Lys Lys Asn Arg Val Ser  
 65 70 75 80  
 Ile Arg Asp Asn Gln Lys Asn His Met Phe Thr Val Thr Met Glu Asn  
 85 90 95  
 Leu Lys Arg Asp Asp Ala Asp Ser Tyr Trp Cys Gly Thr Glu Arg Pro  
 100 105 110  
 Gly Ile Asp Leu Gly Val Lys Val Gln Val Thr Ile Asn Pro Gly Thr  
 115 120 125  
 Gln Thr Ala Val Ser Glu Trp Thr Thr Thr Ala Ser Leu Ala Phe  
 130 135 140  
 Thr Ala Ala Ala Thr Gln Lys Thr Ser Ser Pro Leu Thr Arg Ser Pro

145	150	155	160												
Leu	Lys	Ser	Thr	His	Phe	Leu	Phe	Leu	Leu	Glu	Leu	Pro	Leu		
				165				170			175				
Leu	Leu	Ser	Met	Leu	Gly	Thr	Val	Leu	Trp	Val	Asn	Arg	Pro	Gln	Arg
				180				185			190				
Arg Ser															

<210> 58  
 <211> 333  
 <212> PRT  
 <213> homo sapiens

<400> 58															
Met	Arg	Ile	Trp	Trp	Leu	Leu	Leu	Ala	Ile	Glu	Ile	Cys	Thr	Gly	Asn
1					5				10			15			
Ile	Asn	Ser	Gln	Asp	Thr	Cys	Arg	Gln	Gly	His	Pro	Gly	Ile	Pro	Gly
					20				25			30			
Asn	Pro	Gly	His	Asn	Gly	Leu	Pro	Gly	Arg	Asp	Gly	Arg	Asp	Gly	Ala
					35				40			45			
Lys	Gly	Asp	Lys	Gly	Asp	Ala	Gly	Glu	Pro	Gly	Arg	Pro	Gly	Ser	Pro
					50				55			60			
Gly	Lys	Asp	Gly	Thr	Ser	Gly	Glu	Lys	Gly	Glu	Arg	Gly	Ala	Asp	Gly
					65				70			75			80
Lys	Val	Glu	Ala	Lys	Gly	Ile	Lys	Gly	Asp	Gln	Gly	Ser	Arg	Gly	Ser
					85				90			95			
Pro	Gly	Lys	His	Gly	Pro	Lys	Gly	Leu	Ala	Gly	Pro	Met	Gly	Glu	Lys
					100				105			110			
Gly	Leu	Arg	Gly	Glu	Thr	Gly	Pro	Gln	Gly	Gln	Gly	Asn	Lys	Gly	
					115				120			125			
Asp	Val	Gly	Pro	Thr	Gly	Pro	Glu	Gly	Pro	Arg	Gly	Asn	Ile	Gly	Pro
					130				135			140			
Leu	Gly	Pro	Thr	Gly	Leu	Pro	Gly	Pro	Met	Gly	Pro	Ile	Gly	Lys	Pro
					145				150			155			160
Gly	Pro	Lys	Gly	Glu	Ala	Gly	Pro	Thr	Gly	Pro	Gln	Gly	Glu	Pro	Gly
					165				170			175			
Val	Arg	Gly	Ile	Arg	Gly	Trp	Lys	Gly	Asp	Arg	Gly	Glu	Lys	Gly	Lys
					180				185			190			
Ile	Gly	Glu	Thr	Leu	Val	Leu	Pro	Lys	Ser	Ala	Phe	Thr	Val	Gly	Leu
					195				200			205			
Thr	Val	Leu	Ser	Lys	Phe	Pro	Ser	Ser	Asp	Met	Pro	Ile	Lys	Phe	Asp
					210				215			220			
Lys	Ile	Leu	Tyr	Asn	Glu	Phe	Asn	His	Tyr	Asp	Thr	Ala	Ala	Gly	Lys
					225				230			235			240
Phe	Thr	Cys	His	Ile	Ala	Gly	Val	Tyr	Tyr	Phe	Thr	Tyr	His	Ile	Thr
					245				250			255			
Val	Phe	Ser	Arg	Asn	Val	Gln	Val	Ser	Leu	Val	Lys	Asn	Gly	Val	Lys
					260				265			270			
Ile	Leu	His	Thr	Lys	Asp	Ala	Tyr	Met	Ser	Ser	Glu	Asp	Gln	Ala	Ser
					275				280			285			
Gly	Gly	Ile	Val	Leu	Gln	Leu	Lys	Leu	Gly	Asp	Glu	Val	Trp	Leu	Gln
					290				295			300			
Val	Thr	Gly	Gly	Glu	Arg	Phe	Asn	Gly	Leu	Phe	Ala	Asp	Glu	Asp	Asp
					305				310			315			320
Asp	Thr	Thr	Phe	Thr	Gly	Phe	Leu	Leu	Phe	Ser	Ser	Pro			
					325				330						

<210> 59  
 <211> 225  
 <212> PRT  
 <213> homo sapiens

<400> 59  
 Met Arg Ile Trp Trp Leu Leu Leu Ala Ile Glu Ile Cys Thr Gly Asn  
 1 5 10 15  
 Ile Asn Ser Gln Asp Thr Cys Arg Gln Gly His Pro Gly Ile Pro Gly  
 20 25 30  
 Asn Pro Gly His Asn Gly Leu Pro Gly Arg Asp Gly Arg Asp Gly Ala  
 35 40 45  
 Lys Gly Asp Lys Gly Asp Ala Gly Glu Ala Gly Pro Thr Gly Pro Gln  
 50 55 60  
 Gly Glu Pro Gly Val Arg Gly Ile Arg Gly Trp Lys Gly Asp Arg Gly  
 65 70 75 80  
 Glu Lys Gly Lys Ile Gly Glu Thr Leu Val Leu Pro Lys Ser Ala Phe  
 85 90 95  
 Thr Val Gly Leu Thr Val Leu Ser Lys Phe Pro Ser Ser Asp Met Pro  
 100 105 110  
 Ile Lys Phe Asp Lys Ile Leu Tyr Asn Glu Phe Asn His Tyr Asp Thr  
 115 120 125  
 Ala Ala Gly Lys Phe Thr Cys His Ile Ala Gly Val Tyr Tyr Phe Thr  
 130 135 140  
 Tyr His Ile Thr Val Phe Ser Arg Asn Val Gln Val Ser Leu Val Lys  
 145 150 155 160  
 Asn Gly Val Lys Ile Leu His Thr Lys Asp Ala Tyr Met Ser Ser Glu  
 165 170 175  
 Asp Gln Ala Ser Gly Gly Ile Val Leu Gln Leu Lys Leu Gly Asp Glu  
 180 185 190  
 Val Trp Leu Gln Val Thr Gly Gly Glu Arg Phe Asn Gly Leu Phe Ala  
 195 200 205  
 Asp Glu Asp Asp Asp Thr Thr Phe Thr Gly Phe Leu Leu Phe Ser Ser  
 210 215 220  
 Pro  
 225

<210> 60  
 <211> 205  
 <212> PRT  
 <213> homo sapiens

<400> 60  
 Met Met Arg Thr Leu Ile Thr Thr His Pro Leu Pro Leu Leu Leu  
 1 5 10 15  
 Pro Gln Gln Leu Leu Gln Leu Val Gln Phe Gln Glu Val Asp Thr Asp  
 20 25 30  
 Phe Asp Phe Pro Glu Glu Asp Lys Lys Glu Glu Phe Glu Glu Cys Leu  
 35 40 45  
 Glu Lys Phe Phe Ser Thr Gly Pro Ala Arg Pro Pro Thr Lys Glu Lys  
 50 55 60  
 Val Lys Arg Arg Val Leu Ile Glu Pro Gly Met Pro Leu Asn His Ile  
 65 70 75 80  
 Glu Tyr Cys Asn His Glu Ile Met Gly Lys Asn Val Tyr Tyr Lys His  
 85 90 95  
 Arg Trp Val Ala Glu His Tyr Phe Leu Leu Met Gln Tyr Asp Glu Leu  
 100 105 110  
 Gln Lys Ile Cys Tyr Asn Arg Phe Val Pro Cys Lys Asn Gly Ile Arg

115	120	125
Lys Cys Asn Arg Ser Lys	Gly Leu Val Glu Gly Val	Tyr Cys Asn Leu
130	135	140
Thr Glu Ala Phe Glu Ile Pro Ala Cys Lys	Tyr Glu Ser Leu Tyr Arg	
145	150	155
Lys Gly Tyr Val Leu Ile Thr Cys Ser Trp Gln Asn Glu Met Gln Lys		160
165	170	175
Arg Ile Pro His Thr Ile Asn Asp Leu Val Glu Pro Pro Glu His Arg		
180	185	190
Ser Phe Leu Ser Glu Asp Gly Val Phe Val Ile Ser Pro		
195	200	205

&lt;210&gt; 61

&lt;211&gt; 95

&lt;212&gt; PRT

&lt;213&gt; homo sapiens

&lt;400&gt; 61

Met Glu Val Val Leu Ile Phe Leu Cys Ser Leu Leu Ala His Ile Val			
1	5	10	15
Leu Ala Asp Ala Val Glu Arg Glu Lys	Gln Ile Asp Pro Phe His Tyr		
20	25	30	
Asp Tyr Gln Thr Leu Arg Ile Arg Gly Leu Val Cys Ala Val Val Leu			
35	40	45	
Phe Ser Ile Gly Ile Leu Leu Ile Leu Gly Cys Arg Cys Lys Cys Ser			
50	55	60	
Phe Asn Gln Lys Pro Arg Thr Pro Gly Glu Glu Ala Gln Val Glu			
65	70	75	80
Asn Leu Ile Thr Ala Asn Ala Thr Lys Leu Gln Lys Ala Glu Ser			
85	90	95	

&lt;210&gt; 62

&lt;211&gt; 595

&lt;212&gt; PRT

&lt;213&gt; homo sapiens

&lt;400&gt; 62

Met Glu Val Gly Met Gly Cys Trp Ala Arg Glu Val Leu Val Pro Glu			
1	5	10	15
Gly Pro Leu Tyr Arg Val Ala Gly Thr Ala Val Ser Ile Ser Cys Asn			
20	25	30	
Val Thr Gly Tyr Glu Gly Pro Ala Gln Gln Asn Phe Glu Trp Phe Leu			
35	40	45	
Tyr Arg Pro Glu Ala Pro Asp Thr Ala Leu Gly Ile Val Ser Thr Lys			
50	55	60	
Asp Thr Gln Phe Ser Tyr Ala Val Phe Lys Ser Arg Val Val Ala Gly			
65	70	75	80
Glu Val Gln Val Gln Arg Leu Gln Gly Asp Ala Val Val Leu Lys Ile			
85	90	95	
Ala Arg Leu Gln Ala Gln Asp Ala Gly Ile Tyr Glu Cys His Thr Pro			
100	105	110	
Ser Thr Asp Thr Arg Tyr Leu Gly Ser Tyr Ser Gly Lys Val Glu Leu			
115	120	125	
Arg Val Leu Pro Asp Val Leu Gln Val Ser Ala Ala Pro Pro Gly Pro			
130	135	140	
Arg Gly Arg Gln Ala Pro Thr Ser Pro Pro Arg Met Thr Val His Glu			
145	150	155	160

Gly Gln Glu Leu Ala Leu Gly Cys Leu Ala Arg Thr Ser Thr Gln Lys  
 165 170 175  
 His Thr His Leu Ala Val Ser Phe Gly Arg Ser Val Pro Glu Ala Pro  
 180 185 190  
 Val Gly Arg Ser Thr Leu Gln Glu Val Val Gly Ile Arg Ser Asp Leu  
 195 200 205  
 Ala Val Glu Ala Gly Ala Pro Tyr Ala Glu Arg Leu Ala Ala Gly Glu  
 210 215 220  
 Leu Arg Leu Gly Lys Glu Gly Thr Asp Arg Tyr Arg Met Val Val Gly  
 225 230 235 240  
 Gly Ala Gln Ala Gly Asp Ala Gly Thr Tyr His Cys Thr Ala Ala Glu  
 245 250 255  
 Trp Ile Gln Asp Pro Asp Gly Ser Trp Ala Gln Ile Ala Glu Lys Arg  
 260 265 270  
 Ala Val Leu Ala His Val Asp Val Gln Thr Leu Ser Ser Gln Leu Ala  
 275 280 285  
 Val Thr Val Gly Pro Gly Glu Arg Arg Ile Gly Pro Gly Glu Pro Leu  
 290 295 300  
 Glu Leu Leu Cys Asn Val Ser Gly Ala Leu Pro Pro Ala Gly Arg His  
 305 310 315 320  
 Ala Ala Tyr Ser Val Gly Trp Glu Met Ala Pro Ala Gly His Leu Gly  
 325 330 335  
 Pro Gly Arg Leu Val Ala Gln Leu Asp Thr Glu Gly Val Gly Ser Leu  
 340 345 350  
 Gly Pro Gly Tyr Glu Gly Arg His Ile Ala Met Glu Lys Val Ala Ser  
 355 360 365  
 Arg Thr Tyr Arg Leu Arg Leu Glu Ala Ala Arg Pro Gly Asp Ala Gly  
 370 375 380  
 Thr Tyr Arg Cys Leu Ala Lys Ala Tyr Val Arg Gly Ser Gly Thr Arg  
 385 390 395 400  
 Leu Arg Glu Ala Ala Ser Ala Arg Ser Arg Pro Leu Pro Val His Val  
 405 410 415  
 Arg Glu Glu Gly Val Val Leu Glu Ala Val Ala Trp Leu Ala Gly Gly  
 420 425 430  
 Thr Val Tyr Arg Gly Glu Thr Ala Ser Leu Leu Cys Asn Ile Ser Val  
 435 440 445  
 Arg Gly Gly Pro Pro Gly Leu Arg Leu Ala Ala Ser Trp Trp Val Glu  
 450 455 460  
 Arg Pro Glu Asp Gly Glu Leu Ser Ser Val Pro Ala Gln Leu Val Gly  
 465 470 475 480  
 Gly Val Gly Gln Asp Gly Val Ala Glu Leu Gly Val Arg Pro Gly Gly  
 485 490 495  
 Gly Pro Val Ser Val Glu Leu Val Gly Pro Arg Ser His Arg Leu Arg  
 500 505 510  
 Leu His Ser Leu Gly Pro Glu Asp Glu Gly Val Tyr His Cys Ala Pro  
 515 520 525  
 Ser Ala Trp Val Gln His Ala Asp Tyr Ser Trp Tyr Gln Ala Gly Ser  
 530 535 540  
 Ala Arg Ser Gly Pro Val Thr Val Tyr Pro Tyr Met His Ala Leu Asp  
 545 550 555 560  
 Thr Leu Phe Val Pro Leu Leu Val Gly Thr Gly Val Ala Leu Val Thr  
 565 570 575  
 Gly Ala Thr Val Leu Gly Thr Ile Thr Cys Cys Phe Met Lys Arg Leu  
 580 585 590  
 Arg Lys Arg  
 595

<211> 613  
 <212> PRT  
 <213> homo sapiens

<400> 63

Met Gly Ala Leu Arg Pro Thr Leu Leu Pro Pro Ser Leu Pro Leu Leu  
 1 5 10 15  
 Leu Leu Leu Met Leu Gly Met Gly Cys Trp Ala Arg Glu Val Leu Val  
 20 25 30  
 Pro Glu Gly Pro Leu Tyr Arg Val Ala Gly Thr Ala Val Ser Ile Ser  
 35 40 45  
 Cys Asn Val Thr Gly Tyr Glu Gly Pro Ala Gln Gln Asn Phe Glu Trp  
 50 55 60  
 Phe Leu Tyr Arg Pro Glu Ala Pro Asp Thr Ala Leu Gly Ile Val Ser  
 65 70 75 80  
 Thr Lys Asp Thr Gln Phe Ser Tyr Ala Val Phe Lys Ser Arg Val Val  
 85 90 95  
 Ala Gly Glu Val Gln Val Gln Arg Leu Gln Gly Asp Ala Val Val Leu  
 100 105 110  
 Lys Ile Ala Arg Leu Gln Ala Gln Asp Ala Gly Ile Tyr Glu Cys His  
 115 120 125  
 Thr Pro Ser Thr Asp Thr Arg Tyr Leu Gly Ser Tyr Ser Gly Lys Val  
 130 135 140  
 Glu Leu Arg Val Leu Pro Asp Val Leu Gln Val Ser Ala Ala Pro Pro  
 145 150 155 160  
 Gly Pro Arg Gly Arg Gln Ala Pro Thr Ser Pro Pro Arg Met Thr Val  
 165 170 175  
 His Glu Gly Gln Glu Leu Ala Leu Gly Cys Leu Ala Arg Thr Ser Thr  
 180 185 190  
 Gln Lys His Thr His Leu Ala Val Ser Phe Gly Arg Ser Val Pro Glu  
 195 200 205  
 Ala Pro Val Gly Arg Ser Thr Leu Gln Glu Val Val Gly Ile Arg Ser  
 210 215 220  
 Asp Leu Ala Val Glu Ala Gly Ala Pro Tyr Ala Glu Arg Leu Ala Ala  
 225 230 235 240  
 Gly Glu Leu Arg Leu Gly Lys Glu Gly Thr Asp Arg Tyr Arg Met Val  
 245 250 255  
 Val Gly Gly Ala Gln Ala Gly Asp Ala Gly Thr Tyr His Cys Thr Ala  
 260 265 270  
 Ala Glu Trp Ile Gln Asp Pro Asp Gly Ser Trp Ala Gln Ile Ala Glu  
 275 280 285  
 Lys Arg Ala Val Leu Ala His Val Asp Val Gln Thr Leu Ser Ser Gln  
 290 295 300  
 Leu Ala Val Thr Val Gly Pro Gly Glu Arg Arg Ile Gly Pro Gly Glu  
 305 310 315 320  
 Pro Leu Glu Leu Leu Cys Asn Val Ser Gly Ala Leu Pro Pro Ala Gly  
 325 330 335  
 Arg His Ala Ala Tyr Ser Val Gly Trp Glu Met Ala Pro Ala Gly Ala  
 340 345 350  
 Pro Gly Pro Gly Arg Leu Val Ala Gln Leu Asp Thr Glu Gly Val Gly  
 355 360 365  
 Ser Leu Gly Pro Gly Tyr Glu Gly Arg His Ile Ala Met Glu Lys Val  
 370 375 380  
 Ala Ser Arg Thr Tyr Arg Leu Arg Leu Glu Ala Ala Arg Pro Gly Asp  
 385 390 395 400  
 Ala Gly Thr Tyr Arg Cys Leu Ala Lys Ala Tyr Val Arg Gly Ser Gly  
 405 410 415  
 Thr Arg Leu Arg Glu Ala Ala Ser Ala Arg Ser Arg Pro Leu Pro Val  
 420 425 430

His Val Arg Glu Glu Gly Val Val Leu Glu Ala Val Ala Trp Leu Ala  
 435 440 445  
 Gly Gly Thr Val Tyr Arg Gly Glu Thr Ala Ser Leu Leu Cys Asn Ile  
 450 455 460  
 Ser Val Arg Gly Gly Pro Pro Gly Leu Arg Leu Ala Ala Ser Trp Trp  
 465 470 475 480  
 Val Glu Arg Pro Glu Asp Gly Glu Leu Ser Ser Val Pro Ala Gln Leu  
 485 490 495  
 Val Gly Gly Val Gly Gln Asp Gly Val Ala Glu Leu Gly Val Arg Pro  
 500 505 510  
 Gly Gly Pro Val Ser Val Glu Leu Val Gly Pro Arg Ser His Arg  
 515 520 525  
 Leu Arg Leu His Ser Leu Gly Pro Glu Asp Glu Gly Val Tyr His Cys  
 530 535 540  
 Ala Pro Ser Ala Trp Val Gln His Ala Asp Tyr Ser Trp Tyr Gln Ala  
 545 550 555 560  
 Gly Ser Ala Arg Ser Gly Pro Val Thr Val Tyr Pro Tyr Met His Ala  
 565 570 575  
 Leu Asp Thr Leu Phe Val Pro Leu Leu Val Gly Thr Gly Val Ala Leu  
 580 585 590  
 Val Thr Gly Ala Thr Val Leu Gly Thr Ile Thr Cys Cys Phe Met Lys  
 595 600 605  
 Arg Leu Arg Lys Arg  
 610

<210> 64  
 <211> 596  
 <212> PRT  
 <213> homo sapiens

<400> 64  
 Met Ala Ala Asn Ser Thr Ser Asp Leu His Thr Pro Gly Thr Gln Leu  
 1 5 10 15  
 Ser Val Ala Asp Ile Ile Val Ile Thr Val Tyr Phe Ala Leu Asn Val  
 20 25 30  
 Ala Val Gly Ile Trp Ser Ser Cys Arg Ala Ser Arg Asn Thr Val Asn  
 35 40 45  
 Gly Tyr Phe Leu Ala Gly Arg Asp Met Thr Trp Trp Pro Ile Gly Ala  
 50 55 60  
 Ser Leu Phe Ala Ser Ser Glu Gly Ser Gly Leu Phe Ile Gly Leu Ala  
 65 70 75 80  
 Gly Ser Gly Ala Ala Gly Gly Leu Ala Val Ala Gly Phe Glu Trp Asn  
 85 90 95  
 Ala Thr Tyr Val Leu Ala Leu Ala Trp Val Phe Val Pro Ile Tyr  
 100 105 110  
 Ile Ser Ser Glu Ile Val Thr Leu Pro Glu Tyr Ile Gln Lys Arg Tyr  
 115 120 125  
 Gly Gly Gln Arg Ile Arg Met Tyr Leu Ser Val Leu Ser Leu Leu Leu  
 130 135 140  
 Ser Val Phe Thr Lys Ile Ser Leu Asp Leu Tyr Ala Gly Ala Leu Phe  
 145 150 155 160  
 Val His Ile Cys Leu Gly Trp Asn Phe Tyr Leu Ser Thr Ile Leu Thr  
 165 170 175  
 Leu Gly Ile Thr Ala Leu Tyr Thr Ile Ala Gly Gly Leu Ala Ala Val  
 180 185 190  
 Ile Tyr Thr Asp Ala Leu Gln Thr Leu Ile Met Val Val Gly Ala Val  
 195 200 205  
 Ile Leu Thr Ile Lys Ala Phe Asp Gln Ile Gly Gly Tyr Gly Gln Leu

210	215	220
Glu Ala Ala Tyr Ala Gln Ala Ile Pro Ser Arg Thr Ile Ala Asn Thr		
225	230	235
Thr Cys His Leu Pro Arg Thr Asp Ala Met His Met Phe Arg Asp Pro		240
245	250	255
His Thr Gly Asp Leu Pro Trp Thr Gly Met Thr Phe Gly Leu Thr Ile		
260	265	270
Met Ala Thr Trp Tyr Trp Cys Thr Asp Gln Val Ile Val Gln Arg Ser		
275	280	285
Leu Ser Ala Arg Asp Leu Asn His Ala Lys Ala Gly Ser Ile Leu Ala		
290	295	300
Ser Tyr Leu Lys Met Leu Pro Met Gly Leu Ile Ile Met Pro Gly Met		
305	310	315
Ile Ser Arg Ala Leu Phe Pro Asp Asp Val Gly Cys Val Val Pro Ser		320
325	330	335
Glu Cys Leu Arg Ala Cys Gly Ala Glu Val Gly Cys Ser Asn Ile Ala		
340	345	350
Tyr Pro Lys Leu Val Met Glu Leu Met Pro Ile Gly Leu Arg Gly Leu		
355	360	365
Met Ile Ala Val Met Leu Ala Ala Leu Met Ser Ser Leu Thr Ser Ile		
370	375	380
Phe Asn Ser Ser Ser Thr Leu Phe Thr Met Asp Ile Trp Arg Arg Leu		
385	390	395
Arg Pro Arg Ser Gly Glu Arg Glu Leu Leu Leu Val Gly Arg Leu Val		400
405	410	415
Ile Val Ala Leu Ile Gly Val Ser Val Ala Trp Ile Pro Val Leu Gln		
420	425	430
Asp Ser Asn Ser Gly Gln Leu Phe Ile Tyr Met Gln Ser Val Thr Ser		
435	440	445
Ser Leu Ala Pro Pro Val Thr Ala Val Phe Val Leu Gly Val Phe Trp		
450	455	460
Arg Arg Ala Asn Glu Gln Gly Ala Phe Trp Gly Leu Ile Ala Gly Leu		
465	470	475
Val Val Gly Ala Thr Arg Leu Val Leu Glu Phe Leu Asn Pro Ala Pro		480
485	490	495
Pro Cys Gly Glu Pro Asp Thr Arg Pro Ala Val Leu Gly Ser Ile His		
500	505	510
Tyr Leu His Phe Ala Val Ala Leu Phe Ala Leu Ser Gly Ala Val Val		
515	520	525
Val Ala Gly Ser Leu Leu Thr Pro Pro Gln Ser Val Gln Ile Glu		
530	535	540
Asn Leu Thr Trp Trp Thr Leu Ala Gln Asp Val Pro Leu Gly Thr Lys		
545	550	555
Ala Gly Asp Gly Gln Thr Pro Gln Lys His Ala Phe Trp Ala Arg Val		560
565	570	575
Cys Gly Phe Asn Ala Ile Leu Leu Met Cys Val Asn Ile Phe Phe Tyr		
580	585	590
Ala Tyr Phe Ala		
595		

<210> 65  
<211> 393  
<212> PRT  
<213> homo sapiens

<400> 65  
Met Asp Ser Leu Lys Asn Glu Asn Tyr Asp Leu Val Phe Val Glu Ala  
1 . 5 10 15  
44/79

Phe Asp Phe Cys Ser Phe Leu Ile Ala Glu Lys Leu Val Lys Pro Phe  
 20 25 30  
 Val Ala Ile Leu Pro Thr Thr Phe Gly Ser Leu Asp Phe Gly Leu Pro  
 35 40 45  
 Ser Pro Leu Ser Tyr Val Pro Val Phe Pro Ser Leu Leu Thr Asp His  
 50 55 60  
 Met Asp Phe Trp Gly Arg Val Lys Asn Phe Leu Met Phe Phe Ser Phe  
 65 70 75 80  
 Ser Arg Ser Gln Trp Asp Met Gln Ser Thr Phe Asp Asn Thr Ile Lys  
 85 90 95  
 Glu His Phe Pro Glu Gly Ser Arg Pro Val Leu Ser His Leu Leu  
 100 105 110  
 Lys Ala Glu Leu Trp Phe Val Asn Ser Asp Phe Ala Phe Asp Phe Ala  
 115 120 125  
 Arg Pro Leu Leu Pro Asn Thr Val Tyr Ile Gly Gly Leu Met Glu Lys  
 130 135 140  
 Pro Ile Lys Pro Val Pro Gln Asp Leu Asp Asn Phe Ile Ala Asn Phe  
 145 150 155 160  
 Gly Asp Ala Gly Phe Val Leu Val Ala Phe Gly Ser Met Leu Asn Thr  
 165 170 175  
 His Gln Ser Gln Glu Val Leu Lys Lys Met His Asn Ala Phe Ala His  
 180 185 190  
 Leu Pro Gln Gly Val Ile Trp Thr Cys Gln Ser Ser His Trp Pro Arg  
 195 200 205  
 Asp Val His Leu Ala Thr Asn Val Lys Ile Val Asp Trp Leu Pro Gln  
 210 215 220  
 Ser Asp Leu Leu Ala His Pro Ser Ile Arg Leu Phe Val Thr His Gly  
 225 230 235 240  
 Gly Gln Asn Ser Val Met Glu Ala Ile Arg His Gly Val Pro Met Val  
 245 250 255  
 Gly Leu Pro Val Asn Gly Asp Gln His Gly Asn Met Val Arg Val Val  
 260 265 270  
 Ala Lys Asn Tyr Gly Val Ser Ile Arg Leu Asn Gln Val Thr Ala Asp  
 275 280 285  
 Thr Leu Thr Leu Thr Met Lys Gln Val Ile Glu Asp Lys Arg Tyr Lys  
 290 295 300  
 Ser Ala Val Val Ala Ala Ser Val Ile Leu His Ser Gln Pro Leu Ser  
 305 310 315 320  
 Pro Ala Gln Arg Leu Val Gly Trp Ile Asp His Ile Leu Gln Thr Gly  
 325 330 335  
 Gly Ala Thr His Leu Lys Pro Tyr Ala Phe Gln Gln Pro Trp His Glu  
 340 345 350  
 Gln Tyr Leu Ile Asp Val Phe Val Phe Leu Leu Gly Leu Thr Leu Gly  
 355 360 365  
 Thr Met Trp Leu Cys Gly Lys Leu Leu Gly Val Val Ala Arg Trp Leu  
 370 375 380  
 Arg Gly Ala Arg Lys Val Lys Lys Thr  
 385 390

<210> 66  
 <211> 523  
 <212> PRT  
 <213> homo sapiens

<400> 66  
 Met Val Gly Gln Arg Val Leu Leu Leu Val Ala Phe Leu Leu Ser Gly  
 1 5 10 15  
 Val Leu Leu Ser Glu Ala Ala Lys Ile Leu Thr Ile Ser Thr Leu Gly

20	25	30
Gly Ser His Tyr Leu Leu Leu Asp Arg Val Ser Gln Ile Leu Gln Glu		
35	40	45
His Gly His Asn Val Thr Met Leu His Gln Ser Gly Lys Phe Leu Ile		
50	55	60
Pro Asp Ile Lys Glu Glu Lys Ser Tyr Gln Val Ile Arg Trp Phe		
65	70	75
80		
Ser Pro Glu Asp His Gln Lys Arg Ile Lys Lys His Phe Asp Ser Tyr		
85	90	95
Ile Glu Thr Ala Leu Asp Gly Arg Lys Glu Ser Glu Ala Leu Val Lys		
100	105	110
Leu Met Glu Ile Phe Gly Thr Gln Cys Ser Tyr Leu Leu Ser Arg Lys		
115	120	125
Asp Ile Met Asp Ser Leu Lys Asn Glu Asn Tyr Asp Leu Val Phe Val		
130	135	140
Glu Ala Phe Asp Phe Cys Ser Phe Leu Ile Ala Glu Lys Leu Val Lys		
145	150	155
160		
Pro Phe Val Ala Ile Leu Pro Thr Thr Phe Gly Ser Leu Asp Phe Gly		
165	170	175
Leu Pro Ser Pro Leu Ser Tyr Val Pro Val Phe Pro Ser Leu Leu Thr		
180	185	190
Asp His Met Asp Phe Trp Gly Arg Val Lys Asn Phe Leu Met Phe Phe		
195	200	205
Ser Phe Ser Arg Ser Gln Trp Asp Met Gln Ser Thr Phe Asp Asn Thr		
210	215	220
Ile Lys Glu His Phe Pro Glu Gly Ser Arg Pro Val Leu Ser His Leu		
225	230	235
240		
Leu Leu Lys Ala Glu Leu Trp Phe Val Asn Ser Asp Phe Ala Phe Asp		
245	250	255
Phe Ala Arg Pro Leu Leu Pro Asn Thr Val Tyr Ile Gly Gly Leu Met		
260	265	270
Glu Lys Pro Ile Lys Pro Val Pro Gln Asp Leu Asp Asn Phe Ile Ala		
275	280	285
Asn Phe Gly Asp Ala Gly Phe Val Leu Val Ala Phe Gly Ser Met Leu		
290	295	300
Asn Thr His Gln Ser Gln Glu Val Leu Lys Lys Met His Asn Ala Phe		
305	310	315
320		
Ala His Leu Pro Gln Gly Val Ile Trp Thr Cys Gln Ser Ser His Trp		
325	330	335
Pro Arg Asp Val His Leu Ala Thr Asn Val Lys Ile Val Asp Trp Leu		
340	345	350
Pro Gln Ser Asp Leu Leu Ala His Pro Ser Ile Arg Leu Phe Val Thr		
355	360	365
His Gly Gln Asn Ser Val Met Glu Ala Ile Arg His Gly Val Pro		
370	375	380
Met Val Gly Leu Pro Val Asn Gly Asp Gln His Gly Asn Met Val Arg		
385	390	395
400		
Val Val Ala Lys Asn Tyr Gly Val Ser Ile Arg Leu Asn Gln Val Thr		
405	410	415
Ala Asp Thr Leu Thr Leu Thr Met Lys Gln Val Ile Glu Asp Lys Arg		
420	425	430
Tyr Lys Ser Ala Val Val Ala Ala Ser Val Ile Leu His Ser Gln Pro		
435	440	445
Leu Ser Pro Ala Gln Arg Leu Val Gly Trp Ile Asp His Ile Leu Gln		
450	455	460
Thr Gly Gly Ala Thr His Leu Lys Pro Tyr Ala Phe Gln Gln Pro Trp		
465	470	475
480		
His Glu Gln Tyr Leu Ile Asp Val Phe Val Phe Leu Leu Gly Leu Thr		
485	490	495

Leu	Gly	Thr	Met	Trp	Leu	Cys	Gly	Lys	Leu	Leu	Gly	Val	Val	Ala	Arg
500							505						510		
Trp	Leu	Arg	Gly	Ala	Arg	Lys	Val	Lys	Lys	Thr					
515							520								

<210> 67  
 <211> 252  
 <212> PRT  
 <213> homo sapiens

<400> 67

Met	Ser	Cys	Val	Leu	Gly	Gly	Val	Ile	Pro	Leu	Gly	Leu	Leu	Phe	Leu
1					5			10					15		
Val	Cys	Gly	Ser	Gln	Gly	Tyr	Leu	Leu	Pro	Asn	Val	Thr	Leu	Leu	Glu
					20			25					30		
Glu	Leu	Leu	Ser	Lys	Tyr	Gln	His	Asn	Glu	Ser	His	Ser	Arg	Val	Arg
					35			40				45			
Arg	Ala	Ile	Pro	Arg	Glu	Asp	Lys	Glu	Glu	Ile	Leu	Met	Leu	His	Asn
					50			55			60				
Lys	Leu	Arg	Gly	Gln	Val	Gln	Pro	Gln	Ala	Ser	Asn	Met	Glu	Tyr	Met
					65			70			75			80	
Thr	Trp	Asp	Asp	Glu	Leu	Glu	Lys	Ser	Ala	Ala	Ala	Trp	Ala	Ser	Gln
					85			90			95				
Cys	Ile	Trp	Glu	His	Gly	Pro	Thr	Ser	Leu	Leu	Val	Ser	Ile	Gly	Gln
					100			105			110				
Asn	Leu	Gly	Ala	His	Trp	Gly	Arg	Tyr	Arg	Ser	Pro	Gly	Phe	His	Val
					115			120			125				
Gln	Ser	Trp	Tyr	Asp	Glu	Val	Lys	Asp	Tyr	Thr	Tyr	Pro	Tyr	Pro	Ser
					130			135			140				
Glu	Cys	Asn	Pro	Trp	Cys	Pro	Glu	Arg	Cys	Ser	Gly	Pro	Met	Cys	Thr
					145			150			155			160	
His	Tyr	Thr	Gln	Ile	Val	Trp	Ala	Thr	Thr	Asn	Lys	Ile	Gly	Cys	Ala
					165			170			175				
Val	Asn	Thr	Cys	Arg	Lys	Met	Thr	Val	Trp	Gly	Glu	Val	Trp	Glu	Asn
					180			185			190				
Ala	Val	Tyr	Phe	Val	Cys	Asn	Tyr	Ser	Pro	Lys	Gly	Asn	Trp	Ile	Gly
					195			200			205				
Glu	Ala	Pro	Tyr	Lys	Asn	Gly	Arg	Pro	Cys	Ser	Glu	Cys	Pro	Pro	Ser
					210			215			220				
Tyr	Gly	Gly	Ser	Cys	Arg	Asn	Asn	Leu	Cys	Tyr	Arg	Gly	Arg	Lys	Phe
					225			230			235			240	
Thr	Pro	Asn	Thr	Phe	Ala	Met	Asn	Leu	Pro	Ser	Val				
					245			250							

<210> 68  
 <211> 497  
 <212> PRT  
 <213> homo sapiens

<400> 68

Met	Ser	Cys	Val	Leu	Gly	Gly	Val	Ile	Pro	Leu	Gly	Leu	Leu	Phe	Leu
1					5			10					15		
Val	Cys	Gly	Ser	Gln	Gly	Tyr	Leu	Leu	Pro	Asn	Val	Thr	Leu	Leu	Glu
					20			25					30		
Glu	Leu	Leu	Ser	Lys	Tyr	Gln	His	Asn	Glu	Ser	His	Ser	Arg	Val	Arg
					35			40				45			
Arg	Ala	Ile	Pro	Arg	Glu	Asp	Lys	Glu	Glu	Ile	Leu	Met	Leu	His	Asn

50	55	60
Lys Leu Arg Gly Gln Val Gln Pro Gln Ala Ser Asn Met Glu Tyr Met		
65	70	75
Thr Trp Asp Asp Glu Leu Glu Lys Ser Ala Ala Ala Trp Ala Ser Gln		80
85	90	95
Cys Ile Trp His Gly Pro Thr Ser Leu Leu Val Ser Ile Gly Gln		
100	105	110
Asn Leu Gly Ala His Trp Gly Arg Tyr Arg Ser Pro Gly Phe His Val		
115	120	125
Gln Ser Trp Tyr Asp Glu Val Lys Asp Tyr Thr Tyr Pro Tyr Pro Ser		
130	135	140
Glu Cys Asn Pro Trp Cys Pro Glu Arg Cys Ser Gly Pro Met Cys Thr		
145	150	155
His Tyr Thr Gln Ile Val Trp Ala Thr Thr Asn Lys Ile Gly Cys Ala		160
165	170	175
Val Asn Thr Cys Arg Lys Met Thr Val Trp Gly Glu Val Trp Glu Asn		
180	185	190
Ala Val Tyr Phe Val Cys Asn Tyr Ser Pro Lys Gly Asn Trp Ile Gly		
195	200	205
Glu Ala Pro Tyr Lys Asn Gly Arg Pro Cys Ser Glu Cys Pro Pro Ser		
210	215	220
Tyr Gly Gly Ser Cys Arg Asn Asn Leu Cys Tyr Arg Glu Glu Thr Tyr		
225	230	235
Thr Pro Lys Pro Glu Thr Asp Glu Met Asn Glu Val Glu Thr Ala Pro		
245	250	255
Ile Pro Glu Glu Asn His Val Trp Leu Gln Pro Arg Val Met Arg Pro		
260	265	270
Thr Lys Pro Lys Lys Thr Ser Ala Val Asn Tyr Met Thr Gln Val Val		
275	280	285
Arg Cys Asp Thr Lys Met Lys Asp Arg Cys Lys Gly Ser Thr Cys Asn		
290	295	300
Arg Tyr Gln Cys Pro Ala Gly Cys Leu Asn His Lys Ala Lys Ile Phe		
305	310	315
Gly Thr Leu Phe Tyr Glu Ser Ser Ser Ile Cys Arg Ala Ala Ile		
325	330	335
His Tyr Gly Ile Leu Asp Asp Lys Gly Gly Leu Val Asp Ile Thr Arg		
340	345	350
Asn Gly Lys Val Pro Phe Phe Val Lys Ser Glu Arg His Gly Val Gln		
355	360	365
Ser Leu Ser Lys Tyr Lys Pro Ser Ser Ser Phe Met Val Ser Lys Val		
370	375	380
Lys Val Gln Asp Leu Asp Cys Tyr Thr Val Ala Gln Leu Cys Pro		
385	390	395
Phe Glu Lys Pro Ala Thr His Cys Pro Arg Ile His Cys Pro Ala His		
405	410	415
Cys Lys Asp Glu Pro Ser Tyr Trp Ala Pro Val Phe Gly Thr Asn Ile		
420	425	430
Tyr Ala Asp Thr Ser Ser Ile Cys Lys Thr Ala Val His Ala Gly Val		
435	440	445
Ile Ser Asn Glu Ser Gly Gly Asp Val Asp Val Met Pro Val Asp Lys		
450	455	460
Lys Lys Thr Tyr Val Gly Ser Leu Arg Asn Gly Val Gln Ser Glu Ser		
465	470	475
Leu Gly Thr Pro Arg Asp Gly Lys Ala Phe Arg Ile Phe Ala Val Arg		
485	490	495
Gln		

<210> 69  
 <211> 438  
 <212> PRT  
 <213> homo sapiens

<400> 69  
 Asx Met Leu His Asn Lys Leu Arg Gly Gln Val Gln Pro Gln Ala Ser  
 1 5 10 15  
 Asn Met Glu Tyr Met Thr Trp Asp Asp Glu Leu Glu Lys Ser Ala Ala  
 20 25 30  
 Ala Trp Ala Ser Gln Cys Ile Trp Glu His Gly Pro Thr Ser Leu Leu  
 35 40 45  
 Val Ser Ile Gly Gln Asn Leu Gly Ala His Trp Gly Arg Tyr Arg Ser  
 50 55 60  
 Pro Gly Phe His Val Gln Ser Trp Tyr Asp Glu Val Lys Asp Tyr Thr  
 65 70 75 80  
 Tyr Pro Tyr Pro Ser Glu Cys Asn Pro Trp Cys Pro Glu Arg Cys Ser  
 85 90 95  
 Gly Pro Met Cys Thr His Tyr Thr Gln Ile Val Trp Ala Thr Thr Asn  
 100 105 110  
 Lys Ile Gly Cys Ala Val Asn Thr Cys Arg Lys Met Thr Val Trp Gly  
 115 120 125  
 Glu Val Trp Glu Asn Ala Val Tyr Phe Val Cys Asn Tyr Ser Pro Lys  
 130 135 140  
 Gly Asn Trp Ile Gly Glu Ala Pro Tyr Lys Asn Gly Arg Pro Cys Ser  
 145 150 155 160  
 Glu Cys Pro Pro Ser Tyr Gly Gly Ser Cys Arg Asn Asn Leu Cys Tyr  
 165 170 175  
 Arg Glu Glu Thr Tyr Thr Pro Lys Pro Glu Thr Asp Glu Met Asn Glu  
 180 185 190  
 Val Glu Thr Ala Pro Ile Pro Glu Glu Asn His Val Trp Leu Gln Pro  
 195 200 205  
 Arg Val Met Arg Pro Thr Lys Pro Lys Lys Thr Ser Ala Val Asn Tyr  
 210 215 220  
 Met Thr Gln Val Val Arg Cys Asp Thr Lys Met Lys Asp Arg Cys Lys  
 225 230 235 240  
 Gly Ser Thr Cys Asn Arg Tyr Gln Cys Pro Ala Gly Cys Leu Asn His  
 245 250 255  
 Lys Ala Lys Ile Phe Gly Thr Leu Phe Tyr Glu Ser Ser Ser Ser Ile  
 260 265 270  
 Cys Arg Ala Ala Ile His Tyr Gly Ile Leu Asp Asp Lys Gly Gly Leu  
 275 280 285  
 Val Asp Ile Thr Arg Asn Gly Lys Val Pro Phe Phe Val Lys Ser Glu  
 290 295 300  
 Arg His Gly Val Gln Ser Leu Ser Lys Tyr Lys Pro Ser Ser Ser Phe  
 305 310 315 320  
 Met Val Ser Lys Val Lys Val Gln Asp Leu Asp Cys Tyr Thr Thr Val  
 325 330 335  
 Ala Gln Leu Cys Pro Phe Glu Lys Pro Ala Thr His Cys Pro Arg Ile  
 340 345 350  
 His Cys Pro Ala His Cys Lys Asp Glu Pro Ser Tyr Trp Ala Pro Val  
 355 360 365  
 Phe Gly Thr Asn Ile Tyr Ala Asp Thr Ser Ser Ile Cys Lys Thr Ala  
 370 375 380  
 Val His Ala Gly Val Ile Ser Asn Glu Ser Gly Gly Asp Val Asp Val  
 385 390 395 400  
 Met Pro Val Asp Lys Lys Lys Thr Tyr Val Gly Ser Leu Arg Asn Gly  
 405 410 415  
 Val Gln Ser Glu Ser Leu Gly Thr Pro Arg Asp Gly Lys Ala Phe Arg

420	425	430
Ile Phe Ala Val Arg Gln		
435		
<210> 70		
<211> 308		
<212> PRT		
<213> homo sapiens		
<400> 70		
Met Val Gly Gly Val Leu Ala Ser Leu Gly Phe Val Phe Ser Ala Phe		
1	5	10
Ala Ser Asp Leu Leu His Leu Tyr Leu Gly Leu Gly Leu Ala Gly		
20	25	30
Phe Gly Trp Ala Leu Val Phe Ala Pro Ala Leu Gly Thr Leu Ser Arg		
35	40	45
Tyr Phe Ser Arg Arg Arg Val Leu Ala Val Gly Leu Ala Leu Thr Gly		
50	55	60
Asn Gly Ala Ser Ser Leu Leu Leu Ala Pro Ala Leu Gln Leu Leu Leu		
65	70	75
Asp Thr Phe Gly Trp Arg Gly Ala Leu Leu Leu Gly Ala Ile Thr		
85	90	95
Leu His Leu Thr Pro Cys Gly Ala Leu Leu Leu Pro Leu Val Leu Pro		
100	105	110
Gly Asp Pro Pro Ala Pro Pro Arg Ser Pro Leu Ala Ala Leu Gly Leu		
115	120	125
Ser Leu Phe Thr Arg Arg Ala Phe Ser Ile Phe Ala Leu Gly Thr Ala		
130	135	140
Leu Val Gly Gly Tyr Phe Val Pro Tyr Val His Leu Ala Pro His		
145	150	155
Ala Leu Asp Arg Gly Leu Gly Gly Tyr Gly Ala Ala Leu Val Val Ala		
165	170	175
Val Ala Ala Met Gly Asp Ala Gly Ala Arg Leu Val Cys Gly Trp Leu		
180	185	190
Ala Asp Gln Gly Trp Val Pro Leu Pro Arg Leu Leu Ala Val Phe Gly		
195	200	205
Ala Leu Thr Gly Leu Gly Leu Trp Val Val Gly Leu Val Pro Val Val		
210	215	220
Gly Gly Glu Glu Ser Trp Gly Gly Pro Leu Leu Ala Ala Val Ala		
225	230	235
Tyr Gly Leu Ser Ala Gly Ser Tyr Ala Pro Leu Val Phe Gly Val Leu		
245	250	255
Pro Gly Leu Val Gly Val Gly Val Val Gln Ala Thr Gly Leu Val		
260	265	270
Met Met Leu Met Ser Leu Gly Gly Leu Leu Gly Pro Pro Leu Ser Gly		
275	280	285
Lys Asp Leu Ser Ser Gln Ile Cys Leu Gln Leu Ser Ser Ala Pro Gly		
290	295	300
Val Arg Gly Phe		
305		

<210> 71  
 <211> 447  
 <212> PRT  
 <213> homo sapiens

<400> 71

Met Thr Pro Gln Pro Ala Gly Pro Pro Asp Gly Gly Trp Gly Trp Val  
 1 5 10 15  
 Val Ala Ala Ala Ala Phe Ala Ile Asn Gly Leu Ser Tyr Gly Leu Leu  
 20 25 30  
 Arg Ser Leu Gly Leu Ala Phe Pro Asp Leu Ala Glu His Phe Asp Arg  
 35 40 45  
 Ser Ala Gln Asp Thr Ala Trp Ile Ser Ala Leu Ala Leu Ala Val Gln  
 50 55 60  
 Gln Ala Ala Ser Pro Val Gly Ser Ala Leu Ser Thr Arg Trp Gly Ala  
 65 70 75 80  
 Arg Pro Val Val Met Val Gly Gly Val Leu Ala Ser Leu Gly Phe Val  
 85 90 95  
 Phe Ser Ala Phe Ala Ser Asp Leu Leu His Leu Tyr Leu Gly Leu Gly  
 100 105 110  
 Leu Leu Ala Gly Phe Gly Trp Ala Leu Val Phe Ala Pro Ala Leu Gly  
 115 120 125  
 Thr Leu Ser Arg Tyr Phe Ser Arg Arg Val Leu Ala Val Gly Leu  
 130 135 140  
 Ala Leu Thr Gly Asn Gly Ala Ser Ser Leu Leu Ala Pro Ala Leu  
 145 150 155 160  
 Gln Leu Leu Leu Asp Thr Phe Gly Trp Arg Gly Ala Leu Leu Leu  
 165 170 175  
 Gly Ala Ile Thr Leu His Leu Thr Pro Cys Gly Ala Leu Leu Pro  
 180 185 190  
 Leu Val Leu Pro Gly Asp Pro Pro Ala Pro Pro Arg Ser Pro Leu Ala  
 195 200 205  
 Ala Leu Gly Leu Ser Leu Phe Thr Arg Arg Ala Phe Ser Ile Phe Ala  
 210 215 220  
 Leu Gly Thr Ala Leu Val Gly Gly Tyr Phe Val Pro Tyr Val His  
 225 230 235 240  
 Leu Ala Pro His Ala Leu Asp Arg Gly Leu Gly Gly Tyr Gly Ala Ala  
 245 250 255  
 Leu Val Val Ala Val Ala Ala Met Gly Asp Ala Gly Ala Arg Leu Val  
 260 265 270  
 Cys Gly Trp Leu Ala Asp Gln Gly Trp Val Pro Leu Pro Arg Leu Leu  
 275 280 285  
 Ala Val Phe Gly Ala Leu Thr Gly Leu Gly Leu Trp Val Val Gly Leu  
 290 295 300  
 Val Pro Val Val Gly Gly Glu Glu Ser Trp Gly Gly Pro Leu Leu Ala  
 305 310 315 320  
 Ala Ala Val Ala Tyr Gly Leu Ser Ala Gly Ser Tyr Ala Pro Leu Val  
 325 330 335  
 Phe Gly Val Leu Pro Gly Leu Val Gly Val Gly Gly Val Val Gln Ala  
 340 345 350  
 Thr Gly Leu Val Met Met Leu Met Ser Leu Gly Gly Leu Leu Gly Pro  
 355 360 365  
 Pro Leu Ser Gly Phe Leu Arg Asp Glu Thr Gly Asp Phe Thr Ala Ser  
 370 375 380  
 Phe Leu Leu Ser Gly Ser Leu Ile Leu Ser Gly Ser Phe Ile Tyr Ile  
 385 390 395 400  
 Gly Leu Pro Arg Ala Leu Pro Ser Cys Gly Pro Ala Ser Pro Pro Ala  
 405 410 415  
 Thr Pro Pro Pro Glu Thr Gly Glu Leu Leu Pro Ala Pro Gln Ala Val  
 420 425 430  
 Leu Leu Ser Pro Gly Gly Pro Gly Ser Thr Leu Asp Thr Thr Cys  
 435 440 445

<211> 458  
 <212> PRT  
 <213> homo sapiens

<400> 72

Asx Met Ala Arg Arg Thr Glu Pro Pro Asp Gly Gly Trp Gly Trp Val  
 1 5 10 15  
 Val Val Leu Ser Ala Phe Phe Gln Ser Ala Leu Val Phe Gly Val Leu  
 20 25 30  
 Arg Ser Phe Gly Val Phe Val Glu Phe Val Ala Ala Phe Glu Glu  
 35 40 45  
 Gln Ala Ala Arg Val Ser Trp Ile Ala Ser Ile Gly Ile Ala Val Gln  
 50 55 60  
 Gln Phe Gly Ser Pro Val Gly Ser Ala Leu Ser Thr Lys Phe Gly Pro  
 65 70 75 80  
 Arg Pro Val Val Met Thr Gly Gly Ile Leu Ala Ala Leu Gly Met Leu  
 85 90 95  
 Leu Ala Ser Phe Ala Thr Ser Leu Thr His Leu Tyr Leu Ser Ile Gly  
 100 105 110  
 Leu Leu Ser Gly Ser Gly Trp Ala Leu Thr Phe Ala Pro Thr Leu Ala  
 115 120 125  
 Cys Leu Ser Cys Tyr Phe Ser Arg Arg Ser Leu Ala Thr Gly Leu  
 130 135 140  
 Ala Leu Thr Gly Val Gly Leu Ser Ser Phe Thr Phe Ala Pro Phe Phe  
 145 150 155 160  
 Gln Trp Leu Leu Ser His Tyr Ala Trp Arg Gly Ser Leu Leu Val  
 165 170 175  
 Ser Ala Leu Ser Leu His Leu Val Ala Cys Gly Ala Leu Leu Arg Pro  
 180 185 190  
 Pro Ser Leu Ala Glu Asp Pro Ala Val Gly Gly Pro Arg Ala Gln Leu  
 195 200 205  
 Thr Ser Leu Leu His His Gly Pro Phe Leu Arg Tyr Thr Val Ala Leu  
 210 215 220  
 Thr Leu Ile Asn Thr Gly Tyr Phe Ile Pro Tyr Leu His Leu Val Ala  
 225 230 235 240  
 His Leu Gln Asp Leu Asp Trp Asp Pro Leu Pro Ala Ala Phe Leu Leu  
 245 250 255  
 Ser Val Val Ala Ile Ser Asp Leu Val Gly Arg Val Val Ser Gly Trp  
 260 265 270  
 Leu Gly Asp Ala Val Pro Gly Pro Val Thr Arg Leu Leu Met Leu Trp  
 275 280 285  
 Thr Thr Leu Thr Gly Val Ser Leu Ala Leu Phe Pro Val Ala Gln Ala  
 290 295 300  
 Pro Thr Ala Leu Val Ala Leu Ala Val Ala Tyr Gly Phe Thr Ser Gly  
 305 310 315 320  
 Ala Leu Ala Pro Leu Ala Phe Ser Val Leu Pro Glu Leu Ile Gly Thr  
 325 330 335  
 Arg Arg Ile Tyr Cys Gly Leu Gly Leu Leu Gln Met Ile Glu Ser Ile  
 340 345 350  
 Gly Gly Leu Leu Gly Pro Pro Leu Ser Gly Tyr Leu Arg Asp Val Ser  
 355 360 365  
 Gly Asn Tyr Thr Ala Ser Phe Val Val Ala Gly Ala Phe Leu Leu Ser  
 370 375 380  
 Gly Ser Gly Ile Leu Leu Thr Leu Pro His Phe Phe Cys Phe Ser Thr  
 385 390 395 400  
 Thr Thr Ser Gly Pro Gln Asp Leu Val Thr Glu Ala Leu Asp Thr Lys  
 405 410 415  
 Val Pro Leu Pro Lys Glu Gly Leu Glu Gly Gly Leu Asn Ser Thr Glu  
 420 425 430

Ser Gly Pro Glu Ser Gln Ser Leu Thr Ala Pro Gly Leu Leu Leu Pro  
 435 440 445  
 Arg Leu Gly Leu His Arg Thr Thr Val Pro  
 450 455

<210> 73  
 <211> 169  
 <212> PRT  
 <213> homo sapiens

<400> 73  
 Met Thr Met Lys Thr Ser Gly Ala Thr Cys Asp Ala Asn Ser Val Met  
 1 5 10 15  
 Asn Cys Gly Ile Arg Gly Ser Glu Met Phe Ala Glu Met Asp Leu Arg  
 20 25 30  
 Ala Ile Lys Pro Tyr Gln Thr Leu Ile Lys Lys Val Gly Gln Arg His  
 35 40 45  
 Cys Val Asp Pro Ala Val Ile Ala Ala Ile Ile Ser Arg Glu Ser His  
 50 55 60  
 Gly Gly Ser Val Leu Gln Asp Gly Trp Asp His Arg Gly Leu Lys Phe  
 65 70 75 80  
 Gly Leu Met Gln Leu Asp Lys Gln Thr Tyr His Pro Val Gly Ala Trp  
 85 90 95  
 Asp Ser Lys Glu His Leu Ser Gln Ala Thr Gly Ile Leu Thr Glu Arg  
 100 105 110  
 Ile Lys Ala Ile Gln Lys Lys Phe Pro Thr Trp Ser Val Ala Gln His  
 115 120 125  
 Leu Lys Gly Leu Ser Ala Phe Lys Ser Gly Ile Glu Ala Ile Ala  
 130 135 140  
 Thr Pro Ser Asp Ile Asp Asn Asp Phe Val Asn Asp Ile Ile Ala Arg  
 145 150 155 160  
 Ala Lys Phe Tyr Lys Arg Gln Ser Phe  
 165

<210> 74  
 <211> 186  
 <212> PRT  
 <213> homo sapiens

<400> 74  
 Met Lys Pro His Leu His Pro Arg Leu Tyr His Gly Cys Tyr Gly Asp  
 1 5 10 15  
 Ile Met Thr Met Lys Thr Ser Gly Ala Thr Cys Asp Ala Asn Ser Val  
 20 25 30  
 Met Asn Cys Gly Ile Arg Gly Ser Glu Met Phe Ala Glu Met Asp Leu  
 35 40 45  
 Arg Ala Ile Lys Pro Tyr Gln Thr Leu Ile Lys Lys Val Gly Gln Arg  
 50 55 60  
 His Cys Val Asp Pro Ala Val Ile Ala Ala Ile Ile Ser Arg Glu Ser  
 65 70 75 80  
 His Gly Gly Ser Val Leu Gln Asp Gly Trp Asp His Arg Gly Leu Lys  
 85 90 95  
 Phe Gly Leu Met Gln Leu Asp Lys Gln Thr Tyr His Pro Val Gly Ala  
 100 105 110  
 Trp Asp Ser Lys Glu His Leu Ser Gln Ala Thr Gly Ile Leu Thr Glu  
 115 120 125  
 Arg Ile Lys Ala Ile Gln Lys Lys Phe Pro Thr Trp Ser Val Ala Gln

130	135	140
His Leu Lys Gly Gly Leu Ser Ala Phe Lys Ser Gly Ile Glu Ala Ile		
145	150	155
Ala Thr Pro Ser Asp Ile Asp Asn Asp Phe Val Asn Asp Ile Ile Ala		160
165	170	175
Arg Ala Lys Phe Tyr Lys Arg Gln Ser Phe		
180	185	

<210> 75  
 <211> 675  
 <212> PRT  
 <213> homo sapiens

<400> 75			
Met Glu Ser Gly Thr Ser Ser Pro Gln Pro Pro Gln Leu Asp Pro Leu			
1	5	10	15
Asp Ala Phe Pro Gln Lys Gly Leu Glu Pro Gly Asp Ile Ala Val Leu			
20	25	30	
Val Leu Tyr Phe Leu Phe Val Leu Ala Val Gly Leu Trp Ser Thr Val			
35	40	45	
Lys Thr Lys Arg Asp Thr Val Lys Gly Tyr Phe Leu Ala Gly Gly Asp			
50	55	60	
Met Val Trp Trp Pro Val Gly Ala Ser Leu Phe Ala Ser Asn Val Gly			
65	70	75	80
Ser Gly His Phe Ile Gly Leu Ala Gly Ser Gly Ala Ala Thr Gly Ile			
85	90	95	
Ser Val Ser Ala Tyr Glu Leu Asn Gly Leu Phe Ser Val Leu Met Leu			
100	105	110	
Ala Trp Ile Phe Leu Pro Ile Tyr Ile Ala Gly Gln Val Thr Thr Met			
115	120	125	
Pro Glu Tyr Leu Arg Lys Arg Phe Gly Gly Ile Arg Ile Pro Ile Ile			
130	135	140	
Leu Ala Val Leu Tyr Leu Phe Ile Tyr Ile Phe Thr Lys Ile Ser Val			
145	150	155	160
Asp Met Tyr Ala Gly Ala Ile Phe Ile Gln Gln Ser Leu His Leu Asp			
165	170	175	
Leu Tyr Leu Ala Ile Val Gly Leu Leu Ala Ile Thr Ala Val Tyr Thr			
180	185	190	
Val Ala Gly Gly Leu Ala Ala Val Ile Tyr Thr Asp Ala Leu Gln Thr			
195	200	205	
Leu Ile Met Leu Ile Gly Ala Leu Thr Leu Met Gly Tyr Ser Phe Ala			
210	215	220	
Ala Val Gly Gly Met Glu Gly Leu Lys Glu Lys Tyr Phe Leu Ala Leu			
225	230	235	240
Ala Ser Asn Arg Ser Glu Asn Ser Ser Cys Gly Leu Pro Arg Glu Asp			
245	250	255	
Ala Phe His Ile Phe Arg Asp Pro Leu Thr Ser Asp Leu Pro Trp Pro			
260	265	270	
Gly Val Leu Phe Gly Met Ser Ile Pro Ser Leu Trp Tyr Trp Cys Thr			
275	280	285	
Asp Gln Val Ile Val Gln Arg Thr Leu Ala Ala Lys Asn Leu Ser His			
290	295	300	
Ala Lys Gly Gly Ala Leu Met Ala Ala Tyr Leu Lys Val Leu Pro Leu			
305	310	315	320
Phe Ile Met Val Phe Pro Gly Met Val Ser Arg Ile Leu Phe Pro Asp			
325	330	335	
Gln Val Ala Cys Ala Asp Pro Glu Ile Cys Gln Lys Ile Cys Ser Asn			
340	345	350	

Pro Ser Gly Cys Ser Asp Ile Ala Tyr Pro Lys Leu Val Leu Glu Leu  
 355 360 365  
 Leu Pro Thr Gly Leu Arg Gly Leu Met Met Ala Val Met Val Ala Ala  
 370 375 380  
 Leu Met Ser Ser Leu Thr Ser Ile Phe Asn Ser Ala Ser Thr Ile Phe  
 385 390 395 400  
 Thr Met Asp Leu Trp Asn His Leu Arg Pro Arg Ala Ser Glu Lys Glu  
 405 410 415  
 Leu Met Ile Val Gly Arg Val Phe Val Leu Leu Val Leu Val Ser  
 420 425 430  
 Ile Leu Trp Ile Pro Val Val Gln Ala Ser Gln Gly Gly Gln Leu Phe  
 435 440 445  
 Ile Tyr Ile Gln Ser Ile Ser Ser Tyr Leu Gln Pro Pro Val Ala Val  
 450 455 460  
 Val Phe Ile Met Gly Cys Phe Trp Lys Arg Thr Asn Glu Lys Gly Ala  
 465 470 475 480  
 Phe Trp Gly Leu Ile Ser Gly Leu Leu Leu Gly Leu Val Arg Leu Val  
 485 490 495  
 Leu Asp Phe Ile Tyr Val Gln Pro Arg Cys Asp Gln Pro Asp Glu Arg  
 500 505 510  
 Pro Val Leu Val Lys Ser Ile His Tyr Leu Tyr Phe Ser Met Ile Leu  
 515 520 525  
 Ser Thr Val Thr Leu Ile Thr Val Ser Thr Val Ser Trp Phe Thr Glu  
 530 535 540  
 Pro Pro Ser Lys Glu Met Val Ser His Leu Thr Trp Phe Thr Arg His  
 545 550 555 560  
 Asp Pro Val Val Gln Lys Glu Gln Ala Pro Pro Ala Ala Pro Leu Ser  
 565 570 575  
 Leu Thr Leu Ser Gln Asn Gly Met Pro Glu Ala Ser Ser Ser Ser  
 580 585 590  
 Val Gln Phe Glu Met Val Gln Glu Asn Thr Ser Lys Thr His Ser Cys  
 595 600 605  
 Asp Met Thr Pro Lys Gln Ser Lys Val Val Lys Ala Ile Leu Trp Leu  
 610 615 620  
 Cys Gly Ile Gln Glu Lys Gly Lys Glu Glu Leu Pro Ala Arg Ala Glu  
 625 630 635 640  
 Ala Ile Ile Val Ser Leu Glu Glu Asn Pro Leu Val Lys Thr Leu Leu  
 645 650 655  
 Asp Val Asn Leu Ile Phe Cys Val Ser Cys Ala Ile Phe Ile Trp Gly  
 660 665 670  
 Tyr Phe Ala  
 675

<210> 76  
 <211> 485  
 <212> PRT  
 <213> homo sapiens

<400> 76  
 Met Glu Pro Cys Trp Gly Glu Gly Leu Phe His Leu Ala Pro Pro Arg  
 1 5 10 15  
 His His Pro Gln Lys Ala Asp Trp His Phe Cys Pro Gln His Ile Gln  
 20 25 30  
 Glu Phe Thr Asn Glu Thr Trp Gln Ala Arg Thr Gly Glu Pro Leu Pro  
 35 40 45  
 Asp His Leu Val Leu Leu Met Trp Ser Leu Ile Val Ser Leu Tyr Pro  
 50 55 60  
 Leu Gly Gly Leu Phe Gly Ala Leu Leu Ala Gly Pro Leu Ala Ile Thr

65	70	75	80
Léu Gly Arg Lys Lys Ser	Leu Leu Val Asn Asn Ile	Phe Val Val Ser	
85	90	95	
Ala Ala Ile Leu Phe Gly Phe Ser Arg	Lys Ala Gly Ser Phe Glu Met		
100	105	110	
Ile Met Leu Gly Arg Leu Leu Val	Gly Val Asn Ala Gly Val Ser Met		
115	120	125	
Asn Ile Gln Pro Met Tyr Leu Gly Glu Ser Ala Pro	Lys Glu Leu Arg		
130	135	140	
Gly Ala Val Ala Met Ser Ser Ala Ile Phe Thr	Ala Leu Gly Ile Val		
145	150	155	160
Met Gly Gln Val Val Gly Leu Arg Glu Leu	Leu Gly Pro Gln Ala		
165	170	175	
Trp Pro Leu Leu Ala Ser Cys	Leu Val Pro Gly Ala Leu Gln Leu		
180	185	190	
Ala Ser Leu Pro Leu Leu Pro Glu Ser Pro Arg Tyr	Leu Leu Ile Asp		
195	200	205	
Cys Gly Asp Thr Glu Ala Cys	Leu Ala Ala Leu Arg Arg	Leu Arg Gly	
210	215	220	
Ser Gly Asp Leu Ala Gly Glu Leu Glu Glu Leu	Glu Glu Arg Ala		
225	230	235	240
Ala Cys Gln Gly Cys Arg Ala Arg Arg	Pro Trp Glu Leu Phe Gln His		
245	250	255	
Arg Ala Leu Arg Arg Gln Val Thr Ser	Leu Val Val Leu Gly Ser Ala		
260	265	270	
Met Glu Leu Cys Gly Asn Asp	Ser Val Tyr Ala Tyr Ala Ser	Ser Val	
275	280	285	
Phe Arg Lys Ala Gly Val Pro Glu Ala Lys Ile	Gln Tyr Ala Ile Ile		
290	295	300	
Gly Thr Gly Ser Cys Glu Leu Leu Thr Ala Val	Val Ser Cys Val Val		
305	310	315	320
Ile Glu Arg Val Gly Arg Arg Val Leu Leu	Ile Gly Gly Tyr Ser Leu		
325	330	335	
Met Thr Cys Trp Gly Ser Ile Phe Thr Val Ala	Leu Cys Leu Gln Ser		
340	345	350	
Ser Phe Pro Trp Thr Leu Tyr Leu Ala Met Ala	Cys Ile Phe Ala Phe		
355	360	365	
Ile Leu Ser Phe Gly Ile Gly Pro Ala Gly Val	Thr Gly Ile Leu Ala		
370	375	380	
Thr Glu Leu Phe Asp Gln Met Ala Arg Pro Ala	Ala Cys Met Val Cys		
385	390	395	400
Gly Ala Leu Met Trp Ile Met Leu Ile Leu Val	Gly Leu Gly Phe Pro		
405	410	415	
Phe Ile Met Glu Ala Leu Ser His Phe Leu Tyr	Val Pro Phe Leu Gly		
420	425	430	
Val Cys Val Cys Gly Ala Ile Tyr Thr Gly Leu	Phe Leu Pro Glu Thr		
435	440	445	
Lys Gly Lys Thr Phe Gln Glu Ile Ser Lys	Glu Leu His Arg Leu Asn		
450	455	460	
Phe Pro Arg Arg Ala Gln Gly Pro Thr Trp Arg	Ser Leu Glu Val Ile		
465	470	475	480
Gln Ser Thr Glu Leu			
485			

<210> 77  
<211> 496  
<212> PRT  
<213> homo sapiens

<400> 77  
 Met Arg Ala Leu Arg Arg Leu Ile Gln Gly Arg Ile Leu Leu Leu Thr  
 1 5 10 15  
 Ile Cys Ala Ala Gly Ile Gly Gly Thr Phe Gln Phe Gly Tyr Asn Leu  
 20 25 30  
 Ser Ile Ile Asn Ala Pro Thr Leu His Ile Gln Glu Phe Thr Asn Glu  
 35 40 45  
 Thr Trp Gln Ala Arg Thr Gly Glu Pro Leu Pro Asp His Leu Val Leu  
 50 55 60  
 Leu Met Trp Ser Leu Ile Val Ser Leu Tyr Pro Leu Gly Gly Leu Phe  
 65 70 75 80  
 Gly Ala Leu Leu Ala Gly Pro Leu Ala Ile Thr Leu Gly Arg Lys Lys  
 85 90 95  
 Ser Leu Leu Val Asn Asn Ile Phe Val Val Ser Ala Ala Ile Leu Phe  
 100 105 110  
 Gly Phe Ser Arg Lys Ala Gly Ser Phe Glu Met Ile Met Leu Gly Arg  
 115 120 125  
 Leu Leu Val Gly Val Asn Ala Gly Val Ser Met Asn Ile Gln Pro Met  
 130 135 140  
 Tyr Leu Gly Glu Ser Ala Pro Lys Glu Leu Arg Gly Ala Val Ala Met  
 145 150 155 160  
 Ser Ser Ala Ile Phe Thr Ala Leu Gly Ile Val Met Gly Gln Val Val  
 165 170 175  
 Gly Leu Arg Glu Leu Leu Gly Gly Pro Gln Ala Trp Pro Leu Leu Leu  
 180 185 190  
 Ala Ser Cys Leu Val Pro Gly Ala Leu Gln Leu Ala Ser Leu Pro Leu  
 195 200 205  
 Leu Pro Glu Ser Pro Arg Tyr Leu Leu Ile Asp Cys Gly Asp Thr Glu  
 210 215 220  
 Ala Cys Leu Ala Ala Leu Arg Arg Leu Arg Gly Ser Gly Asp Leu Ala  
 225 230 235 240  
 Gly Glu Leu Glu Leu Glu Glu Arg Ala Ala Cys Gln Gly Cys  
 245 250 255  
 Arg Ala Arg Arg Pro Trp Glu Leu Phe Gln His Arg Ala Leu Arg Arg  
 260 265 270  
 Gln Val Thr Ser Leu Val Val Leu Gly Ser Ala Met Glu Leu Cys Gly  
 275 280 285  
 Asn Asp Ser Val Tyr Ala Tyr Ala Ser Ser Val Phe Arg Lys Ala Gly  
 290 295 300  
 Val Pro Glu Ala Lys Ile Gln Tyr Ala Ile Ile Gly Thr Gly Ser Cys  
 305 310 315 320  
 Glu Leu Leu Thr Ala Val Val Ser Cys Val Val Ile Glu Arg Val Gly  
 325 330 335  
 Arg Arg Val Leu Ile Gly Gly Tyr Ser Leu Met Thr Cys Trp Gly  
 340 345 350  
 Ser Ile Phe Thr Val Ala Leu Cys Leu Gln Ser Ser Phe Pro Trp Thr  
 355 360 365  
 Leu Tyr Leu Ala Met Ala Cys Ile Phe Ala Phe Ile Leu Ser Phe Gly  
 370 375 380  
 Ile Gly Pro Ala Gly Val Thr Gly Ile Leu Ala Thr Glu Leu Phe Asp  
 385 390 395 400  
 Gln Met Ala Arg Pro Ala Ala Cys Met Val Cys Gly Ala Leu Met Trp  
 405 410 415  
 Ile Met Leu Ile Leu Val Gly Leu Gly Phe Pro Phe Ile Met Glu Ala  
 420 425 430  
 Leu Ser His Phe Leu Tyr Val Pro Phe Leu Gly Val Cys Val Cys Gly  
 435 440 445  
 Ala Ile Tyr Thr Gly Leu Phe Leu Pro Glu Thr Lys Gly Lys Thr Phe

450	455	460													
Gln	Glu	Ile	Ser	Lys	Glu	Leu	His	Arg	Leu	Asn	Phe	Pro	Arg	Arg	Ala
465					470					475					480
Gln	Gly	Pro	Thr	Trp	Arg	Ser	Leu	Glu	Val	Ile	Gln	Ser	Thr	Glu	Leu
															485
															490
															495

<210> 78  
<211> 500  
<212> PRT  
<213> homo sapiens

<400> 78

Asx	Met	Leu	His	Ala	Leu	Leu	Arg	Ser	Arg	Met	Ile	Gln	Gly	Arg	Ile
1					5				10					15	
Leu	Leu	Leu	Thr	Ile	Cys	Ala	Ala	Gly	Ile	Gly	Gly	Thr	Phe	Gln	Phe
									20	25				30	
Gly	Tyr	Asn	Leu	Ser	Ile	Ile	Asn	Ala	Pro	Thr	Leu	His	Ile	Gln	Glu
									35	40				45	
Phe	Thr	Asn	Glu	Thr	Trp	Gln	Ala	Arg	Thr	Gly	Glu	Pro	Leu	Pro	Asp
									50	55				60	
His	Leu	Val	Leu	Leu	Met	Trp	Ser	Leu	Ile	Val	Ser	Leu	Tyr	Pro	Leu
									65	70	75			80	
Gly	Gly	Leu	Phe	Gly	Ala	Leu	Leu	Ala	Gly	Pro	Leu	Ala	Ile	Thr	Leu
									85	90				95	
Gly	Arg	Lys	Lys	Ser	Leu	Leu	Val	Asn	Asn	Ile	Phe	Val	Val	Ser	Ala
									100	105				110	
Ala	Ile	Leu	Phe	Gly	Phe	Ser	Arg	Lys	Ala	Gly	Ser	Phe	Glu	Met	Ile
									115	120				125	
Met	Leu	Gly	Arg	Leu	Leu	Val	Gly	Val	Asn	Ala	Gly	Val	Ser	Met	Asn
									130	135				140	
Ile	Gln	Pro	Met	Tyr	Leu	Gly	Glu	Ser	Ala	Pro	Lys	Glu	Leu	Arg	Gly
									145	150	155			160	
Ala	Val	Ala	Met	Ser	Ser	Ala	Ile	Phe	Thr	Ala	Leu	Gly	Ile	Val	Met
									165	170				175	
Gly	Gln	Val	Val	Gly	Leu	Arg	Glu	Leu	Leu	Gly	Gly	Pro	Gln	Ala	Trp
									180	185				190	
Pro	Leu	Leu	Leu	Ala	Ser	Cys	Ieu	Val	Pro	Gly	Ala	Leu	Gln	Leu	Ala
									195	200				205	
Ser	Leu	Pro	Leu	Leu	Pro	Glu	Ser	Pro	Arg	Tyr	Leu	Leu	Ile	Asp	Cys
									210	215				220	
Gly	Asp	Thr	Glu	Ala	Cys	Leu	Ala	Ala	Leu	Arg	Arg	Leu	Arg	Gly	Ser
									225	230	235			240	
Gly	Asp	Leu	Ala	Gly	Glu	Leu	Glu	Leu	Glu	Glu	Glu	Arg	Ala	Ala	
									245	250				255	
Cys	Gln	Gly	Cys	Arg	Ala	Arg	Arg	Pro	Trp	Glu	Leu	Phe	Gln	His	Arg
									260	265				270	
Ala	Leu	Arg	Arg	Gln	Val	Thr	Ser	Leu	Val	Val	Leu	Gly	Ser	Ala	Met
									275	280				285	
Glu	Leu	Cys	Gly	Asn	Asp	Ser	Val	Tyr	Ala	Tyr	Ala	Ser	Ser	Val	Phe
									290	295				300	
Arg	Lys	Ala	Gly	Val	Pro	Glu	Ala	Lys	Ile	Gln	Tyr	Ala	Ile	Ile	Gly
									305	310	315			320	
Thr	Gly	Ser	Cys	Glu	Leu	Leu	Thr	Ala	Val	Val	Ser	Cys	Val	Val	Ile
									325	330				335	
Glu	Arg	Val	Gly	Arg	Arg	Val	Leu	Leu	Ile	Gly	Gly	Tyr	Ser	Leu	Met
									340	345				350	
Thr	Cys	Trp	Gly	Ser	Ile	Phe	Thr	Val	Ala	Leu	Cys	Leu	Gln	Ser	Ser
									355	360				365	

Phe Pro Trp Thr Leu Tyr Leu Ala Met Ala Cys Ile Phe Ala Phe Ile  
 370 375 380  
 Leu Ser Phe Gly Ile Gly Pro Ala Gly Val Thr Gly Ile Leu Ala Thr  
 385 390 395 400  
 Glu Leu Phe Asp Gln Met Ala Arg Pro Ala Ala Cys Met Val Cys Gly  
 405 410 415  
 Ala Leu Met Trp Ile Met Leu Ile Leu Val Gly Leu Gly Phe Pro Phe  
 420 425 430  
 Ile Met Glu Ala Leu Ser His Phe Leu Tyr Val Pro Phe Leu Gly Val  
 435 440 445  
 Cys Val Cys Gly Ala Ile Tyr Thr Gly Leu Phe Leu Pro Glu Thr Lys  
 450 455 460  
 Gly Lys Thr Phe Gln Glu Ile Ser Lys Glu Leu His Arg Leu Asn Phe  
 465 470 475 480  
 Pro Arg Arg Ala Gln Gly Pro Thr Trp Arg Ser Leu Glu Val Ile Gln  
 485 490 495  
 Ser Thr Glu Leu  
 500

<210> 79  
 <211> 1358  
 <212> PRT  
 <213> homo sapiens

<400> 79  
 Met Val Val Val Lys Pro Met Asn Thr Met Ala Pro Val Val Thr Arg  
 1 5 10 15  
 Asn Thr Gly Leu Ile Leu Tyr Glu Gly Gln Ser Arg Pro Leu Thr Gly  
 20 25 30  
 Pro Ala Gly Ser Gly Pro Gln Asn Leu Val Ile Ser Asp Glu Asp Asp  
 35 40 45  
 Leu Glu Ala Val Arg Leu Glu Val Val Ala Gly Leu Arg His Gly His  
 50 55 60  
 Leu Val Ile Leu Gly Ala Ser Ser Gly Ser Ser Ala Pro Lys Ser Phe  
 65 70 75 80  
 Thr Val Ala Glu Leu Ala Ala Gly Gln Val Val Tyr Gln His Asp Asp  
 85 90 95  
 Arg Asp Gly Ser Leu Ser Asp Asn Leu Val Leu Arg Met Val Asp Gly  
 100 105 110  
 Gly Gly Arg His Gln Val Gln Phe Leu Phe Pro Ile Thr Leu Val Pro  
 115 120 125  
 Val Asp Asp Gln Pro Pro Val Leu Asn Ala Asn Thr Gly Leu Thr Leu  
 130 135 140  
 Ala Glu Gly Glu Thr Val Pro Ile Leu Pro Leu Ser Leu Ser Ala Thr  
 145 150 155 160  
 Asp Met Asp Ser Asp Asp Ser Leu Leu Leu Phe Val Leu Glu Ser Pro  
 165 170 175  
 Phe Leu Thr Thr Gly His Leu Leu Leu Arg Gln Thr His Pro Pro His  
 180 185 190  
 Glu Lys Gln Glu Leu Leu Arg Gly Leu Trp Arg Lys Glu Gly Ala Phe  
 195 200 205  
 Tyr Glu Arg Thr Val Thr Glu Trp Gln Gln Asp Ile Thr Glu Gly  
 210 215 220  
 Arg Leu Phe Tyr Arg His Ser Gly Pro His Ser Pro Gly Pro Val Thr  
 225 230 235 240  
 Asp Gln Phe Thr Phe Arg Val Gln Asp Asn His Asp Pro Pro Asn Gln  
 245 250 255  
 Ser Gly Leu Gln Arg Phe Val Ile Arg Ile His Pro Val Asp Arg Leu

260	265	270
Pro Pro Glu Leu Gly Ser Gly Cys	Pro Leu Arg Met Val Val Gln Glu	
275	280	285
Ser Gln Leu Thr Pro Leu Arg Lys Lys	Trp Leu Arg Tyr Thr Asp Leu	
290	295	300
Asp Thr Asp Asp Arg Glu Leu Arg Tyr Thr Val	Thr Gln Ser Pro Thr	
305	310	315
Asp Thr Asp Glu Asn His Leu Pro Ala Pro	Leu Gly Thr Leu Val Leu	
325	330	335
Thr Asp Asn Pro Ser Val Val Val	Thr His Phe Thr Gln Ala Gln Ile	
340	345	350
Asn His His Lys Ile Ala Tyr Arg Pro Pro	Gly Gln Glu Leu Gly Val	
355	360	365
Ala Thr Arg Val Ala Gln Phe Gln Phe	Gln Val Glu Asp Arg Ala Gly	
370	375	380
Asn Val Ala Pro Gly Thr Phe Thr Leu Tyr	Leu His Pro Val Asp Asn	
385	390	395
Gln Pro Pro Glu Ile Leu Asn Thr Gly	Phe Thr Ile Gln Glu Lys Gly	
405	410	415
His His Ile Leu Ser Glu Thr Glu Leu His	Val Asn Asp Val Asp Thr	
420	425	430
Asp Val Ala His Ile Ser Phe Thr Leu Thr	Gln Ala Pro Lys His Gly	
435	440	445
His Met Arg Val Ser Gly Gln Ile Leu His	Val Gly Gly Leu Phe His	
450	455	460
Leu Glu Asp Ile Lys Gln Gly Arg Val Ser	Tyr Ala His Asn Gly Asp	
465	470	475
Lys Ser Leu Thr Asp Ser Cys Ser Leu	Glu Val Ser Asp Arg His His	
485	490	495
Val Val Pro Ile Thr Leu Arg Val Asn Val	Arg Pro Val Asp Asp Glu	
500	505	510
Val Pro Ile Leu Ser His Pro Thr Gly	Thr Leu Glu Ser Tyr Leu Asp	
515	520	525
Val Leu Glu Asn Gly Ala Thr Glu Ile Thr	Ala Asn Val Ile Lys Gly	
530	535	540
Thr Asn Glu Glu Thr Asp Asp Leu Met	Leu Thr Phe Leu Leu Glu Asp	
545	550	555
Pro Pro Leu Tyr Gly Glu Ile Leu Val	Asn Gly Ile Pro Ala Glu Gln	
565	570	575
Phe Thr Gln Arg Asp Ile Leu Glu Gly	Ser Val Val Tyr Thr His Thr	
580	585	590
Ser Gly Glu Ile Gly Leu Leu Pro	Lys Ala Asp Ser Phe Asn Leu Ser	
595	600	605
Leu Ser Asp Met Ser Gln Glu Trp Arg Ile	Gly Asn Thr Ile Gln	
610	615	620
Gly Val Thr Ile Trp Val Thr Ile Leu	Pro Val Asp Ser Gln Ala Pro	
625	630	635
Glu Ile Phe Val Gly Glu Gln Leu Ile	Val Met Glu Gly Asp Lys Ser	
645	650	655
Val Ile Thr Ser Val His Ile Ser Ala	Glu Asp Val Asp Ser Leu Asn	
660	665	670
Asp Asp Ile Leu Cys Thr Ile Val Ile	Gln Pro Thr Ser Gly Tyr Val	
675	680	685
Glu Asn Ile Ser Pro Ala Pro Gly	Ser Glu Lys Ser Arg Ala Gly Ile	
690	695	700
Ala Ile Ser Ala Phe Asn Leu Lys Asp	Leu Arg Gln Gly His Ile Asn	
705	710	715
Tyr Val Gln Ser Val His Lys Gly Val	Glu Pro Val Glu Asp Arg Phe	
725	730	735

Val Phe Arg Cys Ser Asp Gly Ile Asn Phe Ser Glu Arg Gln Phe Phe  
 740 745 750  
 Pro Ile Val Ile Ile Pro Thr Asn Asp Glu Gln Pro Glu Met Phe Met  
 755 760 765  
 Arg Glu Phe Met Val Met Glu Gly Met Ser Leu Val Ile Asp Thr Pro  
 770 775 780  
 Ile Leu Asn Ala Ala Asp Ala Asp Val Pro Leu Asp Asp Leu Thr Phe  
 785 790 795 800  
 Thr Ile Thr Gln Phe Pro Thr His Gly His Ile Met Asn Gln Leu Ile  
 805 810 815  
 Asn Gly Thr Val Leu Val Glu Ser Phe Thr Leu Asp Gln Ile Ile Glu  
 820 825 830  
 Ser Ser Ser Ile Ile Tyr Glu His Asp Asp Ser Glu Thr Gln Glu Asp  
 835 840 845  
 Ser Phe Val Ile Lys Leu Thr Asp Gly Lys His Ser Val Glu Lys Thr  
 850 855 860  
 Val Leu Ile Ile Val Ile Pro Val Asp Asp Glu Thr Pro Arg Met Thr  
 865 870 875 880  
 Ile Asn Asn Gly Leu Glu Ile Glu Ile Gly Asp Thr Lys Ile Ile Asn  
 885 890 895  
 Asn Lys Ile Leu Met Ala Thr Asp Leu Asp Ser Glu Asp Lys Ser Leu  
 900 905 910  
 Val Tyr Ile Ile Arg Tyr Gly Pro Gly His Gly Leu Leu Gln Arg Arg  
 915 920 925  
 Lys Pro Thr Gly Ala Phe Glu Asn Ile Thr Leu Gly Met Asn Phe Thr  
 930 935 940  
 Gln Asp Glu Val Asp Arg Asn Leu Ile Gln Tyr Val His Leu Gly Gln  
 945 950 955 960  
 Glu Gly Ile Arg Asp Leu Ile Lys Phe Asp Val Thr Asp Gly Ile Asn  
 965 970 975  
 Pro Leu Ile Asp Arg Tyr Phe Tyr Val Ser Ile Gly Ser Ile Asp Ile  
 980 985 990  
 Val Phe Pro Asp Val Ile Ser Lys Gly Val Ser Leu Lys Glu Gly Gly  
 995 1000 1005  
 Lys Val Thr Leu Thr Thr Asp Leu Leu Ser Thr Ser Asp Leu Asn Ser  
 1010 1015 1020  
 Pro Asp Glu Asn Leu Val Phe Thr Ile Thr Arg Ala Pro Met Arg Gly  
 1025 1030 1035 1040  
 His Leu Glu Cys Thr Asp Gln Pro Gly Val Ser Ile Thr Ser Phe Thr  
 1045 1050 1055  
 Gln Leu Gln Leu Ala Gly Asn Lys Ile Tyr Tyr Ile His Thr Ala Asp  
 1060 1065 1070  
 Asp Glu Val Lys Met Asp Ser Phe Glu Phe Gln Val Thr Asp Gly Arg  
 1075 1080 1085  
 Asn Pro Val Phe Arg Thr Phe Arg Ile Ser Ile Ser Asp Val Asp Asn  
 1090 1095 1100  
 Lys Lys Pro Val Val Thr Ile His Lys Leu Val Val Ser Glu Ser Glu  
 1105 1110 1115 1120  
 Asn Lys Leu Ile Thr Pro Phe Glu Leu Thr Val Glu Asp Arg Asp Thr  
 1125 1130 1135  
 Pro Asp Lys Leu Leu Lys Phe Thr Ile Thr Gln Val Pro Ile His Gly  
 1140 1145 1150  
 His Leu Leu Phe Asn Asn Thr Arg Pro Val Met Val Phe Thr Lys Gln  
 1155 1160 1165  
 Asp Leu Asn Glu Asn Leu Ile Ser Tyr Lys His Asp Gly Thr Glu Ser  
 1170 1175 1180  
 Ser Glu Asp Ser Phe Ser Phe Thr Val Thr Asp Gly Thr His Thr Asp  
 1185 1190 1195 1200  
 Phe Tyr Val Phe Pro Asp Thr Val Phe Glu Thr Arg Arg Pro Gln Val

1205	1210	1215	
Met Lys Ile Gln Val Leu Ala Val Asp Asn Ser Val Pro Gln Ile Ala			
1220	1225	1230	
Val Asn Lys Gly Ala Ser Thr Leu Arg Thr Leu Ala Thr Gly His Leu			
1235	1240	1245	
Gly Phe Met Ile Thr Ser Lys Ile Leu Lys Val Glu Asp Arg Asp Ser			
1250	1255	1260	
Leu His Ile Ser Leu Arg Phe Ile Val Thr Glu Ala Pro Gln His Gly			
1265	1270	1275	1280
Tyr Leu Leu Asn Leu Asp Lys Gly Asn His Ser Ile Thr Gln Phe Thr			
1285	1290	1295	
Gln Ala Asp Ile Asp Asp Met Lys Ile Cys Tyr Val Leu Arg Glu Gly			
1300	1305	1310	
Ala Asn Ala Thr Ser Asp Met Phe Tyr Phe Ala Val Glu Asp Gly Gly			
1315	1320	1325	
Lys Tyr Ser Pro Leu Leu Val Val Thr Ala Arg Arg Asp Ala Phe Leu			
1330	1335	1340	
Gly Cys Ser Leu Met Thr Leu Leu Gln Glu Val Phe Ile Lys			
1345	1350	1355	

<210> 80  
 <211> 3105  
 <212> PRT  
 <213> homo sapiens

<400> 80			
Met Ala Arg Ser Trp Leu Thr Ala Thr Ser Thr Ser Arg Pro Ala Ala			
1	5	10	15
Phe Gly Arg Ala Leu Leu Ser Pro Gly Leu Ala Gly Ala Ala Gly Val			
20	25	30	
Pro Ala Glu Glu Ala Ile Val Leu Ala Asn Arg Gly Leu Arg Val Pro			
35	40	45	
Phe Gly Arg Glu Val Trp Leu Asp Pro Leu His Asp Leu Val Leu Gln			
50	55	60	
Val Gln Pro Gly Asp Arg Cys Ala Val Ser Val Leu Asp Asn Asp Ala			
65	70	75	80
Leu Ala Gln Arg Pro Gly Arg Leu Ser Pro Lys Arg Phe Pro Cys Asp			
85	90	95	
Phe Gly Pro Gly Glu Val Arg Tyr Ser His Leu Gly Ala Arg Ser Pro			
100	105	110	
Ser Arg Asp Arg Val Arg Leu Gln Leu Arg Tyr Asp Ala Pro Gly Gly			
115	120	125	
Ala Val Val Leu Pro Leu Val Leu Glu Val Glu Val Val Phe Thr Gln			
130	135	140	
Leu Glu Val Val Thr Arg Asn Leu Pro Leu Val Val Glu Glu Leu Leu			
145	150	155	160
Gly Thr Ser Asn Ala Leu Asp Ala Arg Ser Leu Glu Phe Ala Phe Gln			
165	170	175	
Pro Glu Thr Glu Glu Cys Arg Val Gly Ile Leu Ser Gly Leu Gly Ala			
180	185	190	
Leu Pro Arg Tyr Gly Glu Leu Leu His Tyr Pro Gln Val Pro Gly Gly			
195	200	205	
Ala Arg Glu Gly Ala Pro Glu Thr Leu Leu Met Asp Cys Lys Ala			
210	215	220	
Phe Gln Glu Leu Gly Val Arg Tyr Arg His Thr Ala Ala Ser Arg Ser			
225	230	235	240
Pro Asn Arg Asp Trp Ile Pro Met Val Val Glu Leu Arg Ser Arg Gly			
245	250	255	

Ala Pro Val Gly Ser Pro Ala Leu Lys Arg Glu His Phe Gln Val Leu  
 260 265 270  
 Val Arg Ile Arg Gly Gly Ala Glu Asn Thr Ala Pro Lys Pro Ser Phe  
 275 280 285  
 Val Ala Met Met Met Glu Val Asp Gln Phe Val Leu Thr Ala Leu  
 290 295 300  
 Thr Pro Asp Met Leu Ala Ala Glu Asp Ala Glu Ser Pro Ser Asp Leu  
 305 310 315 320  
 Leu Ile Phe Asn Leu Thr Ser Pro Phe Gln Pro Gly Gln Gly Tyr Leu  
 325 330 335  
 Val Ser Thr Asp Asp Arg Ser Leu Pro Leu Ser Ser Phe Thr Gln Arg  
 340 345 350  
 Asp Leu Arg Leu Leu Lys Ile Ala Tyr Gln Pro Pro Ser Glu Asp Ser  
 355 360 365  
 Asp Gln Glu Arg Leu Phe Glu Leu Glu Leu Val Val Asp Leu Glu  
 370 375 380  
 Gly Ala Ala Ser Asp Pro Phe Ala Phe Met Val Val Val Lys Pro Met  
 385 390 395 400  
 Asn Thr Met Ala Pro Val Val Thr Arg Asn Thr Gly Leu Ile Leu Tyr  
 405 410 415  
 Glu Gly Gln Ser Arg Pro Leu Thr Gly Pro Ala Gly Ser Gly Pro Gln  
 420 425 430  
 Asn Leu Val Ile Ser Asp Glu Asp Asp Leu Glu Ala Val Arg Leu Glu  
 435 440 445  
 Val Val Ala Gly Leu Arg His Gly His Leu Val Ile Leu Gly Ala Ser  
 450 455 460  
 Ser Gly Ser Ser Ala Pro Lys Ser Phe Thr Val Ala Glu Leu Ala Ala  
 465 470 475 480  
 Gly Gln Val Val Tyr Gln His Asp Asp Arg Asp Gly Ser Leu Ser Asp  
 485 490 495  
 Asn Leu Val Leu Arg Met Val Asp Gly Gly Arg His Gln Val Gln  
 500 505 510  
 Phe Leu Phe Pro Ile Thr Leu Val Pro Val Asp Asp Gln Pro Pro Val  
 515 520 525  
 Leu Asn Ala Asn Thr Gly Leu Thr Leu Ala Glu Gly Glu Thr Val Pro  
 530 535 540  
 Ile Leu Pro Leu Ser Leu Ser Ala Thr Asp Met Asp Ser Asp Asp Ser  
 545 550 555 560  
 Leu Leu Leu Phe Val Leu Glu Ser Pro Phe Leu Thr Thr Gly His Leu  
 565 570 575  
 Leu Leu Arg Gln Thr His Pro Pro His Glu Lys Gln Glu Leu Leu Arg  
 580 585 590  
 Gly Leu Trp Arg Lys Glu Gly Ala Phe Tyr Glu Arg Thr Val Thr Glu  
 595 600 605  
 Trp Gln Gln Gln Asp Ile Thr Glu Gly Arg Leu Phe Tyr Arg His Ser  
 610 615 620  
 Gly Pro His Ser Pro Gly Pro Val Thr Asp Gln Phe Thr Phe Arg Val  
 625 630 635 640  
 Gln Asp Asn His Asp Pro Pro Asn Gln Ser Gly Leu Gln Arg Phe Val  
 645 650 655  
 Ile Arg Ile His Pro Val Asp Arg Leu Pro Pro Glu Leu Gly Ser Gly  
 660 665 670  
 Cys Pro Leu Arg Met Val Val Gln Glu Ser Gln Leu Thr Pro Leu Arg  
 675 680 685  
 Lys Lys Trp Leu Arg Tyr Thr Asp Leu Asp Thr Asp Asp Arg Glu Leu  
 690 695 700  
 Arg Tyr Thr Val Thr Gln Pro Pro Thr Asp Thr Asp Glu Asn His Leu  
 705 710 715 720  
 Pro Ala Pro Leu Gly Thr Leu Val Leu Thr Asp Asn Pro Ser Val Val

725	730	735
Val Thr His Phe Thr Gln Ala Gln Ile Asn His His Lys Ile Ala Tyr		
740	745	750
Arg Pro Pro Gly Gln Glu Leu Gly Val Ala Thr Arg Val Ala Gln Phe		
755	760	765
Gln Phe Gln Val Glu Asp Arg Ala Gly Asn Val Ala Pro Gly Thr Phe		
770	775	780
Thr Leu Tyr Leu His Pro Val Asp Asn Gln Pro Pro Glu Ile Leu Asn		
785	790	800
Thr Gly Phe Thr Ile Gln Glu Lys Gly His His Ile Leu Ser Glu Thr		
805	810	815
Glu Leu His Val Asn Asp Val Asp Thr Asp Val Ala His Ile Ser Phe		
820	825	830
Thr Leu Thr Gln Ala Pro Lys His Gly His Met Arg Val Ser Gly Gln		
835	840	845
Ile Leu His Val Gly Gly Leu Phe His Leu Glu Asp Ile Lys Gln Gly		
850	855	860
Arg Val Ser Tyr Ala His Asn Gly Asp Lys Ser Leu Thr Asp Ser Cys		
865	870	880
Ser Leu Glu Val Ser Asp Arg His His Val Val Pro Ile Thr Leu Arg		
885	890	895
Val Asn Val Arg Pro Val Asp Asp Glu Val Pro Ile Leu Ser His Pro		
900	905	910
Thr Gly Thr Leu Glu Ser Tyr Leu Asp Val Leu Glu Asn Gly Ala Thr		
915	920	925
Glu Ile Thr Ala Asn Val Ile Lys Gly Thr Asn Glu Glu Thr Asp Asp		
930	935	940
Leu Met Leu Thr Phe Leu Leu Glu Asp Pro Pro Leu Tyr Gly Glu Ile		
945	950	960
Leu Val Asn Gly Ile Pro Ala Glu Gln Phe Thr Gln Arg Asp Ile Leu		
965	970	975
Glu Gly Ser Val Val Tyr Thr His Thr Ser Gly Glu Ile Gly Leu Leu		
980	985	990
Pro Lys Ala Asp Ser Phe Asn Leu Ser Leu Ser Asp Lys Ser Gln Glu		
995	1000	1005
Trp Arg Ile Gly Gly Asn Thr Ile Gln Gly Val Thr Ile Trp Val Thr		
1010	1015	1020
Ile Leu Pro Val Asp Ser Gln Ala Pro Glu Ile Ser Val Gly Glu Gln		
1025	1030	1040
Leu Ile Val Met Glu Gly Asp Lys Ser Val Ile Thr Ser Val His Ile		
1045	1050	1055
Ser Ala Glu Asp Val Asp Ser Leu Asn Asp Asp Ile Leu Cys Thr Ile		
1060	1065	1070
Val Ile Gln Pro Thr Ser Gly Tyr Val Glu Asn Ile Ser Pro Ala Pro		
1075	1080	1085
Gly Ser Glu Lys Ser Arg Ala Gly Ile Ala Ile Ser Ala Phe Asn Leu		
1090	1095	1100
Lys Asp Leu Arg Gln Gly His Ile Asn Tyr Val Gln Ser Val His Lys		
1105	1110	1120
Gly Val Glu Pro Val Glu Asp Arg Phe Val Phe Arg Cys Ser Asp Gly		
1125	1130	1135
Ile Asn Phe Ser Glu Arg Gln Phe Phe Pro Ile Val Ile Ile Pro Thr		
1140	1145	1150
Asn Asp Glu Gln Pro Glu Met Phe Met Arg Glu Phe Met Val Met Glu		
1155	1160	1165
Gly Met Ser Leu Val Ile Asp Thr Pro Ile Leu Asn Ala Ala Asp Ala		
1170	1175	1180
Asp Val Pro Leu Asp Asp Leu Thr Phe Thr Ile Thr Gln Phe Pro Thr		
1185	1190	1200

His Gly His Ile Met Asn Gln Leu Ile Asn Gly Thr Val Leu Val Glu  
 1205 1210 1215  
 Ser Phe Thr Leu Asp Gln Ile Ile Glu Ser Ser Ser Ile Ile Tyr Glu  
 1220 1225 1230  
 His Asp Asp Ser Glu Thr Gln Glu Asp Ser Phe Val Ile Lys Leu Thr  
 1235 1240 1245  
 Asp Gly Lys His Ser Val Glu Lys Thr Val Leu Ile Ile Val Ile Pro  
 1250 1255 1260  
 Val Asp Asp Glu Thr Pro Arg Met Thr Ile Asn Asn Gly Leu Glu Ile  
 1265 1270 1275 1280  
 Glu Ile Gly Asp Thr Lys Ile Ile Asn Asn Lys Ile Leu Met Ala Thr  
 1285 1290 1295  
 Asp Leu Asp Ser Glu Asp Lys Ser Leu Val Tyr Ile Arg Tyr Gly  
 1300 1305 1310  
 Pro Gly His Gly Leu Leu Gln Arg Arg Lys Pro Thr Gly Ala Phe Glu  
 1315 1320 1325  
 Asn Ile Thr Leu Gly Met Asn Phe Thr Gln Asp Glu Val Asp Arg Asn  
 1330 1335 1340  
 Leu Ile Gln Tyr Val His Leu Gly Gln Glu Gly Ile Arg Asp Leu Ile  
 1345 1350 1355 1360  
 Lys Phe Asp Val Thr Asp Gly Ile Asn Pro Leu Ile Asp Arg Tyr Phe  
 1365 1370 1375  
 Tyr Val Ser Ile Gly Ser Ile Asp Ile Val Phe Pro Asp Val Ile Ser  
 1380 1385 1390  
 Lys Gly Val Ser Leu Lys Glu Gly Lys Val Thr Leu Thr Thr Asp  
 1395 1400 1405  
 Leu Leu Ser Thr Ser Asp Leu Asn Ser Pro Asp Glu Asn Leu Val Phe  
 1410 1415 1420  
 Thr Ile Thr Arg Ala Pro Met Arg Gly His Leu Glu Cys Thr Asp Gln  
 1425 1430 1435 1440  
 Pro Gly Val Ser Ile Thr Ser Phe Thr Gln Leu Gln Leu Ala Gly Asn  
 1445 1450 1455  
 Lys Ile Tyr Tyr Ile His Thr Ala Asp Asp Glu Val Lys Met Asp Ser  
 1460 1465 1470  
 Phe Glu Phe Gln Val Thr Asp Gly Arg Asn Pro Val Phe Arg Thr Phe  
 1475 1480 1485  
 Arg Ile Ser Ile Ser Asp Val Asp Asn Lys Pro Val Val Thr Ile  
 1490 1495 1500  
 His Lys Leu Val Val Ser Glu Ser Glu Asn Lys Leu Ile Thr Pro Phe  
 1505 1510 1515 1520  
 Glu Leu Thr Val Glu Asp Arg Asp Thr Pro Asp Lys Leu Leu Lys Phe  
 1525 1530 1535  
 Thr Ile Thr Gln Val Pro Ile His Gly His Leu Leu Phe Asn Asn Thr  
 1540 1545 1550  
 Arg Pro Val Met Val Phe Thr Lys Gln Asp Leu Asn Glu Asn Leu Ile  
 1555 1560 1565  
 Ser Tyr Lys His Asp Gly Thr Glu Ser Ser Glu Asp Ser Phe Ser Phe  
 1570 1575 1580  
 Thr Val Thr Asp Gly Thr His Thr Asp Phe Tyr Val Phe Pro Asp Thr  
 1585 1590 1595 1600  
 Val Phe Glu Thr Arg Arg Pro Gln Val Met Lys Ile Gln Val Leu Ala  
 1605 1610 1615  
 Val Asp Asn Ser Val Pro Gln Ile Ala Val Asn Lys Gly Ala Ser Thr  
 1620 1625 1630  
 Leu Arg Thr Leu Ala Thr Gly His Leu Gly Phe Met Ile Thr Ser Lys  
 1635 1640 1645  
 Ile Leu Lys Val Glu Asp Arg Asp Ser Leu His Ile Ser Leu Arg Phe  
 1650 1655 1660  
 Ile Val Thr Glu Ala Pro Gln His Gly Tyr Leu Leu Asn Leu Asp Lys

1665	1670	1675	1680
Gly Asn His Ser Ile Thr Gln Phe Thr Gln Ala Asp Ile Asp Asp Met			
1685	1690	1695	
Lys Ile Cys Tyr Val Leu Arg Glu Gly Ala Asn Ala Thr Ser Asp Met			
1700	1705	1710	
Phe Tyr Phe Ala Val Glu Asp Gly Gly Gly Asn Lys Leu Thr Tyr Gln			
1715	1720	1725	
Asn Phe Arg Leu Asn Trp Ala Trp Ile Ser Phe Glu Lys Glu Tyr Tyr			
1730	1735	1740	
Leu Val Asn Glu Asp Ser Lys Phe Leu Asp Val Val Leu Lys Arg Arg			
1745	1750	1755	1760
Gly Tyr Leu Gly Glu Thr Ser Phe Ile Ser Ile Gly Thr Arg Asp Arg			
1765	1770	1775	
Thr Ala Glu Lys Asp Lys Asp Phe Lys Gly Lys Ala Gln Lys Gln Val			
1780	1785	1790	
Gln Phe Asn Pro Gly Gln Thr Arg Ala Thr Trp Arg Val Arg Ile Leu			
1795	1800	1805	
Ser Asp Gly Glu His Glu Gln Ser Glu Thr Phe Gln Val Val Leu Ser			
1810	1815	1820	
Glu Pro Val Leu Ala Ala Leu Glu Phe Pro Thr Val Ala Thr Val Glu			
1825	1830	1835	1840
Ile Val Asp Pro Gly Asp Glu Pro Thr Val Phe Ile Pro Gln Ser Lys			
1845	1850	1855	
Tyr Ser Val Glu Glu Asp Val Gly Glu Leu Phe Ile Pro Ile Arg Arg			
1860	1865	1870	
Ser Gly Asp Val Ser Gln Glu Leu Met Val Val Cys Tyr Thr Gln Gln			
1875	1880	1885	
Gly Thr Ala Thr Gly Thr Val Pro Thr Ser Val Leu Ser Tyr Ser Asp			
1890	1895	1900	
Tyr Ile Ser Arg Pro Glu Asp His Thr Ser Val Val Arg Phe Asp Lys			
1905	1910	1915	1920
Asp Glu Arg Glu Lys Leu Cys Arg Ile Val Ile Ile Asp Asp Ser Leu			
1925	1930	1935	
Tyr Glu Glu Glu Thr Phe His Val Leu Leu Ser Met Pro Met Gly			
1940	1945	1950	
Gly Arg Ile Gly Ser Glu Phe Pro Gly Ala Gln Val Thr Ile Val Pro			
1955	1960	1965	
Asp Lys Asp Asp Gly Pro Ser Asp Ser Lys Phe Asn Val Ala Glu Asn			
1970	1975	1980	
Tyr Ser Leu Leu Pro Phe Thr Cys Phe Gln Gly Ser Ile Ala Thr Ala			
1985	1990	1995	2000
Glu Ala Ala Thr Gln Gly Gly Arg Ser Thr Arg Gln Val Ala Ala			
2005	2010	2015	
Val Lys Lys Asp Lys Asp Phe Lys Gly Lys Ala Gln Lys Gln Val Gln			
2020	2025	2030	
Phe Asn Pro Gly Gln Thr Arg Ala Thr Trp Arg Val Arg Ile Leu Ser			
2035	2040	2045	
Asp Gly Glu His Glu Gln Ser Glu Thr Phe Gln Val Val Leu Ser Glu			
2050	2055	2060	
Pro Val Leu Ala Ala Leu Glu Phe Pro Thr Val Ala Thr Val Glu Ile			
2065	2070	2075	2080
Val Asp Pro Gly Asp Ala Cys Pro Trp Gly Glu Glu Ser Asp Gln Ser			
2085	2090	2095	
Ser Gln Gly Leu Lys Leu Gln Ser Phe Leu Thr Lys Met Met Val Ser			
2100	2105	2110	
Thr Asn Leu Leu Glu Asn Ser Phe Ser Arg Glu Asp Gln His Gln Glu			
2115	2120	2125	
Gln Leu Ser Arg Gln Lys Lys Trp Glu Ser Lys Thr Met Ile Ile Tyr			
2130	2135	2140	

Thr Phe Ile Leu Cys Glu Thr Glu Lys Pro Cys Ile Leu Glu Leu Met  
 2145 2150 2155 2160  
 Asp Asp Val Leu Tyr Glu Glu Val Glu Glu Leu Arg Leu Val Leu Gly  
 2165 2170 2175  
 Thr Pro Gln Ser Asn Ser Pro Phe Gly Ala Ala Val Gly Glu Gln Asn  
 2180 2185 2190  
 Glu Thr Leu Ile Arg Ile Arg Asp Asp Ala Asp Lys Thr Val Ile Lys  
 2195 2200 2205  
 Phe Gly Glu Thr Lys Phe Ser Val Thr Glu Pro Lys Glu Pro Gly Glu  
 2210 2215 2220  
 Ser Val Val Ile Arg Ile Pro Val Ile Arg Gln Gly Asp Thr Ser Lys  
 2225 2230 2235 2240  
 Val Ser Ile Val Arg Val His Thr Lys Asp Gly Ser Ala Thr Ser Gly  
 2245 2250 2255  
 Glu Asp Tyr His Pro Val Ser Glu Glu Ile Glu Phe Lys Glu Gly Glu  
 2260 2265 2270  
 Thr Gln His Val Val Glu Ile Glu Val Thr Phe Asp Gly Val Arg Glu  
 2275 2280 2285  
 Met Arg Glu Ala Phe Thr Val His Leu Lys Pro Asp Glu Asn Met Ile  
 2290 2295 2300  
 Ala Glu Met Gln Leu Ser Asn Phe Glu Leu Thr Leu Ser Pro Asp Gly  
 2305 2310 2315 2320  
 Thr Arg Val Gly Asn His Lys Cys Ser Asn Leu Leu Asp Tyr Thr Glu  
 2325 2330 2335  
 Val Lys Thr His Tyr Gly Phe Leu Thr Asp Ala Thr Lys Asn Pro Glu  
 2340 2345 2350  
 Ile Ile Gly Glu Thr Tyr Pro Tyr Gln Tyr Ser Leu Ser Ile Arg Gly  
 2355 2360 2365  
 Ser Thr Thr Leu Arg Phe Tyr Arg Asn Leu Asn Leu Glu Ala Cys Leu  
 2370 2375 2380  
 Trp Glu Phe Val Ser Tyr Tyr Asp Met Ser Glu Leu Leu Ala Asp Cys  
 2385 2390 2395 2400  
 Arg Ser Val Leu Asn Ala Ser Ile Phe His Glu Met Ala Pro Glu Gly  
 2405 2410 2415  
 Lys Gln Ser Lys Cys Leu Val Asn Ser Thr Leu Tyr Ser Ile Leu Glu  
 2420 2425 2430  
 Cys His Glu Ser Leu Pro Asn Phe Cys Ile Ser Ala Leu Arg Met Gly  
 2435 2440 2445  
 Lys Trp Arg Lys Ile Lys Ser Lys Pro Ser Ala Gln Thr Pro Cys Ala  
 2450 2455 2460  
 Gln Arg Leu Arg Gly Phe Ile Asp His Pro Arg Lys Gln Pro Leu Gln  
 2465 2470 2475 2480  
 Gln Ala Ser Ala Asp Pro Gly Met Leu Pro Val Ile Ser Thr Arg Glu  
 2485 2490 2495  
 Leu Ser Asn Phe Glu Leu Thr Leu Ser Pro Asp Gly Thr Arg Val Gly  
 2500 2505 2510  
 Asn His Lys Cys Ser Asn Leu Leu Asp Tyr Thr Glu Val Lys Thr His  
 2515 2520 2525  
 Tyr Gly Phe Leu Thr Asp Ala Thr Lys Asn Pro Glu Ile Ile Gly Glu  
 2530 2535 2540  
 Thr Tyr Pro Tyr Gln Tyr Ser Leu Ser Ile Arg Gly Ser Thr Thr Leu  
 2545 2550 2555 2560  
 Arg Phe Tyr Arg Asn Leu Asn Leu Glu Ala Cys Leu Trp Glu Phe Val  
 2565 2570 2575  
 Ser Tyr Tyr Asp Met Ser Glu Leu Leu Ala Asp Cys Gly Gly Thr Ile  
 2580 2585 2590  
 Gly Thr Asp Gly Gln Val Leu Asn Leu Val Gln Ser Tyr Val Thr Leu  
 2595 2600 2605  
 Arg Val Pro Leu Tyr Val Ser Tyr Val Phe His Ser Pro Val Gly Val

2610	2615	2620
Gly	Gly	Trp
2625	2630	2635
Val	Tyr	Asp
2645	2650	2655
Glu	Ala	Glu
2660	2665	2670
Asp	Glu	Gly
2675	2680	2685
Gly	Leu	Phe
2690	2695	2700
Met	Ser	Ala
2705	2710	2715
Ser	Glu	Pro
2725	2730	2735
Asp	Phe	Ala
2740	2745	2750
Pro	Cys	Thr
2755	2760	2765
Asn	Pro	Arg
2770	2775	2780
Val	Ser	Asp
2785	2790	2795
Leu	Leu	Ser
2805	2810	2815
Gly	Gln	Glu
2820	2825	2830
Arg	Val	Met
2835	2840	2845
Ser	Ile	Glu
2850	2855	2860
Lys	Tyr	Ser
2865	2870	2875
Ser	Leu	Leu
2885	2890	2895
Gln	Ala	Thr
2900	2905	2910
Asp	Asp	Pro
2915	2920	2925
Phe	Lys	Val
2930	2935	2940
Trp	Tyr	Ile
2945	2950	2955
Arg	Gly	Ile
2965	2970	2975
Gly	Lys	Pro
2980	2985	2990
Ser	Thr	Pro
2995	3000	3005
Thr	Asn	Ile
3010	3015	3020
His	Gly	Arg
3025	3030	3035
Pro	Ser	Ser
3045	3050	3055
Gly	Leu	Leu
3060	3065	3070
Gly	Lys	Glu
3075	3080	3085

Ser Glu Pro Met Val Pro Pro Gln Ser His His Asn Asp Ser Ser Glu  
 3090 3095 3100  
 Val  
 3105

<210> 81  
 <211> 457  
 <212> PRT  
 <213> homo sapiens

<400> 81  
 Met Gly Cys Ser Gly Ala Trp Gly Leu Ser Cys Pro Cys Pro Gln Thr  
 1 5 10 15  
 Pro Ser Trp Ala Trp Arg Lys Met Arg Thr Pro Ser Met Arg Asn Arg  
 20 25 30  
 Ser Gly Ala Val Trp Ser Arg Ala Ser Val Pro Phe Ser Ala Trp Glu  
 35 40 45  
 Val Glu Val Gln Met Arg Val Thr Gly Leu Gly Arg Arg Gly Ala Gln  
 50 55 60  
 Gly Met Ala Val Trp Tyr Thr Arg Gly Arg Gly His Val Gly Ser Val  
 65 70 75 80  
 Leu Gly Gly Leu Ala Ser Trp Asp Gly Ile Gly Ile Phe Phe Asp Ser  
 85 90 95  
 Pro Ala Glu Asp Thr Gln Asp Ser Pro Ala Ile Arg Val Leu Ala Ser  
 100 105 110  
 Asp Gly His Ile Pro Ser Glu Gln Pro Gly Asp Gly Ala Ser Gln Gly  
 115 120 125  
 Leu Gly Ser Cys His Trp Asp Phe Arg Asn Arg Pro His Pro Phe Arg  
 130 135 140  
 Ala Arg Ile Thr Tyr Trp Gly Gln Arg Leu Arg Met Ser Leu Asn Ser  
 145 150 155 160  
 Gly Leu Thr Pro Ser Asp Pro Gly Glu Phe Cys Val Asp Val Gly Pro  
 165 170 175  
 Leu Leu Leu Val Pro Gly Gly Phe Phe Gly Val Ser Ala Ala Thr Gly  
 180 185 190  
 Thr Leu Ala Asp Asp His Asp Val Leu Ser Phe Leu Thr Phe Ser Leu  
 195 200 205  
 Ser Glu Pro Ser Pro Glu Val Pro Pro Gln Pro Phe Leu Glu Met Gln  
 210 215 220  
 His Val Arg Leu Ala Arg Gln Leu Glu Gly Leu Trp Ala Arg Leu Gly  
 225 230 235 240  
 Leu Gly Thr Arg Glu Asp Val Thr Pro Lys Ser Asp Ser Glu Ala Gln  
 245 250 255  
 Gly Glu Gly Arg Leu Phe Asp Leu Glu Glu Thr Leu Gly Arg His  
 260 265 270  
 Arg Arg Ile Leu Gln Ala Leu Arg Gly Leu Ser Lys Gln Leu Ala Gln  
 275 280 285  
 Ala Glu Arg Gln Trp Lys Lys Gln Leu Gly Pro Gln Ala Lys Pro Gly  
 290 295 300  
 Leu Thr Glu Ala Gly Asp Ala Ala Val Arg Met Ala Ala Glu Ala Gln  
 305 310 315 320  
 Val Ser Tyr Leu Pro Val Gly Ile Glu His His Phe Leu Glu Leu Asp  
 325 330 335  
 His Ile Leu Gly Leu Leu Gln Glu Glu Leu Arg Gly Pro Ala Lys Ala  
 340 345 350  
 Ala Ala Lys Ala Pro Arg Pro Pro Gly Gln Pro Pro Arg Ala Ser Ser  
 355 360 365  
 Cys Leu Gln Pro Gly Ile Phe Leu Phe Tyr Leu Leu Ile Gln Thr Val

370	375	380
Gly Phe Phe Gly Tyr Val His Phe Arg Arg Pro Val Pro Arg Pro Ala		
385	390	395
Lys Thr Met Ala Phe Met Val Lys Thr Met Val Gly Gly Gln Leu Lys		
405	410	415
Asn Leu Thr Gly Ser Leu Gly Gly Glu Asp Lys Gly Asp Gly Asp		
420	425	430
Lys Ser Ala Ala Glu Ala Gln Gly Met Ser Arg Glu Glu Tyr Glu Glu		
435	440	445
Tyr Gln Lys Gln Leu Val Glu Glu Lys		
450	455	

<210> 82  
 <211> 526  
 <212> PRT  
 <213> homo sapiens .

<400> 82		
Met Pro Ala Val Ser Gly Pro Gly Pro Leu Phe Cys Leu Leu Leu		
1 . . 5 10 15		
Leu Leu Asp Pro His Ser Pro Glu Thr Gly Cys Pro Pro Leu Arg Arg		
20 25 30		
Phe Glu Tyr Lys Leu Ser Phe Lys Gly Pro Arg Leu Ala Leu Pro Gly		
35 40 45		
Ala Gly Ile Pro Phe Trp Ser His His Gly Asp Ala Ile Leu Gly Leu		
50 55 60		
Glu Glu Val Arg Leu Thr Pro Ser Met Arg Asn Arg Ser Gly Ala Val		
65 70 75 80		
Trp Ser Arg Ala Ser Val Pro Phe Ser Ala Trp Glu Val Glu Val Gln		
85 90 95		
Met Arg Val Thr Gly Leu Gly Arg Arg Gly Ala Gln Gly Met Ala Val		
100 105 110		
Trp Tyr Thr Arg Gly Arg Gly His Val Gly Ser Val Leu Gly Gly Leu		
115 120 125		
Ala Ser Trp Asp Gly Ile Gly Ile Phe Phe Asp Ser Pro Ala Glu Asp		
130 135 140		
Thr Gln Asp Ser Pro Ala Ile Arg Val Leu Ala Ser Asp Gly His Ile		
145 150 155 160		
Pro Ser Glu Gln Pro Gly Asp Gly Ala Ser Gln Gly Leu Gly Ser Cys		
165 170 175		
His Trp Asp Phe Arg Asn Arg Pro His Pro Phe Arg Ala Arg Ile Thr		
180 185 190		
Tyr Trp Gly Gln Arg Leu Arg Met Ser Leu Asn Ser Gly Leu Thr Pro		
195 200 205		
Ser Asp Pro Gly Glu Phe Cys Val Asp Val Gly Pro Leu Leu Leu Val		
210 215 220		
Pro Gly Gly Phe Phe Gly Val Ser Ala Ala Thr Gly Thr Leu Ala Asp		
225 230 235 240		
Asp His Asp Val Leu Ser Phe Leu Thr Phe Ser Leu Ser Glu Pro Ser		
245 250 255		
Pro Glu Val Pro Pro Gln Pro Phe Leu Glu Met Gln His Val Arg Leu		
260 265 270		
Ala Arg Gln Leu Glu Gly Leu Trp Ala Arg Leu Gly Leu Gly Thr Arg		
275 280 285		
Glu Asp Val Thr Pro Lys Ser Asp Ser Glu Ala Gln Gly Glu Gly Glu		
290 295 300		
Arg Leu Phe Asp Leu Glu Glu Thr Leu Gly Arg His Arg Arg Ile Leu		
305 310 315 320		

Gln Ala Leu Arg Gly Leu Ser Lys Gln Leu Ala Gln Ala Glu Arg Gln  
 325 330 335  
 Trp Lys Lys Gln Leu Gly Pro Pro Gly Gln Ala Arg Pro Asp Gly Gly  
 340 345 350  
 Trp Ala Leu Asp Ala Ser Cys Gln Ile Pro Ser Thr Pro Gly Arg Gly  
 355 360 365  
 Gly His Leu Ser Met Ser Leu Asn Lys Asp Ser Ala Lys Val Gly Ala  
 370 375 380  
 Leu Leu His Gly Gln Trp Thr Leu Leu Gln Ala Leu Gln Glu Met Arg  
 385 390 395 400  
 Asp Ala Ala Val Arg Met Ala Ala Glu Ala Gln Val Ser Tyr Leu Pro  
 405 410 415  
 Val Gly Ile Glu His His Phe Leu Glu Leu Asp His Ile Leu Gly Leu  
 420 425 430  
 Leu Gln Glu Glu Leu Arg Gly Pro Ala Lys Ala Ala Lys Ala Pro  
 435 440 445  
 Arg Pro Pro Gly Gln Pro Pro Arg Ala Ser Ser Cys Leu Gln Pro Gly  
 450 455 460  
 Ile Phe Leu Phe Tyr Leu Leu Ile Gln Thr Val Gly Phe Phe Gly Tyr  
 465 470 475 480  
 Val His Phe Arg Gln Glu Leu Asn Lys Ser Leu Gln Glu Cys Leu Ser  
 485 490 495  
 Thr Gly Ser Leu Pro Leu Gly Pro Ala Pro His Thr Pro Arg Ala Leu  
 500 505 510  
 Gly Ile Leu Arg Arg Gln Pro Leu Pro Ala Ser Met Pro Ala  
 515 520 525

<210> 83  
 <211> 904  
 <212> PRT  
 <213> homo sapiens

<400> 83  
 Met Leu Leu Ala Leu Cys Ser Ser Leu Ala Leu Ile Phe Ala Ala Pro  
 1 5 10 15  
 Val Ser Gly Gln Leu Glu His Ser Gly Asn Tyr Tyr Cys Thr Ala Asp  
 20 25 30  
 Asn Gly Phe Gly Pro Gln His Ser Glu Val Val Ser Leu Ser Val Thr  
 35 40 45  
 Val Pro Val Ser His Pro Val Leu Thr Leu Ser Ser Ala Glu Ala Leu  
 50 55 60  
 Thr Phe Glu Gly Ala Thr Val Thr Leu His Ser Ser Leu Ile Leu Gln  
 65 70 75 80  
 Ala Pro Leu Ser Val Phe Glu Gly Asp Phe Val Val Leu Arg Cys Arg  
 85 90 95  
 Ala Lys Ala Glu Val Thr Leu Asn Thr Met Tyr Lys Asn Gly Asn Val  
 100 105 110  
 Leu Thr Phe Leu Asn Lys Ser Ser Asp Phe His Ile His His Ala Ser  
 115 120 125  
 Leu Lys Asp Asn Gly Ala Tyr His Phe Thr Gly Phe Asn Gly Ser Asn  
 130 135 140  
 Phe Ser Val Ser Ser Asn Ile Val Lys Ile Gln Val Gln Glu His Leu  
 145 150 155 160  
 Leu Pro Gln Trp Phe Leu Lys Ala Pro Asp Pro Thr Val Ala Leu Ser  
 165 170 175  
 Glu Ile Phe Ser Val Asn Arg Gly Pro Leu Leu Thr Gly Thr Gly Ser  
 180 185 190  
 Arg Val Met Thr Pro Trp Ile Tyr Phe Pro Thr Glu Asp Trp Asn Phe

195	200	205	
Thr Leu Ile Pro Ile Thr Val Asp Asp Ala Cys Lys Arg Pro Cys Ala			
210	215	220	
Pro Arg Ala Pro Trp Glu Val Gly Ser Leu Thr Pro Gly Lys Ser Phe			
225	230	235	240
Gln Gln Lys Gly Asn Pro Asp Leu Leu Met Gly Pro Phe Asp Val Leu			
245	250	255	
His Leu Ser Leu Ile Thr Leu Phe Cys Asn Met Ala Gly Ser Leu Phe			
260	265	270	
Tyr Tyr Met Glu Leu Gly Glu Lys Lys Asp Ala Leu Phe Val Thr Gly			
275	280	285	
Asn Glu Ser Arg Ser Tyr His Trp Phe Gln Lys Phe Ser Leu Ala Gly			
290	295	300	
Gly Gln Glu Ala Asp Gln Lys Leu Trp Phe Pro Pro Gly Leu Met Ser			
305	310	315	320
Gln Asp Ile Phe Ile Tyr Ile Arg Gln Gly Glu Ser Cys Leu Val Ile			
325	330	335	
Glu Met Phe His Gln Val Tyr Arg Arg Pro Ala Gly Gly Val Pro Val			
340	345	350	
Glu His Met Ser Val Trp Ala Leu Arg Val Asn Ser Ser Gly Leu Phe			
355	360	365	
Ala Tyr Ala Asp Gly Trp Leu Phe Thr Leu Phe Gln Leu Gln Ser Val			
370	375	380	
Asp Asn Leu Ser Pro Ser Thr Gln Ser Gln Thr His Glu Gly His Glu			
385	390	395	400
Lys Leu Cys Pro Phe Leu Ala Ile Gly Pro Pro Ala His Ser Arg Gly			
405	410	415	
Ser Phe Leu Arg Ala Lys Lys Ser Leu Val Ala Tyr Ile Lys Gly Asn			
420	425	430	
Gln Leu Ser Phe Pro Pro Val Glu Asp Leu Leu Pro Lys Ser Gln Trp			
435	440	445	
Pro Cys Ile Gln Val Leu Pro Arg Asn Ile Ala Ala Ala His Lys			
450	455	460	
Pro Val Ile Ser Val His Pro Pro Trp Thr Thr Phe Phe Lys Gly Glu			
465	470	475	480
Arg Val Thr Leu Thr Cys Asn Gly Phe Gln Phe Tyr Ala Thr Glu Lys			
485	490	495	
Thr Thr Trp Tyr His Arg His Tyr Trp Gly Glu Lys Leu Thr Leu Thr			
500	505	510	
Pro Gly Asn Thr Leu Glu Val Arg Glu Ser Gly Leu Tyr Arg Cys Gln			
515	520	525	
Ala Arg Gly Ser Pro Arg Ser Asn Pro Val Arg Leu Leu Phe Ser Ser			
530	535	540	
Gly Glu Lys Glu Asp Cys Val Ser Asp Lys Asn Pro Ala Thr Asn His			
545	550	555	560
Thr Pro Met Ser Arg Lys Arg Ser Ser Cys Ser Ser Leu Ser Ala Thr			
565	570	575	
Ser Phe Ile Ala Pro Ala Leu Arg Leu Asp Ser Leu Ile Leu Gln Ala			
580	585	590	
Pro Tyr Ser Val Phe Glu Gly Asp Thr Leu Val Leu Arg Cys His Arg			
595	600	605	
Arg Arg Lys Glu Lys Leu Thr Ala Val Lys Tyr Thr Trp Asn Gly Asn			
610	615	620	
Ile Leu Ser Ile Ser Asn Lys Ser Trp Asp Leu Leu Ile Pro Gln Ala			
625	630	635	640
Ser Ser Asn Asn Asn Gly Asn Tyr Arg Cys Ile Gly Tyr Gly Asp Glu			
645	650	655	
Asn Asp Val Phe Arg Ser Asn Phe Lys Ile Ile Lys Ile Gln Gly Ile			
660	665	670	

Pro Val Ser Gly Val Leu Leu Glu Thr Gln Pro Ser Gly Gly Gln Ala  
 675 680 685  
 Val Glu Gly Glu Met Leu Val Leu Val Cys Ser Val Ala Glu Gly Thr  
 690 695 700  
 Gly Asp Thr Thr Phe Ser Trp His Arg Glu Asp Met Gln Glu Ser Leu  
 705 710 715 720  
 Gly Arg Lys Thr Gln Arg Ser Leu Arg Ala Glu Leu Glu Leu Pro Ala  
 725 730 735  
 Ile Arg Gln Ser His Ala Gly Gly Tyr Tyr Cys Thr Ala Asp Asn Ser  
 740 745 750  
 Tyr Gly Pro Val Gln Ser Met Val Leu Asn Val Thr Val Arg Glu Thr  
 755 760 765  
 Pro Gly Asn Arg Asp Gly Leu Val Ala Ala Gly Ala Thr Gly Gly Leu  
 770 775 780  
 Leu Ser Ala Leu Leu Ala Val Ala Leu Leu Phe His Cys Trp Arg  
 785 790 795 800  
 Arg Arg Lys Ser Val His Pro Lys Lys Gly Asp Leu Val Tyr Ser Glu  
 805 810 815  
 Ile Gln Thr Thr Gln Leu Gly Glu Glu Glu Gly Asn His Gly Asn  
 820 825 830  
 Lys Asn Gln Glu Leu Glu Leu Val Asn Val Gly Glu Ser Phe Ser His  
 835 840 845  
 Arg Ala Cys Ile Trp Ser Thr Leu Met Gly Thr Cys Gln Thr Ile Gly  
 850 855 860  
 Gly Ala Asn Thr Ser Arg Thr Leu Leu Glu Asp Lys Asp Val Ser Val  
 865 870 875 880  
 Val Tyr Ser Glu Val Lys Thr Gln His Pro Asp Asn Ser Ala Gly Lys  
 885 890 895  
 Ile Ser Ser Lys Asp Glu Glu Ser  
 900

<210> 84  
 <211> 515  
 <212> PRT  
 <213> homo sapiens

<400> 84  
 Met Leu Leu Trp Ala Ser Leu Leu Ala Phe Ala Pro Val Cys Gly Gln  
 1 5 10 15  
 Ser Ala Ala Ala His Lys Pro Val Ile Ser Val His Pro Pro Trp Thr  
 20 25 30  
 Thr Phe Phe Lys Gly Glu Arg Val Thr Leu Thr Cys Asn Gly Phe Gln  
 35 40 45  
 Phe Tyr Ala Thr Glu Lys Thr Trp Tyr His Arg His Tyr Trp Gly  
 50 55 60  
 Glu Lys Leu Thr Leu Thr Pro Gly Asn Thr Leu Glu Val Arg Glu Ser  
 65 70 75 80  
 Gly Leu Tyr Arg Cys Gln Ala Arg Gly Ser Pro Arg Ser Asn Pro Val  
 85 90 95  
 Arg Leu Leu Phe Ser Ser Asp Ser Leu Ile Leu Gln Ala Pro Tyr Ser  
 100 105 110  
 Val Phe Glu Gly Asp Thr Leu Val Leu Arg Cys His Arg Arg Arg Lys  
 115 120 125  
 Glu Lys Leu Thr Ala Val Lys Tyr Thr Trp Asn Gly Asn Ile Leu Ser  
 130 135 140  
 Ile Ser Asn Lys Ser Trp Asp Leu Leu Ile Pro Gln Ala Ser Ser Asn  
 145 150 155 160  
 Asn Asn Gly Asn Tyr Arg Cys Ile Gly Tyr Gly Asp Glu Asn Asp Val

165	170	175
Phe Arg Ser Asn Phe Lys Ile Ile Lys Ile Gln Glu Leu Phe Pro His		
180	185	190
Pro Glu Leu Lys Ala Thr Asp Ser Gln Pro Thr Glu Gly Asn Ser Val		
195	200	205
Asn Leu Ser Cys Glu Thr Gln Leu Pro Pro Glu Arg Ser Asp Thr Pro		
210	215	220
Leu His Phe Asn Phe Phe Arg Asp Gly Glu Val Ile Leu Ser Asp Trp		
225	230	235
Ser Thr Tyr Pro Glu Leu Gln Leu Pro Thr Val Trp Arg Glu Asn Ser		
245	250	255
Gly Ser Tyr Trp Cys Gly Ala Glu Thr Val Arg Gly Asn Ile His Lys		
260	265	270
His Ser Pro Ser Leu Gln Ile His Val Gln Arg Ile Pro Val Ser Gly		
275	280	285
Val Leu Leu Glu Thr Gln Pro Ser Gly Gly Gln Ala Val Glu Gly Glu		
290	295	300
Met Leu Val Leu Val Cys Ser Val Ala Glu Gly Thr Gly Asp Thr Thr		
305	310	315
Phe Ser Trp His Arg Glu Asp Met Gln Glu Ser Leu Gly Arg Lys Thr		
325	330	335
Gln Arg Ser Leu Arg Ala Glu Leu Glu Leu Pro Ala Ile Arg Gln Ser		
340	345	350
His Ala Gly Gly Tyr Tyr Cys Thr Ala Asp Asn Ser Tyr Gly Pro Val		
355	360	365
Gln Ser Met Val Leu Asn Val Thr Val Arg Glu Thr Pro Gly Asn Arg		
370	375	380
Asp Gly Leu Val Ala Ala Gly Ala Thr Gly Gly Leu Leu Ser Ala Leu		
385	390	395
Leu Leu Ala Val Ala Leu Leu Phe His Cys Trp Arg Arg Arg Lys Ser		
405	410	415
Gly Val Gly Phe Leu Gly Asp Glu Thr Arg Leu Pro Pro Ala Pro Gly		
420	425	430
Pro Gly Glu Ser Ser His Ser Ile Cys Pro Ala Gln Val Glu Leu Gln		
435	440	445
Ser Leu Tyr Val Asp Val His Pro Lys Lys Gly Asp Leu Val Tyr Ser		
450	455	460
Glu Ile Gln Thr Thr Gln Leu Gly Glu Glu Glu Ala Asn Thr Ser		
465	470	475
Arg Thr Leu Leu Glu Asp Lys Asp Val Ser Val Val Tyr Ser Glu Val		
485	490	495
Lys Thr Gln His Pro Asp Asn Ser Ala Gly Lys Ile Ser Ser Lys Asp		
500	505	510
Glu Glu Ser		
515		

<210> 85  
 <211> 831  
 <212> PRT  
 <213> homo sapiens

<400> 85  
 Asx Met Ala Val Gly Gly His Lys Gly Val Arg Cys Pro Pro Ser  
 1 5 10 15  
 Ala Arg Ser Ser Gln Val Pro Thr Cys Cys Ala Gly Trp Arg Gln Gln  
 20 25 30  
 Gly Asp Glu Cys Gly Ile Ala Val Cys Glu Gly Asn Ser Thr Cys Ser  
 35 40 45

Glu Asn Glu Val Cys Val Arg Pro Gly Glu Cys Arg Cys Arg His Gly  
 50 55 60  
 Tyr Phe Gly Ala Asn Cys Asp Thr Lys Cys Pro Arg Gln Phe Trp Gly  
 65 70 75 80  
 Pro Asp Cys Lys Glu Leu Cys Ser Cys His Pro His Gly Gln Cys Glu  
 85 90 95  
 Asp Val Thr Gly Gln Cys Thr Cys His Ala Arg Arg Trp Gly Ala Arg  
 100 105 110  
 Cys Glu His Ala Cys Gln Cys His Gly Thr Cys His Pro Arg Ser  
 115 120 125  
 Gly Ala Cys Arg Cys Glu Ser Gly Trp Trp Gly Ala Gln Cys Ala Ser  
 130 135 140  
 Ala Cys Tyr Cys Ser Ala Thr Ser Arg Cys Asp Pro Gln Thr Gly Ala  
 145 150 155 160  
 Cys Leu Cys His Ala Gly Trp Trp Gly Arg Ser Cys Asn Asn Gln Cys  
 165 170 175  
 Ala Cys Asn Ser Ser Pro Cys Glu Gln Gln Ser Gly Arg Cys Gln Cys  
 180 185 190  
 Arg Glu Arg Thr Phe Gly Ala Arg Cys Asp Arg Tyr Cys Gln Cys Phe  
 195 200 205  
 Arg Gly Arg Cys His Pro Val Asp Gly Thr Cys Ala Cys Glu Pro Gly  
 210 215 220  
 Tyr Arg Gly Lys Tyr Cys Arg Glu Pro Cys Pro Ala Gly Phe Tyr Gly  
 225 230 235 240  
 Leu Gly Cys Arg Arg Arg Cys Gly Gln Cys Lys Gly Gln Gln Pro Cys  
 245 250 255  
 Thr Val Ala Glu Gly Arg Cys Leu Thr Cys Glu Pro Gly Trp Asn Gly  
 260 265 270  
 Thr Lys Cys Asp Gln Pro Cys Ala Thr Gly Phe Tyr Gly Glu Gly Cys  
 275 280 285  
 Ser His Arg Cys Pro Pro Cys Arg Asp Gly His Ala Cys Asn His Val  
 290 295 300  
 Thr Gly Lys Cys Thr Arg Cys Asn Ala Gly Trp Ile Gly Asp Arg Cys  
 305 310 315 320  
 Glu Thr Lys Cys Ser Asn Gly Thr Tyr Gly Glu Asp Cys Ala Phe Val  
 325 330 335  
 Cys Ala Asp Cys Gly Ser Gly His Cys Asp Phe Gln Ser Gly Arg Cys  
 340 345 350  
 Leu Cys Ser Pro Gly Val His Gly Pro His Cys Asn Val Thr Cys Pro  
 355 360 365  
 Pro Gly Leu His Gly Ala Asp Cys Ala Gln Ala Cys Ser Cys His Glu  
 370 375 380  
 Asp Thr Cys Asp Pro Val Thr Gly Ala Cys His Leu Glu Thr Asn Gln  
 385 390 395 400  
 Arg Lys Gly Val Met Gly Ala Gly Ala Leu Leu Val Leu Val Cys  
 405 410 415  
 Leu Leu Leu Ser Leu Leu Gly Cys Cys Ala Cys Arg Gly Lys Asp  
 420 425 430  
 Pro Thr Arg Arg Pro Arg Pro Arg Glu Leu Ser Leu Gly Arg Lys  
 435 440 445  
 Lys Ala Pro His Arg Leu Cys Gly Arg Phe Ser Arg Ile Ser Met Lys  
 450 455 460  
 Leu Pro Arg Ile Pro Leu Arg Arg Gln Lys Leu Pro Lys Val Val Val  
 465 470 475 480  
 Ala His His Asp Leu Asp Asn Thr Leu Asn Cys Ser Phe Leu Glu Pro  
 485 490 495  
 Pro Ser Gly Leu Glu Gln Pro Ser Pro Ser Trp Ser Ser Arg Ala Ser  
 500 505 510  
 Phe Ser Ser Phe Asp Thr Thr Asp Glu Gly Pro Val Tyr Cys Val Pro

515	520	525
His Glu Glu Ala Pro Ala Glu Ser Arg Asp Pro Glu Val Pro Thr Val		
530	535	540
Pro Ala Glu Ala Pro Ala Pro Ser Pro Val Pro Leu Thr Thr Pro Ala		
545	550	555
Ser Ala Glu Glu Ala Ile Pro Leu Pro Ala Ser Ser Asp Ser Glu Arg		
565	570	575
Ser Ala Ser Ser Val Glu Gly Pro Gly Gly Ala Leu Tyr Ala Arg Val		
580	585	590
Ala Arg Arg Glu Ala Arg Pro Ala Arg Ala Arg Gly Glu Ile Gly Gly		
595	600	605
Leu Ser Leu Ser Pro Ser Pro Glu Arg Arg Lys Pro Pro Pro Pro Asp		
610	615	620
Pro Ala Thr Lys Pro Lys Val Ser Trp Ile His Gly Lys His Ser Ala		
625	630	635
640		
Ala Ala Ala Gly Arg Ala Pro Ser Pro Pro Pro Pro Gly Ser Glu Ala		
645	650	655
Ala Pro Ser Pro Ser Lys Arg Lys Arg Thr Pro Ser Asp Lys Ser Ala		
660	665	670
His Thr Val Glu His Gly Ser Pro Arg Thr Arg Asp Pro Thr Pro Arg		
675	680	685
Pro Pro Gly Leu Pro Glu Glu Ala Thr Ala Leu Ala Ala Pro Ser Pro		
690	695	700
Pro Arg Ala Arg Ala Arg Ala Ala Pro Arg Pro Leu Gly Ala His Gly		
705	710	715
720		
Arg Arg Arg Ser Pro Ala Lys Arg Ala Glu Ala Ala Ser Met Leu Ala		
725	730	735
Ala Asp Val Arg Gly Lys Thr Arg Ser Leu Gly Arg Ala Glu Val Ala		
740	745	750
Leu Gly Ala Gln Gly Pro Arg Glu Lys Pro Ala Pro Pro Gln Lys Ala		
755	760	765
Lys Arg Ser Val Pro Pro Ala Ser Pro Ala Arg Ala Pro Pro Ala Thr		
770	775	780
Glu Thr Pro Gly Pro Glu Lys Ala Ala Thr Asp Leu Pro Ala Pro Glu		
785	790	795
800		
Thr Pro Arg Lys Lys Thr Pro Ile Gln Lys Pro Pro Arg Lys Lys Ser		
805	810	815
Arg Glu Ala Ala Gly Glu Leu Gly Arg Ala Gly Ala Pro Thr Leu		
820	825	830

<210> 86

<211> 871

<212> PRT

<213> homo sapiens

<400> 86

Asx Met Glu Gly Ala Gly Pro Arg Gly Ala Gly Pro Ala Arg Arg Arg		
1	5	10
Gly Ala Gly Gly Pro Pro Ser Pro Leu Leu Pro Ser Leu Leu Leu		
20	25	30
Leu Leu Leu Trp Met Leu Pro Asp Thr Val Ala Pro Gln Glu Leu Asn		
35	40	45
Pro Arg Gly Arg Asn Val Cys Arg Ala Pro Gly Ser Gln Val Pro Thr		
50	55	60
Cys Cys Ala Gly Trp Arg Gln Gln Gly Asp Glu Cys Gly Ile Ala Val		
65	70	75
80		
Cys Glu Gly Asn Ser Thr Cys Ser Glu Asn Glu Val Cys Val Arg Pro		
85	90	95

Gly Glu Cys Arg Cys Arg His Gly Tyr Phe Gly Ala Asn Cys Asp Thr  
 100 105 110  
 Lys Cys Pro Arg Gln Phe Trp Gly Pro Asp Cys Lys Glu Leu Cys Ser  
 115 120 125  
 Cys His Pro His Gly Gln Cys Glu Asp Val Thr Gly Gln Cys Thr Cys  
 130 135 140  
 His Ala Arg Arg Trp Gly Ala Arg Cys Glu His Ala Cys Gln Cys Gln  
 145 150 155 160  
 His Gly Thr Cys His Pro Arg Ser Gly Ala Cys Arg Cys Glu Ser Gly  
 165 170 175  
 Trp Trp Gly Ala Gln Cys Ala Ser Ala Cys Tyr Cys Ser Ala Thr Ser  
 180 185 190  
 Arg Cys Asp Pro Gln Thr Gly Ala Cys Leu Cys His Ala Gly Trp Trp  
 195 200 205  
 Gly Arg Ser Cys Asn Asn Gln Cys Ala Cys Asn Ser Ser Pro Cys Glu  
 210 215 220  
 Gln Gln Ser Gly Arg Cys Gln Cys Arg Glu Arg Thr Phe Gly Ala Arg  
 225 230 235 240  
 Cys Asp Arg Tyr Cys Gln Cys Phe Arg Gly Arg Cys His Pro Val Asp  
 245 250 255  
 Gly Thr Cys Ala Cys Glu Pro Gly Tyr Arg Gly Lys Tyr Cys Arg Glu  
 260 265 270  
 Pro Cys Pro Ala Gly Phe Tyr Gly Leu Gly Cys Arg Arg Cys Gly  
 275 280 285  
 Gln Cys Lys Gly Gln Gln Pro Cys Thr Val Ala Glu Gly Arg Cys Leu  
 290 295 300  
 Thr Cys Glu Pro Gly Trp Asn Gly Thr Lys Cys Asp Gln Pro Cys Ala  
 305 310 315 320  
 Thr Gly Phe Tyr Gly Glu Gly Cys Ser His Arg Cys Pro Pro Cys Arg  
 325 330 335  
 Asp Gly His Ala Cys Asn His Val Thr Gly Lys Cys Thr Arg Cys Asn  
 340 345 350  
 Ala Gly Trp Ile Gly Asp Arg Cys Glu Thr Lys Cys Ser Asn Gly Thr  
 355 360 365  
 Tyr Gly Glu Asp Cys Ala Phe Val Cys Ala Asp Cys Gly Ser Gly His  
 370 375 380  
 Cys Asp Phe Gln Ser Gly Arg Cys Leu Cys Ser Pro Gly Val His Gly  
 385 390 395 400  
 Pro His Cys Asn Val Thr Cys Pro Pro Gly Leu His Gly Ala Asp Cys  
 405 410 415  
 Ala Gln Ala Cys Ser Cys His Glu Asp Thr Cys Asp Pro Val Thr Gly  
 420 425 430  
 Ala Cys His Leu Glu Thr Asn Gln Arg Lys Gly Val Met Gly Ala Gly  
 435 440 445  
 Ala Leu Leu Val Leu Leu Val Cys Leu Leu Leu Ser Leu Leu Gly Cys  
 450 455 460  
 Cys Cys Ala Cys Arg Gly Lys Asp Pro Thr Arg Arg Pro Arg Pro Arg  
 465 470 475 480  
 Arg Glu Leu Ser Leu Gly Arg Lys Lys Ala Pro His Arg Leu Cys Gly  
 485 490 495  
 Arg Phe Ser Arg Ile Ser Met Lys Leu Pro Arg Ile Pro Leu Arg Arg  
 500 505 510  
 Gln Lys Leu Pro Lys Val Val Ala His His Asp Leu Asp Asn Thr  
 515 520 525  
 Leu Asn Cys Ser Phe Leu Glu Pro Pro Ser Gly Leu Glu Gln Pro Ser  
 530 535 540  
 Pro Ser Trp Ser Ser Arg Ala Ser Phe Ser Ser Phe Asp Thr Thr Asp  
 545 550 555 560  
 Glu Gly Pro Val Tyr Cys Val Pro His Glu Glu Ala Pro Ala Glu Ser

565	570	575	
Arg Asp Pro Glu Val Pro Thr Val Pro Ala Glu Ala Pro Ala Pro Ser			
580	585	590	
Pro Val Pro Leu Thr Thr Pro Ala Ser Ala Glu Glu Ala Ile Pro Leu			
595	600	605	
Pro Ala Ser Ser Asp Ser Glu Arg Ser Ala Ser Ser Val Glu Gly Pro			
610	615	620	
Gly Gly Ala Leu Tyr Ala Arg Val Ala Arg Arg Glu Ala Arg Pro Ala			
625	630	635	640
Arg Ala Arg Gly Glu Ile Gly Gly Leu Ser Leu Ser Pro Ser Pro Glu			
645	650	655	
Arg Arg Lys Pro Pro Pro Asp Pro Ala Thr Lys Pro Lys Val Ser			
660	665	670	
Trp Ile His Gly Lys His Ser Ala Ala Ala Gly Arg Ala Pro Ser			
675	680	685	
Pro Pro Pro Pro Gly Ser Glu Ala Ala Pro Ser Pro Ser Lys Arg Lys			
690	695	700	
Arg Thr Pro Ser Asp Lys Ser Ala His Thr Val Glu His Gly Ser Pro			
705	710	715	720
Arg Thr Arg Asp Pro Thr Pro Arg Pro Pro Gly Leu Pro Glu Glu Ala			
725	730	735	
Thr Ala Leu Ala Ala Pro Ser Pro Pro Arg Ala Arg Ala Arg Ala Ala			
740	745	750	
Pro Arg Pro Leu Gly Ala His Gly Arg Arg Arg Ser Pro Ala Lys Arg			
755	760	765	
Ala Glu Ala Ala Ser Met Leu Ala Ala Asp Val Arg Gly Lys Thr Arg			
770	775	780	
Ser Leu Gly Arg Ala Glu Val Ala Leu Gly Ala Gln Gly Pro Arg Glu			
785	790	795	800
Lys Pro Ala Pro Pro Gln Lys Ala Lys Arg Ser Val Pro Pro Ala Ser			
805	810	815	
Pro Ala Arg Ala Pro Pro Ala Thr Glu Thr Pro Gly Pro Glu Lys Ala			
820	825	830	
Ala Thr Asp Leu Pro Ala Pro Glu Thr Pro Arg Lys Lys Thr Pro Ile			
835	840	845	
Gln Lys Pro Pro Arg Lys Lys Ser Arg Glu Ala Ala Gly Glu Leu Gly			
850	855	860	
Arg Ala Gly Ala Pro Thr Leu			
865	870		

<210> 87  
 <211> 134  
 <212> PRT  
 <213> homo sapiens

<400> 87  
 Ile Asp Cys Arg Ala Glu Gln Gly Arg Thr Pro Leu Met Val Ala Val  
 1 5 10 15  
 Gly Leu Pro Asp Pro Ala Leu Arg Ala Arg Phe Val Arg Leu Leu Leu  
 20 25 30  
 Glu Gln Gly Ala Ala Val Asn Leu Arg Asp Glu Arg Gly Arg Thr Ala  
 35 40 45  
 Leu Ser Leu Ala Cys Glu Arg Gly His Leu Asp Ala Val Gln Leu Leu  
 50 55 60  
 Val Gln Phe Ser Gly Asp Pro Glu Ala Ala Asp Ser Ala Gly Asn Ser  
 65 70 75 80  
 Pro Val Met Trp Ala Ala Ala Cys Gly His Gly Ala Val Leu Glu Phe  
 85 90 95

Leu Val Arg Ser Phe Arg Arg Leu Gly Leu Arg Leu Asp Arg Thr Asn  
 100 105 110  
 Arg Ala Gly Leu Thr Ala Leu Gln Leu Ala Ala Ala Arg Gly His Gly  
 115 120 125  
 Thr Cys Val Gln Ala Leu  
 130

<210> 88  
 <211> 324  
 <212> PRT  
 <213> homo sapiens

<400> 88  
 Met Leu Lys Pro Lys Asp Leu Cys Pro Arg Ala Gly Thr Arg Thr Phe  
 1 5 10 15  
 Leu Glu Ala Met Gln Ala Gly Lys Val His Leu Ala Arg Phe Val Leu  
 20 25 30  
 Asp Ala Leu Asp Arg Ser Ile Ile Asp Cys Arg Ala Glu Gln Gly Arg  
 35 40 45  
 Thr Pro Leu Met Val Ala Val Gly Leu Pro Asp Pro Ala Leu Arg Ala  
 50 55 60  
 Arg Phe Val Arg Leu Leu Glu Gln Gly Ala Ala Val Asn Leu Arg  
 65 70 75 80  
 Asp Glu Arg Gly Arg Thr Ala Leu Ser Leu Ala Cys Glu Arg Gly His  
 85 90 95  
 Leu Asp Ala Val Gln Leu Leu Val Gln Phe Ser Gly Asp Pro Glu Ala  
 100 105 110  
 Ala Asp Ser Ala Gly Asn Ser Pro Val Met Trp Ala Ala Ala Cys Gly  
 115 120 125  
 His Gly Ala Val Leu Glu Phe Leu Val Arg Ser Phe Arg Arg Leu Gly  
 130 135 140  
 Leu Arg Leu Asp Arg Thr Asn Arg Ala Gly Leu Thr Ala Leu Gln Leu  
 145 150 155 160  
 Ala Ala Ala Arg Gly His Gly Thr Ser Ala Gly Gly His Gly Gly Glu  
 165 170 175  
 Ala Gly Ser Ala Gly Lys Asn Ser Gly Arg His Arg Ala Gln Gly Ser  
 180 185 190  
 Glu Arg Pro Glu Leu Gly Arg Ser Met Ser Leu Ala Leu Gly Ala Val  
 195 200 205  
 Thr Glu Glu Ala Ala Arg Leu Arg Ala Gly Ala Leu Met Ala Leu  
 210 215 220  
 Pro Asn Ser Pro Gln Ser Ser Gly Thr Gly Arg Trp Arg Ser Gln Glu  
 225 230 235 240  
 Val Leu Glu Gly Ala Pro Pro Thr Leu Ala Gln Ala Pro Ile Gly Leu  
 245 250 255  
 Ser Pro His Pro Glu Gly Gly Pro Gly Ser Gly Arg Leu Gly Leu Arg  
 260 265 270  
 Arg Arg Ser Thr Ala Pro Asp Ile Pro Ser Leu Val Gly Glu Ala Pro  
 275 280 285  
 Gly Pro Glu Ser Gly Pro Glu Leu Glu Ala Asn Ala Leu Ser Val Ser  
 290 295 300  
 Val Pro Gly Pro Asn Pro Trp Gln Ala Gly Thr Glu Ala Val Val Leu  
 305 310 315 320  
 Arg Ala Gln Arg

**INTERNATIONAL SEARCH REPORT**

International application No.

PCT/US01/28462

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(7) : C12N 15/00, 12; C07K 14/435  
US CL : 435/69.1, 320.1, 325; 530/350; 536/23.1, 23.5

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
U.S. : 435/69.1, 320.1, 325; 530/350; 536/23.1, 23.5

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A, P	Genbank Accession No. AC007395, 30 September 2000 (30.09.00), see in particular nucleotides 123581 through 122421.	1-7



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance		
*E* earlier application or patent published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*O* document referring to an oral disclosure, use, exhibition or other means	"&"	document member of the same parent family
*P* document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

30 October 2001 (30.10.2001)

Date of mailing of the international search report

15 JAN 2002

Name and mailing address of the ISA/US

Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703)305-3230

Authorized officer

Marianne P. Allen

Telephone No. 703-308-0196

**INTERNATIONAL SEARCH REPORT**

International application No.

PCT/US01/28462

**Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)**

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claim Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2.  Claim Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
  
3.  Claim Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:  
Please See Continuation Sheet

1.  As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
  
4.  No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-7 with respect to SEQ ID NOS: 1 and 45

Remark on Protest

  

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

**INTERNATIONAL SEARCH REPORT**

International application No.

PCT/US01/28462

**BOX II. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING**

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Claims 1-7 reference SEQ ID NOS. listed in Table 1 on page 24 of the description. Each nucleotide and corresponding amino acid sequence pair in Table 1 forms an inventive concept. Thus, with respect to claims 1-7, SEQ ID NOS: 1 and 45 form the first inventive concept, SEQ ID NOS: 2 and 46 form the second inventive concept, and so forth. There are a total of 44 inventions encompassed by the claims. The different sequence pairs have no obvious special technical feature in common as they appear to be structurally unrelated sequences.

As such, claims 1-7 do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features.